Induction NN
of IN
NF-KB NN
during IN
monocyte NN
differentiation NN
by IN
HIV NN
type NN
1 CD
infection NN
. O

The DT
production NN
of IN
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
( O
HIV-1 NN
) O
progeny NN
was VBD
followed VBN
in IN
the DT
U937 NN
promonocytic JJ
cell NN
line NN
after IN
stimulation NN
either CC
with IN
retinoic JJ
acid NN
or CC
PMA NN
, O
and CC
in IN
purified VBN
human JJ
monocytes NNS
and CC
macrophages NNS
. O

Electrophoretic JJ
mobility NN
shift NN
assays NNS
and CC
Southwestern NN
blotting NN
experiments NNS
were VBD
used VBN
to TO
detect VB
the DT
binding NN
of IN
cellular JJ
transactivation NN
factor NN
NF-KB NN
to TO
the DT
double JJ
repeat-KB JJ|NN
enhancer NN
sequence NN
located JJ
in IN
the DT
long JJ
terminal JJ
repeat NN
. O

PMA NN
treatment NN
, O
and CC
not RB
retinoic JJ
acid NN
treatment NN
of IN
the DT
U937 NN
cells NNS
acts VBZ
in IN
inducing VBG
NF-KB NN
expression NN
in IN
the DT
nuclei NNS
. O

In IN
nuclear JJ
extracts NNS
from IN
monocytes NNS
or CC
macrophages NNS
, O
induction NN
of IN
NF-KB NN
occurred VBD
only RB
if IN
the DT
cells NNS
were VBD
previously RB
infected VBN
with IN
HIV-1 NN
. O

When WRB
U937 NN
cells NNS
were VBD
infected VBN
with IN
HIV-1 NN
, O
no DT
induction NN
of IN
NF-KB NN
factor NN
was VBD
detected VBN
, O
whereas IN
high JJ
level NN
of IN
progeny NN
virions NNS
was VBD
produced VBN
, O
suggesting VBG
that IN
this DT
factor NN
was VBD
not RB
required VBN
for IN
viral JJ
replication NN
. O

These DT
results NNS
indicate VBP
that IN
in IN
monocytic JJ
cell NN
lineage NN
, O
HIV-1 NN
could MD
mimic VB
some DT
differentiation/activation JJ
stimuli NNS
allowing VBG
nuclear JJ
NF-KB NN
expression NN
. O

Positive JJ
and CC
negative JJ
regulation NN
of IN
immunoglobulin NN
gene NN
expression NN
by IN
a DT
novel JJ
B-cell-specific JJ
enhancer NN
element NN
. O

A DT
new JJ
B-cell-specific JJ
enhancer NN
element NN
has VBZ
been VBN
identified VBN
3' JJ
of IN
E4 NN
and CC
the DT
octamerlike JJ
motifs NNS
in IN
the DT
human JJ
immunoglobulin NN
heavy-chain NN
gene NN
enhancer NN
. O

Tandem JJ
copies NNS
of IN
this DT
67-bp JJ
MnlI-AluI NN
fragment NN
, O
when WRB
fused VBN
to TO
the DT
chloramphenicol JJ
acetyltransferase NN
gene NN
driven VBN
by IN
the DT
conalbumin JJ
promoter NN
, O
stimulated VBD
transcription NN
in IN
B NN
cells NNS
but CC
not RB
in IN
Jurkat NN
T NN
cells NNS
or CC
HeLa NN
cells NNS
. O

Footprinting NN
analysis NN
revealed VBD
that IN
the DT
identical JJ
sequence NN
CCGAAACTGAAAAGG NN
, O
designated VBN
E6 NN
, O
was VBD
protected VBN
by IN
nuclear JJ
extracts NNS
from IN
B NN
cells NNS
, O
T NN
cells NNS
, O
or CC
HeLa NN
cells NNS
. O

Gel NN
mobility NN
shift NN
assays NNS
using VBG
a DT
synthetic JJ
E6 NN
motif NN
detected VBD
a DT
B-cell-specific JJ
complex NN
in IN
addition NN
to TO
a DT
ubiquitous JJ
band NN
found VBN
also RB
in IN
T NN
cells NNS
and CC
HeLa NN
cells NNS
. O

In IN
agreement NN
with IN
the DT
results NNS
of IN
gel NN
retardation NN
assays NNS
, O
tandem JJ
copies NNS
of IN
the DT
E6 NN
motif NN
stimulated VBD
transcription NN
in IN
ARH77 NN
and CC
Raji NN
cells NNS
but CC
not RB
in IN
Jurkat NN
or CC
HeLa NN
cells NNS
. O

Furthermore RB
, O
a DT
mutant JJ
E6 NN
motif NN
lost VBD
both CC
in FW
vitro FW
binding NN
activity NN
and CC
in FW
vivo FW
enhancer NN
activity NN
. O

In IN
striking JJ
contrast NN
to TO
the DT
mouse NN
Ig NN
heavy-chain JJ
enhancer NN
, O
in IN
which WDT
the DT
octamer NN
motif NN
acts VBZ
as IN
a DT
B-cell-specific JJ
enhancer NN
element NN
, O
the DT
human JJ
enhancer NN
contains VBZ
an DT
octamerlike JJ
sequence NN
with IN
one CD
base NN
substitution NN
which WDT
bound VBD
octamer-binding JJ
proteins NNS
with IN
only RB
very RB
low JJ
affinity NN
and CC
showed VBD
no DT
enhancer NN
activity NN
of IN
its PRP$
own JJ
. O

Interestingly RB
, O
the DT
MnlI-AluI NN
fragment NN
could MD
suppress VB
the DT
basal-level JJ
activity NN
of IN
the DT
conalbumin JJ
promoter NN
in IN
both CC
Jurkat NN
and CC
HeLa NN
cells NNS
. O

Moreover RB
, O
simian JJ
virus NN
40 CD
enhancer NN
activity NN
was VBD
blocked VBN
by IN
the DT
MnlI-AluI NN
fragment NN
in IN
HeLa NN
cells NNS
but CC
not RB
in IN
B NN
cells NNS
. O

Thus RB
, O
the DT
novel JJ
enhancer NN
element NN
identified VBN
in IN
this DT
study NN
is VBZ
probably RB
a DT
target NN
site NN
for IN
both CC
positive JJ
and CC
negative JJ
factors NNS
. O

The DT
NF NN
kappa NN
B NN
independent JJ
cis-acting JJ
sequences NNS
in IN
HIV-1 NN
LTR NN
responsive NN
to TO
T-cell NN
activation NN
. O

The DT
rate NN
of IN
transcription NN
initiation NN
directed VBN
by IN
the DT
long JJ
terminal JJ
repeat NN
( O
LTR NN
) O
of IN
HIV-1 NN
increases VBZ
in IN
response NN
to TO
mitogenic JJ
stimuli NNS
of IN
T NN
cells NNS
. O

Here RB
we PRP
show VBP
that IN
the DT
response NN
of IN
the DT
HIV-1 NN
LTR NN
may MD
be VB
governed VBN
by IN
two CD
independent JJ
sequences NNS
located JJ
5' JJ
to TO
the DT
site NN
of IN
transcription NN
initiation NN
sequences NNS
that WDT
bind VBP
either CC
NFAT-1 NN
or CC
NF NN
kappa NN
B NN
. O

The DT
rate NN
of IN
LTR-directed JJ
gene NN
expression NN
increased VBD
in IN
response NN
to TO
treatment NN
with IN
either CC
a DT
phorbol NN
ester NN
or CC
tumor NN
necrosis NN
factor NN
alpha NN
if IN
either CC
the DT
NFAT-1 NN
or CC
NF NN
kappa NN
B NN
binding NN
sites NNS
were VBD
deleted VBN
, O
but CC
failed VBD
to TO
respond VB
to TO
these DT
mitogenic JJ
stimuli NNS
if IN
both DT
sequences NNS
were VBD
absent JJ
. O

The DT
HIV-1 NN
mutant JJ
virus NN
containing VBG
both CC
NF NN
kappa NN
B NN
and CC
NFAT-1 NN
deletion NN
was VBD
able JJ
to TO
replicate VB
although IN
at IN
a DT
much JJ
decreased VBN
growth NN
rate NN
, O
while IN
the DT
deletion NN
of IN
NFAT-1 NN
alone RB
increased VBD
the DT
viral JJ
growth NN
rate NN
in IN
Jurkat NN
cells NNS
. O

Neither CC
deletion NN
of IN
NF NN
kappa NN
B NN
nor CC
deletion NN
of IN
NFAT-1 NN
decreased VBD
activation NN
of IN
viral JJ
replication NN
by IN
phorbol NN
ester NN
. O

Specific JJ
depletion NN
of IN
the DT
B-cell NN
population NN
induced VBN
by IN
aberrant JJ
expression NN
of IN
human JJ
interferon NN
regulatory JJ
factor NN
1 CD
gene NN
in IN
transgenic JJ
mice NNS
. O

Interferons NNS
( O
IFNs NNS
) O
are VBP
well RB
known VBN
both CC
as IN
antiviral JJ
proteins NNS
and CC
as IN
potent JJ
regulators NNS
of IN
cell NN
growth NN
and CC
differentiation NN
. O

In IN
fact NN
, O
IFNs NNS
inhibit VBP
growth NN
of IN
various JJ
normal JJ
and CC
transformed VBN
cell NN
types NNS
. O

Previously RB
, O
a DT
nuclear JJ
factor NN
, O
IRF-1 NN
( O
interferon NN
regulatory JJ
factor NN
1 CD
) O
, O
which WDT
binds VBZ
to TO
type NN
I CD
IFN NN
and CC
some DT
IFN-inducible JJ
gene NN
promoters NNS
, O
was VBD
identified VBN
and CC
cloned VBN
. O

Since IN
the DT
IRF-1 NN
gene NN
is VBZ
both CC
virus NN
and CC
IFN NN
inducible JJ
, O
an DT
intriguing JJ
issue NN
is VBZ
raised VBN
as IN
to TO
whether IN
the DT
IRF-1 NN
gene NN
is VBZ
functioning VBG
in IN
IFN-mediated JJ
regulation NN
of IN
cell NN
growth NN
and CC
differentiation NN
. O

In IN
this DT
study NN
, O
we PRP
generated VBD
transgenic JJ
mice NNS
carrying VBG
the DT
human JJ
IRF-1 NN
gene NN
linked VBN
to TO
the DT
human JJ
immunoglobulin NN
heavy-chain JJ
enhancer NN
. O

In IN
the DT
transgenic JJ
mice NNS
, O
all PDT
the DT
lymphoid JJ
tissues NNS
examined VBN
showed VBD
a DT
dramatic JJ
reduction NN
in IN
the DT
number NN
of IN
B NN
lymphocytes NNS
( O
B NN
cells NNS
) O
. O

Preparation NN
and CC
analysis NN
of IN
bone NN
marrow NN
cells NNS
from IN
the DT
chimeric JJ
mice NNS
indicated VBD
that IN
the DT
bone NN
marrow NN
is VBZ
the DT
effective JJ
site NN
for IN
specific JJ
depletion NN
of IN
the DT
B-cell NN
population NN
. O

In IN
fact NN
, O
transgenic JJ
bone NN
marrow NN
cells NNS
cocultured VBN
with IN
a DT
bone NN
marrow-derived JJ
stromal JJ
cell NN
line NN
revealed VBD
an DT
altered JJ
B-cell NN
maturation NN
pattern NN
. O

Identification NN
and CC
cloning NN
of IN
TCF-1 NN
, O
a DT
T NN
lymphocyte-specific JJ
transcription NN
factor NN
containing VBG
a DT
sequence-specific JJ
HMG NN
box NN
. O

CD3-epsilon NN
expression NN
is VBZ
controlled VBN
by IN
a DT
downstream JJ
T NN
lymphocyte-specific JJ
enhancer NN
element NN
. O

We PRP
report VBP
the DT
identification NN
of IN
a DT
T NN
cell-specific JJ
transcription NN
factor NN
, O
TCF-1 NN
, O
binding VBG
to TO
this DT
element NN
. O

The DT
multimerized JJ
recognition NN
motif NN
of IN
TCF-1 NN
constituted VBD
a DT
T NN
cell-specific JJ
enhancer NN
. O

Subsequent JJ
cloning NN
of IN
TCF-1 NN
identified VBD
three CD
splice NN
alternatives NNS
. O

TCF-1 NN
contained VBD
a DT
single JJ
DNA-binding JJ
HMG NN
box NN
most RBS
closely RB
related JJ
to TO
similar JJ
boxes NNS
in IN
the DT
putative JJ
mammalian JJ
sex-determining JJ
gene NN
SRY NN
and CC
in IN
the DT
Schizosaccharomyces FW
pombe FW
Mc NN
mating NN
type NN
gene NN
. O

TCF-1 NN
mRNA NN
was VBD
expressed VBN
uniquely RB
in IN
T NN
lymphocytes NNS
. O

Upon IN
cotransfection NN
into IN
non-T JJ
cells NNS
, O
TCF-1 NN
could MD
transactivate VB
through IN
its PRP$
cognate JJ
motif NN
. O

These DT
results NNS
identify VBP
TCF-1 NN
as IN
a DT
T NN
cell-specific JJ
transcription NN
factor NN
, O
which WDT
might MD
play VB
a DT
role NN
in IN
the DT
establishment NN
of IN
the DT
mature JJ
T NN
cell NN
phenotype NN
. O

Nuclear JJ
factor NN
kappa NN
B NN
activates VBZ
proenkephalin NN
transcription NN
in IN
T NN
lymphocytes NNS
. O

Upon IN
activation NN
, O
T NN
lymphocytes NNS
accumulate VBP
high JJ
levels NNS
of IN
the DT
neuropeptide NN
enkephalin NN
which WDT
correlate VBP
with IN
high JJ
levels NNS
of IN
proenkephalin NN
mRNA NN
in IN
the DT
cells NNS
. O

Here RB
we PRP
investigated VBD
the DT
transcriptional JJ
basis NN
for IN
these DT
changes NNS
. O

The DT
proenkephalin NN
promoter NN
contains VBZ
a DT
sequence NN
GGGGACGTCCCC NN
, O
named VBN
B2 NN
, O
which WDT
is VBZ
similar JJ
to TO
the DT
kappa NN
B NN
sequence NN
GGGGACTTTCC NN
, O
the DT
binding VBG
site NN
of IN
the DT
transcription NN
factor NN
nuclear JJ
factor NN
( O
NF NN
) O
-kappa NN
B NN
. O

Activation NN
of IN
T NN
lymphocytes NNS
induces VBZ
an DT
NF-kappa NN
B-like JJ
binding NN
activity NN
to TO
the DT
B2 NN
site NN
, O
concomitant JJ
with IN
activation NN
of IN
the DT
proenkephalin NN
promoter NN
. O

Mutations NNS
at IN
the DT
B2 NN
site NN
abolish VBP
this DT
transcriptional JJ
activation NN
. O

The DT
purified VBN
homodimer NN
( O
two CD
p50s NNS
) O
of IN
the DT
DNA-binding JJ
subunit NN
of IN
NF-kappa NN
B NN
binds VBZ
the DT
B2 NN
site NN
of IN
proenkephalin NN
relatively RB
better JJR
than IN
does VBZ
the DT
heterotetramer NN
( O
two CD
p65s NNS
plus CC
two CD
p50s NNS
) O
form NN
of IN
the DT
factor NN
. O

Thus RB
, O
it PRP
appears VBZ
that IN
the DT
T-cell-specific JJ
activation NN
of IN
the DT
proenkephalin NN
promoter NN
is VBZ
mediated VBN
by IN
NF-kappa NN
B NN
. O

However RB
, O
as IN
NF-kappa NN
B NN
is VBZ
ubiquitous JJ
and CC
the DT
transcriptional JJ
activation NN
through IN
the DT
B2 NN
site NN
is VBZ
T NN
cell NN
specific JJ
, O
yet RB
another DT
T-cell-specific JJ
factor NN
which WDT
synergizes VBZ
with IN
NF-kappa NN
B NN
should MD
be VB
considered VBN
. O

Expression NN
of IN
c-jun NN
, O
jun NN
B NN
and CC
jun NN
D NN
proto-oncogenes NNS
in IN
human JJ
peripheral-blood JJ
granulocytes NNS
. O

We PRP
have VBP
found VBN
that IN
purified VBN
human JJ
peripheral-blood JJ
granulocytes NNS
express VBP
constitutively RB
significant JJ
levels NNS
of IN
proto-oncogenes NNS
c-jun NN
, O
jun NN
B NN
and CC
jun NN
D NN
mRNA NN
. O

Upon IN
functional JJ
activation NN
of IN
granulocytes NNS
by IN
4 CD
beta-phorbol NN
12-myristate NN
13-acetate NN
( O
PMA NN
) O
, O
the DT
levels NNS
of IN
c-jun NN
, O
jun NN
B NN
and CC
jun NN
D NN
transcripts NNS
were VBD
increased VBN
. O

The DT
three CD
jun NN
genes NNS
showed VBD
a DT
similar JJ
time NN
course NN
in IN
their PRP$
induction NN
by IN
PMA NN
, O
maximal JJ
mRNA NN
levels NNS
being VBG
reached VBN
after IN
60 CD
min NN
of IN
induction NN
. O

These DT
results NNS
suggest VBP
that IN
expression NN
of IN
c-jun NN
, O
jun NN
B NN
and CC
jun NN
D NN
genes NNS
might MD
be VB
involved VBN
in IN
terminal JJ
granulocyte NN
differentiation NN
or CC
in IN
regulating VBG
granulocyte NN
functionality NN
. O

Platelet-activating JJ
factor NN
induces VBZ
phospholipid JJ
turnover NN
, O
calcium NN
flux NN
, O
arachidonic JJ
acid NN
liberation NN
, O
eicosanoid NN
generation NN
, O
and CC
oncogene JJ
expression NN
in IN
a DT
human JJ
B NN
cell NN
line NN
. O

Platelet-activating JJ
factor NN
is VBZ
a DT
potent JJ
mediator NN
of IN
the DT
inflammatory JJ
response NN
. O

Studies NNS
of IN
the DT
actions NNS
of IN
platelet-activating JJ
factor NN
have VBP
centered VBN
mainly RB
around IN
neutrophils NNS
, O
monocytes NNS
, O
and CC
platelets NNS
. O

In IN
this DT
report NN
we PRP
begin VBP
to TO
uncover VB
the DT
influence NN
of IN
platelet-activating NN
factor NN
on IN
B NN
lymphocytes NNS
. O

Employing VBG
the DT
EBV-transformed JJ
human JJ
B NN
cell NN
line NN
SKW6.4 NN
, O
we PRP
demonstrate VBP
that IN
platelet-activating JJ
factor NN
significantly RB
alters VBZ
membrane NN
phospholipid JJ
metabolism NN
indicated VBN
by IN
the DT
incorporation NN
of IN
32P NN
into IN
phosphatidylcholine NN
, O
phosphatidylinositol NN
, O
and CC
phosphatidic JJ
acid NN
but CC
not RB
significantly RB
into IN
phosphatidylethanolamine NN
at IN
concentrations NNS
ranging VBG
from IN
10(-9) CD
to TO
10(-6) CD
M NN
. O

The DT
inactive JJ
precursor NN
, O
lyso-platelet-activating JJ
factor NN
, O
at IN
a DT
concentration NN
as RB
high JJ
as IN
10(-7) CD
M NN
had VBD
no DT
effect NN
on IN
any DT
of IN
the DT
membrane NN
phospholipids NNS
. O

We PRP
also RB
show VBP
that IN
platelet-activating JJ
factor NN
from IN
10(-12) CD
to TO
10(-6) CD
M NN
induced VBD
rapid JJ
and CC
significant JJ
elevation NN
in IN
intracellular JJ
calcium NN
levels NNS
, O
whereas IN
lyso-platelet-activating JJ
factor NN
was VBD
again RB
ineffective JJ
. O

We PRP
further RB
demonstrate VBP
the DT
impact NN
of IN
platelet-activating JJ
factor NN
binding VBG
to TO
B NN
cells NNS
by IN
measuring VBG
platelet-activating JJ
factor NN
induced JJ
arachidonic JJ
acid NN
release NN
and CC
5-hydroxyeicosatetraenoic JJ
acid NN
production NN
. O

Moreover RB
, O
platelet-activating JJ
factor NN
was VBD
capable JJ
of IN
inducing VBG
transcription NN
of IN
the DT
nuclear JJ
proto-oncogenes NNS
c-fos NN
and CC
c-jun NN
. O

Finally RB
we PRP
explored VBD
the DT
possible JJ
role NN
of IN
5-hydroxyeicosatetraenoic JJ
acid NN
as IN
a DT
regulator NN
of IN
arachidonic JJ
acid NN
liberation NN
demonstrating VBG
that IN
endogenous JJ
5-lipoxygenase NN
activity NN
modulates VBZ
platelet-activating JJ
factor NN
induced JJ
arachidonic JJ
acid NN
release NN
perhaps RB
acting VBG
at IN
the DT
level NN
of IN
phospholipase NN
A2 NN
. O

In IN
summary NN
, O
platelet-activating JJ
factor NN
is VBZ
shown VBN
here RB
to TO
have VB
a DT
direct JJ
and CC
profound JJ
effect NN
on IN
a DT
pure JJ
B NN
cell NN
line NN
. O

A DT
novel JJ
HIV-1 NN
isolate JJ
containing VBG
alterations NNS
affecting VBG
the DT
NF-kappa NN
B NN
element NN
. O

Three CD
molecular JJ
clones NNS
of IN
HIV-1 NN
, O
derived VBN
from IN
a DT
single JJ
isolate NN
( O
AL1 NN
) O
, O
exhibited VBD
distinct JJ
replicative JJ
and CC
cytopathic JJ
properties NNS
during IN
propagation NN
in IN
a DT
human JJ
T NN
cell NN
line NN
. O

The DT
phenotypic JJ
differences NNS
observed VBN
were VBD
attributable JJ
, O
in IN
large JJ
part NN
, O
to TO
changes NNS
affecting VBG
the DT
viral JJ
LTR NN
. O

Nucleotide NN
sequence NN
and CC
PCR NN
analyses NNS
demonstrated VBD
the DT
presence NN
of IN
novel JJ
duplications NNS
or CC
deletions NNS
involving VBG
the DT
NF-kappa NN
B NN
motif NN
. O

These DT
changes NNS
in IN
the DT
enhancer NN
element NN
were VBD
identified VBN
in IN
the DT
original JJ
AL1 NN
virus NN
stock NN
. O

Subcloning NN
of IN
the DT
variant JJ
NF-kappa NN
B NN
segments NNS
into IN
LTR-driven JJ
CAT NN
expression NN
vectors NNS
confirmed VBD
a DT
correlation NN
between IN
promoter JJ
activity NN
and CC
replicative/cytopathic JJ
capacity NN
. O

1,25-Dihydroxyvitamin NN
D3 NN
receptor NN
RNA NN
: O
expression NN
in IN
hematopoietic JJ
cells NNS
. O

1,25-Dihydroxyvitamin NN
D3 NN
( O
1,25(OH)2D3 NN
) O
induces VBZ
differentiation NN
and CC
inhibits VBZ
proliferation NN
of IN
myeloid JJ
leukemic JJ
cells NNS
from IN
various JJ
lines NNS
and CC
patients NNS
; O
these DT
effects NNS
are VBP
probably RB
mediated VBN
through IN
the DT
1,25(OH)2D3 NN
receptor NN
. O

Little JJ
is VBZ
known VBN
of IN
expression NN
of IN
1,25(OH)2D3 NN
receptor NN
RNA NN
in IN
hematopoietic JJ
cells NNS
. O

We PRP
examined VBD
the DT
expression NN
and CC
modulation NN
of IN
expression NN
of IN
1,25(OH)2D3 NN
receptor NN
RNA NN
in IN
various JJ
proliferating VBG
and CC
nonproliferating JJ
hematopoietic JJ
cells NNS
. O

Constitutive JJ
expression NN
of IN
1,25(OH)2D3 NN
receptor NN
RNA NN
was VBD
detected VBN
in IN
various JJ
kinds NNS
of IN
hematopoietic JJ
cells NNS
, O
including VBG
macrophages NNS
and CC
activated VBN
T NN
lymphocytes NNS
, O
as RB
well RB
as IN
in IN
cell NN
lines NNS
KG-1 NN
( O
myeloblasts NNS
) O
, O
HL-60 NN
( O
promyelocytes NNS
) O
, O
ML-3 NN
( O
myelomonoblasts NNS
) O
, O
U937 NN
, O
THP-1 NN
( O
monoblasts NNS
) O
, O
K562 NN
( O
erythroblasts NNS
) O
, O
and CC
S-LB1 NN
( O
HTLV-1-transfected JJ
T NN
lymphocytes NNS
) O
. O

Receptor NN
transcripts NNS
were VBD
4.6 CD
kilobases NNS
( O
kb NN
) O
, O
and CC
no DT
variant JJ
sizes NNS
were VBD
observed VBN
. O

All DT
cell NN
lines NNS
examined VBN
in IN
this DT
group NN
also RB
expressed VBD
1,25(OH)2D3 NN
receptors NNS
. O

Most JJS
B NN
lymphocyte NN
lines NNS
expressed VBD
negligible JJ
levels NNS
of IN
1,25(OH)2D3 NN
receptor NN
RNA NN
and CC
protein NN
; O
however RB
; O
analysis NN
of IN
a DT
lymphoid/myeloid JJ
somatic JJ
hybrid NN
suggested VBD
that IN
suppression NN
of IN
expression NN
of IN
1,25(OH)2D3 NN
receptor NN
RNA NN
in IN
B NN
lymphocytes NNS
may MD
be VB
a DT
dominant JJ
characteristic NN
. O

HL-60 NN
cells NNS
were VBD
cultured VBN
with IN
10(-7) CD
mol/L NN
1,25(OH)2D3 NN
for IN
24 CD
to TO
72 CD
hours NNS
, O
and CC
levels NNS
of IN
expression NN
of IN
1,25(OH)2D3 NN
receptor NN
and CC
its PRP$
RNA NN
were VBD
examined VBN
. O

Levels NNS
of IN
RNA NN
coding NN
for IN
the DT
receptor NN
were VBD
not RB
modulated VBN
by IN
exposure NN
to TO
high JJ
levels NNS
of IN
ligand NN
. O

Levels NNS
of IN
occupied VBN
1,25(OH)2D3 NN
receptor NN
protein NN
increased VBD
in IN
these DT
HL-60 NN
cells NNS
; O
but CC
the DT
total JJ
number NN
of IN
1,25(OH)2D3 NN
receptors NNS
decreased VBD
about RB
50 CD
% NN
at IN
24 CD
hours NNS
and CC
returned VBD
toward IN
normal JJ
at IN
72 CD
hours NNS
. O

Steady-state JJ
levels NNS
of IN
1,25(OH)2D3 NN
receptor NN
RNA NN
were VBD
not RB
affected VBN
by IN
terminal JJ
differentiation NN
of IN
HL-60 NN
toward IN
either CC
granulocytes NNS
or CC
macrophages NNS
. O

Nondividing JJ
macrophages NNS
from IN
normal JJ
individuals NNS
also RB
expressed VBD
1,25(OH)2D3 NN
receptor NN
RNA NN
. O

In IN
contrast NN
, O
nondividing JJ
peripheral JJ
blood NN
lymphocytes NNS
from IN
normal JJ
individuals NNS
did VBD
not RB
express VB
1,25(OH)2D3 NN
receptor NN
RNA NN
; O
with IN
stimulation NN
of IN
proliferation NN
of IN
these DT
cells NNS
, O
accumulation NN
of IN
1,25(OH)2D3 NN
receptor NN
RNA NN
increased VBD
markedly RB
. O

Half-life NN
( O
t1/2 NN
) O
of IN
1,25(OH)2D3 NN
receptor NN
RNA NN
in IN
T NN
lymphocytes NNS
was VBD
short JJ
( O
1 CD
hour NN
) O
as IN
determined VBN
by IN
measuring VBG
decay NN
of IN
the DT
message NN
after IN
addition NN
of IN
actinomycin NN
D NN
. O

Consistent JJ
with IN
this DT
short JJ
t1/2 NN
, O
accumulation NN
of IN
1,25(OH)2D3 NN
receptor NN
RNA NN
increased VBD
in IN
cells NNS
as IN
their PRP$
protein NN
synthesis NN
was VBD
inhibited VBN
. O

Further JJ
studies NNS
are VBP
required VBN
to TO
understand VB
the DT
physiologic JJ
role NN
of IN
1,25(OH)2D3 NN
receptors NNS
in IN
myeloid JJ
cells NNS
and CC
proliferating VBG
T NN
lymphocytes NNS
. O

Kappa NN
B NN
binding NN
proteins NNS
are VBP
constitutively RB
expressed VBN
in IN
an DT
IL-2 NN
autocrine NN
human JJ
T NN
cell NN
line NN
. O

The DT
IL-2 NN
and CC
the DT
IL-2-R NN
alpha NN
genes NNS
are VBP
both DT
expressed VBN
transiently RB
in IN
normal JJ
T NN
lymphocytes NNS
after IN
Ag NN
or CC
mitogen NN
activation NN
. O

In IN
contrast NN
, O
the DT
human JJ
T NN
cell NN
line NN
, O
IARC NN
301 CD
, O
expresses VBZ
these DT
two CD
genes NNS
constitutively RB
and CC
we PRP
have VBP
previously RB
demonstrated VBN
that IN
its PRP$
growth NN
depends VBZ
on IN
the DT
autocrine JJ
production NN
of IN
this DT
T NN
cell NN
growth NN
factor NN
and CC
high JJ
affinity NN
IL-2R NN
. O

To TO
dissect VB
the DT
molecular JJ
basis NN
for IN
the DT
unusual JJ
persistent JJ
expression NN
of IN
the DT
IL-2 NN
and CC
IL-2-R NN
alpha NN
genes NNS
in IN
these DT
IARC NN
301 CD
T NN
cells NNS
, O
we PRP
have VBP
analyzed VBN
the DT
interactions NNS
of IN
constitutively RB
expressed VBN
nuclear JJ
proteins NNS
with IN
the DT
5' JJ
flanking JJ
regions NNS
of IN
the DT
IL-2 NN
and CC
IL-2-R NN
alpha NN
genes NNS
using VBG
both DT
DNase NN
I CD
footprinting NN
and CC
gel NN
retardation NN
techniques NNS
. O

We PRP
have VBP
found VBN
that IN
a DT
region NN
in IN
both DT
genes NNS
( O
-276 CD
to TO
-250 CD
for IN
IL-2-R NN
alpha NN
and CC
-203 CD
to TO
-183 CD
for IN
IL-2 NN
) O
, O
which WDT
corresponds VBZ
to TO
a DT
kappa NN
B NN
enhancer NN
element NN
, O
is VBZ
specifically RB
protected VBN
by IN
nuclear JJ
proteins NNS
from IN
IARC NN
301 CD
. O

In IN
agreement NN
with IN
this DT
finding NN
, O
both CC
the DT
IL-2 NN
and CC
IL-2-R NN
alpha NN
promoters NNS
are VBP
active JJ
in IN
transient JJ
transfection NN
assays NNS
in IN
IARC NN
301 CD
cells NNS
. O

In IN
contrast NN
, O
mutation NN
of IN
the DT
kappa NN
B NN
enhancer NN
results VBZ
in IN
markedly RB
attenuated VBN
activities NNS
of IN
both DT
promoters NNS
. O

Two CD
proteins NNS
binding VBG
the DT
kappa NN
B NN
sequence NN
, O
NF-kappa NN
B NN
and CC
KBF1 NN
, O
are VBP
constitutively RB
expressed VBN
in IN
IARC NN
301 CD
nuclei NNS
and CC
induced VBN
by IN
PMA NN
and CC
PHA NN
in IN
Jurkat NN
. O

They PRP
bind VBP
to TO
the DT
kappa NN
B NN
motifs NNS
with IN
different JJ
relative JJ
affinities NNS
that WDT
may MD
reflect VB
their PRP$
different JJ
contribution NN
in IN
the DT
expression NN
of IN
various JJ
promoters NNS
. O

The DT
functional JJ
domains NNS
of IN
the DT
murine JJ
Thy-1 NN
gene NN
promoter NN
. O

The DT
Thy-1 NN
gene NN
promoter NN
resembles VBZ
a DT
" [[DQS]]
housekeeping JJ
" [[DQE]]
promoter NN
in IN
that IN
it PRP
is VBZ
located JJ
within IN
a DT
methylation-free JJ
island NN
, O
lacks VBZ
a DT
canonical JJ
TATA NN
box NN
, O
and CC
displays VBZ
heterogeneity NN
in IN
the DT
5'-end JJ
termini NNS
of IN
the DT
mRNA NN
. O

Using VBG
transgenic JJ
mice NNS
, O
we PRP
show VBP
that IN
this DT
promoter NN
does VBZ
not RB
confer VB
any DT
tissue NN
specificity NN
and CC
is VBZ
active JJ
only RB
in IN
a DT
position-dependent JJ
manner NN
. O

It PRP
can MD
only RB
be VB
activated VBN
in IN
a DT
tissue-specific JJ
manner NN
by IN
elements NNS
that WDT
lie VBP
downstream RB
of IN
the DT
initiation NN
site NN
. O

We PRP
have VBP
analyzed VBN
the DT
functional JJ
domains NNS
of IN
the DT
minimal JJ
Thy-1 NN
promoter NN
and CC
show VB
that IN
the DT
dominant JJ
promoter NN
elements NNS
consist VBP
of IN
multiple JJ
binding VBG
sites NNS
for IN
the DT
transcription NN
factor NN
Sp1 NN
, O
an DT
inverted JJ
CCAAT NN
box NN
, O
and CC
sequences VBZ
proximal JJ
to TO
the DT
transcription NN
start NN
site NN
. O

DNase NN
I CD
and CC
gel NN
mobility NN
shift NN
assays NNS
show VBP
the DT
binding NN
of IN
a DT
number NN
of IN
nuclear JJ
factors NNS
to TO
these DT
elements NNS
, O
including VBG
Sp1 NN
and CC
CP1 NN
. O

Our PRP$
results NNS
show VBP
that IN
the DT
structure NN
of IN
this DT
promoter NN
only RB
permits VBZ
productive JJ
interactions NNS
of IN
the DT
two CD
transcription NN
factors NNS
Sp1 NN
and CC
CP1 NN
with IN
the DT
basal JJ
transcription NN
machinery NN
in IN
the DT
presence NN
of IN
enhancer NN
sequences NNS
. O

Comparison NN
of IN
constitutive JJ
and CC
inducible JJ
transcriptional JJ
enhancement NN
mediated VBN
by IN
kappa NN
B-related JJ
sequences NNS
: O
modulation NN
of IN
activity NN
in IN
B NN
cells NNS
by IN
human JJ
T-cell NN
leukemia NN
virus NN
type NN
I CD
tax NN
gene NN
. O

The DT
kappa NN
B NN
sequence NN
( O
GGGACTTTCC NN
) O
binds VBZ
a DT
factor NN
, O
NF-kappa NN
B NN
, O
that WDT
is VBZ
constitutively RB
found VBN
in IN
its PRP$
functional JJ
, O
DNA NN
binding NN
form NN
only RB
in IN
B NN
lymphocytes NNS
. O

A DT
factor NN
with IN
apparently RB
indistinguishable JJ
sequence NN
specificity NN
can MD
be VB
induced VBN
in IN
many JJ
other JJ
cell NN
types NNS
, O
where WRB
it PRP
is VBZ
used VBN
to TO
regulate VB
inducible JJ
gene NN
expression NN
. O

For IN
example NN
, O
kappa NN
B-related JJ
sequences NNS
have VBP
been VBN
shown VBN
to TO
be VB
important JJ
for IN
the DT
transcription NN
of IN
a DT
few JJ
inducible JJ
genes NNS
, O
such JJ
as IN
the DT
interleukin NN
2 CD
receptor NN
alpha-chain NN
gene NN
and CC
the DT
beta-interferon NN
gene NN
. O

However RB
, O
these DT
genes NNS
are VBP
not RB
constitutively RB
active JJ
in IN
B NN
lymphocytes NNS
, O
suggesting VBG
that IN
other JJ
regulatory JJ
mechanisms NNS
must MD
play VB
a DT
role NN
in IN
determining VBG
the DT
patterns NNS
of IN
expression NN
. O

We PRP
have VBP
investigated VBN
the DT
constitutive JJ
and CC
inducible JJ
transcriptional JJ
activity NN
mediated VBN
by IN
five CD
kappa NN
B-related JJ
sequence NN
elements NNS
in IN
two CD
different JJ
cell NN
types NNS
. O

We PRP
show VBP
that IN
in IN
S194 NN
plasma NN
cells NNS
the DT
activity NN
of IN
each DT
element NN
correlates VBZ
well RB
with IN
the DT
relative JJ
affinity NN
of IN
B-cell-derived JJ
NF-kappa NN
B NN
for IN
that DT
element NN
. O

This DT
leads VBZ
to TO
significantly RB
lower RBR
transcription NN
enhancement NN
by IN
sites NNS
derived VBN
from IN
the DT
interleukin NN
2 CD
receptor NN
or CC
T-cell NN
receptor NN
genes NNS
in IN
S194 NN
cells NNS
. O

However RB
, O
in IN
either CC
EL-4 NN
( O
T NN
) O
cells NNS
or CC
S194 NN
cells NNS
, O
both DT
lower-affinity JJ
sites NNS
can MD
be VB
significantly RB
induced VBN
by IN
the DT
tax NN
gene NN
product NN
of IN
human JJ
T-cell NN
leukemia NN
virus NN
type NN
I CD
, O
showing VBG
that IN
NF-kappa NN
B NN
activity NN
can MD
be VB
modulated VBN
even RB
in IN
a DT
B-cell NN
line NN
that WDT
constitutively RB
expresses VBZ
this DT

Isolation NN
of IN
a DT
rel-related JJ
human JJ
cDNA NN
that WDT
potentially RB
encodes VBZ
the DT
65-kD JJ
subunit NN
of IN
NF-kappa NN
B NN
( O
published VBN
erratum NN
appears VBZ
in IN
Science NNP
1991 CD
Oct NNP
4 CD
; O
254 CD
( O
5028 CD
) O
: O
11 CD
) O

A DT
DNA NN
probe NN
that WDT
spanned VBD
a DT
domain NN
conserved VBN
among IN
the DT
proto-oncogene NN
c-rel NN
, O
the DT
Drosophila NN
morphogen NN
dorsal NN
, O
and CC
the DT
p50 NN
DNA NN
binding NN
subunit NN
of IN
NF-kappa NN
B NN
was VBD
generated VBN
from IN
Jurkat NN
T NN
cell NN
complementary JJ
DNA NN
with IN
the DT
polymerase NN
chain NN
reaction NN
( O
PCR NN
) O
and CC
degenerate JJ
oligonucleotides NNS
. O

This DT
probe NN
was VBD
used VBN
to TO
identify VB
a DT
rel-related JJ
complementary JJ
DNA NN
that WDT
hybridized VBD
to TO
a DT
2.6-kilobase JJ
messenger NN
RNA NN
present JJ
in IN
human JJ
T NN
and CC
B NN
lymphocytes NNS
. O

In FW
vitro FW
transcription NN
and CC
translation NN
of IN
the DT
complementary JJ
DNA NN
resulted VBD
in IN
the DT
synthesis NN
of IN
a DT
protein NN
with IN
an DT
apparent JJ
molecular JJ
size NN
of IN
65 CD
kilodaltons NNS
( O
kD NN
) O
. O

The DT
translated VBN
protein NN
showed VBD
weak JJ
DNA NN
binding NN
with IN
a DT
specificity NN
for IN
the DT
kappa NN
B NN
binding VBG
motif NN
. O

This DT
protein-DNA JJ
complex JJ
comigrated VBN
with IN
the DT
complex NN
obtained VBN
with IN
the DT
purified VBN
human JJ
p65 NN
NF-kappa NN
B NN
subunit NN
and CC
binding NN
was VBD
inhibited VBN
by IN
I NN
kappa NN
B-alpha NN
and CC
-beta NN
proteins NNS
. O

In IN
addition NN
, O
the DT
65-kD JJ
protein NN
associated VBN
with IN
the DT
p50 NN
subunit NN
of IN
NF-kappa NN
B NN
and CC
the DT
kappa NN
B NN
probe NN
to TO
form VB
a DT
complex NN
with IN
the DT
same JJ
electrophoretic JJ
mobility NN
as IN
the DT
NF-kappa NN
B-DNA JJ
complex NN
. O

Therefore RB
the DT
rel-related JJ
65-kD JJ
protein NN
may MD
represent VB
the DT
p65 NN
subunit NN
of IN
the DT
active JJ
NF-kappa NN
B NN
transcription NN
factor NN
complex NN
. O

Lymphocyte NN
glucocorticoid NN
receptor NN
number NN
in IN
posttraumatic JJ
stress NN
disorder NN
. O

OBJECTIVE NN
: O
The DT
authors NNS
' POS
objective NN
was VBD
to TO
investigate VB
the DT
possibility NN
that IN
glucocorticoid NN
receptor NN
changes NNS
may MD
be VB
involved VBN
in IN
the DT
dysregulation NN
of IN
the DT
hypothalamic-pituitary-adrenal JJ
( O
HPA JJ
) O
axis NN
in IN
posttraumatic JJ
stress NN
disorder NN
( O
PTSD NN
) O
. O

METHOD NN
: O
They PRP
measured VBD
the DT
number NN
of IN
lymphocyte NN
cytosolic JJ
glucocorticoid NN
receptors NNS
and CC
plasma NN
cortisol NN
concentrations NNS
in IN
15 CD
consecutively RB
admitted VBN
male JJ
combat NN
Vietnam NN
veterans NNS
with IN
PTSD NN
and CC
in IN
a DT
normal JJ
comparison NN
group NN
of IN
11 CD
subjects NNS
. O

RESULTS NNS
: O
Both CC
the DT
patients NNS
and CC
the DT
normal JJ
comparison NN
subjects NNS
showed VBD
a DT
morning-to-afternoon JJ
decline NN
in IN
glucocorticoid NN
receptor NN
concentrations NNS
, O
paralleling VBG
the DT
normal JJ
diurnal JJ
decline NN
in IN
cortisol NN
levels NNS
. O

The DT
number NN
of IN
glucocorticoid NN
receptors NNS
was VBD
63 CD
% NN
greater JJR
in IN
the DT
morning NN
and CC
26 CD
% NN
greater JJR
in IN
the DT
afternoon NN
in IN
the DT
patients NNS
with IN
PTSD NN
than IN
in IN
the DT
normal JJ
subjects NNS
. O

No DT
group NN
differences NNS
in IN
cortisol NN
levels NNS
were VBD
observed VBN
, O
nor CC
were VBD
glucocorticoid NN
receptor NN
number NN
and CC
cortisol NN
levels NNS
correlated VBD
. O

The DT
number NN
of IN
morning NN
glucocorticoid NN
receptors NNS
was VBD
positively RB
correlated VBN
with IN
symptoms NNS
of IN
PTSD NN
and CC
anxiety NN
. O

CONCLUSIONS NNS
: O
These DT
results NNS
provide VBP
further JJ
evidence NN
for IN
a DT
dysregulation NN
of IN
the DT
HPA JJ
axis NN
in IN
PTSD NN
. O

The DT
finding NN
that IN
patients NNS
with IN
PTSD NN
had VBD
a DT
substantially RB
greater JJR
number NN
of IN
lymphocyte NN
glucocorticoid NN
receptors NNS
than IN
normal JJ
comparison NN
subjects NNS
is VBZ
consistent JJ
with IN
the DT
authors NNS
' POS
previous JJ
observations NNS
of IN
low JJ
24-hour JJ
urinary JJ
cortisol NN
excretion NN
in IN
subjects NNS
with IN
PTSD NN
. O

Furthermore RB
, O
the DT
receptor NN
changes NNS
observed VBN
are VBP
opposite JJ
of IN
those DT
reported VBN
in IN
major JJ
depressive JJ
disorder NN
. O

The DT
present JJ
data NNS
, O
along IN
with IN
other JJ
findings NNS
of IN
HPA JJ
abnormalities NNS
in IN
PTSD NN
, O
support VBP
the DT
possibility NN
of IN
a DT
greater JJR
negative JJ
feedback NN
sensitivity NN
at IN
one CD
or CC
more JJR
levels NNS
of IN
the DT
HPA JJ
axis NN
. O

A DT
thymus-specific JJ
member NN
of IN
the DT
HMG NN
protein NN
family NN
regulates VBZ
the DT
human JJ
T NN
cell NN
receptor NN
C NN
alpha NN
enhancer NN
. O

The DT
human JJ
T NN
cell-specific JJ
transcription NN
factor NN
TCF-1 NN
alpha NN
plays VBZ
a DT
key JJ
role NN
in IN
the DT
tissue-specific JJ
activation NN
of IN
the DT
T NN
cell NN
receptor NN
( O
TCR NN
) O
C NN
alpha NN
enhancer NN
and CC
binds VBZ
to TO
pyrimidine-rich JJ
elements NNS
( O
5'-PyCTTTG-3' NN
) O
present JJ
in IN
a DT
variety NN
of IN
other JJ
T NN
cell-specific JJ
control NN
regions NNS
. O

Using VBG
amino NN
acid NN
sequence NN
information NN
derived VBN
from IN
the DT
DNA NN
affinity-purified JJ
protein NN
, O
we PRP
have VBP
now RB
isolated VBN
cDNA NN
clones NNS
encoding VBG
TCF-1 NN
alpha NN
. O

The DT
TCF-1 NN
alpha NN
cDNA NN
contains VBZ
a DT
single JJ
68-amino-acid JJ
domain NN
that WDT
is VBZ
homologous JJ
to TO
a DT
region NN
conserved VBN
among IN
high-mobility JJ
group NN
( O
HMG NN
) O
and CC
nonhistone JJ
chromosomal JJ
proteins NNS
. O

Expression NN
of IN
full-length JJ
and CC
mutant JJ
cDNA NN
clones NNS
in IN
bacteria NNS
reveal VBP
that IN
the DT
single JJ
HMG NN
motif NN
, O
which WDT
is VBZ
predicted VBN
to TO
contain VB
two CD
extended VBN
alpha-helical JJ
segments NNS
, O
is VBZ
sufficient JJ
to TO
direct VB
the DT
sequence-specific JJ
binding NN
of IN
TCF-1 NN
alpha NN
to TO
DNA NN
. O

Northern NN
blot NN
experiments NNS
demonstrate VBP
further RBR
that IN
TCF-1 NN
alpha NN
mRNA NN
is VBZ
highly RB
tissue NN
specific JJ
, O
found VBN
primarily RB
in IN
the DT
thymus NN
or CC
T NN
cell NN
lines NNS
. O

The DT
immature JJ
CEM NN
T NN
cell NN
line NN
expresses VBZ
relatively RB
low JJ
levels NNS
of IN
TCF-1 NN
alpha NN
mRNA NN
, O
which WDT
are VBP
increased VBN
upon IN
activation NN
of IN
these DT
cells NNS
by IN
phorbol NN
esters NNS
. O

Interestingly RB
, O
the DT
cloned VBN
TCF-1 NN
alpha NN
protein NN
is VBZ
a DT
potent JJ
transcriptional JJ
activator NN
of IN
the DT
human JJ
TCR NN
alpha NN
enhancer NN
in IN
nonlymphoid JJ
cell NN
lines NNS
, O
whereas IN
the DT
activity NN
of IN
the DT
endogenous JJ
protein NN
in IN
T NN
cell NN
lines NNS
is VBZ
strongly RB
dependent JJ
on IN
an DT
additional JJ
T NN
cell-specific JJ
protein NN
that WDT
interacts VBZ
with IN
the DT
core NN
enhancer NN
. O

TCF-1 NN
alpha NN
is VBZ
currently RB
unique JJ
among IN
the DT
newly RB
emerging VBG
family NN
of IN
DNA-binding JJ
regulatory JJ
proteins NNS
that WDT
share VBP
the DT
HMG NN
motif NN
in IN
that IN
it PRP
is VBZ
a DT
highly RB
tissue-specific JJ
RNA NN
polymerase NN
II CD
transcription NN
factor NN
. O

Immune JJ
response NN
of IN
peripheral JJ
blood NN
mononuclear JJ
cells NNS
to TO
HBx-antigen NN
of IN
hepatitis NN
B NN
virus NN
. O

The DT
hepatitis NN
B NN
virus NN
genome NN
encodes VBZ
a DT
transcriptional JJ
transactivator NN
protein NN
designated VBN
HBxAg NN
. O

We PRP
have VBP
investigated VBN
whether IN
this DT
antigen NN
is VBZ
a DT
target NN
structure NN
for IN
human JJ
T-lymphocytes NNS
. O

Using VBG
recombinant JJ
HBxAg NN
protein NN
, O
we PRP
found VBD
HBxAg-specific JJ
stimulation NN
of IN
peripheral JJ
blood NN
mononuclear JJ
cells NNS
in IN
patients NNS
with IN
acute JJ
hepatitis NN
B NN
virus NN
infection NN
( O
6 CD
of IN
6 CD
) O
and CC
chronic JJ
hepatitis NN
B NN
virus NN
infection NN
( O
6 CD
of IN
17 CD
) O
but CC
not RB
in IN
healthy JJ
individuals NNS
. O

With IN
HBxAg-specific JJ
synthetic JJ
polypeptides NNS
, O
several JJ
T-cell NN
epitopes NNS
were VBD
identified VBN
. O

Most JJS
were VBD
located JJ
in IN
the DT
carboxyterminal JJ
half NN
of IN
the DT
HBxAg NN
protein NN
. O

Five CD
T-cell NN
clones NNS
specific JJ
for IN
a DT
T-cell NN
epitope NN
located JJ
at IN
the DT
carboxyterminal JJ
region NN
of IN
HBxAg NN
were VBD
established VBN
and CC
found VBN
to TO
belong VB
to TO
the DT
CD2/CD4-positive JJ
, O
CD8-negative JJ
subtype NN
. O

These DT
data NNS
establish VBP
for IN
the DT
first JJ
time NN
HBxAg NN
as IN
an DT
antigen NN
in IN
the DT
cellular JJ
immune JJ
response NN
. O

A DT
study NN
on IN
the DT
circadian JJ
rhythm NN
of IN
glucocorticoid NN
receptor NN
. O

Circadian JJ
rhythm NN
in IN
glucocorticoid NN
receptor NN
( O
GR NN
) O
was VBD
studied VBN
in IN
the DT
rat NN
liver NN
and CC
human JJ
peripheral JJ
leukocytes NNS
. O

For IN
rats NNS
exposed VBN
to TO
a DT
natural JJ
environmental JJ
photic JJ
cycle NN
or CC
a DT
12L NN
: O
12D NN
artificial JJ
light NN
regime NN
, O
peak JJ
values NNS
of IN
hepatic JJ
GR NN
were VBD
detected VBN
between IN
23:00 CD
and CC
02:00 CD
h NN
. O

Except IN
for IN
a DT
4-hour JJ
advancement NN
of IN
the DT
peak NN
, O
a DT
similar JJ
circadian JJ
rhythm NN
of IN
hepatic JJ
GR NN
was VBD
detected VBN
in IN
rats NNS
reared VBN
under IN
a DT
reversed VBN
lighting NN
regimen NNS
( O
12D NN
: O
12L NN
; O
lights NNS
on IN
between IN
18:30 CD
and CC
06:30 CD
h NN
) O
. O

In IN
human JJ
leukocytes NNS
, O
the DT
peak JJ
value NN
of IN
GR NN
was VBD
found VBN
to TO
parallel VB
that DT
of IN
plasma NN
cortisol NN
with IN
high JJ
and CC
low JJ
values NNS
detected VBN
at IN
04:00-08:00 CD
h NN
and CC
23:00-24:00 CD
h NN
, O
respectively RB
. O

In IN
patients NNS
suffering VBG
from IN
Cushing NN
's POS
syndrome NN
, O
the DT
circadian JJ
rhythm NN
of IN
plasma NN
cortisol NN
either CC
disappeared VBD
or CC
was VBD
inverted VBN
while IN
that DT
of IN
GR NN
did VBD
not RB
significantly RB
deviate VB
from IN
the DT
normal JJ
subjects NNS
. O

For IN
apoplexic JJ
patients NNS
with IN
lesions NNS
localized JJ
to TO
the DT
base NN
of IN
the DT
brain NN
as IN
indicated VBN
by IN
computerized VBN
tomography NN
, O
the DT
diurnal JJ
variation NN
of IN
GR NN
was VBD
abolished VBN
. O

Conversely RB
, O
diurnal JJ
rhythmicity NN
persisted VBD
in IN
apoplexy NN
patients NNS
whose WP$
lesions NNS
were VBD
in IN
the DT
cerebral JJ
cortex NN
. O

Thus RB
, O
we PRP
postulated VBD
that IN
the DT
circadian JJ
modification NN
of IN
GR NN
was VBD
independent JJ
of IN
the DT
diurnal JJ
fluctuations NNS
in IN
plasma NN
cortisol NN
level NN
or CC
the DT
circadian JJ
variations NNS
in IN
environmental JJ
lighting NN
and CC
that IN
the DT
rhythmicity NN
might MD
be VB
regulated VBN
by IN
the DT
' [[DQS]]
circadian JJ
pacemaker NN
' [[DQE]]
located JJ
in IN
the DT
human JJ
basal JJ
brain NN
. O

These DT
diurnal JJ
variations NNS
in IN
GR NN
might MD
serve VB
to TO
coordinate VB
the DT
reactivity NN
of IN
the DT
target NN
cells NNS
to TO
cortisol NN
because IN
the DT
diurnal JJ
rhythms NNS
of IN
a DT
GR-mediated JJ
response NN
, O
the DT
fractional JJ
inhibition NN
of IN
chemotactic JJ
migration NN
rate NN
of IN
polymorphonuclear JJ
leukocytes NNS
by IN
cortisol NN
, O
were VBD
found VBN
to TO
be VB
synchronous JJ
with IN
those DT
of IN
GR NN
. O

Multiple JJ
Oct2 NN
isoforms NNS
are VBP
generated VBN
by IN
alternative JJ
splicing NN
. O

The DT
interaction NN
of IN
the DT
Oct2 NN
transcription NN
factor NN
with IN
the DT
cognate JJ
octamer NN
motif NN
ATGCAAAT NN
is VBZ
a DT
critical JJ
determinant NN
of IN
the DT
lymphoid-specific JJ
expression NN
of IN
immunoglobulin NN
genes NNS
. O

Ectopic JJ
expression NN
of IN
cloned VBN
Oct2 NN
cDNA NN
was VBD
shown VBN
to TO
be VB
sufficient JJ
to TO
reconstitute VB
at IN
least JJS
some DT
aspects NNS
of IN
this DT
regulation NN
in IN
non-lymphoid JJ
cells NNS
. O

We PRP
describe VBP
the DT
isolation NN
and CC
characterization NN
of IN
multiple JJ
cDNAs NNS
encoding VBG
mouse NN
Oct2 NN
from IN
a DT
mature JJ
B-cell NN
line NN
and CC
we PRP
show VBP
that IN
a DT
variety NN
of IN
isoforms NNS
of IN
this DT
transcription NN
factor NN
is VBZ
generated VBN
from IN
a DT
single JJ
gene NN
by IN
an DT
alternative JJ
splicing NN
mechanism NN
. O

All PDT
the DT
isoforms NNS
retain VBP
the DT
previously RB
characterized VBN
POU-domain NN
and CC
are VBP
therefore RB
able JJ
to TO
bind VB
to TO
the DT
octamer NN
motif NN
. O

Different JJ
amounts NNS
of IN
the DT
various JJ
isoforms NNS
are VBP
present JJ
within IN
the DT
same JJ
B-cell NN
regardless RB
of IN
the DT
developmental JJ
stage NN
of IN
B-cell NN
differentiation NN
and CC
at IN
least JJS
some DT
of IN
the DT
isoforms NNS
are VBP
conserved VBN
between IN
mouse NN
and CC
humans NNS
. O

In IN
cotransfection NN
experiments NNS
we PRP
show VBP
that IN
all PDT
the DT
isoforms NNS
are VBP
able JJ
to TO
activate VB
an DT
octamer NN
containing VBG
promoter NN
element NN
in IN
fibroblasts NNS
revealing VBG
an DT
unexpected JJ
functional JJ
redundancy NN
. O

Finally RB
, O
we PRP
show VBP
that IN
one CD
of IN
the DT
isoforms NNS
encodes VBZ
the DT
previously RB
described VBN
lymphoid-specific JJ
Oct2B NN
protein NN
which WDT
has VBZ
been VBN
suggested VBN
to TO
be VB
involved VBN
in IN
the DT
function NN
of IN
the DT
octamer NN
motif NN
in IN
the DT
context NN
of IN
the DT
immunoglobulin NN
heavy-chain NN
( O
IgH NN
) O
enhancer NN
. O

Murine JJ
and CC
human JJ
T-lymphocyte NN
GATA-3 NN
factors NNS
mediate VBP
transcription NN
through IN
a DT
cis-regulatory JJ
element NN
within IN
the DT
human JJ
T-cell NN
receptor NN
delta NN
gene NN
enhancer NN
. O

A DT
family NN
of IN
transcriptional JJ
activators NNS
has VBZ
recently RB
been VBN
identified VBN
in IN
chickens NNS
; O
these DT
transcriptional JJ
activators NNS
recognize VBP
a DT
common JJ
consensus NN
motif NN
( O
WGATAR NN
) O
through IN
a DT
conserved VBN
C4 NN
zinc NN
finger NN
DNA-binding JJ
domain NN
. O

One CD
of IN
the DT
members NNS
of IN
this DT
multigene JJ
family NN
, O
cGATA-3 NN
, O
is VBZ
most RBS
abundantly RB
expressed VBN
in IN
the DT
T-lymphocyte NN
cell NN
lineage NN
. O

Analysis NN
of IN
human JJ
and CC
murine JJ
GATA-3 NN
factors NNS
shows VBZ
a DT
striking JJ
degree NN
of IN
amino NN
acid NN
sequence NN
identity NN
and CC
similar JJ
patterns NNS
of IN
tissue NN
specificity NN
of IN
expression NN
in IN
these DT
three CD
organisms NNS
. O

The DT
murine JJ
and CC
human JJ
factors NNS
are VBP
abundantly RB
expressed VBN
in IN
a DT
variety NN
of IN
human JJ
and CC
murine JJ
T-cell NN
lines NNS
and CC
can MD
activate VB
transcription NN
through IN
a DT
tissue-specific JJ
GATA-binding JJ
site NN
identified VBN
within IN
the DT
human JJ
T-cell NN
receptor NN
delta NN
gene NN
enhancer NN
. O

We PRP
infer VBP
that IN
the DT
murine JJ
and CC
human JJ
GATA-3 NN
proteins NNS
play VBP
a DT
central JJ
and CC
highly RB
conserved VBN
role NN
in IN
vertebrate NN
T-cell-specific JJ
transcriptional JJ
regulation NN
. O

Processing NN
of IN
the DT
precursor NN
of IN
NF-kappa NN
B NN
by IN
the DT
HIV-1 NN
protease NN
during IN
acute JJ
infection NN
. O

Transcription NN
of IN
the DT
human JJ
immunodeficiency NN
virus NN
type-1 NN
( O
HIV-1 NN
) O
genome NN
is VBZ
regulated VBN
in IN
part NN
by IN
cellular JJ
factors NNS
and CC
is VBZ
stimulated VBN
by IN
activation NN
of IN
latently RB
infected JJ
T NN
cells NNS
. O

T-cell NN
activation NN
also RB
correlates VBZ
with IN
the DT
induction NN
of IN
the DT
factor NN
NF-kappa NN
B NN
which WDT
binds VBZ
to TO
two CD
adjacent JJ
sites NNS
in IN
the DT
HIV-1 NN
long JJ
terminal JJ
repeat NN
. O

This DT
factor NN
consists VBZ
of IN
two CD
DNA-binding JJ
subunits NNS
of IN
relative JJ
molecular JJ
mass NN
50,000 CD
( O
50K CD
) O
associated VBN
with IN
two CD
65K CD
subunits NNS
. O

It PRP
is VBZ
located JJ
in IN
the DT
nucleus NN
in IN
mature JJ
B NN
cells NNS
, O
but CC
is VBZ
present JJ
in IN
other JJ
cell NN
types NNS
as IN
an DT
inactive JJ
cytoplasmic JJ
complex NN
. O

External JJ
stimuli NNS
, O
including VBG
those DT
that WDT
activate VBP
T NN
cells NNS
, O
result VBP
in IN
nuclear JJ
translocation NN
of IN
active JJ
NF-kappa NN
B NN
. O

The DT
cloning NN
of IN
the DT
complementary JJ
DNA NN
for IN
the DT
50K CD
subunit NN
helped VBD
to TO
identify VB
an DT
exclusively RB
cytoplasmic JJ
105K CD
precursor NN
( O
p105 NN
) O
( O
V.B. NNP
, O
P.K. NNP
and CC
A.I. NNP
, O
manuscript NN
submitted VBN
) O
. O

The DT
expression NN
of IN
active JJ
NF-kappa NN
B NN
might MD
therefore RB
also RB
be VB
regulated VBN
by IN
the DT
extent NN
of IN
processing NN
of IN
p105 NN
. O

Because IN
HIV-1 NN
requires VBZ
active JJ
NF-kappa NN
B NN
for IN
efficient JJ
transcription NN
, O
we PRP
tested VBD
the DT
effect NN
of IN
HIV-1 NN
infection NN
on IN
the DT
processing NN
of IN
the DT
human JJ
105K CD
precursor NN
. O

We PRP
show VBP
here RB
that IN
the DT
HIV-1 NN
protease NN
can MD
process VB
p105 NN
and CC
increases VBZ
levels NNS
of IN
active JJ
nuclear JJ
NF-kappa NN
B NN
complex NN
. O

Vitamin NN
D NN
receptor NN
expression NN
in IN
human JJ
lymphocytes NNS
. O

Signal NN
requirements NNS
and CC
characterization NN
by IN
western NN
blots NNS
and CC
DNA NN
sequencing NN
. O

The DT
signals NNS
controlling VBG
the DT
expression NN
of IN
the DT
receptor NN
protein NN
for IN
1 CD
alpha,25-dihydroxyvitamin NN
D3 NN
in IN
normal JJ
human JJ
lymphocytes NNS
and CC
the DT
relationship NN
of IN
this DT
protein NN
to TO
the DT
classical JJ
vitamin NN
D NN
receptor NN
were VBD
examined VBN
. O

Lymphocytes NNS
activated VBN
with IN
the DT
OKT3 NN
antibody NN
to TO
the DT
T-cell NN
antigen NN
receptor NN
expressed VBD
fewer JJR
binding VBG
sites NNS
as IN
compared VBN
to TO
lymphocytes NNS
that WDT
were VBD
activated VBN
by IN
the DT
polyclonal JJ
activator NN
phytohemagglutinin NN
( O
PHA NN
) O
. O

However RB
, O
combination NN
of IN
OKT3 NN
and CC
phorbol NN
myristate NN
acetate NN
produced VBD
a DT
concentration NN
of IN
binding VBG
sites NNS
similar JJ
to TO
the DT
PHA-activated JJ
cells NNS
. O

The DT
receptor NN
from IN
OKT3 NN
and CC
OKT3 NN
+ CC
phorbol NN
myristate NN
acetate-activated JJ
lymphocytes NNS
exhibited VBD
decreased VBN
binding NN
to TO
DNA-cellulose NN
compared VBN
to TO
PHA-activated JJ
lymphocytes NNS
. O

In IN
lymphocytes NNS
activated VBN
either CC
by IN
PHA NN
or CC
OKT3 NN
( O
but CC
not RB
in IN
resting VBG
cells NNS
) O
, O
a DT
50-kDa JJ
species NNS
cross-reacting VBG
with IN
a DT
monoclonal JJ
antibody NN
against IN
the DT
intestinal JJ
vitamin NN
D NN
receptor NN
was VBD
detected VBN
. O

Finally RB
, O
RNA NN
from IN
activated VBN
lymphocytes NNS
was VBD
amplified VBN
by IN
polymerase NN
chain NN
reaction NN
using VBG
oligonucleotide NN
primers NNS
flanking VBG
the DT
196 CD
base NN
pair NN
long JJ
region NN
encoding VBG
the DT
DNA-binding JJ
domain NN
of IN
the DT
human JJ
intestinal JJ
receptor NN
. O

The DT
amplified VBN
product NN
showed VBD
an DT
identical JJ
nucleotide NN
sequence NN
to TO
the DT
DNA-binding JJ
domain NN
of IN
the DT
human JJ
intestinal JJ
receptor NN
. O

These DT
findings NNS
suggest VBP
that IN
expression NN
of IN
the DT
1,25-(OH)2D3 NN
receptor NN
in IN
lymphocytes NNS
is VBZ
triggered VBN
by IN
distinct JJ
and CC
contingent JJ
signals NNS
, O
and CC
that IN
the DT
protein NN
and CC
the DT
mRNA NN
encoding VBG
it PRP
are VBP
identical JJ
to TO
the DT
classical JJ
vitamin NN
D NN
receptor NN
. O

Cloning NN
of IN
murine JJ
TCF-1 NN
, O
a DT
T NN
cell-specific JJ
transcription NN
factor NN
interacting VBG
with IN
functional JJ
motifs NNS
in IN
the DT
CD3-epsilon NN
and CC
T NN
cell NN
receptor NN
alpha NN
enhancers NNS
. O

CD3-epsilon NN
gene NN
expression NN
is VBZ
confined VBN
to TO
the DT
T NN
cell NN
lineage NN
. O

We PRP
have VBP
recently RB
identified VBN
and CC
cloned VBN
a DT
human JJ
transcription NN
factor NN
, O
TCF-1 NN
, O
that WDT
binds VBZ
to TO
a DT
functional JJ
element NN
in IN
the DT
T NN
lymphocyte-specific JJ
enhancer NN
of IN
CD3-epsilon NN
. O

In IN
a DT
panel NN
of IN
human JJ
cell NN
lines NNS
, O
TCF-1 NN
expression NN
was VBD
restricted JJ
to TO
T NN
lineage NN
cells NNS
. O

TCF-1 NN
belonged VBD
to TO
a DT
novel JJ
family NN
of IN
genes NNS
that WDT
contain VBP
the DT
so-called JJ
high JJ
mobility NN
group NN
1 CD
( O
HMG NN
) O
box NN
. O

Here RB
we PRP
report VBP
the DT
cloning NN
of IN
murine JJ
TCF-1 NN
. O

Two CD
splice NN
alternatives NNS
were VBD
identified VBN
that WDT
were VBD
not RB
previously RB
observed VBN
in IN
human JJ
TCF-1 NN
. O

Murine JJ
and CC
human JJ
TCF-1 NN
displayed VBD
a DT
95.5 CD
% NN
overall JJ
amino NN
acid NN
homology NN
. O

Recombinant JJ
murine JJ
and CC
human JJ
TCF-1 NN
recognized VBD
the DT
same JJ
sequence NN
motif NN
in IN
the DT
CD3-epsilon NN
enhancer NN
as IN
judged VBN
by IN
gel NN
retardation NN
and CC
methylation NN
interference NN
assays NNS
. O

With IN
the DT
murine JJ
cDNA NN
clones NNS
several JJ
aspects NNS
of IN
TCF-1 NN
were VBD
analyzed VBN
. O

First RB
, O
deletion NN
analysis NN
revealed VBD
that IN
a DT
region NN
of IN
TCF-1 NN
containing VBG
the DT
HMG NN
box NN
was VBD
sufficient JJ
for IN
sequence-specific JJ
binding NN
. O

Second RB
, O
by IN
high JJ
stringency NN
Northern NN
blotting NN
and CC
in FW
situ FW
hybridization NN
, O
TCF-1 NN
expression NN
was VBD
shown VBN
to TO
be VB
confined VBN
to TO
the DT
thymus NN
and CC
to TO
the DT
T NN
cell NN
areas NNS
of IN
the DT
spleen NN
. O

Third RB
, O
TCF-1 NN
bound VBD
specifically RB
to TO
a DT
functional JJ
T NN
cell-specific JJ
element NN
in IN
the DT
T NN
cell NN
receptor NN
alpha NN
( O
TCR-alpha NN
) O
enhancer NN
. O

The DT
T NN
lineage-specific JJ
expression NN
and CC
the DT
affinity NN
for IN
functional JJ
motifs NNS
in IN
the DT
TCR-alpha NN
and CC
CD3-epsilon NN
enhancers NNS
imply VBP
an DT
important JJ
role NN
for IN
TCF-1 NN
in IN
the DT
establishment NN
of IN
the DT
mature JJ
T NN
cell NN
phenotype NN
. O

HIV NN
enhancer NN
activity NN
perpetuated VBN
by IN
NF-kappa NN
B NN
induction NN
on IN
infection NN
of IN
monocytes NNS
( O
see VB
comments NNS
) O

Permissiveness NN
to TO
replication NN
of IN
human JJ
immunodeficiency NN
virus NN
( O
HIV NN
) O
differs VBZ
in IN
T NN
lymphocytes NNS
and CC
macrophages NNS
. O

In IN
T NN
cells NNS
, O
HIV NN
transcription NN
is VBZ
poorly RB
detected VBN
in FW
vivo FW
. O

Cloned VBN
, O
normal JJ
T NN
lymphocytes NNS
show VBP
very RB
little JJ
, O
if IN
any DT
, O
basal JJ
activity NN
of IN
the DT
HIV NN
enhancer NN
and CC
low JJ
nuclear JJ
expression NN
of IN
NF-kappa NN
B NN
, O
a DT
potent JJ
transcriptional JJ
activator NN
of IN
the DT
HIV NN
enhancer NN
. O

In IN
contrast NN
, O
fixed JJ
tissue NN
macrophages NNS
express VBP
detectable JJ
HIV NN
proteins NNS
, O
indicating VBG
permanent JJ
virus NN
transcription NN
. O

One CD
explanation NN
for IN
the DT
perpetuation NN
of IN
virus NN
infection NN
in IN
macrophages NNS
could MD
be VB
sustained JJ
nuclear JJ
NF-kappa NN
B NN
expression NN
. O

However RB
, O
the DT
U937 NN
monocytic JJ
cell NN
line NN
, O
which WDT
is VBZ
fully RB
permissive JJ
to TO
HIV NN
replication NN
, O
is VBZ
known VBN
to TO
express VB
only RB
low JJ
levels NNS
of IN
nuclear JJ
NF-kappa NN
B NN
. O

We PRP
show VBP
here RB
that IN
chronic JJ
HIV VBP
infection NN
results VBZ
in IN
both CC
induction NN
of IN
a DT
nuclear JJ
factor NN
with IN
antigenic JJ
properties NNS
indistinguishable JJ
from IN
those DT
of IN
NF-kappa NN
B NN
and CC
permanently RB
increased VBN
HIV NN
enhancer NN
activity NN
. O

This DT
phenomenon NN
, O
which WDT
is VBZ
independent JJ
of IN
tumour NN
necrosis NN
factor NN
, O
is VBZ
associated VBN
with IN
HIV NN
replication NN
, O
and CC
is VBZ
thus RB
likely JJ
to TO
explain VB
at IN
least JJS
in IN
part NN
the DT
perpetuation NN
of IN
HIV NN
infection NN
in IN
monocytes NNS
. O

Role NN
for IN
the DT
Epstein-Barr JJ
virus NN
nuclear JJ
antigen NN
2 CD
in IN
viral JJ
promoter NN
switching VBG
during IN
initial JJ
stages NNS
of IN
infection NN
. O

During IN
latent JJ
Epstein-Barr JJ
virus NN
( O
EBV NN
) O
infection NN
of IN
human JJ
B NN
lymphocytes NNS
, O
six CD
viral JJ
nuclear JJ
antigen NN
( O
EBNAs NNS
) O
are VBP
expressed VBN
from IN
long JJ
primary JJ
transcripts NNS
by IN
means NNS
of IN
alternative JJ
splicing NN
and CC
alternative JJ
polyadenylylation NN
sites NNS
. O

These DT
transcripts NNS
initiate VBP
from IN
one CD
of IN
two CD
promoters NNS
, O
Cp NN
or CC
Wp NN
, O
that WDT
function VBP
in IN
a DT
mutually RB
exclusive JJ
fashion NN
. O

Wp NN
is VBZ
exclusively RB
utilized VBN
during IN
the DT
initial JJ
stages NNS
of IN
infection NN
of IN
primary JJ
B NN
lymphocytes NNS
, O
followed VBN
by IN
a DT
switch NN
to TO
Cp NN
usage NN
. O

These DT
studies NNS
have VBP
been VBN
extended VBN
to TO
show VB
that IN
( O
i LS
) O
a DT
mutant JJ
EBV NN
strain NN
lacking VBG
the DT
gene NN
encoding VBG
EBNA NN
2 CD
fails VBZ
to TO
switch VB
from IN
Wp NN
to TO
Cp NN
usage NN
in IN
primary JJ
B NN
lymphocytes NNS
, O
although IN
the DT
virus NN
contains VBZ
a DT
functional JJ
Cp NN
; O
( O
ii LS
) O
a DT
region NN
from IN
-429 CD
to TO
-245 CD
base NN
pairs NNS
upstream JJ
of IN
Cp NN
is VBZ
essential JJ
for IN
Cp NN
activity NN
in IN
B NN
lymphocytes NNS
, O
but CC
only RB
in IN
the DT
context NN
of IN
upstream JJ
and CC
downstream JJ
sequences NNS
; O
( O
iii LS
) O
this DT
region NN
contains VBZ
an DT
EBNA NN
2-dependent JJ
enhancer NN
; O
and CC
( O
iv LS
) O
DNase NN
I CD
protection NN
employing VBG
nuclear JJ
extracts NNS
from IN
B NN
and CC
T NN
lymphocytes NNS
revealed VBD
a DT
B-cell-specific JJ
footprint NN
in IN
the DT
region NN
of IN
the DT
EBNA NN
2-dependent JJ
enhancer NN
. O

These DT
results NNS
support VBP
a DT
model NN
for IN
viral JJ
promoter NN
switching NN
during IN
the DT
initial JJ
stages NNS
of IN
infection NN
in IN
which WDT
Wp NN
activity NN
leads VBZ
to TO
the DT
expression NN
of IN
EBNA NN
2 CD
, O
followed VBN
by IN
activation NN
of IN
Cp NN
through IN
the DT
EBNA NN
2-dependent JJ
enhancer NN
. O

Glucocorticoid NN
receptor NN
characteristics NNS
in IN
monocytes NNS
of IN
patients NNS
with IN
corticosteroid-resistant JJ
bronchial JJ
asthma NN
. O

The DT
mechanism NN
of IN
corticosteroid NN
resistance NN
in IN
bronchial JJ
asthma NN
has VBZ
been VBN
studied VBN
by IN
determining VBG
the DT
rank NN
order NN
of IN
potency NN
for IN
different JJ
corticosteroids NNS
in IN
inhibiting VBG
the DT
generation NN
of IN
a DT
3 CD
kD NN
molecule NN
from IN
peripheral JJ
blood NN
monocytes NNS
isolated VBN
from IN
corticosteroid-sensitive JJ
( O
CS JJ
) O
and CC
corticosteroid-resistant JJ
( O
CR JJ
) O
asthmatic JJ
subjects NNS
, O
which WDT
augments VBZ
leukotriene NN
B4 NN
( O
LTB4 NN
) O
generation NN
by IN
human JJ
neutrophils NNS
( O
PMN NN
) O
stimulated VBN
by IN
calcium NN
ionophore NN
. O

In IN
addition NN
, O
binding VBG
studies NNS
with IN
( O
3H NN
) O
dexamethasone NN
have VBP
been VBN
performed VBN
to TO
determine VB
the DT
dissociation NN
constant NN
( O
Kd NN
) O
and CC
receptor NN
numbers NNS
( O
Ro NN
) O
in IN
the DT
monocytes NNS
of IN
these DT
two CD
groups NNS
of IN
subjects NNS
. O

The DT
concentration NN
of IN
corticosteroid NN
producing VBG
50 CD
% NN
inhibition NN
( O
IC50 NN
) O
was VBD
600 CD
nM NN
, O
70 CD
nM NN
, O
and CC
0.5 CD
nM NN
for IN
hydrocortisone NN
, O
methylprednisolone NN
, O
and CC
dexamethasone NN
, O
respectively RB
, O
in IN
monocytes NNS
from IN
CS JJ
individuals NNS
. O

There EX
was VBD
only RB
weak JJ
inhibition NN
of IN
the DT
generation NN
of IN
enhancing NN
activity NN
by IN
the DT
corticosteroids NNS
in IN
the DT
CR JJ
asthmatic JJ
individuals NNS
. O

The DT
dexamethasone NN
Kd NN
was VBD
2.45 CD
+/- CC
0.58 CD
nM NN
( O
mean NN
+/- CC
SEM NN
, O
n NN
= JJ
6 CD
) O
in IN
the DT
CS JJ
group NN
and CC
1.6 CD
+/- CC
0.35 CD
nM NN
( O
mean NN
+/- CC
SEM NN
, O
n NN
= JJ
6 CD
) O
in IN
the DT
CR JJ
group NN
of IN
patients NNS
( O
p NN
= JJ
0.14 CD
) O
. O

The DT
Ro NN
in IN
the DT
CS JJ
group NN
was VBD
3,605 CD
+/- CC
984 CD
binding VBG
sites NNS
per IN
nucleus NN
( O
mean NN
+/- CC
SEM NN
, O
n NN
= JJ
6 CD
) O
and CC
4,757 CD
+/- CC
692 CD
binding VBG
sites NNS
per IN
nucleus NN
( O
mean NN
+/- CC
SEM NN
, O
n NN
= JJ
6 CD
) O
in IN
the DT
CR JJ
group NN
( O
p NN
= JJ
0.23 CD
) O
. O

These DT
findings NNS
indicate VBP
that IN
corticosteroid NN
resistance NN
in IN
bronchial JJ
asthma NN
can MD
not RB
be VB
explained VBN
by IN
abnormalities NNS
in IN
corticosteroid NN
receptor NN
characteristics NNS
. O

Tissue-specific JJ
expression NN
of IN
the DT
platelet NN
GPIIb NN
gene NN
. O

One CD
of IN
the DT
major JJ
objectives NNS
in IN
the DT
study NN
of IN
thrombogenesis NN
is VBZ
to TO
determine VB
the DT
mechanisms NNS
by IN
which WDT
a DT
hematopoietic JJ
progenitor NN
is VBZ
activated VBN
and CC
committed VBN
to TO
the DT
megakaryocytic JJ
lineage NN
. O

Recent JJ
development NN
of IN
primary JJ
cultures NNS
of IN
human JJ
megakaryocytes NNS
and CC
the DT
molecular JJ
cloning NN
of IN
genes NNS
that WDT
are VBP
specific JJ
to TO
this DT
lineage NN
offer VBP
the DT
possibility NN
of IN
getting VBG
some DT
insights NNS
into IN
the DT
genetic JJ
mechanisms NNS
that WDT
control VBP
megakaryocytopoiesis NNS
. O

One CD
gene NN
of IN
interest NN
is VBZ
the DT
glycoprotein NN
IIb NN
( O
GPIIb NN
) O
gene NN
; O
GPIIb NN
, O
the DT
alpha NN
subunit NN
of IN
the DT
platelet NN
cytoadhesin NN
GPIIb-IIIa NN
, O
is VBZ
produced VBN
in IN
megakaryocytes NNS
at IN
an DT
early JJ
stage NN
of IN
the DT
differentiation NN
, O
whereas IN
the DT
other JJ
subunit NN
of IN
this DT
complex NN
, O
GPIIIa NN
, O
is VBZ
expressed VBN
in IN
other JJ
cells NNS
. O

For IN
these DT
reasons NNS
, O
the DT
5'-flanking JJ
region NN
of IN
the DT
GPIIb NN
gene NN
was VBD
used VBN
to TO
identify VB
the DT
regions NNS
that WDT
interact VBP
with IN
DNA-binding JJ
nuclear JJ
factors NNS
. O

A DT
fragment NN
extending VBG
from IN
-643 CD
to TO
+33 CD
is VBZ
capable JJ
of IN
controlling VBG
the DT
tissue-specific JJ
expression NN
of IN
the DT
CAT NN
gene NN
in IN
transfection NN
experiments NNS
. O

Within IN
this DT
region NN
, O
we PRP
have VBP
identified VBN
several JJ
sequences NNS
that WDT
are VBP
implicated VBN
in IN
DNA NN
protein NN
interactions NNS
as IN
shown VBN
in IN
DNAse NN
I NN
footprints NNS
and CC
gel NN
mobility NN
shift NN
assays NNS
. O

One CD
region NN
, O
centered VBN
at IN
-54 CD
, O
is VBZ
similar JJ
to TO
a DT
nuclear JJ
factor NN
E1-binding JJ
site NN
, O
and CC
a DT
region NN
located JJ
at IN
position NN
-233 CD
contains VBZ
a DT
CCAAT NN
motif NN
. O

Two CD
domains NNS
centered VBN
at IN
positions NNS
-345 CD
and CC
-540 CD
, O
respectively RB
, O
bind VBP
proteins NNS
that WDT
are VBP
present JJ
in IN
megakaryocytic JJ
cells NNS
and CC
nonrelated JJ
cells NNS
as RB
well RB
. O

Finally RB
, O
two CD
other JJ
domains NNS
, O
located JJ
at IN
positions NNS
-460 CD
and CC
-510 CD
, O
interact VBP
with IN
proteins NNS
that WDT
are VBP
only RB
present JJ
in IN
megakaryocytic JJ
cells NNS
. O

In IN
addition NN
, O
deletion NN
of IN
the DT
region NN
containing VBG
these DT
two CD
domains NNS
results VBZ
in IN
a DT
significant JJ
decrease NN
of IN
the DT
promoter NN
activity NN
. O

It PRP
is VBZ
very RB
likely JJ
that IN
these DT
domains NNS
bind VBP
megakaryocyte-specific JJ
nuclear JJ
proteins NNS
acting VBG
as IN
positive JJ
transcription NN
factors NNS
. O

Inhibition NN
of IN
protein NN
phosphatases NNS
by IN
okadaic JJ
acid NN
induces VBZ
AP1 NN
in IN
human JJ
T NN
cells NNS
. O

To TO
examine VB
the DT
role NN
of IN
protein NN
phosphatases NNS
in IN
T NN
cell NN
activation NN
, O
Jurkat NN
cells NNS
were VBD
treated VBN
with IN
okadaic JJ
acid NN
, O
an DT
inhibitor NN
of IN
type NN
1 CD
and CC
2A NN
phosphatases NNS
, O
and CC
nuclear JJ
extracts NNS
were VBD
examined VBN
for IN
the DT
presence NN
of IN
AP1 NN
as IN
a DT
measure NN
of IN
early JJ
T NN
cell NN
activation NN
. O

Okadaic JJ
acid NN
was VBD
found VBN
to TO
be VB
a DT
potent JJ
inducer NN
of IN
AP1 NN
. O

In IN
contrast NN
to TO
phorbol NN
esters NNS
such JJ
as IN
phorbol NN
myristate NN
acetate NN
( O
PMA NN
) O
, O
the DT
induction NN
of IN
AP1 NN
by IN
okadaic JJ
acid NN
occurs VBZ
predominantly RB
by IN
transcriptional JJ
activation NN
of IN
the DT
jun NN
and CC
fos NN
family NN
of IN
proto-oncogenes NNS
. O

Surprisingly RB
, O
while IN
the DT
addition NN
of IN
phytohemagglutinin NN
further RB
enhanced VBD
the DT
induction NN
of IN
AP1 NN
, O
the DT
addition NN
of IN
PMA NN
inhibited VBD
it PRP
. O

Okadaic JJ
acid NN
treatment NN
was VBD
found VBN
to TO
dramatically RB
increase VB
mRNA NN
transcripts NNS
of IN
the DT
jun NN
family NN
of IN
proto-oncogenes NNS
including VBG
c-jun NN
, O
junD NN
, O
and CC
junB NN
and CC
to TO
a DT
lesser JJR
extent NN
the DT
fos NN
family NN
including VBG
c-fos NN
and CC
fra-1 NN
. O

By IN
comparison NN
, O
PMA NN
is VBZ
a DT
very RB
inefficient JJ
inducer NN
of IN
the DT
jun NN
gene NN
family NN
in IN
Jurkat NN
cells NNS
. O

Similar JJ
to TO
its PRP$
effect NN
on IN
the DT
induction NN
of IN
AP1 NN
by IN
okadaic JJ
acid NN
, O
PMA NN
inhibits VBZ
the DT
induction NN
of IN
c-jun NN
mRNA NN
by IN
okadaic JJ
acid NN
. O

Transfection NN
of IN
c-jun NN
promoter NN
constructs NNS
confirmed VBD
the DT
marked JJ
difference NN
between IN
PMA NN
and CC
okadaic JJ
acid NN
in IN
inducing VBG
c-jun NN
transcription NN
. O

The DT
induction NN
of IN
AP1 NN
by IN
okadaic JJ
acid NN
suggests VBZ
that IN
protein NN
phosphatases NNS
1 CD
and CC
2A NN
( O
PP1 NN
and CC
PP2A NN
) O
may MD
be VB
involved VBN
in IN
T NN
cell NN
activation NN
as IN
important JJ
negative JJ
regulators NNS
of IN
the DT
transcription NN
factor NN
AP1 NN
. O

Demonstration NN
of IN
estrogen NN
and CC
progesterone NN
receptors NNS
as RB
well RB
as IN
Ki-67 NN
and CC
p-145 NN
antigens NNS
in IN
single JJ
tumor NN
cells NNS
from IN
blood NN
and CC
pleural JJ
effusions NNS
using VBG
a DT
slide NN
assay NN
. O

We PRP
describe VBP
a DT
slide NN
assay NN
that WDT
allows VBZ
the DT
demonstration NN
of IN
antigens NNS
localized JJ
in IN
the DT
nucleus NN
from IN
isolated VBN
white JJ
blood NN
cells NNS
as RB
well RB
as IN
from IN
single JJ
tumor NN
cells NNS
derived VBN
from IN
malignant JJ
effusions NNS
. O

With IN
the DT
antibodies NNS
Ki-67 NN
and CC
anti-p-145 NN
an DT
increased VBN
rate NN
of IN
nuclear JJ
and CC
nucleolar JJ
staining NN
resulted VBD
in IN
cells NNS
from IN
highly RB
malignant JJ
lymphomas NNS
. O

An DT
almost RB
identical JJ
reaction NN
was VBD
obtained VBN
when WRB
tumor NN
cells NNS
from IN
malignant JJ
effusions NNS
were VBD
tested VBN
. O

Cells NNS
isolated VBN
from IN
the DT
blood NN
of IN
patients NNS
with IN
leukemic JJ
spread NN
of IN
lymphomas NNS
of IN
low JJ
malignancy NN
yielded VBD
a DT
weak JJ
staining NN
comparable JJ
to TO
that DT
of IN
normal JJ
mesothelial JJ
cells NNS
from IN
non-tumorous JJ
cavity NN
fluids NNS
. O

The DT
detection NN
of IN
estrogen NN
and CC
progesterone NN
receptors NNS
( O
ER NN
and CC
PR NN
) O
localized JJ
in IN
the DT
cell NN
nucleus NN
can MD
be VB
achieved VBN
by IN
the DT
same JJ
assay NN
. O

The DT
reaction NN
is VBZ
enhanced VBN
by IN
incubation NN
of IN
the DT
tumor NN
cells NNS
for IN
30 CD
min NN
at IN
37 CD
degrees NNS
C NN
prior RB
to TO
fixation NN
. O

Pleural JJ
effusions NNS
from IN
20 CD
patients NNS
with IN
breast NN
cancer NN
were VBD
tested VBN
. O

ER NN
was VBD
positive JJ
in IN
13 CD
and CC
PR NN
was VBD
positive JJ
in IN
12 CD
of IN
the DT
20 CD
samples NNS
. O

In IN
5 CD
cases NNS
there EX
was VBD
a DT
divergent JJ
reaction NN
with IN
ER NN
and CC
PR NN
antibody NN
. O

The DT
hormone NN
receptors NNS
of IN
the DT
primary JJ
tumor NN
were VBD
known VBN
in IN
15 CD
( O
ER NN
) O
and CC
14 CD
( O
PR NN
) O
patients NNS
, O
respectively RB
. O

In IN
each DT
cohort NN
there EX
was VBD
only RB
one CD
case NN
with IN
a DT
negative JJ
reaction NN
of IN
the DT
primary JJ
tumor NN
and CC
a DT
positive JJ
reaction NN
with IN
the DT
isolated VBN
tumor NN
cells NNS
from IN
the DT
pleural JJ
effusions NNS
. O

These DT
results NNS
indicate VBP
that IN
the DT
demonstration NN
of IN
hormone NN
receptor NN
proteins NNS
in IN
cells NNS
from IN
malignant JJ
effusions NNS
is VBZ
possible JJ
and CC
that IN
there EX
is VBZ
a DT
correlation NN
with IN
the DT
status NN
of IN
the DT
primary JJ
site NN
of IN
cancer NN
. O

Transforming VBG
growth NN
factor-beta NN
suppresses VBZ
human JJ
B NN
lymphocyte NN
Ig NN
production NN
by IN
inhibiting VBG
synthesis NN
and CC
the DT
switch NN
from IN
the DT
membrane NN
form NN
to TO
the DT
secreted JJ
form NN
of IN
Ig NN
mRNA NN
. O

Transforming VBG
growth NN
factor-beta NN
( O
TGF-beta NN
) O
inhibits VBZ
B NN
cell NN
Ig NN
secretion NN
and CC
reduces VBZ
B NN
cell NN
membrane NN
Ig NN
expression NN
. O

The DT
addition NN
of IN
TGF-beta NN
to TO
human JJ
B NN
lymphocyte NN
cultures NNS
stimulated VBN
with IN
Staphylococcus FW
aureus FW
Cowan NN
strain NN
I NN
and CC
IL-2 NN
completely RB
inhibited VBD
B NN
cell NN
Ig NN
secretion NN
( O
greater JJR
than IN
90 CD
% NN
) O
and CC
decreased VBD
B NN
cell NN
surface NN
IgM NN
, O
IgD NN
, O
kappa NN
L NN
chain NN
, O
and CC
lambda NN
L NN
chain NN
expression NN
. O

In IN
contrast NN
, O
TGF-beta NN
had VBD
only RB
minimal JJ
effects NNS
on IN
two CD
other JJ
B NN
cell NN
membrane NN
proteins NNS
, O
HLA-DR NN
and CC
CD20 NN
. O

Internal JJ
labeling NN
with IN
(35S)methionine NN
and CC
immunoprecipitation NN
with IN
anti-IgM JJ
, O
anti-kappa JJ
, O
and CC
anti-lambda JJ
antibodies NNS
revealed VBD
a DT
striking JJ
reduction NN
in IN
kappa NN
L NN
chain NN
in IN
the DT
presence NN
of IN
TGF-beta NN
. O

A DT
less RBR
pronounced JJ
reduction NN
in IN
lambda NN
L NN
chain NN
and CC
microH NN
chain NN
was VBD
also RB
noted VBN
. O

Northern NN
blot NN
analysis NN
of IN
RNA NN
purified VBN
from IN
B NN
cells NNS
treated VBN
with IN
TGF-beta NN
for IN
varying VBG
time NN
intervals NNS
revealed VBD
a DT
significant JJ
decrease NN
in IN
steady JJ
state NN
kappa NN
and CC
lambda NN
L NN
chain NN
mRNA NN
levels NNS
. O

Furthermore RB
, O
a DT
significant JJ
decrease NN
in IN
the DT
switch NN
from IN
the DT
membrane NN
forms NNS
of IN
mu NN
and CC
gamma NN
to TO
their PRP$
respective JJ
secreted JJ
forms NNS
was VBD
noted VBN
in IN
the DT
presence NN
of IN
TGF-beta NN
. O

Nuclear JJ
run-on JJ
experiments NNS
demonstrated VBD
decreased VBN
transcription NN
of IN
kappa NN
L NN
chain NN
. O

The DT
effects NNS
of IN
TGF-beta NN
on IN
two CD
transcriptional JJ
regulatory JJ
factors NNS
, O
Oct-2 NN
and CC
nuclear JJ
factor NN
( O
NF NN
) O
kappa NN
B NN
, O
known VBN
to TO
be VB
important JJ
in IN
Ig NN
gene NN
transcription NN
were VBD
examined VBN
. O

Oct-2 NN
mRNA NN
levels NNS
and CC
both DT
Oct-2 NN
and CC
NF-kappa NN
B NN
proteins NNS
in IN
nuclear JJ
extracts NNS
were VBD
not RB
altered VBN
by IN
treatment NN
with IN
TGF-beta NN
. O

In IN
contrast NN
, O
levels NNS
of IN
the DT
transcriptional JJ
factor NN
AP-1 NN
, O
which WDT
is VBZ
not RB
known VBN
to TO
be VB
important JJ
in IN
B NN
cell NN
Ig NN
production NN
, O
were VBD
reduced VBN
by IN
TGF-beta NN
. O

These DT
findings NNS
demonstrate VBP
that IN
TGF-beta NN
decreases VBZ
B NN
lymphocyte NN
Ig NN
secretion NN
by IN
inhibiting VBG
the DT
synthesis NN
of IN
Ig NN
mRNA NN
and CC
inhibiting VBG
the DT
switch NN
from IN
the DT
membrane NN
form NN
to TO
the DT
secreted JJ
forms NNS
of IN
mu NN
and CC
gamma NN
mRNA NN
. O

The DT
mechanism NN
by IN
which WDT
TGF-beta NN
inhibits VBZ
Ig NN
chain NN
synthesis NN
is VBZ
unclear JJ
although IN
it PRP
does VBZ
not RB
involve VB
inhibition NN
of IN
the DT
binding NN
of IN
NF-kappa NN
B NN
or CC
Oct-2 NN
to TO
their PRP$
respective JJ
target NN
sequences NNS
. O

Differentiation-associated JJ
expression NN
of IN
the DT
Epstein-Barr JJ
virus NN
BZLF1 NN
transactivator NN
protein NN
in IN
oral JJ
hairy JJ
leukoplakia NN
. O

The DT
BZLF1 NN
protein NN
of IN
Epstein-Barr JJ
virus NN
( O
EBV NN
) O
is VBZ
a DT
key JJ
immediate-early JJ
protein NN
which WDT
has VBZ
been VBN
shown VBN
to TO
disrupt VB
virus NN
latency NN
in IN
EBV-infected JJ
B NN
cells NNS
. O

We PRP
have VBP
generated VBN
a DT
monoclonal JJ
antibody NN
, O
BZ1 NN
, O
to TO
BZLF1 NN
which WDT
reacts VBZ
in IN
immunohistology NN
, O
immunoblotting NN
, O
and CC
immunoprecipitation NN
and CC
which WDT
recognizes VBZ
both CC
the DT
active JJ
, O
dimeric JJ
form NN
and CC
the DT
inactive JJ
, O
monomeric JJ
form NN
of IN
the DT
protein NN
. O

Biopsies NNS
of IN
oral JJ
hairy JJ
leukoplakia NN
, O
an DT
AIDS-associated JJ
lesion NN
characterized VBN
by IN
high-level JJ
EBV NN
replication NN
, O
were VBD
examined VBN
by IN
immunohistochemistry NN
using VBG
the DT
BZ1 NN
monoclonal JJ
antibody NN
. O

A DT
differentiation-associated JJ
pattern NN
of IN
BZLF1 NN
expression NN
was VBD
observed VBN
, O
BZ1 NN
reacting VBG
with IN
nuclei NNS
of IN
the DT
upper JJ
spinous JJ
layer NN
of IN
the DT
lesion NN
. O

This DT
finding NN
suggests VBZ
that IN
the DT
BZLF1 NN
promoter NN
may MD
be VB
regulated VBN
by IN
the DT
degree NN
of IN
squamous JJ
differentiation NN
. O

A DT
comparison NN
of IN
in FW
situ FW
hybridization NN
to TO
EBV NN
DNA NN
and CC
viral JJ
capsid NN
antigen NN
staining VBG
with IN
BZ1 NN
reactivity NN
suggested VBD
that IN
BZLF1 NN
expression NN
precedes VBZ
rampant JJ
virus NN
replication NN
. O

The DT
inability NN
to TO
detect VB
EBV NN
in IN
the DT
lower RBR
epithelial JJ
layers NNS
of IN
oral JJ
hairy JJ
leukoplakia NN
raises VBZ
questions NNS
concerning VBG
the DT
nature NN
of IN
EBV NN
latency NN
and CC
persistence NN
in IN
stratified JJ
squamous JJ
epithelium NN
. O

Transactivation NN
of IN
the DT
human JJ
immunodeficiency NN
virus NN
promoter NN
by IN
human JJ
herpesvirus NN
6 CD
( O
HHV-6 NN
) O
strains VBZ
GS NN
and CC
Z-29 NN
in IN
primary JJ
human JJ
T NN
lymphocytes NNS
and CC
identification NN
of IN
transactivating VBG
HHV-6 NN
( O
GS NN
) O
gene NN
fragments NNS
. O

Human JJ
herpesvirus NN
6 CD
( O
HHV-6 NN
) O
can MD
activate VB
the DT
human JJ
immunodeficiency NN
virus NN
( O
HIV NN
) O
promoter NN
and CC
accelerate VB
cytopathic JJ
effects NNS
in IN
HIV-infected JJ
human JJ
T NN
cells NNS
. O

This DT
study NN
examines VBZ
the DT
regions NNS
of IN
the DT
HIV NN
promoter NN
required VBN
for IN
HHV-6 NN
transactivation NN
in IN
a DT
heterogeneous JJ
population NN
of IN
primary JJ
human JJ
T NN
lymphocytes NNS
with IN
or CC
without IN
antigenic JJ
stimulation NN
. O

Two CD
different JJ
strains NNS
of IN
HHV-6 NN
, O
GS NN
and CC
Z29 NN
, O
transactivated VBD
the DT
HIV NN
promoter NN
. O

The DT
GS NN
strain NN
transactivated VBD
the DT
promoter NN
in IN
both CC
stimulated VBN
and CC
resting VBG
T NN
cells NNS
, O
while IN
the DT
Z29 NN
strain NN
increased VBD
HIV NN
promoter NN
activity NN
only RB
in IN
stimulated VBN
T NN
cells NNS
. O

Three CD
DNA NN
clones NNS
containing VBG
HHV-6 NN
( O
GS NN
) O
genomic JJ
fragments NNS
transactivated VBD
the DT
HIV NN
promoter NN
in IN
cotransfected VBN
T NN
cells NNS
. O

A DT
21.4-kb JJ
DNA NN
clone NN
, O
pZVB70 NN
, O
showed VBD
the DT
highest JJS
transactivating NN
ability NN
, O
while IN
two CD
other JJ
DNA NN
fragments NNS
, O
pZVB10 NN
( O
6.2 CD
kb NN
) O
and CC
pZVH14 NN
( O
8.7 CD
kb NN
) O
, O
showed VBD
lower JJR
activity NN
. O

One CD
of IN
these DT
clones NNS
, O
pZVH14 NN
, O
activated VBD
the DT
HIV NN
promoter NN
construct NN
containing VBG
a DT
mutation NN
in IN
the DT
NF NN
kappa NN
B NN
site NN
. O

However RB
, O
this DT
mutated VBN
NF NN
kappa NN
B NN
promoter NN
was VBD
not RB
transactivated VBN
during IN
HHV-6 NN
( O
GS NN
) O
infection NN
or CC
after IN
cotransfection NN
with IN
pZVB70 NN
or CC
pZVB10 NN
. O

These DT
data NNS
indicate VBP
that IN
the DT
NF NN
kappa NN
B NN
sites NNS
of IN
the DT
HIV NN
promoter NN
are VBP
essential JJ
for IN
its PRP$
transactivation NN
during IN
HHV-6 NN
( O
GS NN
) O
infection NN
. O

By IN
increasing VBG
HIV NN
promoter NN
activity NN
in IN
primary JJ
T NN
lymphocytes NNS
, O
HHV-6 NN
may MD
consequently RB
increase VB
HIV NN
replication NN
, O
leading VBG
to TO
an DT
increase NN
in IN
the DT
cytopathic JJ
effect NN
on IN
coinfected VBN
human JJ
T NN
cells NNS
. O

The DT
rhombotin NN
family NN
of IN
cysteine-rich JJ
LIM-domain JJ
oncogenes NNS
: O
distinct JJ
members NNS
are VBP
involved VBN
in IN
T-cell NN
translocations NNS
to TO
human JJ
chromosomes NNS
11p15 NN
and CC
11p13 NN
. O

A DT
chromosomal NN
translocation NN
in IN
a DT
T-cell NN
leukemia NN
involving VBG
the DT
short JJ
arm NN
of IN
human JJ
chromosome NN
11 CD
at IN
band NN
11p15 NN
disrupts VBZ
the DT
rhombotin NN
gene NN
. O

This DT
gene NN
encodes VBZ
a DT
protein NN
with IN
duplicated JJ
cysteine-rich JJ
regions NNS
called VBN
LIM NN
domains NNS
, O
which WDT
show VBP
homology NN
to TO
zinc-binding JJ
proteins NNS
and CC
to TO
iron-sulfur JJ
centers NNS
of IN
ferredoxins NNS
. O

Two CD
homologues NNS
of IN
the DT
rhombotin NN
gene NN
have VBP
now RB
been VBN
isolated VBN
. O

One CD
of IN
these DT
, O
designated VBN
Rhom-2 NN
, O
is VBZ
located JJ
on IN
human JJ
chromosome NN
11 CD
at IN
band NN
11p13 NN
, O
where WRB
a DT
cluster NN
of IN
T-cell NN
leukemia-specific JJ
translocations NNS
occur VBP
; O
all DT
translocation NN
breakpoints NNS
at IN
11p13 NN
are VBP
upstream JJ
of IN
the DT
Rhom-2 NN
gene NN
. O

Human JJ
and CC
mouse NN
Rhom-2 NN
are VBP
highly RB
conserved VBN
and CC
, O
like IN
rhombotin NN
, O
encode VBP
two CD
tandem JJ
cysteine-rich JJ
LIM NN
domains NNS
. O

Rhom-2 NN
mRNA NN
is VBZ
expressed VBN
in IN
early JJ
mouse NN
development NN
in IN
central JJ
nervous JJ
system NN
, O
lung NN
, O
kidney NN
, O
liver NN
, O
and CC
spleen NN
but CC
only RB
very RB
low JJ
levels NNS
occur VBP
in IN
thymus NN
. O

The DT
other JJ
gene NN
, O
designated VBN
Rhom-3 NN
, O
is VBZ
not RB
on IN
chromosome NN
11 CD
but CC
also RB
retains VBZ
homology NN
to TO
the DT
LIM NN
domain NN
of IN
rhombotin NN
. O

Since IN
the DT
Rhom-2 NN
gene NN
is VBZ
such JJ
a DT
common JJ
site NN
of IN
chromosomal JJ
damage NN
in IN
T-cell NN
tumors NNS
, O
the DT
consistency NN
of IN
translocations NNS
near IN
the DT
rhombotin NN
gene NN
was VBD
further RB
examined VBN
. O

A DT
second JJ
translocation NN
adjacent JJ
to TO
rhombotin NN
was VBD
found VBN
and CC
at IN
the DT
same JJ
position NN
as IN
in IN
the DT
previous JJ
example NN
. O

Therefore RB
, O
chromosome NN
bands NNS
11p15 NN
( O
rhombotin NN
) O
and CC
11p13 NN
( O
Rhom-2 NN
) O
are VBP
consistent JJ
sites NNS
of IN
chromosome NN
translocation NN
in IN
T-cell NN
leukemia NN
, O
with IN
the DT
11p15 NN
target NN
more RBR
rarely RB
involved VBN
. O

The DT
results NNS
define VBP
the DT
rhombotin NN
gene NN
family NN
as IN
a DT
class NN
of IN
T-cell NN
oncogenes NNS
with IN
duplicated JJ
cysteine-rich JJ
LIM NN
domains NNS
. O

The DT
human JJ
myelomonocytic JJ
cell NN
line NN
U-937 NN
as IN
a DT
model NN
for IN
studying VBG
alterations NNS
in IN
steroid-induced JJ
monokine NN
gene NN
expression NN
: O
marked JJ
enhancement NN
of IN
lipopolysaccharide-stimulated JJ
interleukin-1 NN
beta NN
messenger NN
RNA NN
levels NNS
by IN
1,25-dihydroxyvitamin NN
D3 NN
. O

The DT
active JJ
metabolite NN
of IN
vitamin NN
D NN
, O
1,25-dihydroxyvitamin NN
D3 NN
( O
1,25-(OH)2D3 NN
) O
, O
is VBZ
a DT
potent JJ
regulator NN
of IN
human JJ
monocyte/macrophage JJ
function NN
in FW
vitro FW
. O

To TO
establish VB
a DT
model NN
for IN
1,25-(OH)2D3 NN
regulation NN
of IN
human JJ
monocyte NN
monokine NN
synthesis NN
, O
three CD
human JJ
cell NN
lines NNS
( O
U-937 NN
, O
THP-1 NN
, O
and CC
HL-60 NN
) O
were VBD
examined VBN
for IN
: O
1 LS
) O
the DT
presence NN
of IN
functional JJ
1,25-(OH)2D3 NN
receptors NNS
; O
2 LS
) O
the DT
accumulation NN
of IN
interleukin-1 NN
beta NN
( O
IL-1 NN
beta NN
) O
mRNA NN
and CC
IL-1 NN
beta NN
protein NN
in IN
response NN
to TO
lipopolysaccharide NN
( O
LPS NN
) O
; O
and CC
3 LS
) O
the DT
regulation NN
of IN
this DT
response NN
by IN
1,25-(OH)2D3 NN
. O

All DT
three CD
cell NN
lines NNS
expressed VBD
vitamin NN
D NN
receptor NN
and CC
had VBD
increased VBN
levels NNS
of IN
IL-1 NN
beta NN
mRNA NN
in IN
response NN
to TO
LPS NN
. O

Preincubation NN
of IN
cells NNS
with IN
1,25-(OH)2D3 NN
augmented VBD
IL-1 NN
beta NN
mRNA NN
levels NNS
only RB
in IN
U-937 NN
and CC
HL-60 NN
cells NNS
. O

From IN
these DT
data NNS
, O
and CC
taking VBG
into IN
consideration NN
their PRP$
state NN
of IN
differentiation NN
and CC
relative JJ
ease NN
of IN
culture NN
, O
U-937 NN
was VBD
chosen VBN
over IN
HL-60 NN
and CC
THP-1 NN
as IN
the DT
cell NN
line NN
we PRP
further RB
characterized VBD
. O

In IN
U-937 NN
cells NNS
, O
optimum JJ
time NN
and CC
dose NN
of IN
pretreatment NN
with IN
1,25-(OH)2D3 NN
were VBD
determined VBN
to TO
be VB
12-24 CD
h NN
at IN
a DT
receptor NN
saturating JJ
concentration NN
of IN
1,25-(OH)2D3 NN
( O
10 CD
nM NN
) O
. O

Preincubation NN
of IN
cells NNS
with IN
1,25-(OH)2D3 NN
had VBD
no DT
effect NN
on IN
the DT
time NN
course NN
of IN
IL-1 NN
beta NN
mRNA NN
appearance NN
in IN
response NN
to TO
LPS NN
. O

However RB
, O
exposure NN
of IN
U-937 NN
cells NNS
to TO
1,25-(OH)2D3 NN
increased VBD
by IN
200 CD
% NN
the DT
level NN
of IN
IL-1 NN
beta NN
mRNA NN
detected VBD
and CC
decreased VBD
by IN
three CD
orders NNS
of IN
magnitude NN
the DT
concentration NN
of IN
LPS NN
required VBN
to TO
achieve VB
steady JJ
state NN
mRNA NN
levels NNS
equivalent JJ
to TO
those DT
observed VBN
in IN
U-937 NN
cells NNS
not RB
preincubated VBN
with IN
the DT
hormone.2+o NN

Cortivazol NN
mediated VBD
induction NN
of IN
glucocorticoid NN
receptor NN
messenger NN
ribonucleic JJ
acid NN
in IN
wild-type JJ
and CC
dexamethasone-resistant JJ
human JJ
leukemic NN
( O
CEM NN
) O
cells NNS
. O

Cortivazol NN
is VBZ
a DT
phenylpyrazolo JJ
glucocorticoid NN
of IN
high JJ
potency NN
and CC
unusual JJ
structure NN
. O

In IN
both CC
wild-type JJ
and CC
highly RB
dexamethasone NN
( O
dex NN
) O
-resistant JJ
clones NNS
of IN
the DT
human JJ
leukemic JJ
cell NN
line NN
CEM NN
, O
exposure NN
to TO
cortivazol NN
leads VBZ
to TO
cell NN
death NN
. O

It PRP
has VBZ
been VBN
shown VBN
recently RB
that IN
in IN
wild-type JJ
CEM NN
cells NNS
but CC
not RB
in IN
a DT
dex-resistant JJ
, O
glucocorticoid NN
receptor NN
( O
GR NN
) O
-defective JJ
clone NN
ICR-27 NN
TK-3 NN
, O
dex NN
induces VBZ
GR NN
mRNA NN
. O

To TO
test VB
the DT
hypothesis NN
that IN
cortivazol NN
acts VBZ
in IN
dex-resistant JJ
cells NNS
by IN
making VBG
use NN
of IN
the DT
residual JJ
GR NN
found VBN
there RB
, O
wild-type JJ
and CC
dex-resistant JJ
clones NNS
were VBD
treated VBN
with IN
various JJ
concentrations NNS
of IN
cortivazol NN
and CC
induction NN
of IN
GR NN
mRNA NN
was VBD
studied VBN
. O

Cortivazol NN
significantly RB
induced VBD
GR NN
mRNA NN
in IN
the DT
normal JJ
CEM-C7 NN
as RB
well RB
as IN
in IN
two CD
classes NNS
of IN
dex-resistant JJ
clones NNS
, O
although IN
the DT
dex-resistant JJ
clones NNS
needed VBD
at IN
least JJS
10 CD
times NNS
more JJR
cortivazol NN
than IN
the DT
normal JJ
cells NNS
for IN
significant JJ
GR NN
mRNA NN
induction NN
. O

Increased VBN
levels NNS
of IN
GR NN
mRNA NN
were VBD
noticed VBN
as RB
early RB
as IN
3 CD
h NN
after IN
treatment NN
. O

A DT
general JJ
correlation NN
between IN
induction NN
of IN
GR NN
mRNA NN
and CC
lysis NN
of IN
the DT
normal JJ
and CC
dex-resistant JJ
cells NNS
was VBD
found VBN
. O

Positive JJ
induction NN
of IN
GR NN
mRNA NN
might MD
be VB
one CD
of IN
the DT
earliest JJS
crucial JJ
steps NNS
in IN
the DT
lysis NN
of IN
normal JJ
and CC
dex-resistant JJ
CEM NN
cells NNS
, O
or CC
might MD
serve VB
as IN
a DT
marker NN
for IN
the DT
process NN
. O

However RB
, O
the DT
lysis NN
pathway NN
in IN
the DT
dex-resistant JJ
cells NNS
is VBZ
defective JJ
in IN
that IN
dex-resistant JJ
clones NNS
needed VBD
significantly RB
more JJR
cortivazol NN
than IN
the DT
normal JJ
cells NNS
for IN
lysis NN
of IN
the DT
cells NNS
. O

Expression NN
of IN
1,25(OH)2D3 NN
receptors NNS
on IN
alveolar JJ
lymphocytes NNS
from IN
patients NNS
with IN
pulmonary JJ
granulomatous JJ
diseases NNS
. O

1,25(OH)2D3 NN
is VBZ
known VBN
to TO
be VB
produced VBN
at IN
sites NNS
of IN
granulomatous JJ
reactions NNS
. O

In IN
order NN
to TO
characterize VB
the DT
cell NN
types NNS
that WDT
are VBP
targets NNS
for IN
this DT
immunoregulatory JJ
hormone NN
, O
we PRP
have VBP
evaluated VBN
the DT
expression NN
of IN
1,25(OH)2D3 NN
receptors NNS
on IN
peripheral JJ
blood NN
T-lymphocytes NNS
and CC
those DT
recovered VBN
from IN
the DT
lung NN
by IN
bronchoalveolar JJ
lavage NN
from IN
patients NNS
with IN
pulmonary JJ
granulomatous JJ
diseases NNS
( O
tuberculosis NN
and CC
sarcoidosis NN
) O
and CC
from IN
normal JJ
control NN
subjects NNS
using VBG
combined JJ
autoradiographic JJ
and CC
immunohistochemical JJ
techniques NNS
. O

Lavage NN
T-lymphocytes NNS
from IN
patients NNS
with IN
tuberculosis NN
or CC
with IN
sarcoidosis NN
, O
but CC
not RB
those DT
from IN
normal JJ
control NN
subjects NNS
, O
expressed VBD
1,25(OH)2D3 NN
receptors NNS
as IN
demonstrated VBN
by IN
binding NN
of IN
(3H)1,25(OH)2D3 NN
, O
which WDT
was VBD
inhibited VBN
by IN
the DT
presence NN
of IN
excess JJ
unlabeled JJ
1,25(OH)2D3 NN
, O
but CC
not RB
by IN
the DT
presence NN
of IN
unlabeled JJ
25(OH)D3 NN
( O
receptor-positive JJ
lymphocytes NNS
: O
sarcoidosis NN
, O
20 CD
+/- CC
12 CD
% NN
; O
tuberculosis NN
, O
31 CD
+/- CC
17 CD
% NN
) O
. O

In IN
contrast NN
, O
blood NN
lymphocytes NNS
from IN
patients NNS
with IN
granulomatous JJ
diseases NNS
did VBD
not RB
express VB
detectable JJ
1,25(OH)2D3 NN
receptors NNS
. O

The DT
percentage NN
of IN
lavage NN
T-lymphocytes NNS
expressing VBG
1,25(OH)2D3 NN
receptors NNS
was VBD
significantly RB
greater JJR
for IN
patients NNS
with IN
tuberculosis NN
presenting VBG
with IN
isolated VBN
hilar JJ
adenopathy JJ
than IN
for IN
patients NNS
with IN
pulmonary JJ
infiltrates NNS
and/or CC
cavities NNS
. O

1,25(OH)2D3 NN
receptors NNS
were VBD
expressed VBN
to TO
a DT
greater JJR
extent NN
on IN
CD8+ JJ
T-lymphocytes NNS
than IN
on IN
CD4+ JJ
T-lymphocytes NNS
in IN
sarcoidosis NN
, O
whereas IN
a DT
greater JJR
proportion NN
of IN
CD4+ JJ
than IN
of IN
CD8+ JJ
T-lymphocytes NNS
from IN
patients NNS
with IN
tuberculosis NN
were VBD
receptor-positive JJ
. O

These DT
findings NNS
support VBP
the DT
conclusion NN
that IN
the DT
interaction NN
of IN
1,25(OH)2D3 NN
with IN
its PRP$
receptor NN
on IN
T-lymphocytes NNS
may MD
play VB
an DT
important JJ
role NN
in IN
the DT
regulation NN
of IN
granulomatous JJ
reactions NNS
, O
but CC
because IN
these DT
receptors NNS
are VBP
expressed VBN
on IN
different JJ
lymphocyte NN
populations NNS
, O
the DT
net JJ
effect NN
of IN
this DT
potent JJ
immunoregulatory JJ
molecule NN
is VBZ
likely RB
different JJ
in IN
sarcoidosis NN
and CC
tuberculosis NN
. O

Inhibition NN
of IN
transcription NN
factors NNS
belonging VBG
to TO
the DT
rel/NF-kappa NN
B NN
family NN
by IN
a DT
transdominant JJ
negative JJ
mutant NN
. O

The DT
KBF1 NN
factor NN
, O
which WDT
binds VBZ
to TO
the DT
enhancer NN
A NN
located JJ
in IN
the DT
promoter NN
of IN
the DT
mouse NN
MHC NN
class NN
I CD
gene NN
H-2Kb NN
, O
is VBZ
indistinguishable JJ
from IN
the DT
p50 NN
DNA NN
binding NN
subunit NN
of IN
the DT
transcription NN
factor NN
NF-kappa NN
B NN
, O
which WDT
regulates VBZ
a DT
series NN
of IN
genes NNS
involved VBN
in IN
immune JJ
and CC
inflammatory JJ
responses NNS
. O

The DT
KBF1/p50 NN
factor NN
binds VBZ
as IN
a DT
homodimer NN
but CC
can MD
also RB
form VB
heterodimers NNS
with IN
the DT
products NNS
of IN
other JJ
members NNS
of IN
the DT
same JJ
family NN
, O
like IN
the DT
c-rel NN
and CC
v-rel NN
( O
proto NN
) O
oncogenes NNS
. O

The DT
dimerization NN
domain NN
of IN
KBF1/p50 NN
is VBZ
contained VBN
between IN
amino NN
acids NNS
201 CD
and CC
367 CD
. O

A DT
mutant NN
of IN
KBF1/p50 NN
( O
delta NN
SP NN
) O
, O
unable JJ
to TO
bind VB
to TO
DNA NN
but CC
able JJ
to TO
form VB
homo- JJ
or CC
heterodimers NNS
, O
has VBZ
been VBN
constructed VBN
. O

This DT
protein NN
reduces VBZ
or CC
abolishes VBZ
in FW
vitro FW
the DT
DNA NN
binding NN
activity NN
of IN
wild-type JJ
proteins NNS
of IN
the DT
same JJ
family NN
( O
KBF1/p50 NN
, O
c- NN
and CC
v-rel NN
) O
. O

This DT
mutant JJ
also RB
functions NNS
in FW
vivo FW
as IN
a DT
trans-acting JJ
dominant JJ
negative JJ
regulator NN
: O
the DT
transcriptional JJ
inducibility NN
of IN
the DT
HIV NN
long JJ
terminal JJ
repeat NN
( O
which WDT
contains VBZ
two CD
potential JJ
NF-kappa NN
B NN
binding NN
sites NNS
) O
by IN
phorbol NN
ester NN
( O
PMA NN
) O
is VBZ
inhibited VBN
when WRB
it PRP
is VBZ
co-transfected VBN
into IN
CD4+ JJ
T NN
cells NNS
with IN
the DT
delta NN
SP NN
mutant NN
. O

Similarly RB
the DT
basal JJ
as RB
well RB
as IN
TNF NN
or CC
IL1-induced JJ
activity NN
of IN
the DT
MHC NN
class NN
I CD
H-2Kb NN
promoter NN
can MD
be VB
inhibited VBN
by IN
this DT
mutant NN
in IN
two CD
different JJ
cell NN
lines NNS
. O

These DT
results NNS
constitute VBP
the DT
first JJ
formal JJ
demonstration NN
that IN
these DT
genes NNS
are VBP
regulated VBN
by IN
members NNS
of IN
the DT
rel/NF-kappa NN
B NN
family NN
. O

Human JJ
erythroid JJ
5-aminolevulinate NN
synthase NN
: O
promoter NN
analysis NN
and CC
identification NN
of IN
an DT
iron-responsive JJ
element NN
in IN
the DT
mRNA NN
. O

5-Aminolevulinate NN
synthase NN
( O
ALAS NN
) O
catalyzes VBZ
the DT
first JJ
step NN
of IN
the DT
heme NN
biosynthetic JJ
pathway NN
. O

cDNA NN
clones NNS
for IN
the DT
human JJ
erythroid JJ
ALAS NN
isozyme NN
were VBD
isolated VBN
from IN
a DT
fetal JJ
liver NN
library NN
. O

It PRP
can MD
be VB
deduced VBN
that IN
the DT
erythroid JJ
ALAS NN
precursor NN
protein NN
has VBZ
a DT
molecular JJ
weight NN
of IN
64.6 CD
kd NN
, O
and CC
is VBZ
similar JJ
in IN
size NN
to TO
the DT
previously RB
isolated VBN
human JJ
housekeeping JJ
ALAS NN
precursor NN
of IN
molecular JJ
weight NN
70.6 CD
kd NN
. O

The DT
mature JJ
mitochondrial JJ
forms NNS
of IN
the DT
erythroid JJ
and CC
housekeeping JJ
ALAS NN
isozymes NNS
are VBP
predicted VBN
to TO
have VB
molecular JJ
weights NNS
of IN
59.5 CD
kd NN
and CC
64.6 CD
kd NN
, O
respectively RB
. O

The DT
two CD
isozymes NNS
show VBP
little JJ
amino NN
acid NN
identity NN
in IN
their PRP$
N-terminal JJ
signal NN
sequences NNS
but CC
have VBP
considerable JJ
sequence NN
identity NN
in IN
the DT
C-terminal JJ
two-thirds CD
of IN
their PRP$
proteins NNS
. O

An DT
analysis NN
of IN
the DT
immediate JJ
promoter NN
of IN
the DT
human JJ
erythroid JJ
ALAS NN
gene NN
revealed VBD
several JJ
putative JJ
erythroid-specific JJ
cis-acting JJ
elements NNS
including VBG
both PDT
a DT
GATA-1 NN
and CC
an DT
NF-E2 NN
binding NN
site NN
. O

An DT
iron-responsive JJ
element NN
( O
IRE NN
) O
motif NN
has VBZ
been VBN
identified VBN
in IN
the DT
5'-untranslated JJ
region NN
of IN
the DT
human JJ
erythroid JJ
ALAS NN
mRNA NN
, O
but CC
is VBZ
not RB
present JJ
in IN
the DT
housekeeping JJ
ALAS NN
mRNA NN
. O

Gel NN
retardation NN
experiments NNS
established VBD
that IN
this DT
IRE NN
motif NN
formed VBD
a DT
protein-RNA JJ
complex NN
with IN
cytosolic JJ
extracts NNS
from IN
human JJ
K562 NN
cells NNS
and CC
this DT
binding NN
was VBD
strongly RB
competed VBN
with IN
IRE NN
transcripts NNS
from IN
ferritin NN
or CC
transferrin NN
receptor NN
mRNAs NNS
. O

A DT
transcript NN
of IN
the DT
ALAS NN
IRE NN
, O
mutated VBN
in IN
the DT
conserved VBN
loop NN
of IN
the DT
IRE NN
, O
did VBD
not RB
readily RB
form VB
this DT
protein-RNA JJ
complex NN
. O

These DT
results NNS
suggest VBP
that IN
the DT
IRE NN
motif NN
in IN
the DT
ALAS NN
mRNA NN
is VBZ
functional JJ
and CC
imply VBP
that IN
translation NN
of IN
the DT
mRNA NN
is VBZ
controlled VBN
by IN
cellular JJ
iron NN
availability NN
during IN
erythropoiesis NN
. O

Human JJ
tumor NN
necrosis NN
factor NN
alpha NN
gene NN
regulation NN
in IN
phorbol NN
ester NN
stimulated VBD
T NN
and CC
B NN
cell NN
lines NNS
. O

The DT
minimal JJ
region NN
of IN
the DT
human JJ
tumor NN
necrosis NN
factor NN
alpha NN
( O
TNF-alpha NN
) O
gene NN
promoter NN
necessary JJ
for IN
its PRP$
transcriptional JJ
induction NN
by IN
phorbol NN
esters NNS
( O
PMA NN
) O
in IN
human JJ
T NN
and CC
B NN
lymphocyte NN
cell NN
lines NNS
has VBZ
been VBN
localized JJ
between IN
-52 CD
and CC
+89 CD
nucleotides NNS
( O
nt NN
) O
relative JJ
to TO
the DT
gene NN
's POS
transcriptional JJ
start NN
site NN
. O

Comparison NN
of IN
these DT
sequences NNS
to TO
those DT
required VBN
to TO
mediate VB
virus NN
or CC
lipopolysaccharide NN
( O
LPS NN
) O
induction NN
of IN
the DT
gene NN
reveal VB
significant JJ
differences NNS
, O
and CC
thus RB
, O
the DT
sequence NN
requirements NNS
for IN
PMA NN
induction NN
are VBP
distinct JJ
from IN
those DT
that WDT
mediate VBP
induction NN
by IN
virus NN
or CC
LPS NN
. O

Although IN
three CD
sites NNS
in IN
the DT
TNF-alpha NN
promoter NN
( O
kappa NN
1 CD
, O
kappa NN
2 CD
, O
and CC
kappa NN
3 CD
) O
specifically RB
bind VBP
the DT
transcription NN
factor NN
NF-kappa NN
B NN
in IN
lymphoid JJ
nuclear JJ
extracts NNS
, O
TNF-alpha NN
mRNA NN
induction NN
by IN
PMA NN
does VBZ
not RB
correlate VB
with IN
NF-kappa NN
B NN
binding NN
activities NNS
displayed VBN
by IN
different JJ
T NN
and CC
B NN
cell NN
lines NNS
. O

Moreover RB
, O
kappa NN
1 CD
- O
kappa NN
3 CD
can MD
each DT
be VB
deleted VBN
from IN
the DT
TNF-alpha NN
promoter NN
with IN
little JJ
effect NN
on IN
the DT
gene NN
's POS
inducibility NN
by IN
PMA NN
. O

Therefore RB
, O
TNF-alpha NN
mRNA NN
induction NN
by IN
PMA NN
, O
like IN
its PRP$
induction NN
by IN
virus NN
and CC
LPS NN
, O
is VBZ
not RB
primarily RB
mediated VBN
by IN
NF-kappa NN
B NN
, O
but CC
rather RB
is VBZ
mediated VBN
through IN
other JJ
sequences NNS
and CC
protein NN
factors NNS
. O

Surprisingly RB
, O
multimers NNS
of IN
kappa NN
1 CD
- O
kappa NN
3 CD
can MD
confer VB
PMA NN
inducibility NN
on IN
a DT
heterologous JJ
promoter NN
in IN
a DT
B NN
( O
Raji NN
) O
, O
but CC
not RB
a DT
T NN
( O
HUT78 NN
) O
cell NN
line NN
. O

However WRB
they PRP
are VBP
not RB
functional JJ
on IN
a DT
truncated VBN
TNF-alpha NN
promoter NN
, O
indicating VBG
that IN
promoter NN
context NN
and CC
cell NN
type NN
specificity NN
influence VBP
the DT
PMA NN
inducible JJ
function NN
of IN
these DT
NF-kappa NN
B NN
binding NN
sites NNS
. O

Towards IN
a DT
molecular JJ
understanding NN
of IN
T-cell NN
differentiation NN
. O

Lymphoid JJ
differentiation NN
is VBZ
one CD
of IN
the DT
best RBS
studied VBN
examples NNS
of IN
mammalian JJ
development NN
. O

Here RB
Hans NNP
Clevers NNP
and CC
Michael NNP
Owen NNP
describe VBP
how WRB
the DT
cloning NN
of IN
the DT
genes NNS
that WDT
encode VBP
T-cell-specific JJ
membrane NN
proteins NNS
allows VBZ
the DT
identification NN
of IN
transcription NN
factors NNS
that WDT
control VBP
the DT
expression NN
of IN
these DT
T-cell NN
genes NNS
. O

Such JJ
transcription NN
factors NNS
play VBP
a DT
key JJ
role NN
in IN
the DT
development NN
of IN
the DT
mature JJ
T-cell NN
phenotype NN
by IN
functioning VBG
as IN
' [[DQS]]
master JJ
regulators NNS
of IN
T-cell NN
differentiation NN
' [[DQE]]
. O

Regulation NN
of IN
jun NN
and CC
fos NN
gene NN
expression NN
in IN
human JJ
monocytes NNS
by IN
the DT
macrophage NN
colony-stimulating JJ
factor NN
. O

The DT
macrophage NN
colony-stimulating JJ
factor NN
( O
M-CSF NN
) O
is VBZ
required VBN
for IN
the DT
growth NN
and CC
differentiation NN
of IN
mononuclear JJ
phagocytes NNS
. O

However RB
, O
the DT
signaling NN
events NNS
responsible JJ
for IN
these DT
effects NNS
remain VBP
unclear JJ
. O

The DT
present JJ
studies NNS
have VBP
examined VBN
the DT
effects NNS
of IN
M-CSF NN
on IN
potential JJ
signaling NN
pathways NNS
involving VBG
expression NN
of IN
the DT
jun NN
and CC
fos NN
early JJ
response NN
genes NNS
. O

Low JJ
levels NNS
of IN
c-jun NN
transcripts NNS
were VBD
detectable JJ
in IN
resting VBG
human JJ
peripheral JJ
blood NN
monocytes NNS
. O

Treatment NN
of IN
these DT
cells NNS
with IN
10(3) CD
units/ml NNS
human JJ
recombinant JJ
M-CSF NN
was VBD
associated VBN
with IN
rapid JJ
and CC
transient JJ
increases NNS
in IN
c-jun NN
mRNA NN
levels NNS
. O

Nuclear JJ
run-on JJ
assays NNS
and CC
mRNA NN
stability NN
studies NNS
demonstrated VBD
that IN
M-CSF NN
regulates VBZ
c-jun NN
expression NN
by IN
both CC
an DT
increase NN
in IN
transcription NN
rate NN
and CC
a DT
prolongation NN
in IN
the DT
half-life NN
of IN
c-jun NN
transcripts NNS
. O

M-CSF NN
treatment NN
was VBD
also RB
associated VBN
with IN
a DT
rapid JJ
induction NN
of IN
the DT
jun-B NN
gene NN
, O
although IN
expression NN
of IN
this DT
gene NN
was VBD
prolonged JJ
compared VBN
to TO
that DT
of IN
c-jun NN
. O

We PRP
further RB
demonstrate VBP
that IN
M-CSF NN
increases VBZ
c-fos NN
mRNA NN
levels NNS
in IN
human JJ
monocytes NNS
through IN
control NN
at IN
both CC
the DT
transcriptional JJ
and CC
posttranscriptional JJ
levels NNS
. O

Maximal JJ
induction NN
of IN
the DT
c-fos NN
gene NN
was VBD
followed VBN
by IN
that DT
for IN
the DT
fos-B NN
gene NN
. O

Moreover RB
, O
M-CSF-induced JJ
expression NN
of IN
the DT
fos-related JJ
gene NN
, O
fra-1 NN
, O
was VBD
delayed VBN
compared VBN
to TO
that DT
for IN
both DT
c-fos NN
and CC
fos-B NN
. O

Taken VBN
together RB
, O
the DT
results NNS
indicate VBP
that IN
M-CSF NN
treatment NN
is VBZ
associated VBN
with IN
differential JJ
activation NN
of IN
multiple JJ
members NNS
of IN
the DT
jun/fos NN
family NN
and CC
that IN
expression NN
of IN
these DT
genes NNS
could MD
contribute VB
to TO
nuclear JJ
signaling NN
mechanisms NNS
that WDT
regulate VBP
a DT
specific JJ
program NN
of IN
monocyte NN
differentiation NN
. O

Cloning NN
of IN
a DT
human JJ
homeobox NN
gene NN
that WDT
resembles VBZ
a DT
diverged JJ
Drosophila NN
homeobox NN
gene NN
and CC
is VBZ
expressed VBN
in IN
activated VBN
lymphocytes NNS
. O

A DT
new JJ
homeobox NN
gene NN
, O
HB24 NN
, O
has VBZ
been VBN
isolated VBN
from IN
a DT
human JJ
B-lymphocyte NN
cDNA NN
library NN
. O

Northern JJ|NN
blot NN
analysis NN
of IN
polyadenylated JJ
RNA NN
purified VBN
from IN
activated VBN
human JJ
B NN
cells NNS
revealed VBD
a DT
single JJ
mRNA NN
transcript NN
of IN
approximately RB
2.3 CD
kb NN
. O

Two CD
cDNA NN
clones NNS
were VBD
sequenced VBN
and CC
provided VBN
2,250 CD
nucleotides NNS
( O
nt NN
) O
of IN
DNA NN
sequence NN
information NN
. O

There EX
is VBZ
a DT
single JJ
methionine NN
codon-initiated JJ
open JJ
reading NN
frame NN
of IN
1,458 CD
nt NN
in IN
frame NN
with IN
a DT
homeobox NN
and CC
a DT
CAX NN
repeat NN
, O
and CC
the DT
open JJ
reading NN
frame NN
is VBZ
predicted VBN
to TO
encode VB
a DT
protein NN
of IN
51,659 CD
daltons NNS
. O

When WRB
the DT
homeodomain NN
from IN
HB24 NN
was VBD
compared VBN
to TO
known JJ
mammalian JJ
and CC
Drosophila NN
homeodomains NNS
it PRP
was VBD
found VBN
to TO
be VB
only RB
moderately RB
conserved VBN
, O
but CC
when WRB
it PRP
was VBD
compared VBN
to TO
a DT
highly RB
diverged JJ
Drosophila FW
homeodomain NN
, O
H2.0 NN
, O
it PRP
was VBD
found VBN
to TO
be VB
80 CD
% NN
identical JJ
. O

The DT
HB24 NN
mRNA NN
was VBD
absent JJ
or CC
present JJ
at IN
low JJ
levels NNS
in IN
normal JJ
B NN
and CC
T NN
lymphocytes NNS
; O
however RB
, O
with IN
the DT
appropriate JJ
activation NN
signal NN
HB24 NN
mRNA NN
was VBD
induced VBN
within IN
several JJ
hours NNS
even RB
in IN
the DT
presence NN
of IN
cycloheximide NN
. O

Characterization NN
of IN
HB24 NN
expression NN
in IN
lymphoid JJ
and CC
select JJ
developing VBG
tissues NNS
was VBD
performed VBN
by IN
in FW
situ FW
hybridization NN
. O

Positive JJ
hybridization NN
was VBD
found VBN
in IN
thymus NN
, O
tonsil NN
, O
bone NN
marrow NN
, O
developing VBG
vessels NNS
, O
and CC
in IN
fetal JJ
brain NN
. O

HB24 NN
is VBZ
likely JJ
to TO
have VB
an DT
important JJ
role NN
in IN
lymphocytes NNS
as RB
well RB
as IN
in IN
certain JJ
developing VBG
tissues NNS
. O

Severe JJ
5-fluorouracil NN
toxicity NN
secondary JJ
to TO
dihydropyrimidine NN
dehydrogenase NN
deficiency NN
. O

A DT
potentially RB
more RBR
common JJ
pharmacogenetic JJ
syndrome NN
. O

This DT
study NN
describes VBZ
the DT
inheritance NN
of IN
a DT
defect NN
in IN
pyrimidine NN
catabolism NN
and CC
its PRP$
association NN
with IN
drug-induced JJ
toxicity NN
in IN
a DT
patient NN
receiving VBG
5-fluorouracil NN
( O
FUra NN
) O
as IN
adjuvant JJ
chemotherapy NN
for IN
breast NN
carcinoma NN
. O

The DT
study NN
population NN
included VBD
the DT
affected VBN
patient NN
( O
proband NN
) O
, O
nine CD
of IN
her PRP$
blood NN
relatives NNS
, O
and CC
seven CD
healthy JJ
volunteers NNS
. O

The DT
activity NN
of IN
dihydropyrimidine NN
dehydrogenase NN
( O
DPD NN
) O
, O
the DT
initial JJ
enzyme NN
of IN
pyrimidine NN
( O
and CC
FUra NN
) O
catabolism NN
, O
in IN
peripheral JJ
blood NN
mononuclear JJ
cells NNS
was VBD
measured VBN
in IN
each DT
subject NN
by IN
a DT
specific JJ
radiometric JJ
assay NN
using VBG
FUra NN
as IN
the DT
substrate NN
. O

The DT
proband NN
had VBD
no DT
detectable JJ
DPD NN
activity NN
. O

When WRB
enzyme NN
levels NNS
in IN
the DT
proband NN
and CC
relatives NNS
were VBD
compared VBN
with IN
that DT
in NN
controls NNS
, O
an DT
autosomal JJ
recessive JJ
pattern NN
of IN
inheritance NN
was VBD
demonstrated VBN
. O

This DT
is VBZ
the DT
third JJ
patient NN
with IN
severe JJ
FUra NN
toxicity NN
secondary JJ
to TO
an DT
alteration NN
in IN
pyrimidine NN
catabolism NN
and CC
the DT
second NN
from IN
our PRP$
clinic NN
population NN
suggesting VBG
that IN
the DT
frequency NN
of IN
this DT
genetic JJ
defect NN
may MD
be VB
greater JJR
than IN
previously RB
thought VBN
. O

Monitoring VBG
DPD NN
activity NN
may MD
be VB
important JJ
in IN
the DT
management NN
of IN
patients NNS
experiencing VBG
severe JJ
toxicity NN
secondary JJ
to TO
FUra NN
chemotherapy NN
. O

Characterization NN
of IN
an DT
immediate-early JJ
gene NN
induced VBN
in IN
adherent JJ
monocytes NNS
that WDT
encodes VBZ
I NN
kappa NN
B-like JJ
activity NN
. O

We PRP
have VBP
cloned VBN
a DT
group NN
of IN
cDNAs NNS
representing VBG
mRNAs NNS
that WDT
are VBP
rapidly RB
induced VBN
following VBG
adherence NN
of IN
human JJ
monocytes NNS
. O

One CD
of IN
the DT
induced VBN
transcripts NNS
( O
MAD-3 NN
) O
encodes VBZ
a DT
protein NN
of IN
317 CD
amino NN
acids NNS
with IN
one CD
domain NN
containing VBG
five CD
tandem JJ
repeats NNS
of IN
the DT
cdc10/ankyrin JJ
motif NN
, O
which WDT
is VBZ
60 CD
% NN
similar JJ
( O
46 CD
% NN
identical JJ
) O
to TO
the DT
ankyrin NN
repeat NN
region NN
of IN
the DT
precursor NN
of IN
NF-kappa NN
B/KBF1 NN
p50 NN
. O

The DT
C-terminus NN
has VBZ
a DT
putative JJ
protein NN
kinase NN
C NN
phosphorylation NN
site NN
. O

In FW
vitro FW
translated VBN
MAD-3 NN
protein NN
was VBD
found VBN
to TO
specifically RB
inhibit VB
the DT
DNA-binding JJ
activity NN
of IN
the DT
p50/p65 NN
NF-kappa NN
B NN
complex NN
but CC
not RB
that DT
of IN
the DT
p50/p50 NN
KBF1 NN
factor NN
or CC
of IN
other JJ
DNA-binding JJ
proteins NNS
. O

The DT
MAD-3 NN
cDNA NN
encodes VBZ
an DT
I NN
kappa NN
B-like JJ
protein NN
that WDT
is VBZ
likely JJ
to TO
be VB
involved VBN
in IN
regulation NN
of IN
transcriptional JJ
responses NNS
to TO
NF-kappa NN
B NN
, O
including VBG
adhesion-dependent JJ
pathways NNS
of IN
monocyte NN
activation NN
. O

Reactive JJ
oxygen NN
intermediates NNS
as IN
apparently RB
widely RB
used VBN
messengers NNS
in IN
the DT
activation NN
of IN
the DT
NF-kappa NN
B NN
transcription NN
factor NN
and CC
HIV-1 NN
. O

Hydrogen NN
peroxide NN
and CC
oxygen NN
radicals NNS
are VBP
agents NNS
commonly RB
produced VBN
during IN
inflammatory JJ
processes NNS
. O

In IN
this DT
study NN
, O
we PRP
show VBP
that IN
micromolar JJ
concentrations NNS
of IN
H2O2 NN
can MD
induce VB
the DT
expression NN
and CC
replication NN
of IN
HIV-1 NN
in IN
a DT
human JJ
T NN
cell NN
line NN
. O

The DT
effect NN
is VBZ
mediated VBN
by IN
the DT
NF-kappa NN
B NN
transcription NN
factor NN
which WDT
is VBZ
potently RB
and CC
rapidly RB
activated VBN
by IN
an DT
H2O2 NN
treatment NN
of IN
cells NNS
from IN
its PRP$
inactive JJ
cytoplasmic JJ
form NN
. O

N-acetyl-L-cysteine NN
( O
NP NN
) O
, O
a DT
well RB
characterized VBN
antioxidant NN
which WDT
counteracts VBZ
the DT
effects NNS
of IN
reactive JJ
oxygen NN
intermediates NNS
( O
ROI NN
) O
in IN
living VBG
cells NNS
, O
prevented VBD
the DT
activation NN
of IN
NF-kappa NN
B NN
by IN
H2O2 NN
. O

NP NN
and CC
other JJ
thiol JJ
compounds NNS
also RB
blocked VBD
the DT
activation NN
of IN
NF-kappa NN
B NN
by IN
cycloheximide NN
, O
double-stranded JJ
RNA NN
, O
calcium NN
ionophore NN
, O
TNF-alpha NN
, O
active JJ
phorbol NN
ester NN
, O
interleukin-1 NN
, O
lipopolysaccharide NN
and CC
lectin NN
. O

This DT
suggests VBZ
that IN
diverse JJ
agents NNS
thought VBN
to TO
activate VB
NF-kappa NN
B NN
by IN
distinct JJ
intracellular JJ
pathways NNS
might MD
all DT
act VB
through IN
a DT
common JJ
mechanism NN
involving VBG
the DT
synthesis NN
of IN
ROI NN
. O

ROI NN
appear VBP
to TO
serve VB
as IN
messengers NNS
mediating VBG
directly RB
or CC
indirectly RB
the DT
release NN
of IN
the DT
inhibitory JJ
subunit NN
I NN
kappa NN
B NN
from IN
NF-kappa NN
B NN
. O

HTLV-1 NN
Tax NN
induces VBZ
expression NN
of IN
various JJ
immediate JJ
early JJ
serum NN
responsive JJ
genes NNS
. O

Human JJ
T-cell NN
leukemia NN
virus NN
type NN
1 CD
( O
HTLV-1 NN
) O
is VBZ
an DT
etiological JJ
agent NN
of IN
adult JJ
T-cell NN
leukemia NN
( O
ATL NN
) O
. O

We PRP
showed VBD
here RB
by IN
mobility-shift NN
assay NN
that IN
T-cell NN
lines NNS
transformed VBN
with IN
the DT
virus NN
contained VBD
high JJ
levels NNS
of IN
AP-1 NN
activities NNS
. O

Consistent JJ
with IN
this DT
result NN
, O
these DT
cell NN
lines NNS
expressed VBD
increased VBN
levels NNS
of IN
mRNAs NNS
encoding VBG
the DT
AP-1 NN
proteins NNS
, O
c-Fos NN
, O
Fra-1 NN
, O
c-Jun NN
, O
JunB NN
, O
and CC
JunD NN
. O

Previously RB
, O
transcription NN
of IN
the DT
c-fos NN
gene NN
has VBZ
been VBN
reported VBN
to TO
be VB
transactivated VBN
by IN
the DT
viral JJ
transcription NN
factor NN
, O
Tax1 NN
. O

By IN
using VBG
the DT
human JJ
T-cell NN
line NN
( O
JPX-9 NN
) O
, O
in IN
which WDT
expression NN
of IN
the DT
Tax1 NN
is VBZ
inducible JJ
, O
we PRP
showed VBD
that IN
expression NN
of IN
mRNAs NNS
for IN
Fra-1 NN
, O
c-Jun NN
, O
and CC
JunD NN
was VBD
also RB
transactivated VBN
by IN
Tax1 NN
. O

Moreover RB
, O
Tax1 NN
activated VBD
expression NN
of IN
two CD
other JJ
transcription NN
factors NNS
having VBG
zinc NN
finger NN
motifs NNS
, O
Egr-1 NN
and CC
Egr-2 NN
, O
in IN
the DT
same JJ
cells NNS
. O

The DT
Tax1-inducible JJ
transcription NN
factors NNS
identified VBN
here RB
are VBP
encoded VBN
by IN
the DT
members NNS
of IN
immediate JJ
early JJ
genes NNS
under IN
the DT
control NN
of IN
growth NN
signals NNS
. O

Thus RB
, O
Tax1 NN
was VBD
suggested VBN
to TO
replace VB
growth NN
signals NNS
, O
at IN
least JJS
in IN
part NN
, O
by IN
this DT
mechanism NN
. O

Contribution NN
of IN
NF-kappa NN
B NN
and CC
Sp1 NN
binding NN
motifs NNS
to TO
the DT
replicative JJ
capacity NN
of IN
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
: O
distinct JJ
patterns NNS
of IN
viral JJ
growth NN
are VBP
determined VBN
by IN
T-cell NN
types NNS
. O

Starting VBG
with IN
a DT
replication-incompetent JJ
molecular JJ
clone NN
of IN
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
, O
lacking VBG
all PDT
the DT
NF-kappa NN
B NN
and CC
Sp1 NN
binding NN
sites NNS
present JJ
in IN
the DT
native JJ
long JJ
terminal JJ
repeat NN
( O
LTR NN
) O
, O
proviruses NNS
containing VBG
reconstructed VBN
LTRs NNS
with IN
individual JJ
or CC
combinations NNS
of IN
NF-kappa NN
B NN
and CC
Sp1 NN
elements NNS
were VBD
generated VBN
and CC
evaluated VBN
for IN
their PRP$
capacity NN
to TO
produce VB
virus NN
progeny NN
following VBG
transfection-cocultivation NN
. O

Virus NN
stocks NNS
obtained VBN
from IN
these DT
experiments NNS
exhibited VBD
a DT
continuum NN
of IN
replicative JJ
capacities NNS
in IN
different JJ
human JJ
T-cell NN
types NNS
depending VBG
on IN
which WDT
element NN
( O
s NNS
) O
was VBD
present JJ
in IN
the DT
LTR NN
. O

For IN
example NN
, O
in IN
experiments NNS
involving VBG
proviral JJ
clones NNS
with IN
LTRs NNS
containing VBG
one CD
or CC
two CD
NF-kappa NN
B NN
elements NNS
( O
and CC
no DT
Sp1 NN
binding NN
sites NNS
) O
, O
a DT
hierarchy NN
of IN
cellular JJ
permissivity NN
to TO
virus NN
replication NN
( O
peripheral JJ
blood NN
lymphocytes NNS
= JJ
MT4 NN
greater JJR
than IN
H9 NN
greater JJR
than IN
CEM NN
greater JJR
than IN
Jurkat NN
) O
was VBD
observed VBN
. O

Of IN
note NN
was VBD
the DT
associated VBN
emergence NN
of IN
second-site JJ
LTR NN
revertants NNS
which WDT
involved VBD
an DT
alteration NN
of IN
the DT
TATA NN
box NN
. O

These DT
results NNS
suggest VBP
that IN
the DT
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
LTR NN
possesses VBZ
functional JJ
redundancy NN
which WDT
ensures VBZ
virus NN
replication NN
in IN
different JJ
T-cell NN
types NNS
and CC
is VBZ
capable JJ
of IN
changing VBG
depending VBG
on IN
the DT
particular JJ
combination NN
of IN
transcriptional JJ
factors NNS
present JJ
. O

Enhancement NN
of IN
human JJ
immunodeficiency NN
virus NN
1 CD
replication NN
in IN
monocytes NNS
by IN
1,25-dihydroxycholecalciferol NN
. O

Human JJ
immunodeficiency NN
virus NN
( O
HIV NN
) O
expression NN
and CC
replication NN
are VBP
under IN
tight JJ
regulatory JJ
control NN
. O

We PRP
demonstrate VBP
that IN
1,25-dihydroxycholecalciferol NN
( O
1,25-(OH)2D3 NN
) O
enhances VBZ
the DT
replication NN
of IN
monocyte- NN
and CC
lymphocyte-tropic JJ
strains NNS
of IN
HIV-1 NN
up IN
to TO
10,000-fold RB
in IN
monocyte NN
cell NN
lines NNS
, O
peripheral JJ
blood NN
monocytes NNS
, O
and CC
unfractionated JJ
peripheral JJ
blood NN
mononuclear JJ
cells NNS
. O

1,25(OH)2D3 NN
is VBZ
therefore RB
one CD
of IN
the DT
most RBS
potent JJ
regulators NNS
of IN
HIV-1 NN
replication NN
described VBN
to TO
date NN
. O

Precursors NNS
of IN
1,25(OH)2D3 NN
enhance VBP
HIV-1 NN
replication NN
in IN
proportion NN
to TO
their PRP$
affinity NN
for IN
the DT
1,25(OH)2D3 NN
intracellular JJ
receptor NN
, O
suggesting VBG
that IN
1,25(OH)2D3 NN
influences VBZ
HIV-1 NN
replication NN
by IN
mechanisms NNS
involving VBG
this DT
receptor NN
. O

These DT
studies NNS
may MD
have VB
important JJ
implications NNS
for IN
the DT
design NN
of IN
effective JJ
therapy NN
of IN
HIV-1 NN
infection NN
. O

Inhibition NN
of IN
HIV-1 NN
replication NN
and CC
NF-kappa NN
B NN
activity NN
by IN
cysteine NN
and CC
cysteine NN
derivatives NNS
. O

HIV-1 NN
proviral JJ
DNA NN
contains VBZ
two CD
binding VBG
sites NNS
for IN
the DT
transcription NN
factor NN
NF-kappa NN
B NN
. O

HIV-1-infected JJ
individuals NNS
have VBP
, O
on IN
average NN
, O
abnormally RB
high JJ
levels NNS
of IN
tumour NN
necrosis NN
factor NN
alpha NN
( O
TNF NN
alpha NN
) O
and CC
abnormally RB
low JJ
plasma NN
cysteine NN
levels NNS
. O

We PRP
therefore RB
investigated VBD
the DT
effects NNS
of IN
cysteine NN
and CC
related JJ
thiols NNS
on IN
HIV-1 NN
replication NN
and CC
NF-kappa NN
B NN
expression NN
. O

The DT
experiments NNS
in IN
this DT
report NN
show VBP
that IN
cysteine NN
or CC
N-acetylcysteine NN
( O
NP NN
) O
raise VBP
the DT
intracellular JJ
glutathione NN
( O
GSH NN
) O
level NN
and CC
inhibit VBP
HIV-1 NN
replication NN
in IN
persistently RB
infected JJ
Molt-4 NN
and CC
U937 NN
cells NNS
. O

However RB
, O
inhibition NN
of IN
HIV-1 NN
replication NN
appears VBZ
not RB
to TO
be VB
directly RB
correlated VBN
with IN
GSH NN
levels NNS
. O

Cysteine NN
and CC
NP NN
also RB
inhibit VBP
NF-kappa NN
B NN
activity NN
as IN
determined VBN
by IN
electrophoretic JJ
mobility NN
shift NN
assays NNS
and CC
chloramphenicol NN
acetyl-transferase NN
( O
CAT NN
) O
gene NN
expression NN
under IN
control NN
of IN
NF-kappa NN
B NN
binding NN
sites NNS
in IN
uninfected JJ
cells NNS
. O

This DT
suggests VBZ
that IN
the DT
cysteine NN
deficiency NN
in IN
HIV-1-infected JJ
individuals NNS
may MD
cause VB
an DT
over-expression NN
of IN
NF-kappa NN
B-dependent JJ
genes NNS
and CC
enhance VB
HIV-1 NN
replication NN
. O

NP NN
may MD
be VB
considered VBN
for IN
the DT
treatment NN
of IN
HIV-1-infected JJ
individuals NNS
. O

Glucocorticoid NN
receptors NNS
in IN
systemic JJ
lupus NN
erythematosus NN
. O

Glucocorticosteroids NNS
remain VBP
the DT
major JJ
treatment NN
modality NN
for IN
systemic JJ
lupus NN
erythematosus NN
( O
SLE NN
) O
, O
but CC
their PRP$
mechanism NN
of IN
action NN
is VBZ
unclear JJ
. O

Over IN
the DT
past JJ
decade NN
it PRP
has VBZ
become VBN
clear JJ
that IN
glucocorticosteroid NN
receptors NNS
play VBP
a DT
significant JJ
role NN
in IN
the DT
mechanism NN
of IN
glucocorticosteroid NN
action NN
. O

We PRP
studied VBD
glucocorticosteroid NN
receptor NN
density NN
and CC
affinity NN
on IN
peripheral JJ
blood NN
mononuclear JJ
cells NNS
by IN
the DT
glucocorticosteroid NN
binding NN
assay NN
in IN
33 CD
patients NNS
with IN
SLE NN
who WP
had VBD
taken VBN
no DT
glucocorticosteroid NN
for IN
the DT
previous JJ
6 CD
months NNS
and CC
in IN
32 CD
healthy JJ
controls NNS
. O

Patients NNS
' POS
disease NN
activity NN
was VBD
measured VBN
by IN
the DT
SLE NN
Disease NN
Activity NN
Index NN
( O
SLEDAI NN
) O
. O

Glucocorticosteroid NN
receptors NNS
on IN
leukocytes NNS
of IN
patients NNS
with IN
SLE NN
were VBD
significantly RB
higher JJR
than IN
in IN
healthy JJ
controls NNS
( O
4419 CD
+/- CC
306 CD
vs CC
3369 CD
+/- CC
196 CD
, O
p NN
less JJR
than IN
0.005 CD
) O
. O

The DT
binding NN
affinity NN
was VBD
not RB
different JJ
between IN
patients NNS
and CC
controls NNS
. O

There EX
was VBD
no DT
correlation NN
between IN
glucocorticosteroid NN
receptor NN
number NN
and CC
SLE NN
disease NN
activity NN
. O

( O
Changes NNS
in IN
leucocytic JJ
estrogen NN
receptor NN
levels NNS
in IN
patients NNS
with IN
gynecomastia NN
) O

The DT
number NN
of IN
estrogen NN
receptor NN
( O
ER NN
) O
in IN
human JJ
peripheral JJ
leucocytes NNS
in IN
13 CD
men NNS
with IN
gynecomastia NNS
were VBD
measured VBN
by IN
radioligand NN
binding NN
method NN
. O

The DT
results NNS
were VBD
compared VBN
with IN
those DT
of IN
13 CD
sex- NN
and CC
age-matched JJ
healthy JJ
subjects NNS
. O

It PRP
was VBD
found VBN
that IN
the DT
number NN
of IN
ER NN
in IN
leucocytes NNS
was VBD
significantly RB
increased VBN
in IN
gynecomastia NN
( O
Rs NN
of IN
leucocytes NNS
were VBD
1054 CD
+/- CC
254 CD
sites/cell NN
) O
. O

It PRP
suggested VBD
that IN
increase NN
of IN
ER NN
levels NNS
play VBP
an DT
important JJ
role NN
in IN
the DT
pathogenesis NN
of IN
gynecomastia NN
. O

( O
Changes NNS
in IN
levels NNS
of IN
leucocytic JJ
estrogen NN
receptor NN
in IN
patients NNS
with IN
menopausal JJ
type NN
II CD
diabetes NNS
and CC
its PRP$
significance NN
) O

The DT
number NN
of IN
estrogen NN
receptors NNS
( O
ER NN
) O
in IN
human JJ
peripheral JJ
leucocytes NNS
in IN
12 CD
women NNS
with IN
menopausal JJ
type NN
II CD
diabetes NNS
was VBD
measured VBN
with IN
radio-ligand JJ
binding NN
method NN
. O

The DT
results NNS
were VBD
compared VBN
with IN
those DT
of IN
12 CD
menopausal JJ
women NNS
without IN
diabetes NNS
and CC
12 CD
normal JJ
women NNS
of IN
childbearing JJ
age NN
. O

It PRP
was VBD
found VBN
that IN
the DT
number NN
of IN
ER NN
in IN
the DT
patients NNS
was VBD
significantly RB
decreased VBN
. O

Our PRP$
data NNS
indicate VBP
that IN
decrease NN
of IN
ER NN
level NN
in IN
leukocytes NNS
may MD
be VB
related JJ
to TO
the DT
pathogenesis NN
of IN
type NN
II CD
diabetes NNS
in IN
menopausal JJ
period NN
. O

Lymphocyte NN
glucocorticoid NN
receptor NN
binding NN
during IN
depression NN
and CC
after IN
clinical JJ
recovery NN
. O

Lymphocyte NN
glucocorticoid NN
receptor NN
binding NN
parameters NNS
were VBD
studied VBN
in IN
15 CD
severely RB
depressed JJ
patients NNS
during IN
depression NN
and CC
after IN
clinical JJ
recovery NN
, O
and CC
in IN
15 CD
healthy JJ
controls NNS
. O

There EX
was VBD
no DT
difference NN
in IN
glucocorticoid NN
receptor NN
number NN
or CC
affinity NN
between IN
depressed JJ
patients NNS
and CC
recovered JJ
or CC
control NN
subjects NNS
. O

Afternoon NN
ACTH NN
and CC
cortisol NN
concentrations NNS
did VBD
not RB
differ VB
significantly RB
between IN
the DT
three CD
groups NNS
. O

No DT
relationship NN
could MD
be VB
established VBN
between IN
glucocorticoid NN
receptor NN
binding NN
and CC
antidepressant JJ
medication NN
. O

These DT
data NNS
support VBP
the DT
view NN
of IN
an DT
impaired JJ
ligand-induced JJ
plasticity NN
of IN
glucocorticoid NN
receptor NN
regulation NN
rather RB
than IN
the DT
hypothesis NN
of IN
decreased VBN
glucocorticoid NN
receptor NN
numbers NNS
during IN
depression NN
. O

Nuclear JJ
association NN
of IN
a DT
T-cell NN
transcription NN
factor NN
blocked VBN
by IN
FK-506 NN
and CC
cyclosporin NN
A NN
( O
see VB
comments NNS
) O

Cyclosporin NN
A NN
and CC
FK506 NN
inhibit VBP
T- NN
and CC
B-cell NN
activation NN
and CC
other JJ
processes NNS
essential JJ
to TO
an DT
effective JJ
immune JJ
response NN
. O

In IN
T NN
lymphocytes NNS
these DT
drugs NNS
disrupt VBP
an DT
unknown JJ
step NN
in IN
the DT
transmission NN
of IN
signals NNS
from IN
the DT
T-cell NN
antigen NN
receptor NN
to TO
cytokine NN
genes NNS
that WDT
coordinate VBP
the DT
immune JJ
response NN
. O

The DT
putative JJ
intracellular JJ
receptors NNS
for IN
FK506 NN
and CC
cyclosporin NN
are VBP
cis-trans JJ
prolyl JJ
isomerases NNS
. O

Binding NN
of IN
the DT
drug NN
inhibits VBZ
isomerase NN
activity NN
, O
but CC
studies NNS
with IN
other JJ
prolyl JJ
isomerase NN
inhibitors NNS
and CC
analysis NN
of IN
cyclosporin-resistant JJ
mutants NNS
in IN
yeast NN
suggest VBP
that IN
the DT
effects NNS
of IN
the DT
drug NN
result VBP
from IN
the DT
formation NN
of IN
an DT
inhibitory JJ
complex NN
between IN
the DT
drug NN
and CC
isomerase NN
, O
and CC
not RB
from IN
inhibition NN
of IN
isomerase NN
activity NN
. O

A DT
transcription NN
factor NN
, O
NF-AT NN
, O
which WDT
is VBZ
essential JJ
for IN
early JJ
T-cell NN
gene NN
activation NN
, O
seems VBZ
to TO
be VB
a DT
specific JJ
target NN
of IN
cyclosporin NN
A NN
and CC
FK506 NN
action NN
because IN
transcription NN
directed VBN
by IN
this DT
protein NN
is VBZ
blocked VBN
in IN
T NN
cells NNS
treated VBN
with IN
these DT
drugs NNS
, O
with IN
little JJ
or CC
no DT
effect NN
on IN
other JJ
transcription NN
factors NNS
such JJ
as IN
AP-1 NN
and CC
NF-kappa NN
B NN
. O

Here RB
we PRP
demonstrate VBP
that IN
NF-AT NN
is VBZ
formed VBN
when WRB
a DT
signal NN
from IN
the DT
antigen NN
receptor NN
induces VBZ
a DT
pre-existing JJ
cytoplasmic JJ
subunit NN
to TO
translocate VB
to TO
the DT
nucleus NN
and CC
combine VB
with IN
a DT
newly RB
synthesized VBN
nuclear JJ
subunit NN
of IN
NF-AT NN
. O

FK506 NN
and CC
cyclosporin NN
A NN
block VBP
translocation NN
of IN
the DT
cytoplasmic JJ
component NN
without IN
affecting VBG
synthesis NN
of IN
the DT
nuclear JJ
subunit NN
. O

Regulation NN
of IN
M-CSF NN
expression NN
by IN
M-CSF NN
: O
role NN
of IN
protein NN
kinase NN
C NN
and CC
transcription NN
factor NN
NF NN
kappa NN
B NN
. O

Macrophage-colony-stimulating JJ
factor NN
( O
M-CSF NN
) O
, O
also RB
referred VBN
to TO
as IN
CSF-1 NN
, O
regulates VBZ
the DT
survival NN
, O
growth NN
, O
differentiation NN
and CC
functional JJ
activity NN
of IN
monocytes NNS
by IN
binding VBG
to TO
a DT
single JJ
class NN
of IN
high-affinity JJ
cell NN
surface NN
receptors NNS
, O
known VBN
to TO
be VB
the DT
product NN
of IN
the DT
c-fms NN
protooncogene NN
. O

The DT
detection NN
of IN
both CC
M-CSF NN
and CC
c-fms NN
expression NN
by IN
cells NNS
of IN
the DT
monocyte NN
lineage NN
has VBZ
suggested VBN
that IN
M-CSF NN
may MD
act VB
by IN
an DT
autocrine JJ
mechanism NN
. O

Interestingly RB
, O
it PRP
has VBZ
been VBN
shown VBN
that IN
M-CSF NN
can MD
induce VB
the DT
expression NN
of IN
its PRP$
own JJ
gene NN
. O

Although IN
sensitivity NN
to TO
M-CSF NN
can MD
be VB
modulated VBN
by IN
regulation NN
of IN
receptor NN
expression NN
and CC
function NN
, O
M-CSF NN
responsiveness NN
is VBZ
largely RB
determined VBN
at IN
a DT
postreceptor NN
level NN
. O

To TO
date NN
, O
little JJ
is VBZ
known VBN
about IN
the DT
intracellular JJ
pathway NN
of IN
M-CSF NN
signal NN
transduction NN
. O

We PRP
have VBP
therefore RB
investigated VBN
the DT
changes NNS
in IN
protein NN
kinase NN
C NN
( O
PKC NN
) O
activity NN
upon IN
exposure NN
of IN
monocytes NNS
to TO
M-CSF NN
. O

We PRP
show VBP
that IN
M-CSF NN
activates VBZ
and CC
translocates VBZ
PKC NN
. O

Inhibition NN
of IN
PKC NN
by IN
the DT
isoquinoline NN
derivative JJ
H7 NN
abolishes VBZ
induction NN
of IN
M-CSF NN
by IN
M-CSF NN
. O

Furthermore RB
, O
activation NN
of IN
PKC NN
was VBD
pertussis-toxin-sensitive JJ
and CC
was VBD
associated VBN
with IN
the DT
detection NN
of IN
an DT
NF NN
kappa NN
B NN
protein NN
in IN
nuclear JJ
extracts NNS
of IN
M-CSF-induced JJ
blood NN
monocytes NNS
but CC
not RB
in IN
monocytes NNS
exposed VBN
to TO
medium NN
treatment NN
only RB
. O

The DT
results NNS
suggest VBP
that IN
M-CSF NN
induction NN
of IN
M-CSF NN
involves VBZ
G NN
proteins NNS
, O
PKC NN
and CC
NF NN
kappa NN
B NN
. O

NF-kappa NN
B NN
activation NN
by IN
tumor NN
necrosis NN
factor NN
alpha NN
in IN
the DT
Jurkat NN
T NN
cell NN
line NN
is VBZ
independent JJ
of IN
protein NN
kinase NN
A NN
, O
protein NN
kinase NN
C NN
, O
and CC
Ca(2+)-regulated JJ
kinases NNS
. O

NF-kappa NN
B NN
is VBZ
a DT
DNA-binding JJ
regulatory JJ
factor NN
able JJ
to TO
control VB
transcription NN
of IN
a DT
number NN
of IN
genes NNS
, O
including VBG
human JJ
immunodeficiency NN
virus NN
( O
HIV NN
) O
genes NNS
. O

In IN
T NN
cells NNS
, O
NF-kappa NN
B NN
is VBZ
activated VBN
upon IN
cellular JJ
treatment NN
by IN
phorbol NN
esters NNS
and CC
the DT
cytokine NN
tumor NN
necrosis NN
factor NN
alpha NN
( O
TNF NN
alpha NN
) O
. O

In IN
the DT
present JJ
work NN
, O
we PRP
investigated VBD
the DT
molecular JJ
events NNS
leading VBG
to TO
NF-kappa NN
B NN
activation NN
by IN
TNF NN
alpha NN
in IN
a DT
human JJ
T NN
cell NN
line NN
( O
Jurkat NN
) O
and CC
its PRP$
subclone JJ
JCT6 NN
, O
which WDT
presents VBZ
a DT
deficiency NN
in IN
the DT
PKA NN
transduction NN
pathway NN
. O

We PRP
found VBD
that IN
in IN
both DT
cell NN
lines NNS
, O
both CC
phorbol NN
ester NN
and CC
TNF NN
alpha NN
were VBD
able JJ
to TO
activate VB
NF-kappa NN
B NN
. O

Phorbol NN
activation NN
was VBD
positively RB
modulated VBN
by IN
Ca2+ NN
influx NN
while IN
TNF NN
alpha NN
activation NN
was VBD
not RB
. O

Furthermore RB
, O
while IN
PMA NN
activation NN
was VBD
inhibited VBN
by IN
the DT
PKC NN
inhibitor NN
staurosporin NN
, O
the DT
TNF NN
alpha NN
effect NN
was VBD
unchanged JJ
. O

TNF NN
alpha NN
did VBD
not RB
activate VB
cAMP NN
production NN
and CC
its PRP$
signal NN
was VBD
not RB
modulated VBN
by IN
cAMP NN
activators NNS
. O

Moreover RB
, O
cAMP NN
activators NNS
did VBD
not RB
activate VB
NF-kappa NN
B NN
in IN
Jurkat NN
cells NNS
. O

Thus RB
, O
TNF NN
alpha-induced JJ
NF-kappa NN
B NN
activation NN
was VBD
found VBN
to TO
be VB
mediated VBN
by IN
none NN
of IN
the DT
major JJ
signal-mediating JJ
kinases NNS
such JJ
as IN
protein NN
kinase NN
C NN
( O
PKC NN
) O
, O
protein NN
kinase NN
A NN
, O
or CC
Ca(2+)-regulated JJ
kinases NNS
. O

Furthermore RB
, O
we PRP
found VBD
that IN
cytoplasmic JJ
acidification NN
facilitated VBD
NF-kappa NN
B NN
activation NN
by IN
both CC
TNF NN
alpha NN
and CC
PKC NN
, O
by IN
a DT
mechanism NN
that WDT
increases VBZ
NF-kappa NN
B/I NN
kappa NN
B NN
dissociation NN
without IN
affecting VBG
the DT
NF-kappa NN
B NN
translocation NN
step NN
. O

NF-kappa NN
B NN
activity NN
in IN
T NN
cells NNS
stably RB
expressing VBG
the DT
Tax NN
protein NN
of IN
human JJ
T NN
cell NN
lymphotropic JJ
virus NN
type NN
I CD
. O

The DT
effect NN
of IN
constitutive JJ
Tax NN
expression NN
on IN
the DT
interaction NN
of IN
NF-kappa NN
B NN
with IN
its PRP$
recognition NN
sequence NN
and CC
on IN
NF-kappa NN
B-dependent JJ
gene NN
expression NN
was VBD
examined VBN
in IN
T NN
lymphoid JJ
Jurkat NN
cell NN
lines NNS
( O
19D NN
and CC
9J NN
) O
stably RB
transformed VBN
with IN
a DT
Tax NN
expression NN
vector NN
. O

Tax NN
expressing NN
T NN
cell NN
lines NNS
contained VBD
a DT
constitutive JJ
level NN
of IN
NF-kappa NN
B NN
binding NN
activity NN
, O
detectable JJ
by IN
mobility NN
shift NN
assay NN
and CC
uv NN
cross-linking NN
using VBG
a DT
palindromic JJ
NF-kappa NN
B NN
probe NN
homologous JJ
to TO
the DT
interferon NN
beta NN
PRDII NN
site NN
. O

In IN
Jurkat NN
and CC
NC2.10 NN
induction NN
with IN
phorbol NN
esters NNS
resulted VBD
in IN
the DT
appearance NN
of IN
new JJ
DNA NN
binding NN
proteins NNS
of IN
85 CD
, O
75 CD
, O
and CC
54 CD
kDa NN
, O
whereas IN
in IN
Tax NN
expressing NN
cells NNS
the DT
85-kDa JJ
protein NN
and CC
a DT
92-kDa JJ
DNA NN
binding NN
protein NN
were VBD
constitutively RB
induced VBN
. O

Expression NN
of IN
Tax NN
protein NN
in IN
19D NN
and CC
9J NN
resulted VBD
in IN
transcription NN
of IN
the DT
endogenous JJ
NF-kappa NN
B-dependent JJ
granulocyte-macrophage JJ
colony NN
stimulating NN
factor NN
gene NN
and CC
increased VBD
basal JJ
level NN
expression NN
of IN
transfected VBN
NF-kappa NN
B-regulated JJ
promoters NNS
. O

Nonetheless RB
transcription NN
of IN
both CC
the DT
endogenous JJ
and CC
the DT
transfected VBN
gene NN
was VBD
inducible JJ
by IN
PMA NN
treatment NN
. O

Tax NN
expression NN
in IN
Jurkat NN
T NN
cells NNS
may MD
alter VB
the DT
stoichiometry NN
of IN
NF-kappa NN
B NN
DNA NN
binding NN
proteins NNS
and CC
thus RB
change VB
the DT
expression NN
of IN
NF-kappa NN
B-regulated JJ
promoters NNS
. O

Regulation NN
of IN
glucocorticoid NN
receptors NNS
in IN
human JJ
mononuclear JJ
cells NNS
: O
effects NNS
of IN
glucocorticoid NN
treatment NN
, O
Cushing NN
's POS
disease NN
and CC
ketoconazole NN
. O

Glucocorticoid NN
receptors NNS
( O
GcR NN
) O
were VBD
determined VBN
by IN
a DT
whole JJ
cell NN
assay NN
in IN
human JJ
mononulear JJ
leukocytes NNS
( O
hMNL NN
) O
from IN
control NN
subjects NNS
, O
patients NNS
receiving VBG
glucocorticoid NN
therapy NN
for IN
systemic JJ
diseases NNS
and CC
Cushing NN
's POS
disease NN
patients NNS
with IN
or CC
without IN
ketoconazole NN
therapy NN
. O

Prolonged JJ
corticosteroid NN
treatment NN
resulted VBD
in IN
down-regulation NN
of IN
GcR NN
, O
while IN
the DT
mean NN
level NN
of IN
GcR NN
in IN
Cushing NN
's POS
disease NN
was VBD
normal JJ
. O

In IN
this DT
group NN
, O
however RB
, O
receptor NN
levels NNS
and CC
morning NN
plasma NN
cortisol NN
values NNS
showed VBD
a DT
negative JJ
correlation NN
, O
indicating VBG
a DT
subtle JJ
down-regulatory JJ
effect NN
. O

Furthermore RB
, O
GcR NN
were VBD
unaltered JJ
after IN
these DT
patients NNS
received VBD
ketoconazole NN
, O
in IN
spite NN
of IN
a DT
marked JJ
reduction NN
in IN
morning NN
plasma NN
cortisol NN
and CC
urinary JJ
free JJ
cortisol NN
. O

We PRP
also RB
observed VBD
that IN
ketoconazole NN
was VBD
a DT
weak JJ
competitor NN
of IN
GcR NN
in IN
intact JJ
cells NNS
, O
although IN
it PRP
significantly RB
inhibited VBD
(3H) NN
dexamethasone NN
binding NN
in IN
cytosolic JJ
preparations NNS
from IN
rat NN
tissues NNS
. O

The DT
results NNS
suggested VBD
that IN
GcR NN
in IN
hMNL NN
are VBP
down-regulated VBN
by IN
synthetic JJ
steroids NNS
given VBN
in FW
vivo FW
, O
but CC
they PRP
showed VBD
very RB
mild JJ
down-regulation NN
in IN
hypercortisolemic JJ
patients NNS
suffering VBG
from IN
Cushing NN
's POS
disease NN
. O

Finally RB
, O
we PRP
did VBD
not RB
observed VBN
either CC
up-regulation NN
or CC
antagonism NN
of IN
GcR NN
by IN
ketoconazole NN
treatment NN
, O
at IN
the DT
time NN
that IN
cortisol NN
levels NNS
of IN
patients NNS
with IN
Cushing NN
's POS
disease NN
were VBD
reduced VBN
. O

This DT
indicates VBZ
that IN
the DT
beneficial JJ
effects NNS
of IN
ketoconazole NN
in IN
Cushing NN
's POS
disease NN
are VBP
due JJ
to TO
adrenal JJ
cortisol NN
suppression NN
and CC
not RB
to TO
interaction NN
with IN
GcR NN
of IN
target NN
cells NNS
, O
and CC
that IN
the DT
process NN
of IN
GcR NN
regulation NN
in IN
hMNL NN
is VBZ
a DT
complex JJ
phenomenon NN
awaiting VBG
further RBR
elucidation NN
. O

Glucocorticoid NN
receptors NNS
in IN
lymphocytes NNS
in IN
anorexia NN
nervosa NN
. O

OBJECTIVE NN
: O
The DT
aim NN
was VBD
to TO
explore VB
the DT
down-regulation NN
of IN
the DT
glucocorticoid NN
receptors NNS
during IN
hypercortisolaemia NN
in IN
anorexia NN
nervosa NN
. O

DESIGN NN
: O
Urine NN
and CC
plasma NN
samples NNS
were VBD
obtained VBN
for IN
cortisol NN
determination NN
and CC
blood NN
lymphocytes NNS
were VBD
isolated VBN
for IN
receptor NN
binding NN
studies NNS
. O

PATIENTS NNS
: O
Sixteen CD
anorexic JJ
patients NNS
, O
aged JJ
16-27 CD
years NNS
, O
with IN
a DT
mean NN
+/- CC
SEM NN
body NN
mass NN
index NN
of IN
14.2 CD
+/- CC
2.0 CD
( O
ranging VBG
from IN
11.1 CD
to TO
17.4 CD
) O
, O
and CC
15 CD
normal JJ
women NNS
were VBD
studied VBN
. O

Six CD
patients NNS
were VBD
reinvestigated VBN
after IN
a DT
significant JJ
weight NN
gain NN
. O

MEASUREMENTS NNS
: O
The DT
binding NN
capacity NN
and CC
affinity NN
of IN
the DT
glucocorticoid NN
receptors NNS
were VBD
measured VBN
with IN
dexamethasone NN
as IN
ligand NN
on IN
lymphocytes NNS
. O

RESULTS NNS
: O
In IN
patients NNS
, O
both DT
total JJ
and CC
free JJ
plasma NN
cortisol NN
concentrations NNS
were VBD
higher JJR
than IN
in IN
the DT
normal JJ
women NNS
, O
as IN
was VBD
their PRP$
urinary JJ
free JJ
cortisol NN
; O
the DT
number NN
of IN
glucocorticoid NN
receptors NNS
per IN
cell NN
( O
Ro NN
) O
and CC
the DT
binding NN
affinity NN
( O
Kd NN
) O
for IN
dexamethasone NN
were VBD
, O
however RB
, O
not RB
significantly RB
different JJ
( O
Ro NN
: O
7687 CD
+/- CC
1750 CD
vs CC
7347 CD
+/- CC
1285 CD
sites/cell NN
; O
Kd NN
: O
7.7 CD
+/- CC
2.4 CD
vs CC
7.4 CD
+/- CC
1.7 CD
nM NN
at IN
24 CD
degrees NNS
C NN
) O
. O

After IN
weight NN
gain NN
( O
14 CD
+/- CC
2 CD
to TO
16 CD
+/- CC
2 CD
kg/m2 NN
) O
, O
receptor NN
numbers NNS
were VBD
8421 CD
+/- CC
2126 CD
( O
pre JJ|RB
) O
and CC
9011 CD
+/- CC
500 CD
( O
post JJ|RB
) O
sites/cell NN
, O
which WDT
are VBP
not RB
significantly RB
different JJ
( O
P NN
greater JJR
than IN
0.2 CD
) O
; O
the DT
Kd NN
was VBD
unchanged JJ
( O
9.3 CD
+/- CC
2.6 CD
vs CC
9.2 CD
+/- CC
2.4 CD
nM NN
) O
. O

CONCLUSIONS NNS
Hypercortisolaemia NN
does VBZ
not RB
down-regulate VB
the DT
lymphocyte NN
glucocorticoid NN
receptors NNS
in IN
anorexia NN
nervosa NN
and CC
a DT
post-receptor JJ
defect NN
might MD
be VB
involved VBN
in IN
peripheral JJ
tissue NN
resistance NN
to TO
the DT
effects NNS
of IN
glucocorticoid NN
hormones NNS
in IN
undernutrition NN
. O

Tumor NN
necrosis NN
factor-alpha NN
mRNA NN
accumulation NN
in IN
human JJ
myelomonocytic JJ
cell NN
lines NNS
. O

Role NN
of IN
transcriptional JJ
regulation NN
by IN
DNA NN
sequence NN
motifs NNS
and CC
mRNA NN
stabilization NN
. O

The DT
cytokine NN
TNF NN
mediates VBZ
many JJ
of IN
the DT
pathologic JJ
signs NNS
of IN
cachexia NN
, O
inflammation NN
, O
and CC
sepsis NN
. O

The DT
current JJ
work NN
describes VBZ
the DT
regulation NN
of IN
TNF NN
in IN
human JJ
myelomonocytic JJ
cell NN
lines NNS
after IN
PMA NN
stimulation NN
. O

The DT
cell NN
lines NNS
exhibit VBP
a DT
low JJ
level NN
of IN
constitutive JJ
TNF NN
mRNA NN
expression NN
. O

Within IN
2 CD
to TO
4 CD
h NN
of IN
PMA NN
exposure NN
, O
steady JJ
state NN
levels NNS
of IN
TNF NN
mRNA NN
are VBP
markedly RB
elevated JJ
in IN
all DT
myelomonocytic JJ
cell NN
lines NNS
studied VBN
. O

This DT
rise NN
is VBZ
due JJ
to TO
increased VBN
mRNA NN
stability NN
, O
which WDT
increased VBD
by IN
almost RB
twofold RB
, O
and CC
to TO
an DT
overall JJ
increase NN
in IN
transcription NN
, O
which WDT
rises VBZ
by IN
more JJR
than IN
sixfold RB
. O

At IN
the DT
level NN
of IN
the DT
genomic JJ
TNF NN
gene NN
, O
a DT
DNase NN
I CD
hypersensitive JJ
site NN
is VBZ
detected VBN
within IN
the DT
TNF NN
promoter NN
between IN
-200 CD
to TO
-100 CD
bp NN
relative JJ
to TO
the DT
transcription NN
initiation NN
site NN
. O

Although IN
absent JJ
in IN
nonexpressing VBG
erythroleukemia NN
cell NN
lines NNS
, O
the DT
DNase NN
I CD
site NN
is VBZ
present JJ
in IN
uninduced JJ
myelomonocytic JJ
cell NN
lines NNS
and CC
is VBZ
not RB
changed VBN
after IN
PMA NN
induction NN
. O

The DT
PMA NN
induction NN
of IN
c-fos NN
mRNA NN
correlated VBD
well RB
with IN
TNF NN
gene NN
induction NN
; O
expression NN
of IN
genes NNS
encoding VBG
other JJ
proteins NNS
in IN
the DT
AP-1 NN
complex NN
( O
junB NN
and CC
junD NN
) O
were VBD
also RB
induced VBN
by IN
PMA NN
. O

The DT
nuclear JJ
extracts NNS
from IN
resting VBG
and CC
induced VBN
ML-1 NN
cells NNS
contain VBP
proteins NNS
binding VBG
specifically RB
to TO
the DT
AP-1 NN
, O
AP-2 NN
, O
and CC
NF NN
kappa NN
B NN
sequence NN
located JJ
within IN
the DT
TNF NN
promoter NN
. O

PMA NN
induction NN
increases VBZ
the DT
level NN
of IN
a DT
number NN
of IN
specific JJ
binding VBG
complexes NNS
relative JJ
to TO
the DT
resting VBG
cells NNS
. O

The DT
regulatory JJ
mechanisms NNS
of IN
the DT
human JJ
and CC
murine JJ
TNF NN
genes NNS
are VBP
discussed VBN
. O

USF-related JJ
transcription NN
factor NN
, O
HIV-TF1 NN
, O
stimulates VBZ
transcription NN
of IN
human JJ
immunodeficiency NN
virus-1 NN
. O

The DT
transcription NN
factor NN
HIV-TF1 NN
, O
which WDT
binds VBZ
to TO
a DT
region NN
about IN
60 CD
bp NN
upstream JJ
from IN
the DT
enhancer NN
of IN
the DT
human JJ
immunodeficiency NN
virus-1 NN
( O
HIV-1 NN
) O
, O
was VBD
purified VBN
from IN
human JJ
B NN
cells NNS
. O

HIV-TF1 NN
had VBD
a DT
molecular JJ
weight NN
of IN
39,000 CD
. O

Binding NN
of IN
HIV-TF1 NN
to TO
the DT
HIV NN
long JJ
terminal JJ
repeat NN
( O
LTR NN
) O
activated VBD
transcription NN
from IN
the DT
HIV NN
promoter NN
in FW
vitro FW
. O

The DT
HIV-TF1-binding JJ
site NN
in IN
HIV NN
LTR NN
was VBD
similar JJ
to TO
the DT
site NN
recognized VBN
by IN
upstream JJ
stimulatory JJ
factor NN
( O
USF NN
) O
in IN
the DT
adenovirus NN
major JJ
late JJ
promoter NN
. O

DNA-binding JJ
properties NNS
of IN
HIV-TF1 NN
suggested VBD
that IN
HIV-TF1 NN
might MD
be VB
identical JJ
or CC
related JJ
to TO
USF NN
. O

Interestingly RB
, O
treatment NN
of IN
purified VBN
HIV-TF1 NN
by IN
phosphatase NN
greatly RB
reduced VBD
its PRP$
DNA-binding JJ
activity NN
, O
suggesting VBG
that IN
phosphorylation NN
of IN
HIV-TF1 NN
was VBD
essential JJ
for IN
DNA NN
binding NN
. O

The DT
disruption NN
of IN
HIV-TF1-binding JJ
site NN
induced VBD
a DT
60 CD
% NN
decrease NN
in IN
the DT
level NN
of IN
transcription NN
from IN
the DT
HIV NN
promoter NN
in FW
vivo FW
. O

These DT
results NNS
suggest VBP
that IN
HIV-TF1 NN
is VBZ
involved VBN
in IN
transcriptional JJ
regulation NN
of IN
HIV-1 NN
. O

The DT
effect NN
of IN
toremifene NN
therapy NN
on IN
serum NN
immunoglobulin NN
levels NNS
in IN
breast NN
cancer NN
. O

Estrogens NNS
and CC
anti-estrogens NNS
enhance VBP
the DT
number NN
of IN
immunoglobulin NN
( O
Ig NN
) O
-secreting NN
cells NNS
in IN
pokeweed NN
mitogen NN
( O
PWM NN
) O
-stimulated JJ
lymphocyte NN
cultures NNS
. O

Lymphocytes NNS
from IN
patients NNS
who WP
have VBP
received VBN
anti-estrogen NN
therapy NN
show VBP
similar JJ
enhancement NN
of IN
Ig-secreting JJ
cells NNS
after IN
PWM NN
stimulation NN
. O

In IN
this DT
study NN
the DT
effect NN
of IN
anti-estrogen NN
( O
toremifene NN
) O
therapy NN
on IN
serum NN
immunoglobulin NN
( O
IgA NN
, O
IgM NN
, O
IgG NN
) O
levels NNS
in IN
breast NN
cancer NN
patients NNS
was VBD
investigated VBN
. O

Serum NN
Ig NN
levels NNS
were VBD
followed VBN
up RB
to TO
two CD
years NNS
after IN
or CC
during IN
the DT
therapy NN
. O

An DT
unexpected JJ
finding NN
was VBD
that IN
the DT
Ig NN
levels NNS
decreased VBD
during IN
the DT
follow-up JJ
period NN
. O

This DT
decrease NN
was VBD
seen VBN
in IN
patients NNS
who WP
responded VBD
to TO
the DT
therapy NN
as RB
well RB
as IN
in IN
those DT
who WP
did VBD
not RB
. O

HIV1 NN
infection NN
of IN
human JJ
monocytes NNS
and CC
macrophages NNS
promotes VBZ
induction NN
or CC
translocation NN
of IN
NF-KB-related JJ
factors NNS
. O

In IN
1991 CD
, O
we PRP
demonstrated VBD
, O
using VBG
electrophoretic JJ
mobility NN
shift NN
assays NNS
, O
that IN
3 CD
different JJ
factors NNS
( O
termed VBN
B1 NN
, O
B2 NN
and CC
B3 NN
) O
with IN
affinity NN
for IN
the DT
KB-enhancer JJ|NN
target NN
sequence NN
were VBD
specifically RB
detected VBN
in IN
nuclear JJ
extracts NNS
from IN
HIV1-infected JJ
monocytes NNS
and CC
macrophages NNS
. O

The DT
B2 NN
factor NN
was VBD
induced VBN
in IN
the DT
nuclei NNS
of IN
these DT
cells NNS
only RB
upon IN
HIV1 NN
infection NN
. O

The DT
B3 NN
factor NN
was VBD
only RB
slightly RB
evident JJ
in IN
nuclei NNS
of IN
uninfected JJ
cells NNS
but CC
was VBD
readily RB
detectable JJ
in IN
nuclei NNS
of IN
infected JJ
monocytes NNS
. O

Its PRP$
expression NN
remained VBD
very RB
low JJ
in IN
nuclei NNS
of IN
HIV1-infected JJ
macrophages NNS
. O

In IN
this DT
paper NN
, O
we PRP
demonstrate VBP
that IN
the DT
B2 NN
factor NN
is VBZ
expressed VBN
in IN
the DT
cytosol NN
of IN
monocytes NNS
and CC
macrophages NNS
as IN
a DT
DNA-binding JJ
protein NN
, O
indicating VBG
that IN
it PRP
is VBZ
not RB
associated VBN
with IN
an DT
inhibitor NN
( O
IKB NN
) O
. O

This DT
factor NN
remained VBD
clustered VBN
in IN
the DT
cytosol NN
and CC
was VBD
translocated VBN
to TO
the DT
nuclei NNS
only RB
after IN
HIV1 NN
infection NN
. O

The DT
B3 NN
factor NN
is VBZ
detected VBN
in IN
the DT
cytosol NN
only RB
when WRB
cells NNS
are VBP
HIV1-infected JJ
. O

The DT
role NN
of IN
HIV1 NN
infection NN
in IN
the DT
expression NN
and CC
the DT
translocation NN
of IN
these DT
factors NNS
is VBZ
discussed VBN
. O

Induction NN
of IN
NF-kappa NN
B NN
during IN
monocyte NN
differentiation NN
is VBZ
associated VBN
with IN
activation NN
of IN
HIV-gene JJ
expression NN
. O

Cells NNS
of IN
the DT
monocyte-macrophage JJ
lineage NN
are VBP
important JJ
targets NNS
of IN
HIV NN
infection NN
. O

We PRP
report VBP
here RB
that IN
the DT
phenotypic JJ
differentiation NN
of IN
monocyte NN
cell NN
lines NNS
induced VBN
by IN
phorbol NN
esters NNS
or CC
tumour NN
necrosis NN
factor NN
alpha NN
( O
TNF NN
alpha NN
) O
is VBZ
associated VBN
with IN
expression NN
of IN
nuclear JJ
factor NN
kappa NN
B NN
( O
NF-kappa NN
B NN
) O
. O

In IN
parallel NN
with IN
such JJ
differentiation NN
, O
HIV NN
transcription NN
, O
monitored VBN
using VBG
an DT
HIV NN
long JJ
terminal JJ
repeat NN
reporter NN
gene NN
construct NN
, O
is VBZ
activated VBN
in IN
such JJ
cells NNS
under IN
the DT
influence NN
of IN
enhanced VBN
NF-kappa NN
B NN
expression NN
. O

Also RB
, O
in IN
a DT
promonocyte JJ
cell NN
line NN
chronically RB
infected VBN
with IN
HIV NN
, O
NF-kappa NN
B NN
expression NN
and CC
HIV NN
transcription NN
were VBD
enhanced VBN
on IN
stimulation NN
with IN
phorbol NN
ester NN
or CC
TNF NN
alpha NN
. O

Thus RB
, O
stimulation NN
of IN
monocyte NN
cell NN
lines NNS
by IN
phorbol NN
esters NNS
or CC
TNF NN
alpha NN
induces VBZ
cell NN
differentiation NN
and CC
activates VBZ
HIV NN
transcription NN
. O

Such PDT
a DT
process NN
may MD
have VB
fundamental JJ
implications NNS
in IN
AIDS NN
pathogenesis NN
in FW
vivo FW
and CC
may MD
be VB
important JJ
in IN
disease NN
progression NN
induced VBN
by IN
opportunistic JJ
infections NNS
directly RB
or CC
indirectly RB
involving VBG
macrophages NNS
. O

A DT
nuclear JJ
factor NN
NF-GM2 NN
that WDT
interacts VBZ
with IN
a DT
regulatory JJ
region NN
of IN
the DT
GM-CSF NN
gene NN
essential JJ
for IN
its PRP$
induction NN
in IN
responses NNS
to TO
T-cell NN
activation NN
: O
purification NN
from IN
human JJ
T-cell NN
leukemia NN
line NN
Jurkat NN
cells NNS
and CC
similarity NN
to TO
NF-kappa NN
B NN
. O

Activation NN
of IN
T NN
cells NNS
by IN
antigen NN
, O
lectin NN
, O
or CC
a DT
combination NN
of IN
phorbol-12-myristate NN
acetate NN
( O
PMA NN
) O
and CC
calcium NN
ionophore NN
( O
A23187 NN
) O
leads VBZ
to TO
the DT
induction NN
of IN
genes NNS
for IN
a DT
set NN
of IN
lymphokines NNS
, O
including VBG
granulocyte-macrophage JJ
colony-stimulating JJ
factor NN
( O
GM-CSF NN
) O
. O

We PRP
demonstrated VBD
in IN
earlier JJR
studies NNS
that IN
the DT
upstream JJ
region NN
of IN
the DT
mouse NN
GM-CSF NN
promoter NN
at IN
positions NNS
between IN
-95 CD
and CC
-73 CD
is VBZ
essential JJ
for IN
transcriptional JJ
activation NN
in IN
response NN
to TO
PMA/A23187 NN
. O

This DT
region NN
contains VBZ
two CD
DNA-binding JJ
motifs NNS
, O
GM2 NN
and CC
GC-box NN
. O

The DT
GM2 NN
sequence NN
( O
GGTAGTTCCC NN
) O
is VBZ
recognized VBN
by IN
an DT
inducible JJ
factor NN
NF-GM2 NN
; O
the DT
other JJ
( O
CCGCCC NN
) O
by IN
constitutive JJ
factors NNS
A1 NN
, O
A2 NN
, O
and CC
B NN
. O

To TO
elucidate VB
the DT
mechanism NN
of IN
GM-CSF NN
gene NN
activation NN
, O
we PRP
have VBP
purified VBN
the DT
inducible JJ
factor NN
NF-GM2 NN
from IN
the DT
nuclear JJ
extract NN
of IN
stimulated VBN
Jurkat NN
cells NNS
on IN
the DT
basis NN
of IN
specific JJ
DNA-binding JJ
activity NN
. O

The DT
purified VBN
NF-GM2 NN
consists VBZ
of IN
50 CD
( O
p50 NN
) O
and CC
65 CD
kDa NN
( O
p65 NN
) O
polypeptides NNS
and CC
has VBZ
a DT
binding NN
activity NN
specific JJ
for IN
both CC
the DT
GM-CSF NN
and CC
immunoglobulin NN
kappa NN
( O
GGAAAGTCCC NN
) O
enhancers NNS
. O

Electrophoretically RB
purified VBN
p50 NN
alone RB
can MD
form VB
a DT
protein-DNA JJ
complex NN
, O
but CC
in IN
the DT
mixture NN
, O
p50 NN
associates VBZ
preferentially RB
with IN
p65 NN
to TO
form VB
the DT
NF-GM2 NN
complex NN
. O

In IN
addition NN
, O
p65 NN
gave VBD
per FW
se FW
, O
with IN
low JJ
affinity NN
, O
a DT
protein-DNA JJ
complex NN
that WDT
migrated VBD
more RBR
slowly RB
than IN
native JJ
NF-GM2 NN
complex NN
. O

Furthermore RB
, O
an DT
antiserum NN
against IN
KBF1 NN
( O
identical JJ
to TO
50 CD
kDa NN
NF-kappa NN
B NN
protein NN
) O
reacted VBD
with IN
the DT
p50 NN
of IN
NF-GM2 NN
, O
indicating VBG
that IN
the DT
NF-GM2 NN
polypeptide NN
can MD
not RB
be VB
immunologically RB
differentiated VBN
from IN
the DT
50 CD
kDa NN
subunit NN
of IN
NF-kappa NN
B NN
. O

The DT
purified VBN
NF-GM2 NN
activated VBD
in FW
vitro FW
transcription NN
from IN
the DT
kappa NN
B NN
enhancer NN
, O
while IN
it PRP
failed VBD
to TO
stimulate VB
transcription NN
from IN
the DT
GM-CSF NN
promoter NN
harboring VBG
the DT
GM2 NN
sequence NN
. O

This DT
suggests VBZ
that IN
the DT
activation NN
mechanism NN
of IN
the DT
GM-CSF NN
gene NN
through IN
the DT
GM2/GC-box JJ|NN
sequence NN
is VBZ
different JJ
from IN
that DT
of IN
genes NNS
carrying VBG
the DT
kappa NN
B NN
enhancer NN
alone RB
. O

Glucocorticoid NN
receptors NNS
in IN
normal JJ
leukocytes NNS
: O
effects NNS
of IN
age NN
, O
gender NN
, O
season NN
, O
and CC
plasma NN
cortisol NN
concentrations NNS
. O

We PRP
measured VBD
glucocorticoid NN
receptors NNS
( O
GR NN
) O
in IN
mononuclear JJ
leukocytes NNS
( O
MNL NN
) O
isolated VBN
from IN
peripheral JJ
blood NN
of IN
145 CD
apparently RB
healthy JJ
volunteers NNS
( O
86 CD
men NNS
and CC
59 CD
women NNS
) O
. O

An DT
age-related JJ
decrease NN
in IN
the DT
number NN
of IN
GR NN
was VBD
suggested VBN
between IN
subjects NNS
younger JJR
than IN
20 CD
years NNS
and CC
elderly JJ
subjects NNS
; O
there EX
was VBD
no DT
apparent JJ
seasonal JJ
variation NN
in IN
GR NN
. O

Gender NN
difference NN
in IN
the DT
number NN
of IN
GR NN
was VBD
not RB
significant JJ
, O
although IN
women NNS
showed VBD
slightly RB
fewer JJR
GR NN
. O

Eight CD
patients NNS
with IN
dermatomyositis/polymyositis NN
were VBD
examined VBN
to TO
determine VB
whether IN
the DT
number NN
of IN
GR NN
in IN
MNL NN
could MD
be VB
down-regulated VBN
by IN
their PRP$
cognate JJ
ligands NNS
. O

The DT
number NN
of IN
GR NN
in IN
MNL NN
from IN
these DT
patients NNS
was VBD
significantly RB
decreased VBN
one CD
month NN
after IN
the DT
initiation NN
of IN
prednisolone NN
therapy NN
. O

However RB
, O
in IN
normal JJ
subjects NNS
, O
the DT
GR NN
in IN
MNL NN
did VBD
not RB
demonstrate VB
circadian JJ
variation NN
, O
in IN
contrast NN
to TO
concentrations NNS
of IN
plasma NN
cortisol NN
. O

Anti-CD2 JJ
receptor NN
antibodies NNS
activate VBP
the DT
HIV NN
long JJ
terminal JJ
repeat NN
in IN
T NN
lymphocytes NNS
. O

The DT
CD2 NN
T NN
lymphocyte NN
glycoprotein NN
surface NN
molecule NN
mediates VBZ
both CC
cell NN
to TO
cell NN
adhesion NN
and CC
T NN
cell NN
activation NN
, O
two CD
processes NNS
that WDT
are VBP
involved VBN
in IN
the DT
spread NN
of IN
HIV NN
infection NN
. O

Treatment NN
of IN
chronically RB
HIV-infected JJ
PBMC NN
with IN
anti-CD2 JJ
mAb NN
has VBZ
been VBN
shown VBN
to TO
induce VB
the DT
expression NN
of IN
infectious JJ
virus NN
from IN
these DT
cultures NNS
. O

In IN
this DT
study NN
we PRP
investigated VBD
the DT
mechanisms NNS
whereby WRB
anti-CD2 JJ
antibodies NNS
stimulate VBP
viral JJ
production NN
. O

We PRP
demonstrate VBP
that IN
treatment NN
of IN
transiently RB
transfected VBN
T NN
lymphocytes NNS
with IN
anti-CD2 JJ
antibodies NNS
results VBZ
in IN
activation NN
of IN
the DT
HIV NN
long JJ
terminal JJ
repeat NN
. O

Furthermore RB
, O
CAT NN
assays NNS
using VBG
mutated VBN
HIV NN
long JJ
terminal JJ
repeat-CAT NN
constructs NNS
and CC
gel NN
shift NN
assays NNS
demonstrate VBP
that IN
this DT
activation NN
is VBZ
dependent JJ
on IN
the DT
NF-kappa NN
B NN
enhancer NN
. O

These DT
studies NNS
suggest VBP
that IN
interaction NN
of IN
CD2 NN
with IN
its PRP$
natural JJ
ligand NN
, O
LFA-3 NN
, O
may MD
play VB
a DT
role NN
in IN
regulation NN
of IN
HIV NN
expression NN
. O

Nuclear JJ
transcription NN
factors NNS
that WDT
bind VBP
to TO
elements NNS
of IN
the DT
IL-2 NN
promoter NN
. O

Induction NN
requirements NNS
in IN
primary JJ
human JJ
T NN
cells NNS
. O

Prior JJ
studies NNS
have VBP
identified VBN
several JJ
elements NNS
that WDT
contribute VBP
to TO
the DT
activity NN
of IN
the DT
IL-2 NN
promoter NN
in IN
the DT
stimulated VBN
T NN
cell NN
line NN
, O
Jurkat NN
. O

The DT
sites NNS
and CC
their PRP$
corresponding JJ
nuclear JJ
binding VBG
factors NNS
include VBP
: O
NF-kappa NN
B NN
, O
AP-1 NN
, O
AP-3 NN
, O
OCT-1 NN
, O
and CC
NF-AT NN
. O

The DT
latter JJ
" [[DQS]]
nuclear JJ
factor NN
for IN
activated VBN
T NN
cells NNS
" [[DQE]]
likely RB
contributes VBZ
to TO
the DT
tissue NN
specificity NN
of IN
IL-2 NN
gene NN
expression NN
. O

Using VBG
electrophoretic JJ
mobility NN
shift NN
assays NNS
, O
we PRP
have VBP
studied VBN
these DT
transcription NN
factors NNS
in IN
primary JJ
T NN
cells NNS
from IN
human JJ
blood NN
to TO
verify VB
their PRP$
presence NN
in IN
a DT
physiologic JJ
setting NN
and CC
to TO
identify VB
the DT
signals NNS
that WDT
stimulate VBP
factor NN
activity NN
. O

All DT
factors NNS
are VBP
induced VBN
in IN
the DT
nuclei NNS
of IN
T NN
cells NNS
upon IN
activation NN
with IN
mitogens NNS
but CC
not RB
with IN
exogenous JJ
IL-2 NN
growth NN
factor NN
. O

However RB
, O
the DT
signaling NN
requirements NNS
and CC
sensitivity NN
to TO
protein NN
synthesis NN
inhibitors NNS
differ VBP
considerably RB
. O

Only RB
the DT
activities NNS
for IN
NF-AT NN
and CC
AP-1 NN
sites NNS
require VBP
two CD
signals NNS
for IN
optimal JJ
induction NN
, O
i.e. FW
, O
PMA NN
plus CC
either CC
lectin NN
or CC
antibody NN
to TO
the DT
CD3 NN
or CC
CD28 NN
surface NN
molecules NNS
. O

Other JJ
factors NNS
are VBP
induced VBN
by IN
lectin NN
, O
antibody NN
, O
and/or CC
PMA NN
alone RB
. O

After IN
appropriate JJ
stimulation NN
, O
both CC
NF-AT NN
and CC
AP-1 NN
are VBP
peculiarly RB
sensitive JJ
to TO
the DT
protein NN
synthesis NN
inhibitor NN
anisomycin NN
. O

Our PRP$
data NNS
correlate VBP
the DT
activity NN
of IN
NF-AT NN
and CC
AP-1 NN
in IN
gel NN
shift NN
assays NNS
with IN
the DT
two CD
signals NNS
requirements NNS
for IN
IL-2 NN
gene NN
expression NN
. O

An DT
erythroid JJ
specific JJ
enhancer NN
upstream JJ
to TO
the DT
gene NN
encoding VBG
the DT
cell-type JJ
specific JJ
transcription NN
factor NN
GATA-1 NN
. O

The DT
transcription NN
factor NN
GATA-1 NN
is VBZ
expressed VBN
in IN
a DT
subset NN
of IN
hemopoietic JJ
cells NNS
, O
where WRB
it PRP
mediates VBZ
the DT
cell-type JJ
specific JJ
expression NN
of IN
several JJ
genes NNS
. O

We PRP
have VBP
cloned VBN
the DT
mouse NN
and CC
human JJ
GATA-1 NN
genes NNS
. O

A DT
region NN
upstream JJ
to TO
the DT
first JJ
exon NN
, O
and CC
highly RB
conserved VBN
between IN
mouse NN
and CC
man NN
, O
acts VBZ
as IN
an DT
erythroid JJ
specific JJ
enhancer NN
in IN
transient JJ
assays NNS
, O
if IN
linked VBN
to TO
the DT
GATA-1 NN
or CC
to TO
the DT
SV40 NN
promoter NN
. O

The DT
activity NN
of IN
the DT
enhancer NN
is VBZ
almost RB
completely RB
dependent JJ
on IN
the DT
integrity NN
of IN
a DT
dimeric JJ
GATA-1 NN
binding NN
site NN
. O

Demonstration NN
of IN
a DT
1,25-dihydroxyvitamin NN
D3-responsive JJ
protein NN
in IN
human JJ
lymphocytes NNS
: O
immunologic JJ
crossreactivity NN
and CC
inverse JJ
regulation NN
with IN
the DT
vitamin NN
D NN
receptor NN
. O

Using VBG
Western NN
blot NN
analysis NN
with IN
a DT
monoclonal JJ
antibody NN
recognizing VBG
a DT
17-amino NN
acid NN
epitope NN
of IN
the DT
1,25-dihydroxyvitamin NN
D3 NN
( O
1,25(OH)2D3 NN
) O
receptor NN
, O
we PRP
have VBP
detected VBN
two CD
crossreacting VBG
proteins NNS
in IN
activated VBN
normal JJ
human JJ
lymphocytes NNS
. O

The DT
smaller JJR
of IN
the DT
two CD
proteins NNS
( O
50 CD
kDa NN
) O
was VBD
indistinguishable JJ
from IN
the DT
classical JJ
1,25(OH)2D3 NN
receptor NN
and CC
, O
similar JJ
to TO
the DT
classical JJ
1,25(OH)2D3 NN
receptor NN
, O
was VBD
upregulated VBN
in IN
a DT
dose-dependent JJ
fashion NN
by IN
1,25(OH)2D3 NN
. O

The DT
larger JJR
crossreacting VBG
protein NN
exhibited VBD
an DT
electrophoretic JJ
mobility NN
of IN
80 CD
kDa NN
, O
was VBD
localized JJ
in IN
the DT
cell NN
cytosol NN
, O
and CC
appeared VBD
to TO
be VB
specific JJ
for IN
activated VBN
lymphocytes NNS
since IN
it PRP
was VBD
not RB
detected VBN
in IN
several JJ
other JJ
human JJ
cells NNS
including VBG
monocytes NNS
. O

More RBR
strikingly RB
, O
the DT
80-kDa JJ
protein NN
was VBD
downregulated VBN
in IN
a DT
dose-dependent JJ
fashion NN
by IN
1,25(OH)2D3 NN
; O
this DT
effect NN
was VBD
independent JJ
of IN
the DT
mode NN
of IN
lymphocyte NN
activation NN
and CC
specific JJ
for IN
the DT
1,25(OH)2D3 NN
metabolite NN
of IN
vitamin NN
D3 NN
. O

However RB
, O
two CD
potent JJ
immunosuppressive JJ
agents NNS
, O
glucocorticoids NNS
and CC
cyclosporin NN
A DT
, O
also RB
inhibited VBD
the DT
80-kDa JJ
protein NN
. O

T-helper-cell JJ
determinants NNS
in IN
protein NN
antigens NNS
are VBP
preferentially RB
located JJ
in IN
cysteine-rich JJ
antigen NN
segments NNS
resistant JJ
to TO
proteolytic JJ
cleavage NN
by IN
cathepsin NN
B NN
, O
L NN
, O
and CC
D NN
. O

We PRP
report VBP
on IN
a DT
computer NN
algorithm NN
capable JJ
of IN
predicting VBG
the DT
location NN
of IN
T-helper-cell NN
epitopes NNS
in IN
protein NN
antigen NN
( O
Ag NN
) O
by IN
analysing VBG
the DT
Ag NN
amino NN
acid NN
sequence NN
. O

The DT
algorithm NN
was VBD
constructed VBN
with IN
the DT
aim NN
of IN
identifying VBG
segments NNS
in IN
Ag NN
which WDT
are VBP
resistant JJ
to TO
proteolytic JJ
degradation NN
by IN
the DT
enzymes NNS
cathepsin NN
B NN
, O
L NN
, O
and CC
D NN
. O

These DT
are VBP
prominent JJ
enzymes NNS
in IN
the DT
endocytic JJ
pathway NN
through IN
which WDT
soluble JJ
protein NN
Ag NN
enter VBP
APC NN
, O
and CC
resistant JJ
segments NNS
in IN
Ag NN
may MD
, O
therefore RB
, O
be VB
expected VBN
to TO
contain VB
more JJR
T-cell NN
determinants NNS
than IN
susceptible JJ
segments NNS
. O

From IN
information NN
available JJ
in IN
the DT
literature NN
on IN
the DT
substrate JJ
specificity NN
of IN
the DT
three CD
enzymes NNS
, O
it PRP
is VBZ
clear JJ
that IN
a DT
cysteine NN
is VBZ
not RB
accepted VBN
in IN
any DT
of IN
the DT
S2 NN
, O
S1 NN
, O
S1' NN
, O
and CC
S2' NN
subsites NNS
of IN
cathepsin NN
B NN
and CC
L NN
, O
and CC
not RB
in IN
the DT
S1 NN
and CC
S1' NN
subsites NNS
of IN
cathepsin NN
D NN
. O

Moreover RB
, O
we PRP
have VBP
noticed VBN
that IN
cysteine-containing JJ
T-cell NN
determinants NNS
in IN
a DT
number NN
of IN
protein NN
Ag NN
are VBP
particularly RB
rich JJ
in IN
the DT
amino NN
acids NNS
alanine NN
, O
glycine NN
, O
lysine NN
, O
leucine NN
, O
serine NN
, O
threonine NN
, O
and CC
valine NN
. O

By IN
searching VBG
protein NN
Ag NN
for IN
clusters NNS
of IN
amino NN
acids NNS
containing VBG
cysteine NN
and CC
two CD
of IN
the DT
other JJ
amino NN
acids NNS
we PRP
were VBD
able JJ
to TO
predict VB
17 CD
out IN
of IN
23 CD
empirically RB
known VBN
T-cell NN
determinants NNS
in IN
the DT
Ag NN
with IN
a DT
relatively RB
low JJ
number NN
of IN
false JJ
( O
positive JJ
) O
predictions NNS
. O

Furthermore RB
, O
we PRP
present VBP
a DT
new JJ
principle NN
for IN
searching VBG
Ag NN
for IN
potential JJ
amphipatic JJ
alpha-helical JJ
protein NN
segments NNS
. O

Such JJ
segments NNS
accord VBP
well RB
with IN
empirically RB
known JJ
T-cell NN
determinants NNS
and CC
our PRP$
algorithm NN
produces VBZ
a DT
lower JJR
number NN
of IN
false JJ
positive JJ
predictions NNS
than IN
the DT
principle NN
based VBN
on IN
discrete JJ
Fourier NN
transformations NNS
previously RB
described VBN
. O

A DT
human JJ
putative JJ
lymphocyte NN
G0/G1 NN
switch NN
gene NN
containing VBG
a DT
CpG-rich JJ
island NN
encodes VBZ
a DT
small JJ
basic JJ
protein NN
with IN
the DT
potential NN
to TO
be VB
phosphorylated VBN
. O

Genes NNS
actively RB
involved VBN
in IN
the DT
G0/G1 NN
switch NN
( O
G0S NN
genes NNS
) O
may MD
be VB
differentially RB
expressed VBN
during IN
the DT
lectin-induced JJ
switch NN
of IN
lymphocytes NNS
from IN
the DT
G0 NN
to TO
the DT
G1 NN
phases NNS
of IN
the DT
cell NN
cycle NN
. O

This DT
paper NN
presents VBZ
studies NNS
of IN
G0S2 NN
, O
a DT
member NN
of IN
a DT
set NN
of IN
putative JJ
G0S NN
genes NNS
, O
for IN
which WDT
cDNAs NNS
were VBD
cloned VBN
and CC
selected VBN
on IN
the DT
basis NN
of IN
differential JJ
cDNA NN
hybridization NN
. O

G0S2 NN
mRNA NN
increases VBZ
transiently RB
within IN
1-2 CD
hr NN
of IN
the DT
addition NN
of IN
lectin NN
or CC
cycloheximide NN
to TO
cultured VBN
blood NN
mononuclear JJ
cells NNS
. O

Comparison NN
of IN
a DT
nearly RB
full-length JJ
cDNA NN
sequence NN
with IN
the DT
corresponding JJ
genomic JJ
sequence NN
reveals VBZ
one CD
small JJ
intron NN
and CC
an DT
open JJ
reading NN
frame NN
in IN
the DT
second JJ
exon NN
. O

The DT
derived VBN
103-amino-acid JJ
basic JJ
protein NN
has VBZ
two CD
potential JJ
alpha-helical JJ
domains NNS
separated VBN
by IN
a DT
hydrophobic JJ
region NN
with IN
the DT
potential NN
to TO
generate VB
turns NNS
and CC
assume VB
a DT
beta-sheet JJ
conformation NN
. O

Consistent JJ
with IN
involvement NN
in IN
the DT
G0/G1 NN
switch NN
, O
the DT
protein NN
contains VBZ
potential JJ
sites NNS
for IN
phosphorylation NN
by IN
protein NN
kinase NN
C NN
and CC
casein NN
kinase NN
II CD
. O

The DT
gene NN
contains VBZ
a DT
CpG-rich JJ
island NN
suggesting VBG
expression NN
in IN
the DT
germ NN
line NN
. O

An DT
upstream JJ
segment NN
contains VBZ
tandem JJ
dinucleotide NN
repeats NNS
(CT)19/(CA)16 NN
. O

There EX
is VBZ
a DT
suitably RB
located JJ
TATA NN
box NN
, O
but CC
potential JJ
sites NNS
for IN
CCAAT-box NN
binding NN
factors NNS
are VBP
far RB
upstream JJ
, O
embedded JJ
in IN
a DT
42-nucleotide JJ
repeat NN
element NN
. O

Potential JJ
sites NNS
for IN
transcription NN
factors NNS
AP1 NN
, O
AP2 NN
, O
and CC
AP3 NN
are VBP
consistent JJ
with IN
rapid JJ
transcriptional JJ
activation NN
in IN
response NN
to TO
inducing VBG
agents NNS
. O

Synergism NN
between IN
two CD
distinct JJ
elements NNS
of IN
the DT
HTLV-I NN
enhancer NN
during IN
activation NN
by IN
the DT
trans-activator NN
of IN
HTLV-I NN
. O

We PRP
have VBP
conducted VBN
functional JJ
studies NNS
of IN
the DT
enhancer NN
elements NNS
of IN
human JJ
T-cell NN
leukemia NN
virus NN
type NN
I CD
( O
HTLV-I NN
) O
using VBG
the DT
human JJ
T-cell NN
lines NNS
Jurkat NN
and CC
MOLT NN
4 CD
, O
which WDT
are VBP
negative JJ
for IN
HTLV-I NN
, O
and CC
MT-2 NN
and CC
TL-Mor NN
, O
which WDT
carry VBP
the DT
proviral JJ
genome NN
of IN
HTLV-I NN
. O

Two CD
distinct JJ
elements NNS
have VBP
been VBN
implicated VBN
in IN
function NN
of IN
the DT
HTLV-I NN
enhancer NN
. O

One CD
is VBZ
the DT
21-base-pair JJ
( O
bp NN
) O
core NN
element NN
that WDT
is VBZ
responsible JJ
for IN
trans-activation NN
by IN
the DT
HTLV-I NN
trans-activator NN
p40tax NN
and CC
that WDT
has VBZ
the DT
ability NN
to TO
bind VB
to TO
cyclic-AMP NN
responsive JJ
element NN
binding NN
factor NN
( O
CREB NN
) O
-like JJ
factor NN
( O
s NNS
) O
. O

The DT
other JJ
is VBZ
a DT
region NN
interposed VBN
between IN
the DT
21-bp JJ
elements NNS
. O

In IN
this DT
study NN
we PRP
demonstrate VBP
that IN
a DT
subfragment NN
( O
C26 NN
) O
in IN
the DT
region NN
between IN
the DT
21-bp JJ
elements NNS
is VBZ
involved VBN
in IN
trans-activation NN
by IN
p40tax NN
, O
possibly RB
through IN
binding NN
to TO
an DT
NF-kappa NN
B-like JJ
nuclear JJ
factor NN
or CC
factors NNS
. O

Formation NN
of IN
the DT
protein-DNA JJ
complex NN
with IN
the DT
C26 NN
subfragment NN
was VBD
positively RB
affected VBN
by IN
p40tax NN
. O

The DT
C26 NN
element NN
conferred VBD
partial JJ
responsiveness NN
to TO
p40tax NN
when WRB
linked VBN
to TO
one CD
copy NN
of IN
the DT
21-bp JJ
element NN
that WDT
, O
by IN
itself PRP
, O
showed VBD
little JJ
activation NN
in IN
response NN
to TO
p40tax NN
. O

However RB
, O
the DT
C26 NN
element NN
alone RB
, O
even RB
when WRB
repeated VBN
, O
could MD
not RB
be VB
activated VBN
by IN
p40tax NN
, O
unlike IN
other JJ
NF-kappa NN
B-binding JJ
elements NNS
. O

In IN
contrast NN
, O
the DT
C26 NN
element NN
itself PRP
was VBD
profoundly RB
activated VBN
upon IN
stimulation NN
with IN
12-O-tetradecanoylphorbol-13-acetate NN
. O

These DT
findings NNS
therefore RB
suggest VBP
that IN
the DT
HTLV-I NN
enhancer NN
contains VBZ
multiple JJ
functional JJ
elements NNS
, O
including VBG
binding VBG
sites NNS
for IN
at IN
least JJS
CREB- NN
and CC
NF-kappa NN
B-like JJ
factors NNS
, O
which WDT
synergistically RB
cooperate VBP
in IN
activation NN
of IN
the DT
HTLV-I NN
enhancer NN
in IN
response NN
to TO
p40tax NN
. O

Our PRP$
results NNS
also RB
demonstrate VBP
that IN
TPA-dependent JJ
activation NN
of IN
the DT
HTLV-I NN
enhancer NN
may MD
be VB
mediated VBN
through IN
the DT
C26 NN
element NN
. O

v-erbA NN
overexpression NN
is VBZ
required VBN
to TO
extinguish VB
c-erbA NN
function NN
in IN
erythroid JJ
cell NN
differentiation NN
and CC
regulation NN
of IN
the DT
erbA NN
target NN
gene NN
CAII NN
. O

The DT
v-erbA NN
oncoprotein NN
represents VBZ
a DT
retrovirus-transduced JJ
oncogenic JJ
version NN
of IN
the DT
thyroid NN
hormone NN
( O
T3/T4 NN
) O
receptor NN
c-erbA NN
( O
type NN
alpha NN
) O
. O

It PRP
contributes VBZ
to TO
virus-induced JJ
erythroleukemia NN
by IN
efficiently RB
arresting VBG
differentiation NN
of IN
red JJ
cell NN
progenitors NNS
and CC
by IN
suppressing VBG
transcription NN
of IN
erythrocyte-specific JJ
genes NNS
. O

Here RB
, O
we PRP
show VBP
that IN
v-erbA NN
and CC
c-erbA NN
bind VBP
directly RB
to TO
sequences NNS
within IN
the DT
promoter NN
of IN
the DT
erythrocyte-specific JJ
carbonic JJ
anhydrase NN
II CD
( O
CAII NN
) O
, O
a DT
gene NN
whose WP$
transcription NN
is VBZ
efficiently RB
suppressed VBN
by IN
v-erbA NN
. O

This DT
erbA-binding JJ
site NN
confers VBZ
thyroid NN
hormone NN
responsiveness NN
to TO
a DT
heterologous JJ
promoter NN
in IN
transient JJ
expression NN
experiments NNS
and CC
is VBZ
a DT
target NN
for IN
efficient JJ
down-regulation NN
of IN
CAII NN
transcription NN
by IN
the DT
v-erbA NN
oncoprotein NN
. O

In IN
stably RB
transformed VBN
erythroblasts NNS
coexpressing VBG
the DT
v-erbA NN
oncoprotein NN
and CC
the DT
c-erbA/T3 NN
receptor NN
at IN
an DT
approximately RB
equimolar JJ
ratio NN
, O
c-erbA NN
activity NN
is VBZ
dominant JJ
over IN
v-erbA NN
. O

T3 NN
efficiently RB
induced VBD
erythroid JJ
differentiation NN
in IN
these DT
cells NNS
, O
thus RB
overcoming VBG
the DT
v-erbA-mediated JJ
differentiation NN
arrest NN
. O

Likewise RB
, O
T3 NN
activated VBD
CAII NN
transcription NN
as RB
well RB
as IN
transient JJ
expression NN
of IN
a DT
T3-responsive JJ
reporter NN
gene NN
containing VBG
the DT
CAII-specific JJ
erbA-binding JJ
site NN
. O

The DT
c-erbA-dependent JJ
activation NN
of IN
this DT
CAII NN
reporter NN
construct NN
could MD
only RB
be VB
suppressed VBN
by IN
very RB
high JJ
amounts NNS
of IN
v-erbA NN
. O

Our PRP$
results NNS
suggest VBP
that IN
overexpression NN
of IN
v-erbA NN
is VBZ
required VBN
for IN
its PRP$
function NN
as IN
an DT
oncoprotein NN
. O

Inhibition NN
of IN
phorbol NN
ester-induced JJ
monocytic JJ
differentiation NN
by IN
dexamethasone NN
is VBZ
associated VBN
with IN
down-regulation NN
of IN
c-fos NN
and CC
c-jun NN
( O
AP-1 NN
) O
. O

Previous JJ
studies NNS
have VBP
shown VBN
that IN
treatment NN
of IN
human JJ
myeloid JJ
leukemia NN
cells NNS
with IN
12-O-tetradecanoylphorbol-13-acetate NN
( O
TPA NN
) O
is VBZ
associated VBN
with IN
induction NN
of IN
monocytic JJ
differentiation NN
and CC
expression NN
of IN
the DT
c-jun NN
and CC
c-fos NN
early JJ
response NN
genes NNS
. O

The DT
present JJ
work NN
demonstrates VBZ
that IN
the DT
glucocorticoid NN
dexamethasone NN
inhibits VBZ
TPA-induced JJ
increases NNS
in IN
c-jun NN
and CC
c-fos NN
mRNA NN
levels NNS
in IN
U-937 NN
leukemia NN
cells NNS
. O

These DT
findings NNS
were VBD
associated VBN
with IN
a DT
block NN
in IN
appearance NN
of IN
the DT
monocytic JJ
phenotype NN
, O
including VBG
inhibition NN
of IN
TPA-induced JJ
increases NNS
in IN
lamin NN
A NN
, O
lamin NN
C NN
, O
and CC
vimentin NN
transcripts NNS
. O

Other JJ
studies NNS
have VBP
demonstrated VBN
that IN
TPA-induced JJ
monocytic JJ
differentiation NN
and CC
expression NN
of IN
the DT
c-jun NN
and CC
c-fos NN
genes NNS
in IN
myeloid JJ
leukemia NN
cells NNS
are VBP
regulated VBN
by IN
protein NN
kinase NN
C NN
( O
PKC NN
) O
. O

The DT
finding NN
that IN
dexamethasone NN
has VBZ
no DT
effect NN
on IN
TPA-induced JJ
activation NN
of IN
PKC NN
suggests VBZ
that IN
this DT
glucocorticoid NN
inhibits VBZ
signals NNS
downstream JJ
or CC
parallel JJ
to TO
this DT
enzyme NN
. O

Nuclear JJ
run-on JJ
assays NNS
demonstrate VBP
that IN
: O
( O
1 LS
) O
induction NN
of IN
c-jun NN
and CC
c-fos NN
expression NN
by IN
TPA NN
is VBZ
regulated VBN
by IN
transcriptional JJ
mechanisms NNS
, O
( O
2 LS
) O
TPA-induced JJ
expression NN
of IN
c-jun NN
and CC
c-fos NN
does VBZ
not RB
require VB
protein NN
synthesis NN
, O
and CC
( O
3 LS
) O
TPA-induced JJ
expression NN
of IN
both DT
genes NNS
is VBZ
inhibited VBN
at IN
the DT
transcriptional JJ
level NN
by IN
dexamethasone NN
. O

To TO
further RB
define VB
the DT
effects NNS
of IN
dexamethasone NN
at IN
the DT
molecular JJ
level NN
, O
we PRP
prepared VBD
a DT
series NN
of IN
deleted VBN
c-jun NN
promoter NN
fragments NNS
linked VBN
to TO
the DT
chloramphenicol NN
acetyltransferase NN
( O
CAT NN
) O
gene NN
. O

Increases NNS
in IN
CAT NN
activity NN
during IN
transient JJ
expression NN
of IN
these DT
constructs NNS
in IN
TPA-treated JJ
U-937 NN
cells NNS
could MD
be VB
assigned VBN
to TO
the DT
region NN
( O
-97 CD
to TO
-20 CD
) O
of IN
the DT
promoter NN
that WDT
contains VBZ
the DT
AP-1 NN
binding NN
site NN
. O

This DT
induction NN
of IN
CAT NN
activity NN
was VBD
sensitive JJ
to TO
dexamethasone NN
. O

These DT
findings NNS
suggest VBP
that IN
dexamethasone NN
down-regulates VBZ
TPA-induced JJ
transcription NN
of IN
the DT
c-jun NN
gene NN
during IN
monocytic JJ
differentiation NN
by IN
inhibiting VBG
activation NN
of IN
the DT
AP-1 NN
site NN
. O

Charybdotoxin-sensitive JJ
, O
Ca(2+)-dependent JJ
membrane NN
potential JJ
changes NNS
are VBP
not RB
involved VBN
in IN
human JJ
T NN
or CC
B NN
cell NN
activation NN
and CC
proliferation NN
. O

The DT
involvement NN
of IN
ion NN
channels NNS
in IN
B NN
and CC
T NN
lymphocyte NN
activation NN
is VBZ
supported VBN
by IN
many JJ
reports NNS
of IN
changes NNS
in IN
ion NN
fluxes NNS
and CC
membrane NN
potential NN
after IN
mitogen NN
binding NN
. O

Human JJ
T NN
and CC
B NN
lymphocytes NNS
demonstrate VBP
an DT
early JJ
and CC
transient JJ
hyperpolarization NN
after IN
ligand JJ
binding NN
. O

Inasmuch RB
as IN
the DT
change NN
in IN
membrane NN
potential NN
is VBZ
dependent JJ
on IN
elevation NN
of IN
free JJ
cytosolic JJ
calcium NN
, O
the DT
hyperpolarization NN
is VBZ
presumably RB
through IN
opening NN
of IN
Ca(2+)-stimulated JJ
K+ NN
channels NNS
. O

We PRP
have VBP
used VBN
charybdotoxin NN
, O
a DT
known JJ
inhibitor NN
of IN
Ca(2+)-dependent JJ
K+ NN
channels NNS
, O
to TO
study VB
the DT
role NN
of IN
these DT
channels NNS
in IN
lymphocyte NN
activation NN
and CC
mitogenesis NN
. O

We PRP
demonstrate VBP
that IN
charybdotoxin NN
inhibits VBZ
the DT
ligand-induced JJ
transient JJ
membrane NN
hyperpolarization NN
in IN
B NN
and CC
T NN
cells NNS
in IN
a DT
dose-dependent JJ
fashion NN
, O
without IN
affecting VBG
changes NNS
in IN
cytosolic JJ
Ca2+ NN
. O

However RB
, O
blockade NN
of IN
the DT
Ca(2+)-activated JJ
K+ NN
channel NN
is VBZ
not RB
associated VBN
with IN
changes NNS
in IN
cell-cycle JJ
gene NN
activation NN
, O
IL-2 NN
production NN
, O
IL-2R NN
expression NN
or CC
B NN
and CC
T NN
cell NN
mitogenesis NN
. O

These DT
results NNS
imply VBP
that IN
membrane NN
potential JJ
changes NNS
secondary JJ
to TO
the DT
ligand-dependent JJ
opening NN
of IN
Ca(2+)-activated JJ
K+ NN
channels NNS
are VBP
not RB
involved VBN
in IN
B NN
and CC
T NN
lymphocyte NN
activation NN
and CC
mitogenesis NN
. O

Evaluation NN
of IN
the DT
role NN
of IN
ligand NN
and CC
thermal JJ
activation NN
of IN
specific JJ
DNA NN
binding NN
by IN
in FW
vitro FW
synthesized VBN
human JJ
glucocorticoid NN
receptor NN
. O

We PRP
have VBP
used VBN
a DT
DNA-binding/immunoprecipitation JJ
assay NN
to TO
analyze VB
the DT
capacity NN
of IN
human JJ
glucocorticoid NN
receptor NN
( O
hGR NN
) O
, O
generated VBN
in IN
rabbit NN
reticulocyte NN
lysates NNS
, O
to TO
bind VB
DNA NN
. O

In FW
vitro FW
translated VBN
hGR NN
was VBD
indistinguishable JJ
from IN
native JJ
hGR NN
, O
as IN
determined VBN
by IN
migration NN
on IN
sodium NN
dodecyl NN
sulfate-polyacrylamide JJ
gels NNS
, O
sedimentation NN
on IN
sucrose NN
density NN
gradients NNS
, O
and CC
reactivity NN
with IN
antipeptide JJ
antibodies NNS
generated VBN
against IN
hGR NN
. O

In IN
addition NN
, O
cell-free JJ
synthesized VBN
hGR NN
was VBD
capable JJ
of IN
specific JJ
binding NN
to TO
glucocorticoid NN
response NN
element NN
( O
GRE NN
) O
-containing JJ
DNA NN
fragments NNS
. O

Using VBG
this DT
assay NN
system NN
, O
we PRP
have VBP
evaluated VBN
the DT
contributions NNS
of IN
ligand NN
binding NN
and CC
heat NN
activation NN
to TO
DNA NN
binding NN
by IN
these DT
glucocorticoid NN
receptors NNS
. O

In FW
vitro FW
translated VBN
hGR NN
was VBD
capable JJ
of IN
selective JJ
DNA NN
binding NN
even RB
in IN
the DT
absence NN
of IN
glucocorticoid NN
. O

Treatment NN
with IN
dexamethasone NN
or CC
the DT
antiglucocorticoid JJ
RU486 NN
had VBD
no DT
additional JJ
effect NN
on IN
the DT
DNA-binding JJ
capacity NN
when WRB
receptor NN
preparations NNS
were VBD
maintained VBN
at IN
0 CD
C NN
( O
no DT
activation NN
) O
. O

In IN
contrast NN
, O
addition NN
of IN
either CC
ligand NN
or CC
antagonist NN
in IN
combination NN
with IN
a DT
heat NN
activation NN
step NN
promoted VBD
DNA NN
binding NN
by IN
approximately RB
3-fold RB
over IN
that DT
of IN
heat-activated JJ
unliganded JJ
receptors NNS
. O

Agonist NN
( O
dexamethasone NN
) O
was VBD
slightly RB
more JJR
effective JJ
in IN
supporting VBG
specific JJ
DNA NN
binding NN
than IN
antagonist NN
( O
RU486 NN
) O
. O

DNA NN
binding NN
by IN
in FW
vitro FW
synthesized VBN
GR NN
was VBD
blocked VBN
by IN
the DT
addition NN
of IN
sodium NN
molybdate NN
to TO
the DT
receptor NN
preparations NNS
before IN
steroid NN
addition NN
and CC
thermal JJ
activation NN
. O

Addition NN
of IN
KCl NN
resulted VBD
in IN
less RBR
DNA NN
binding NN
either CC
due JJ
to TO
blockage NN
of IN
DNA-receptor JJ
complex NN
formation NN
or CC
disruption NN
of IN
the DT
complexes NNS
. O

The DT
specificity NN
of IN
DNA NN
binding NN
by IN
cell-free JJ
synthesized VBN
hGR NN
was VBD
analyzed VBN
further RB
by IN
examining VBG
the DT
abilities NNS
of IN
various JJ
DNAs NNS
to TO
compete VB
for IN
binding VBG
to TO
a DT
naturally RB
occurring VBG
GRE NN
found VBD
in IN
the DT
mouse NN
mammary JJ
tumor NN
virus-long JJ
terminal JJ
repeat NN
. O

Oligonucleotides NNS
containing VBG
the DT
consensus NN
GRE NN
were VBD
the DT
most RBS
efficient JJ
competitors NNS
, O
and CC
fragments NNS
containing VBG
regulatory JJ
sequences NNS
from IN
glucocorticoid-repressible JJ
genes NNS
were VBD
somewhat RB
competitive JJ
, O
whereas IN
single JJ
stranded JJ
oligonucleotides NNS
were VBD
unable JJ
to TO
compete VB
for IN
mouse NN
mammary JJ
tumor NN
virus-long JJ
terminal JJ
repeat NN
DNA NN
binding NN
, O
except IN
when WRB
competitor NN
was VBD
present JJ
at IN
extremely RB
high JJ
concentrations NNS
. O

Together RB
these DT
studies NNS
indicate VBP
that IN
hGR NN
synthesized VBN
in IN
rabbit NN
reticulocyte NN
lysates NNS
displays VBZ
many JJ
of IN
the DT
same JJ
properties NNS
, O
including VBG
GRE-specific JJ
DNA NN
binding NN
, O
observed VBN
for IN
glucocorticoid NN
receptor NN
present JJ
in IN
cytosolic JJ
extracts NNS
of IN
mammalian JJ
cells NNS
and CC
tissues NNS
. O

Similarities NNS
between IN
the DT
effects NNS
of IN
dexamethasone NN
and CC
RU486 NN
suggest VBP
that IN
the DT
antiglucocorticoid JJ
properties NNS
of IN
RU486 NN
do VBP
not RB
occur VB
at IN
the DT
level NN
of IN
specific JJ
DNA NN
binding NN
. O

One CD
base NN
pair NN
change NN
abolishes VBZ
the DT
T NN
cell-restricted JJ
activity NN
of IN
a DT
kB-like JJ
proto-enhancer NN
element NN
from IN
the DT
interleukin NN
2 CD
promoter NN
. O

The DT
inducible JJ
, O
T NN
cell-specific JJ
enhancers NNS
of IN
murine JJ
and CC
human JJ
Interleukin NN
2 CD
( O
Il-2 NN
) O
genes NNS
contain VBP
the DT
kB-like JJ
sequence NN
GGGATTTCACC NN
as IN
an DT
essential JJ
cis-acting JJ
enhancer NN
motif NN
. O

When WRB
cloned VBN
in IN
multiple JJ
copies NNS
this DT
so-called JJ
TCEd NN
( O
distal JJ
T NN
cell NN
element NN
) O
acts VBZ
as IN
an DT
inducible JJ
proto-enhancer NN
element NN
in IN
E14 NN
T NN
lymphoma NN
cells NNS
, O
but CC
not RB
in IN
HeLa NN
cells NNS
. O

In IN
extracts NNS
of IN
induced VBN
, O
Il-2 NN
secreting NN
El4 NN
cells NNS
three CD
individual JJ
protein NN
factors NNS
bind VBP
to TO
TCEd NN
DNA NN
. O

The DT
binding NN
of IN
the DT
most RBS
prominent JJ
factor NN
, O
named VBN
TCF-1 NN
( O
T NN
cell NN
factor NN
1 CD
) O
, O
is VBZ
correlated VBN
with IN
the DT
proto-enhancer NN
activity NN
of IN
TCEd NN
. O

TCF-1 NN
consists VBZ
of IN
two CD
polypeptides NNS
of IN
about RB
50 CD
kD NN
and CC
105 CD
kD NN
; O
the DT
former JJ
seems VBZ
to TO
be VB
related JJ
to TO
the DT
50 CD
kD NN
polypeptide NN
of IN
NF-kB NN
. O

Purified VBN
NF-kB NN
is VBZ
also RB
able JJ
to TO
bind VB
to TO
the DT
TCEd NN
, O
but CC
TCF-1 NN
binds VBZ
stronger JJR
than IN
NF-kB NN
to TO
TCEd NN
DNA NN
. O

The DT
conversion NN
of IN
the DT
TCEd NN
to TO
a DT
' [[DQS]]
perfect JJ
' [[DQE]]
NF-kB NN
binding NN
site NN
leads VBZ
to TO
a DT
tighter JJR
binding NN
of IN
NF-kB NN
to TO
TCEd NN
DNA NN
and CC
, O
as IN
a DT
functional JJ
consequence NN
, O
to TO
the DT
activity NN
of IN
the DT
' [[DQS]]
converted VBN
' [[DQE]]
TCEd NN
motifs NNS
in IN
HeLa NN
cells NNS
. O

Thus RB
, O
the DT
substitution NN
of IN
the DT
underlined VBN
A NN
residue NN
to TO
a DT
C NN
within IN
the DT
GGGATTTCACC NN
motif NN
abolishes VBZ
its PRP$
T NN
cell-restricted JJ
activity NN
and CC
leads VBZ
to TO
its PRP$
functioning VBG
in IN
both CC
El4 NN
cells NNS
and CC
HeLa NN
cells NNS
. O

These DT
results NNS
indicate VBP
that IN
lymphocyte-specific JJ
factors NNS
binding VBG
to TO
the DT
TCEd NN
are VBP
involved VBN
in IN
the DT
control NN
of IN
T NN
cell NN
specific-transcription NN
of IN
the DT
Il-2 NN
gene NN
. O

Negative JJ
regulation NN
of IN
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
expression NN
in IN
monocytes NNS
: O
role NN
of IN
the DT
65-kDa JJ
plus CC
50-kDa JJ
NF-kappa NN
B NN
dimer NN
. O

Although IN
monocytic JJ
cells NNS
can MD
provide VB
a DT
reservoir NN
for IN
viral JJ
production NN
in FW
vivo FW
, O
their PRP$
regulation NN
of IN
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
( O
HIV-1 NN
) O
transcription NN
can MD
be VB
either CC
latent JJ
, O
restricted JJ
, O
or CC
productive JJ
. O

These DT
differences NNS
in IN
gene NN
expression NN
have VBP
not RB
been VBN
molecularly RB
defined VBN
. O

In IN
THP-1 NN
cells NNS
with IN
restricted JJ
HIV NN
expression NN
, O
there EX
is VBZ
an DT
absence NN
of IN
DNA-protein JJ
binding NN
complex NN
formation NN
with IN
the DT
HIV-1 NN
promoter-enhancer NN
associated VBN
with IN
markedly RB
less JJR
viral JJ
RNA NN
production NN
. O

This DT
absence NN
of IN
binding NN
was VBD
localized JJ
to TO
the DT
NF-kappa NN
B NN
region NN
of IN
the DT
HIV-1 NN
enhancer NN
; O
the DT
65-kDa JJ
plus CC
50-kDa JJ
NF-kappa NN
B NN
heterodimer NN
was VBD
preferentially RB
lost VBN
. O

Adding VBG
purified VBN
NF-kappa NN
B NN
protein NN
to TO
nuclear JJ
extracts NNS
from IN
cells NNS
with IN
restricted JJ
expression NN
overcomes VBZ
this DT
lack NN
of IN
binding NN
. O

In IN
addition NN
, O
treatment NN
of IN
these DT
nuclear JJ
extracts NNS
with IN
sodium NN
deoxycholate NN
restored VBD
their PRP$
ability NN
to TO
form VB
the DT
heterodimer NN
, O
suggesting VBG
the DT
presence NN
of IN
an DT
inhibitor NN
of IN
NF-kappa NN
B NN
activity NN
. O

Furthermore RB
, O
treatment NN
of IN
nuclear JJ
extracts NNS
from IN
these DT
cells NNS
that WDT
had VBD
restricted JJ
expression NN
with IN
lipopolysaccharide NN
increased VBD
viral JJ
production NN
and CC
NF-kappa NN
B NN
activity NN
. O

Antiserum NN
specific JJ
for IN
NF-kappa NN
B NN
binding NN
proteins NNS
, O
but CC
not RB
c-rel-specific JJ
antiserum NN
, O
disrupted VBD
heterodimer NN
complex NN
formation NN
. O

Thus RB
, O
both DT
NF-kappa NN
B-binding JJ
complexes NNS
are VBP
needed VBN
for IN
optimal JJ
viral JJ
transcription NN
. O

Binding NN
of IN
the DT
65-kDa JJ
plus CC
50-kDa JJ
heterodimer NN
to TO
the DT
HIV-1 NN
enhancer NN
can MD
be VB
negatively RB
regulated VBN
in IN
monocytes NNS
, O
providing VBG
one CD
mechanism NN
restricting VBG
HIV-1 NN
gene NN
expression NN
. O

Isolation NN
of IN
a DT
candidate NN
repressor/activator NN
, O
NF-E1 NN
( O
YY-1 NN
, O
delta NN
) O
, O
that WDT
binds VBZ
to TO
the DT
immunoglobulin NN
kappa NN
3' JJ
enhancer NN
and CC
the DT
immunoglobulin NN
heavy-chain NN
mu NN
E1 NN
site NN
. O

We PRP
have VBP
determined VBN
that IN
the DT
developmental JJ
control NN
of IN
immunoglobulin NN
kappa NN
3' JJ
enhancer NN
( O
kappa NN
E3' NN
) O
activity NN
is VBZ
the DT
result NN
of IN
the DT
combined JJ
influence NN
of IN
positive- JJ
and CC
negative-acting JJ
elements NNS
. O

We PRP
show VBP
that IN
a DT
central JJ
core NN
in IN
the DT
kappa NN
E3' NN
enhancer NN
is VBZ
active JJ
at IN
the DT
pre-B-cell JJ
stage NN
but CC
is VBZ
repressed VBN
by IN
flanking VBG
negative-acting JJ
elements NNS
. O

The DT
negative-acting JJ
sequences NNS
repress VBP
enhancer NN
activity NN
in IN
a DT
position- NN
and CC
orientation-independent JJ
manner NN
at IN
the DT
pre-B-cell JJ
stage NN
. O

We PRP
have VBP
isolated VBN
a DT
human JJ
cDNA NN
clone NN
encoding VBG
a DT
zinc NN
finger NN
protein NN
( O
NF-E1 NN
) O
that WDT
binds VBZ
to TO
the DT
negative-acting JJ
segment NN
of IN
the DT
kappa NN
E3' NN
enhancer NN
. O

This DT
protein NN
also RB
binds VBZ
to TO
the DT
immunoglobulin NN
heavy-chain NN
enhancer NN
mu NN
E1 NN
site NN
. O

NF-E1 NN
is VBZ
encoded VBN
by IN
the DT
same JJ
gene NN
as IN
the DT
YY-1 NN
protein NN
, O
which WDT
binds VBZ
to TO
the DT
adeno-associated JJ
virus NN
P5 NN
promoter NN
. O

NF-E1 NN
is VBZ
also RB
the DT
human JJ
homologue NN
of IN
the DT
mouse NN
delta NN
protein NN
, O
which WDT
binds VBZ
to TO
ribosomal JJ
protein NN
gene NN
promoters NNS
. O

The DT
predicted VBN
amino NN
acid NN
sequence NN
of IN
this DT
protein NN
contains VBZ
features NNS
characteristic JJ
of IN
transcriptional JJ
activators NNS
as RB
well RB
as IN
transcriptional JJ
repressors NNS
. O

Cotransfection NN
studies NNS
with IN
this DT
cDNA NN
indicate VBP
that IN
it PRP
can MD
repress VB
basal JJ
promoter NN
activity NN
. O

The DT
apparent JJ
dual JJ
function NN
of IN
this DT
protein NN
is VBZ
discussed VBN
. O

Clone NN
pAT NN
133 CD
identifies VBZ
a DT
gene NN
that WDT
encodes VBZ
another DT
human JJ
member NN
of IN
a DT
class NN
of IN
growth NN
factor-induced JJ
genes NNS
with IN
almost RB
identical JJ
zinc-finger NN
domains NNS
. O

We PRP
report VBP
the DT
structure NN
and CC
regulation NN
of IN
a DT
gene NN
represented VBN
by IN
clone NN
pAT NN
133 CD
, O
which WDT
is VBZ
induced VBN
upon IN
transition NN
from IN
a DT
resting JJ
state NN
( O
G0 NN
) O
through IN
the DT
early JJ
phase NN
of IN
the DT
cell NN
cycle NN
( O
G1 NN
) O
. O

The DT
pAT NN
133 CD
gene NN
is VBZ
immediately RB
induced VBN
, O
with IN
FOS-like JJ
kinetics NNS
, O
in IN
human JJ
T NN
cells NNS
and CC
in IN
fibroblasts NNS
. O

Primary JJ
structure NN
analysis NN
showed VBD
that IN
the DT
encoded VBN
protein NN
contains VBZ
three CD
tandem JJ
zinc-finger NN
sequences NNS
of IN
the DT
type NN
Cys2-Xaa12-His2 NN
. O

This DT
zinc-finger NN
region NN
, O
which WDT
is VBZ
thought VBN
to TO
bind VB
DNA NN
in IN
a DT
sequence-specific JJ
manner NN
, O
is VBZ
similar JJ
( O
greater JJR
than IN
80 CD
% NN
on IN
the DT
amino NN
acid NN
level NN
) O
to TO
two CD
previously RB
described VBN
transcription NN
factors NNS
pAT NN
225/EGR1 NN
and CC
pAT NN
591/EGR2 NN
. O

Except IN
for IN
the DT
conserved VBN
zinc-finger NN
domains NNS
, O
the DT
amino NN
acid NN
sequences NNS
of IN
the DT
three CD
proteins NNS
are VBP
distinct JJ
. O

This DT
structural JJ
similarity NN
suggests VBZ
that IN
the DT
pAT NN
133 CD
gene NN
encodes VBZ
a DT
transcription NN
factor NN
with IN
a DT
specific JJ
biological JJ
function NN
. O

Comparing VBG
the DT
regulation NN
of IN
these DT
related JJ
zinc-finger-encoding JJ
genes NNS
showed VBD
coordinate JJ
induction NN
upon IN
mitogenic JJ
stimulation NN
of IN
resting VBG
T NN
lymphocytes NNS
and CC
of IN
resting VBG
fibroblasts NNS
. O

However RB
, O
upon IN
transition NN
from IN
a DT
proliferating JJ
( O
G1 NN
) O
to TO
a DT
resting JJ
state NN
of IN
the DT
cell NN
cycle NN
the DT
three CD
genes NNS
were VBD
differently RB
regulated VBN
. O

In IN
human JJ
histiocytic JJ
U937 NN
cells NNS
mRNA NN
of IN
clone NN
pAT NN
133 CD
was VBD
constitutively RB
expressed VBN
, O
whereas IN
mRNA NN
of IN
pAT NN
225/EGR1 NN
was VBD
induced VBN
upon IN
induction NN
of IN
terminal JJ
differentiation NN
. O

In IN
contrast NN
mRNA NN
representing VBG
pAT NN
591/EGR2 NN
was VBD
not RB
expressed VBN
in IN
these DT
cells NNS
. O

This DT
difference NN
in IN
gene NN
regulation NN
suggests VBZ
distinct JJ
biological JJ
roles NNS
in IN
the DT
control NN
of IN
cell NN
proliferation NN
for IN
the DT
respective JJ
proteins NNS
. O

cAMP-dependent JJ
regulation NN
of IN
proenkephalin NN
by IN
JunD NN
and CC
JunB NN
: O
positive JJ
and CC
negative JJ
effects NNS
of IN
AP-1 NN
proteins NNS
. O

We PRP
demonstrate VBP
that IN
JunD NN
, O
a DT
component NN
of IN
the DT
AP-1 NN
transcription NN
factor NN
complex NN
, O
activates VBZ
transcription NN
of IN
the DT
human JJ
proenkephalin NN
gene NN
in IN
a DT
fashion NN
that WDT
is VBZ
completely RB
dependent JJ
upon IN
the DT
cAMP-dependent JJ
protein NN
kinase NN
, O
protein NN
kinase NN
A NN
. O

Activation NN
of IN
proenkephalin NN
transcription NN
by IN
JunD NN
is VBZ
dependent JJ
upon IN
a DT
previously RB
characterized VBN
cAMP- NN
, O
phorbol NN
ester- NN
, O
and CC
Ca(2+)-inducible JJ
enhancer NN
, O
and CC
JunD NN
is VBZ
shown VBN
to TO
bind VB
the DT
enhancer NN
as IN
a DT
homodimer NN
. O

Another DT
component NN
of IN
the DT
AP-1 NN
transcription NN
complex NN
, O
JunB NN
, O
is VBZ
shown VBN
to TO
inhibit VB
activation NN
mediated VBN
by IN
JunD NN
. O

As IN
a DT
homodimer NN
JunB NN
is VBZ
unable JJ
to TO
bind VB
the DT
enhancer NN
; O
however RB
in IN
the DT
presence NN
of IN
c-Fos NN
, O
high-affinity JJ
binding NN
is VBZ
observed VBN
. O

Furthermore RB
, O
JunD NN
is VBZ
shown VBN
to TO
activate VB
transcription NN
of IN
genes NNS
linked VBN
to TO
both CC
cAMP NN
and CC
phorbol NN
ester NN
response NN
elements NNS
in IN
a DT
protein NN
kinase NN
A-dependent JJ
fashion NN
, O
further RB
blurring VBG
the DT
distinction NN
between IN
these DT
response NN
elements NNS
. O

These DT
results NNS
demonstrate VBP
that IN
the DT
transcriptional JJ
activity NN
of IN
an DT
AP-1-related JJ
protein NN
is VBZ
regulated VBN
by IN
the DT
cAMP-dependent JJ
second-messenger NN
pathway NN
and CC
suggest VBP
that IN
JunD NN
and CC
other JJ
AP-1-related JJ
proteins NNS
may MD
play VB
an DT
important JJ
role NN
in IN
the DT
regulation NN
of IN
gene NN
expression NN
by IN
cAMP-dependent JJ
intracellular JJ
signaling NN
pathways NNS
. O

Glucocorticoid NN
resistance NN
in IN
chronic JJ
asthma NN
. O

Glucocorticoid NN
pharmacokinetics NNS
, O
glucocorticoid NN
receptor NN
characteristics NNS
, O
and CC
inhibition NN
of IN
peripheral JJ
blood NN
T NN
cell NN
proliferation NN
by IN
glucocorticoids NNS
in FW
vitro FW
. O

A DT
total NN
of IN
37 CD
chronic JJ
, O
severe JJ
, O
nonsmoking JJ
asthmatic JJ
patients NNS
with IN
documented JJ|VBN
reversible JJ
airways NNS
obstruction NN
were VBD
classified VBN
as IN
glucocorticoid-sensitive JJ
or CC
-resistant JJ
on IN
the DT
basis NN
of IN
changes NNS
in IN
FEV1 NN
, O
FVC NN
, O
and CC
peak JJ
expiratory NN
flow NN
( O
PEF NN
) O
after IN
oral JJ
prednisolone NN
. O

The DT
resistant JJ
patients NNS
showed VBD
no DT
significant JJ
improvements NNS
in IN
airflow NN
limitation NN
. O

Phytohemagglutinin NN
( O
PHA NN
) O
-induced JJ
proliferation NN
of IN
peripheral JJ
blood NN
T NN
lymphocytes NNS
from IN
the DT
sensitive JJ
but CC
not RB
the DT
resistant JJ
asthmatic JJ
patients NNS
was VBD
significantly RB
( O
p NN
less JJR
than IN
0.01 CD
) O
inhibited VBN
by IN
dexamethasone NN
( O
10(-7) CD
mol/L NN
) O
, O
reflecting VBG
a DT
shift NN
of IN
the DT
dose-response JJ
curve NN
. O

When WRB
all PDT
the DT
asthmatic JJ
patients NNS
were VBD
analyzed VBN
together RB
, O
there EX
was VBD
a DT
significant JJ
correlation NN
between IN
the DT
degree NN
of IN
sensitivity NN
of IN
T NN
cells NNS
to TO
dexamethasone NN
and CC
the DT
clinical JJ
responsiveness NN
to TO
prednisolone JJ
( O
p NN
less RBR
than IN
0.01 CD
) O
. O

No DT
differences NNS
were VBD
observed VBN
between IN
six CD
of IN
the DT
sensitive JJ
and CC
resistant JJ
patients NNS
in IN
the DT
clearance NN
of IN
plasma NN
prednisolone JJ
derived VBN
from IN
orally RB
administered VBN
prednisone NN
. O

Peripheral JJ
blood NN
mononuclear JJ
cell NN
glucocorticoid NN
receptors NNS
were VBD
also RB
characterized VBN
in IN
five CD
sensitive JJ
and CC
seven CD
resistant JJ
patients NNS
. O

The DT
numbers NNS
and CC
binding NN
affinities NNS
of IN
these DT
receptors NNS
could MD
not RB
account VB
for IN
the DT
observed VBN
difference NN
in IN
the DT
susceptibility NN
of IN
these DT
cells NNS
to TO
functional JJ
inhibition NN
by IN
dexamethasone NN
in FW
vitro FW
. O

These DT
results NNS
suggest VBP
that IN
clinical JJ
glucocorticoid NN
resistance NN
in IN
chronic JJ
asthma NN
does VBZ
not RB
reflect VB
abnormal JJ
glucocorticoid NN
clearance NN
but CC
may MD
be VB
due JJ
at IN
least JJS
partly RB
to TO
a DT
relative JJ
insensitivity NN
of IN
T NN
lymphocytes NNS
to TO
glucocorticoids NNS
. O

This DT
lack NN
of IN
sensitivity NN
is VBZ
unexplained JJ
but CC
is VBZ
not RB
attributable JJ
to TO
abnormalities NNS
of IN
cellular JJ
glucocorticoid NN
receptors NNS
. O

Regulation NN
of IN
interleukin-1 NN
beta NN
production NN
by IN
glucocorticoids NNS
in IN
human JJ
monocytes NNS
: O
the DT
mechanism NN
of IN
action NN
depends VBZ
on IN
the DT
activation NN
signal NN
. O

Glucocorticoids NNS
are VBP
known VBN
to TO
downregulate VB
interleukin-1 NN
beta NN
production NN
in IN
monocytic JJ
cells NNS
by IN
two CD
different JJ
mechanims NNS
: O
direct JJ
inhibition NN
of IN
the DT
gene NN
transcription NN
and CC
destabilization NN
of IN
the DT
preformed JJ
interleukin-1 NN
beta NN
mRNA NN
. O

Now RB
we PRP
have VBP
examined VBN
the DT
effect NN
of IN
the DT
nature NN
of IN
the DT
monocyte NN
activating NN
signal NN
on IN
these DT
two CD
inhibitory JJ
mechanims NNS
. O

When WRB
human JJ
monocytes NNS
were VBD
preincubated VBN
with IN
dexamethasone NN
for IN
1 CD
hour NN
and CC
then RB
stimulated VBN
either CC
with IN
bacterial JJ
lipopolysaccharide NN
or CC
phorbol NN
myristate NN
, O
it PRP
was VBD
found VBN
that IN
dexamethasone NN
inhibited VBD
the DT
lipopolysaccharide-induced JJ
interleukin-1 NN
beta NN
protein NN
production NN
, O
but CC
the DT
phorbol NN
myristate-induced JJ
production NN
was VBD
increased VBN
3-10 CD
fold RB
. O

This DT
difference NN
was VBD
also RB
seen VBN
at IN
the DT
mRNA NN
level NN
. O

When WRB
dexamethasone NN
was VBD
added VBN
to TO
the DT
cultures NNS
3 CD
hours NNS
after IN
the DT
stimulators NNS
, O
it PRP
clearly RB
decreased VBD
the DT
interleukin-1 NN
beta NN
mRNA NN
levels NNS
regardless RB
of IN
the DT
stimulator NN
used VBN
( O
although IN
the DT
effect NN
was VBD
clearly RB
weaker JJR
on IN
the DT
PMA-induced JJ
mRNA NN
) O
. O

Thus RB
these DT
data NNS
suggest VBP
that IN
the DT
phorbol NN
myristate-induced JJ
signal NN
( O
prolonged JJ
protein NN
kinase NN
C NN
activation NN
? O
) O
can MD
not RB
be VB
inhibited VBN
by IN
prior JJ
incubation NN
with IN
dexamethasone NN
and CC
it PRP
also RB
protects VBZ
the DT
induced VBN
mRNA NN
for IN
the DT
degradative JJ
action NN
of IN
dexamethasone NN
. O

Identification NN
of IN
transcriptional JJ
suppressor NN
proteins NNS
that WDT
bind VBP
to TO
the DT
negative JJ
regulatory JJ
element NN
of IN
the DT
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
. O

Two CD
different JJ
proteins NNS
which WDT
independently RB
bound VBD
to TO
neighboring VBG
sequences NNS
within IN
the DT
negative JJ
regulatory JJ
element NN
( O
NRE NN
) O
of IN
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
( O
HIV-1 NN
) O
were VBD
detected VBN
in IN
the DT
nuclear JJ
extract NN
of IN
a DT
virus-infected JJ
human JJ
T NN
cell NN
line NN
. O

One CD
of IN
the DT
factors NNS
bound VBD
to TO
a DT
novel JJ
dyad NN
symmetrical JJ
sequence NN
. O

This DT
sequence NN
is VBZ
well RB
conserved VBN
in IN
various JJ
HIV-1 NN
isolates NNS
and CC
partial JJ
homology NN
was VBD
found VBN
with IN
the DT
promoter JJ
region NN
of IN
the DT
human JJ
retinoblastoma NN
gene NN
. O

Similar JJ
DNA NN
binding NN
activity NN
was VBD
detected VBN
in IN
a DT
variety NN
of IN
virus-uninfected JJ
human JJ
T NN
cell NN
lines NNS
and CC
HeLa NN
cells NNS
by IN
means NNS
of IN
a DT
gel NN
mobility NN
shift NN
assay NN
. O

The DT
other JJ
factor NN
bound VBN
to TO
a DT
putative JJ
AP-1 NN
recognition NN
sequence NN
predicted VBD
for IN
the DT
HIV-1 NN
NRE NN
. O

However RB
, O
this DT
factor NN
did VBD
not RB
bind VB
to TO
a DT
typical JJ
AP-1 NN
site NN
. O

The DT
insertion NN
of IN
multiple JJ
copies NNS
of IN
the DT
binding VBG
site NN
for IN
the DT
former JJ
or CC
latter JJ
factor NN
into IN
a DT
heterologous JJ
promoter NN
reduced VBD
the DT
promoter NN
activity NN
to TO
one-tenth CD
or CC
one-third CD
, O
respectively RB
. O

Thus RB
, O
each DT
factor NN
may MD
function VB
as IN
a DT
novel JJ
negative JJ
regulator NN
of IN
transcription NN
. O

Constitutive JJ
activation NN
of IN
NF-kB NN
in IN
human JJ
thymocytes NNS
. O

NF-kB NN
is VBZ
a DT
eukaryotic JJ
transcription NN
regulatory JJ
factor NN
. O

In IN
T NN
cells NNS
and CC
T NN
cell NN
lines NNS
, O
NF-kB NN
is VBZ
bound VBN
to TO
a DT
cytoplasmic JJ
proteic JJ
inhibitor NN
, O
the DT
IkB NN
. O

Treatment NN
of IN
T NN
cells NNS
with IN
mitogens NNS
( O
phorbol NN
esters NNS
) O
or CC
cytokines NNS
( O
TNF NN
alpha NN
) O
induces VBZ
NF-kB NN
nuclear JJ
translocation NN
and CC
the DT
subsequent JJ
expression NN
of IN
NF-kB NN
dependent JJ
T NN
cell NN
genes NNS
. O

Here RB
we PRP
examined VBD
the DT
activation NN
of IN
NF-kB NN
in IN
human JJ
T NN
cell NN
thymic JJ
progenitors NNS
. O

We PRP
report VBP
differences NNS
in IN
(Ca2+)i NN
requirement NN
for IN
NF-kB NN
activation NN
in IN
thymocytes NNS
as IN
compared VBN
to TO
mature JJ
T NN
cells NNS
. O

Furthermore RB
, O
our PRP$
results NNS
indicated VBD
that IN
thymocytes NNS
have VBP
a DT
constitutively RB
active JJ
form NN
of IN
NF-kB NN
, O
suggesting VBG
that IN
they PRP
are VBP
activated VBN
in FW
vivo FW
. O

The DT
role NN
of IN
jun NN
and CC
fos NN
gene NN
family NN
members NNS
in IN
12-O-tetradecanoylphorbol-13-acetate NN
induced VBD
hemopoietic JJ
differentiation NN
. O

Terminal JJ
differentiation NN
of IN
the DT
leukemic JJ
cell NN
lines NNS
U-937 NN
and CC
HL-60 NN
by IN
12-O-tetradecanoylphorbol-13-acetate NN
is VBZ
accompanied VBN
by IN
marked JJ
changes NNS
in IN
gene NN
expression NN
. O

In IN
this DT
study NN
, O
we PRP
demonstrate VBP
that IN
the DT
expression NN
of IN
jun NN
and CC
fos NN
gene NN
family NN
members NNS
is VBZ
induced VBN
with IN
variable JJ
kinetics NNS
during IN
12-O-tetradecanoylphorbol-13-acetate NN
induced VBD
differentiation NN
, O
with IN
c-jun NN
expression NN
best RB
paralleling JJ
differentiation NN
. O

The DT
generation NN
of IN
AP-1 NN
complexes NNS
, O
as IN
measured VBN
by IN
DNA NN
binding NN
activity NN
, O
closely RB
parallels VBZ
morphological JJ
differentiation NN
. O

Furthermore RB
, O
the DT
ability NN
of IN
these DT
complexes NNS
to TO
regulate VB
gene NN
expression NN
is VBZ
demonstrated VBN
by IN
increased VBN
transcription NN
from IN
an DT
AP-1 NN
driven VBN
reporter NN
construct NN
and CC
marked JJ
increases NNS
in IN
the DT
expression NN
of IN
endogenous JJ
AP-1 NN
regulated JJ
genes NNS
. O

Differentiation NN
assays NNS
using VBG
water NN
soluble JJ
phorbol NN
esters NNS
reveal VBP
that IN
differentiation NN
becomes VBZ
irreversible JJ
soon RB
after IN
AP-1 NN
appears VBZ
. O

This DT
tight JJ
correlation NN
between IN
c-jun NN
expression NN
, O
the DT
generation NN
of IN
AP-1 NN
activity NN
, O
and CC
differentiation NN
suggests VBZ
a DT
critical JJ
role NN
for IN
this DT
gene NN
and CC
transcriptional JJ
complex NN
during IN
this DT
process NN
. O

TCF-1 NN
, O
a DT
T NN
cell-specific JJ
transcription NN
factor NN
of IN
the DT
HMG NN
box NN
family NN
, O
interacts VBZ
with IN
sequence NN
motifs NNS
in IN
the DT
TCR NN
beta NN
and CC
TCR NN
delta NN
enhancers NNS
. O

We PRP
have VBP
recently RB
identified VBN
and CC
cloned VBN
TCF-1 NN
, O
a DT
T NN
cell-specific JJ
transcription NN
factor NN
with IN
specificity NN
for IN
the DT
AACAAAG NN
motif NN
in IN
the DT
CD3 NN
epsilon NN
enhancer NN
and CC
for IN
the DT
TTCAAAG NN
motif NN
in IN
the DT
TCR NN
alpha NN
enhancer NN
. O

TCF-1 NN
belongs VBZ
to TO
the DT
family NN
of IN
transcription-regulating JJ
proteins NNS
which WDT
share VBP
a DT
region NN
of IN
homology NN
termed VBN
the DT
HMG-box NN
. O

Here RB
, O
we PRP
show VBP
by IN
gel NN
retardation NN
analysis NN
that IN
TCF-1 NN
specifically RB
recognizes VBZ
the DT
T NN
beta NN
5 CD
element NN
of IN
the DT
TCR NN
beta NN
enhancer NN
and CC
the DT
T NN
delta NN
7 CD
element NN
of IN
the DT
TCR NN
delta NN
enhancer NN
. O

Comparison NN
of IN
the DT
sequences NNS
of IN
all DT
elements NNS
recognized VBN
by IN
TCF-1 NN
defines VBZ
a DT
consensus NN
motif NN
A/T NN
A/T NN
C NN
A NN
A/G NN
A NN
G NN
. O

These DT
observations NNS
imply VBP
that IN
TCF-1 NN
is VBZ
involved VBN
in IN
the DT
control NN
of IN
several JJ
T NN
cell-specific JJ
genes NNS
and CC
might MD
thus RB
play VB
an DT
important JJ
role NN
in IN
the DT
establishment NN
and CC
maintenance NN
of IN
the DT
mature JJ
T NN
cell NN
phenotype NN
. O

The DT
cellular JJ
oncogene NN
c-myb NN
can MD
interact VB
synergistically RB
with IN
the DT
Epstein-Barr JJ
virus NN
BZLF1 NN
transactivator NN
in IN
lymphoid JJ
cells NNS
. O

Regulation NN
of IN
replicative JJ
functions NNS
in IN
the DT
Epstein-Barr JJ
virus NN
( O
EBV NN
) O
genome NN
is VBZ
mediated VBN
through IN
activation NN
of IN
a DT
virally RB
encoded VBN
transcription NN
factor NN
, O
Z NN
( O
BZLF1 NN
) O
. O

We PRP
have VBP
shown VBN
that IN
the DT
Z NN
gene NN
product NN
, O
which WDT
binds VBZ
to TO
AP-1 NN
sites NNS
as IN
a DT
homodimer NN
and CC
has VBZ
sequence NN
similarity NN
to TO
c-Fos NN
, O
can MD
efficiently RB
activate VB
the DT
EBV NN
early JJ
promoter NN
, O
BMRF1 NN
, O
in IN
certain JJ
cell NN
types NNS
( O
i.e. FW
, O
HeLa NN
cells NNS
) O
but CC
not RB
others NNS
( O
i.e. FW
, O
Jurkat NN
cells NNS
) O
. O

Here RB
we PRP
demonstrate VBP
that IN
the DT
c-myb NN
proto-oncogene NN
product NN
, O
which WDT
is VBZ
itself PRP
a DT
DNA-binding JJ
protein NN
and CC
transcriptional JJ
transactivator NN
, O
can MD
interact VB
synergistically RB
with IN
Z NN
in IN
activating VBG
the DT
BMRF1 NN
promoter NN
in IN
Jurkat NN
cells NNS
( O
a DT
T-cell NN
line NN
) O
or CC
Raji NN
cells NNS
( O
an DT
EBV-positive JJ
B-cell NN
) O
, O
whereas IN
the DT
c-myb NN
gene NN
product NN
by IN
itself PRP
has VBZ
little JJ
effect NN
. O

The DT
simian JJ
virus NN
40 CD
early JJ
promoter NN
is VBZ
also RB
synergistically RB
activated VBN
by IN
the DT
Z/c-myb NN
combination NN
. O

Synergistic JJ
transactivation NN
of IN
the DT
BMRF1 NN
promoter NN
by IN
the DT
Z/c-myb NN
combination NN
appears VBZ
to TO
involve VB
direct JJ
binding NN
by IN
the DT
Z NN
protein NN
but CC
not RB
the DT
c-myb NN
protein NN
. O

A DT
30-bp JJ
sequence NN
in IN
the DT
BMRF1 NN
promoter NN
which WDT
contains VBZ
a DT
Z NN
binding NN
site NN
( O
a DT
consensus NN
AP-1 NN
site NN
) O
is VBZ
sufficient JJ
to TO
transfer VB
high-level JJ
lymphoid-specific JJ
responsiveness NN
to TO
the DT
Z/c-myb NN
combination NN
to TO
a DT
heterologous JJ
promoter NN
. O

That IN
the DT
c-myb NN
oncogene NN
product NN
can MD
interact VB
synergistically RB
with IN
an DT
EBV-encoded JJ
member NN
of IN
the DT
leucine NN
zipper NN
protein NN
family NN
suggests VBZ
c-myb NN
is VBZ
likely JJ
to TO
engage VB
in IN
similar JJ
interactions NNS
with IN
cellularly RB
encoded VBN
transcription NN
factors NNS
. O

The DT
29-kDa JJ
proteins NNS
phosphorylated VBN
in IN
thrombin-activated JJ
human JJ
platelets NNS
are VBP
forms NNS
of IN
the DT
estrogen NN
receptor-related JJ
27-kDa JJ
heat NN
shock NN
protein NN
. O

Thrombin NN
plays VBZ
a DT
critical JJ
role NN
in IN
platelet NN
activation NN
, O
hemostasis NN
, O
and CC
thrombosis NN
. O

Cellular JJ
activation NN
by IN
thrombin NN
leads VBZ
to TO
the DT
phosphorylation NN
of IN
multiple JJ
proteins NNS
, O
most JJS
of IN
which WDT
are VBP
unidentified JJ
. O

We PRP
have VBP
characterized VBN
several JJ
29-kDa JJ
proteins NNS
that WDT
are VBP
rapidly RB
phosphorylated VBN
following VBG
exposure NN
of IN
intact JJ
human JJ
platelets NNS
to TO
thrombin NN
. O

A DT
murine JJ
monoclonal JJ
antibody NN
raised VBN
to TO
an DT
unidentified JJ
estrogen NN
receptor-related JJ
29-kDa JJ
protein NN
selectively RB
recognized VBD
these DT
proteins NNS
as RB
well RB
as IN
a DT
more RBR
basic JJ
, O
unphosphorylated JJ
27-kDa JJ
protein NN
. O

Cellular JJ
activation NN
by IN
thrombin NN
led VBN
to TO
a DT
marked JJ
shift NN
in IN
the DT
proportion NN
of IN
protein NN
from IN
the DT
27-kDa JJ
unphosphorylated JJ
form NN
to TO
the DT
29-kDa JJ
phosphoprotein NN
species NNS
. O

Using VBG
this DT
antibody NN
, O
we PRP
isolated VBD
and CC
sequenced VBD
a DT
human JJ
cDNA NN
clone NN
encoding VBG
a DT
protein NN
that WDT
was VBD
identical JJ
to TO
the DT
mammalian JJ
27-kDa JJ
heat NN
shock NN
protein NN
( O
HSP27 NN
) O
, O
a DT
protein NN
of IN
uncertain JJ
function NN
that WDT
is VBZ
known VBN
to TO
be VB
phosphorylated VBN
to TO
several JJ
forms NNS
and CC
to TO
be VB
transcriptionally RB
induced VBN
by IN
estrogen NN
. O

The DT
29-kDa JJ
proteins NNS
were VBD
confirmed VBN
to TO
be VB
phosphorylated VBN
forms NNS
of IN
HSP27 NN
by IN
immunoprecipitation NN
studies NNS
. O

Thus RB
, O
the DT
" [[DQS]]
estrogen NN
receptor-related JJ
protein NN
" [[DQE]]
is VBZ
HSP27 NN
, O
and CC
the DT
three CD
major JJ
29-kDa JJ
proteins NNS
phosphorylated VBN
in IN
thrombin-activated JJ
platelets NNS
are VBP
forms NNS
of IN
HSP27 NN
. O

These DT
data NNS
suggest VBP
a DT
role NN
for IN
HSP27 NN
in IN
the DT
signal NN
transduction NN
events NNS
of IN
platelet NN
activation NN
. O

Characterization NN
of IN
a DT
cofactor NN
that WDT
regulates VBZ
dimerization NN
of IN
a DT
mammalian JJ
homeodomain NN
protein NN
. O

Dimerization NN
among IN
transcription NN
factors NNS
has VBZ
become VBN
a DT
recurrent JJ
theme NN
in IN
the DT
regulation NN
of IN
eukaryotic JJ
gene NN
expression NN
. O

Hepatocyte NN
nuclear JJ
factor-1 NN
alpha NN
( O
HNF-1 NN
alpha NN
) O
is VBZ
a DT
homeodomain-containing JJ
protein NN
that WDT
functions VBZ
as IN
a DT
dimer NN
. O

A DT
dimerization NN
cofactor NN
of IN
HNF-1 NN
alpha NN
( O
DCoH NN
) O
was VBD
identified VBN
that WDT
displayed VBD
a DT
restricted JJ
tissue NN
distribution NN
and CC
did VBD
not RB
bind VB
to TO
DNA NN
, O
but CC
, O
rather RB
, O
selectively RB
stabilized VBD
HNF-1 NN
alpha NN
dimers NNS
. O

The DT
formation NN
of IN
a DT
stable JJ
tetrameric JJ
DCoH-HNF-1 NN
alpha NN
complex NN
, O
which WDT
required VBD
the DT
dimerization NN
domain NN
of IN
HNF-1 NN
alpha NN
, O
did VBD
not RB
change VB
the DT
DNA NN
binding NN
characteristics NNS
of IN
HNF-1 NN
alpha NN
, O
but CC
enhanced VBD
its PRP$
transcriptional JJ
activity NN
. O

However RB
, O
DCoH NN
did VBD
not RB
confer VB
transcriptional JJ
activation NN
to TO
the DT
GAL4 NN
DNA NN
binding NN
domain NN
. O

These DT
results NNS
indicate VBP
that IN
DCoH NN
regulates VBZ
formation NN
of IN
transcriptionally RB
active JJ
tetrameric JJ
complexes NNS
and CC
may MD
contribute VB
to TO
the DT
developmental JJ
specificity NN
of IN
the DT
complex NN
. O

High JJ
affinity NN
aldosterone NN
binding VBG
to TO
plasma NN
membrane NN
rich JJ
fractions NNS
from IN
mononuclear JJ
leukocytes NNS
: O
is VBZ
there EX
a DT
membrane NN
receptor NN
for IN
mineralocorticoids NNS
? O

In FW
vitro FW
effects NNS
of IN
aldosterone NN
on IN
the DT
intracellular JJ
concentrations NNS
of IN
sodium NN
, O
potassium NN
and CC
calcium NN
, O
cell NN
volume NN
and CC
the DT
sodium-proton-antiport NN
have VBP
been VBN
described VBN
in IN
intact JJ
human JJ
mononuclear JJ
leukocytes NNS
( O
HML NN
) O
. O

In IN
the DT
present JJ
paper NN
, O
the DT
binding NN
of IN
a DT
(125I)-labeled JJ
aldosterone NN
derivative JJ
to TO
plasma NN
membrane NN
rich JJ
fractions NNS
of IN
HML NN
was VBD
studied VBN
. O

High JJ
affinity NN
binding NN
of IN
the DT
radioligand NN
with IN
an DT
apparent JJ
Kd NN
of IN
approximately RB
0.1 CD
nM NN
was VBD
found VBN
. O

Aldosterone NN
displaced VBD
the DT
tracer NN
at IN
a DT
similar JJ
Kd NN
. O

Both CC
canrenone NN
and CC
cortisol NN
were VBD
inactive JJ
as IN
ligands NNS
up RB
to TO
concentrations NNS
of IN
0.1 CD
microM NN
. O

The DT
findings NNS
are VBP
the DT
first JJ
to TO
demonstrate VB
membrane NN
binding NN
sites NNS
with IN
a DT
high JJ
affinity NN
for IN
aldosterone NN
, O
but CC
not RB
for IN
cortisol NN
. O

These DT
data NNS
are VBP
perfectly RB
compatible JJ
with IN
major JJ
properties NNS
of IN
steroidal JJ
effects NNS
on IN
the DT
sodium-proton-antiport NN
in IN
HML NN
and CC
thus RB
very RB
likely RB
represent VBP
membrane NN
receptors NNS
for IN
aldosterone NN
. O

Transcription NN
factor NN
requirements NNS
for IN
U2 NN
snRNA-encoding JJ
gene NN
activation NN
in IN
B NN
lymphoid JJ
cells NNS
. O

Transcription NN
of IN
a DT
human JJ
U2 NN
small JJ
nuclear JJ
RNA NN
( O
snRNA NN
) O
-encoding JJ
gene NN
in IN
HeLa NN
cells NNS
requires VBZ
a DT
distal JJ
enhancer NN
element NN
, O
which WDT
is VBZ
composed VBN
of IN
one CD
octamer NN
motif NN
( O
Oct NN
) O
and CC
three CD
Sp NN
1-binding JJ
sites NNS
. O

To TO
study VB
the DT
transcription NN
factor NN
requirement NN
in IN
B-cells NNS
, O
different JJ
U2 NN
enhancer NN
constructions NNS
were VBD
transfected VBN
into IN
the DT
lymphoid JJ
cell NN
line NN
, O
BJA-B NN
. O

The DT
results NNS
showed VBD
that IN
the DT
activation NN
of IN
U2 NN
snRNA NN
transcription NN
in IN
B-cells NNS
also RB
requires VBZ
an DT
enhancer NN
comprising VBG
both CC
the DT
Oct NN
and CC
at IN
least JJS
one CD
Sp NN
1-binding JJ
site NN
. O

Deletion NN
of IN
all PDT
the DT
Sp NN
1-binding JJ
sites NNS
from IN
the DT
enhancer NN
reduces VBZ
transcription NN
by IN
80-90 CD
% NN
in IN
HeLa NN
, O
as RB
well RB
as IN
in IN
BJA-B NN
cells NNS
, O
whereas IN
the DT
removal NN
of IN
the DT
octamer-binding JJ
site NN
reduces VBZ
transcription NN
to TO
levels NNS
below IN
detection NN
in IN
both DT
cell NN
types NNS
. O

Enhancers NNS
containing VBG
a DT
single JJ
Oct NN
have VBP
, O
nevertheless RB
, O
the DT
capacity NN
to TO
partially RB
activate VB
U2 NN
snRNA NN
transcription NN
in IN
both DT
HeLa NN
cells NNS
, O
in IN
which WDT
only RB
OTF-1 NN
is VBZ
expressed VBN
, O
and CC
in IN
BJA-B NN
cells NNS
in IN
which WDT
OTF-2 NN
is VBZ
the DT
predominantly RB
expressed VBN
octamer-binding JJ
factor NN
. O

The DT
most RBS
likely JJ
interpretation NN
of IN
our PRP$
results NNS
is VBZ
that IN
both CC
the DT
ubiquitous JJ
transcription NN
factor NN
, O
OTF-1 NN
, O
and CC
the DT
B-cell-specific JJ
transcription NN
factor NN
, O
OTF-2 NN
, O
can MD
activate VB
U2 NN
snRNA NN
transcription NN
. O

The DT
results NNS
also RB
revealed VBD
a DT
similar JJ
functional JJ
cooperation NN
between IN
the DT
transcription NN
factors NNS
which WDT
bind VBP
to TO
the DT
Oct NN
and CC
the DT
adjacent JJ
Sp NN
1-binding JJ
site NN
in IN
BJA-B NN
cells NNS
, O
as IN
has VBZ
been VBN
observed VBN
in IN
HeLa NN
cells NNS
, O
since IN
a DT
template NN
which WDT
contains VBZ
a DT
weak JJ
binding VBG
site NN
for IN
OTFs NNS
expresses VBZ
wild-type JJ
levels NNS
of IN
U2 NN
snRNA NN
in IN
both DT
cell NN
types NNS
when WRB
the DT
weak JJ
octamer-binding JJ
site NN
is VBZ
combined VBN
with IN
a DT
Sp NN
1-binding JJ
site NN
. O

Cortisol NN
receptor NN
resistance NN
: O
the DT
variability NN
of IN
its PRP$
clinical JJ
presentation NN
and CC
response NN
to TO
treatment NN
. O

Primary JJ
( O
partial JJ
) O
cortisol NN
receptor NN
resistance NN
was VBD
previously RB
reported VBN
in IN
a DT
total NN
of IN
7 CD
patients NNS
and CC
14 CD
asymptomatic JJ
family NN
members NNS
. O

Its PRP$
occurrence NN
is VBZ
considered VBN
to TO
be VB
extremely RB
rare JJ
. O

In IN
the DT
present JJ
study NN
we PRP
report VBP
on IN
6 CD
patients NNS
( O
2 CD
males NNS
and CC
4 CD
females NNS
) O
with IN
the DT
syndrome NN
. O

The DT
first JJ
male JJ
patient NN
presented VBD
with IN
mild JJ
hypertension NN
. O

Hydrochlorothiazide NN
therapy NN
resulted VBD
in IN
life-threatening JJ
hypokalemia NN
. O

The DT
second JJ
male JJ
patient NN
had VBD
slight JJ
hypertension NN
without IN
hypokalemia NN
. O

All DT
four CD
female JJ
patients NNS
presented VBD
between IN
the DT
age NN
of IN
20-30 CD
yr NN
with IN
acne NN
, O
hirsutism NN
, O
and CC
irregular JJ
menstruations NNS
. O

Low JJ
dose NN
dexamethasone NN
therapy NN
( O
1-1.5 CD
mg/day NN
) O
was VBD
of IN
clinical JJ
benefit NN
in IN
these DT
patients NNS
. O

All DT
patients NNS
showed VBD
insufficient JJ
suppression NN
of IN
serum NN
cortisol NN
concentrations NNS
in IN
the DT
overnight JJ
1-mg JJ
dexamethasone NN
test NN
. O

The DT
diurnal JJ
rhythm NN
of IN
ACTH NN
and CC
cortisol NN
was VBD
intact JJ
, O
albeit IN
at IN
an DT
elevated JJ
level NN
. O

There EX
was VBD
a DT
normal JJ
increase NN
in IN
ACTH NN
, O
cortisol NN
, O
and CC
GH NN
( O
except IN
in IN
one CD
obese JJ
patient NN
) O
in IN
response NN
to TO
insulin-induced JJ
hypoglycemia NN
, O
while IN
cortisol NN
production NN
was VBD
elevated JJ
in IN
three CD
patients NNS
. O

Circulating VBG
adrenal JJ
androgen NN
levels NNS
were VBD
increased VBN
in IN
all DT
patients NNS
. O

Glucocorticoid NN
receptors NNS
were VBD
investigated VBN
in IN
a DT
whole JJ
cell NN
dexamethasone NN
binding NN
assay NN
in IN
mononuclear JJ
leukocytes NNS
. O

In IN
the DT
first JJ
male JJ
patient NN
, O
the DT
number NN
of IN
receptors NNS
was VBD
very RB
low JJ
, O
while IN
the DT
affinity NN
was VBD
lower JJR
than IN
that DT
in IN
controls NNS
. O

A DT
lowered JJ
affinity NN
to TO
dexamethasone NN
was VBD
found VBN
in IN
one CD
female JJ
patient NN
, O
while IN
a DT
lowered JJ
number NN
of IN
receptors NNS
was VBD
found VBN
in IN
three CD
patients NNS
. O

In IN
the DT
second JJ
male JJ
patient NN
, O
no DT
abnormalities NNS
were VBD
found VBN
. O

As IN
a DT
bioassay NN
for IN
glucocorticoid NN
action NN
we PRP
also RB
measured VBD
dexamethasone NN
suppressibility NN
of IN
mitogen-stimulated JJ
incorporation NN
of IN
(3H)thymidine NN
in IN
mononuclear JJ
leukocytes NNS
. O

In IN
the DT
male JJ
patient NN
with IN
normal JJ
receptor NN
status NN
, O
dexamethasone NN
suppressibility NN
of IN
(3H)thymidine NN
incorporation NN
was VBD
significantly RB
lower JJR
than IN
that DT
in IN
healthy JJ
controls NNS
with IN
respect NN
to TO
both CC
maximal JJ
suppression NN
and CC
IC50 NN
. O

Partial JJ
cortisol NN
receptor NN
resistance NN
might MD
be VB
less RBR
rare JJ
than IN
previously RB
thought VBN
. O

In IN
the DT
six CD
patients NNS
presented VBN
, O
at IN
least JJS
three CD
different JJ
forms NNS
can MD
be VB
recognized VBN
. O

Therapy NN
with IN
dexamethasone NN
was VBD
successful JJ
in IN
female JJ
patients NNS
with IN
acne NN
and CC
hirsutism NN
, O
as IN
the DT
secondary JJ
increase NN
in IN
the DT
production NN
of IN
adrenal JJ
androgens NNS
was VBD
effectively RB
controlled VBN
. O

Kappa NN
B-specific JJ
DNA NN
binding NN
proteins NNS
are VBP
differentially RB
inhibited VBN
by IN
enhancer NN
mutations NNS
and CC
biological JJ
oxidation NN
. O

Kappa NN
B NN
( O
kappa NN
B NN
) O
enhancer NN
binding NN
proteins NNS
isolated VBN
from IN
the DT
nuclei NNS
of IN
activated VBN
human JJ
T NN
cells NNS
produce VBP
two CD
distinct JJ
nucleoprotein NN
complexes NNS
when WRB
incubated VBN
with IN
the DT
kappa NN
B NN
element NN
from IN
the DT
interleukin-2 NN
receptor-alpha NN
( O
IL-2R NN
alpha NN
) O
gene NN
. O

These DT
two CD
DNA-protein JJ
complexes NNS
are VBP
composed VBN
of IN
at IN
least JJS
four CD
host NN
proteins NNS
( O
p50 NN
, O
p55 NN
, O
p75 NN
, O
p85 NN
) O
, O
each DT
of IN
which WDT
shares VBZ
structural JJ
similarity NN
with IN
the DT
v-rel NN
oncogene NN
product NN
. O

Nuclear JJ
expression NN
of IN
these DT
proteins NNS
is VBZ
induced VBN
with IN
distinctly RB
biphasic JJ
kinetics NNS
following VBG
phorbol NN
ester NN
activation NN
of IN
T NN
cells NNS
( O
p55/p75 NN
early JJ
and CC
p50/p85 NN
late JJ
) O
. O

DNA-protein JJ
crosslinking NN
studies NNS
have VBP
revealed VBN
that IN
the DT
more RBR
rapidly RB
migrating VBG
B2 NN
complex NN
contains VBZ
both CC
p50 NN
and CC
p55 NN
while IN
the DT
more RBR
slowly RB
migrating VBG
B1 NN
complex NN
is VBZ
composed VBN
of IN
p50 NN
, O
p55 NN
, O
p75 NN
, O
and CC
p85 NN
. O

Site-directed JJ
mutagenesis NN
of IN
the DT
wild-type JJ
IL-2R NN
alpha NN
kappa NN
B NN
enhancer NN
( O
GGGGAATCTCCC NN
) O
has VBZ
revealed VBN
that IN
the DT
binding NN
of IN
p50 NN
and CC
p55 NN
( O
B2 NN
complex NN
) O
is VBZ
particularly RB
sensitive JJ
to TO
alteration NN
of IN
the DT
5' JJ
triplet NN
of IN
deoxyguanosine NN
residues NNS
. O

In IN
contrast NN
, O
formation NN
of IN
the DT
B1 NN
complex NN
, O
reflecting VBG
the DT
binding NN
of IN
p75 NN
and CC
p85 NN
, O
critically RB
depends VBZ
upon IN
the DT
more RBR
3' JJ
sequences NNS
of IN
this DT
enhancer NN
element NN
. O

DNA NN
binding NN
by IN
all DT
four CD
of IN
these DT
Rel-related JJ
factors NNS
is VBZ
blocked VBN
by IN
selective JJ
chemical JJ
modification NN
of IN
lysine NN
and CC
arginine NN
residues NNS
, O
suggesting VBG
that IN
both DT
of IN
these DT
basic JJ
amino NN
acids NNS
are VBP
required VBN
for IN
binding VBG
to TO
the DT
kappa NN
B NN
element NN
. O

Similarly RB
, O
covalent JJ
modification NN
of IN
free JJ
sulfhydryl NN
groups NNS
with IN
diamide NN
( O
reversible JJ
) O
or CC
N-ethylmaleimide NN
( O
irreversible JJ
) O
results VBZ
in IN
a DT
complete JJ
loss NN
of IN
DNA NN
binding NN
activity NN
. O

In IN
contrast NN
, O
mild JJ
oxidation NN
with IN
glucose NN
oxidase NN
selectively RB
inhibits VBZ
p75 NN
and CC
p85 NN
binding NN
while IN
not RB
blocking VBG
p50 NN
and CC
p55 NN
interactions NNS
. O

These DT
findings NNS
suggest VBP
that IN
reduced VBN
cysteine NN
thiols NNS
play VBP
an DT
important JJ
role NN
in IN
the DT
DNA NN
binding NN
activity NN
of IN
this DT
family NN
of IN
Rel-related JJ
transcription NN
factors NNS
. O

A DT
novel JJ
mitogen-inducible JJ
gene NN
product NN
related JJ
to TO
p50/p105-NF-kappa NN
B NN
participates VBZ
in IN
transactivation NN
through IN
a DT
kappa NN
B NN
site NN
. O

A DT
Rel-related JJ
, O
mitogen-inducible JJ
, O
kappa NN
B-binding JJ
protein NN
has VBZ
been VBN
cloned VBN
as IN
an DT
immediate-early JJ
activation NN
gene NN
of IN
human JJ
peripheral JJ
blood NN
T NN
cells NNS
. O

The DT
cDNA NN
has VBZ
an DT
open JJ
reading NN
frame NN
of IN
900 CD
amino NN
acids NNS
capable JJ
of IN
encoding VBG
a DT
97-kDa JJ
protein NN
. O

This DT
protein NN
is VBZ
most RBS
similar JJ
to TO
the DT
105-kDa JJ
precursor NN
polypeptide NN
of IN
p50-NF-kappa NN
B NN
. O

Like IN
the DT
105-kDa JJ
precursor NN
, O
it PRP
contains VBZ
an DT
amino-terminal JJ
Rel-related JJ
domain NN
of IN
about IN
300 CD
amino NN
acids NNS
and CC
a DT
carboxy-terminal JJ
domain NN
containing VBG
six CD
full JJ
cell NN
cycle NN
or CC
ankyrin NN
repeats NNS
. O

In FW
vitro-translated JJ
proteins NNS
, O
truncated VBN
downstream RB
of IN
the DT
Rel NN
domain NN
and CC
excluding VBG
the DT
repeats NNS
, O
bind VBP
kappa NN
B NN
sites NNS
. O

We PRP
refer VBP
to TO
the DT
kappa NN
B-binding JJ
, O
truncated VBN
protein NN
as IN
p50B NN
by IN
analogy NN
with IN
p50-NF-kappa NN
B NN
and CC
to TO
the DT
full-length JJ
protein NN
as IN
p97 NN
. O

p50B NN
is VBZ
able JJ
to TO
form VB
heteromeric JJ
kappa NN
B-binding JJ
complexes NNS
with IN
RelB NN
, O
as RB
well RB
as IN
with IN
p65 NN
and CC
p50 NN
, O
the DT
two CD
subunits NNS
of IN
NF-kappa NN
B NN
. O

Transient-transfection NN
experiments NNS
in IN
embryonal JJ
carcinoma NN
cells NNS
demonstrate VBP
a DT
functional JJ
cooperation NN
between IN
p50B NN
and CC
RelB NN
or CC
p65 NN
in IN
transactivation NN
of IN
a DT
reporter NN
plasmid NN
dependent JJ
on IN
a DT
kappa NN
B NN
site NN
. O

The DT
data NNS
imply VBP
the DT
existence NN
of IN
a DT
complex JJ
family NN
of IN
NF-kappa NN
B-like JJ
transcription NN
factors NNS
. O

( O
Changes NNS
in IN
leucocytic JJ
estrogen NN
receptor NN
levels NNS
in IN
patients NNS
with IN
climacteric JJ
syndrome NN
and CC
therapeutic JJ
effect NN
of IN
liuwei FW
dihuang FW
pills NNS
) O

The DT
numbers NNS
of IN
estrogen NN
receptor NN
( O
ER NN
) O
in IN
human JJ
peripheral JJ
leucocytes NNS
in IN
22 CD
women NNS
with IN
climacteric JJ
syndrome NN
were VBD
measured VBN
by IN
radioligand NN
method NN
. O

The DT
results NNS
were VBD
compared VBN
with IN
those DT
of IN
12 CD
normal JJ
child-bearing-age JJ
women NNS
. O

It PRP
wat VBD
found VBN
that IN
the DT
contents NNS
of IN
leucocytic JJ
ER NN
in IN
climacteric JJ
syndrome NN
patients NNS
were VBD
significantly RB
lower JJR
than IN
normal JJ
child-bearing-age JJ
women NNS
. O

The DT
authors NNS
used VBD
a DT
Chinese JJ
prescription NN
-- O
Liuwei FW
Dihuang FW
Pills NNS
( O
LDP NN
) O
to TO
treat VB
the DT
patients NNS
for IN
2 CD
months NNS
. O

The DT
numbers NNS
of IN
leucocytic JJ
ER NN
were VBD
significantly RB
increased VBN
after IN
treatment NN
. O

The DT
data NNS
indicate VBP
that IN
decrease NN
of IN
ER NN
levels NNS
in IN
cell NN
may MD
involve VB
in IN
the DT
pathogenesis NN
of IN
climacteric JJ
syndrome NN
. O

LDP NN
not RB
only RB
increases VBZ
plasma NN
estradiol NN
levels NNS
, O
but CC
also RB
increases VBZ
the DT
leucocytic JJ
ER NN
levels NNS
. O

This DT
may MD
be VB
the DT
basis NN
of IN
the DT
therapeutic JJ
effect NN
on IN
the DT
disease NN
. O

A DT
novel JJ
primer NN
extension NN
method NN
to TO
detect VB
the DT
number NN
of IN
CAG NN
repeats NNS
in IN
the DT
androgen NN
receptor NN
gene NN
in IN
families NNS
with IN
X-linked JJ
spinal JJ
and CC
bulbar JJ
muscular JJ
atrophy NN
. O

X-linked JJ
spinal JJ
and CC
bulbar JJ
muscular JJ
atrophy NN
( O
SBMA NN
) O
, O
an DT
adult-onset JJ
form NN
of IN
motor NN
neuron NN
disease NN
, O
was VBD
recently RB
reported VBN
to TO
be VB
caused VBN
by IN
amplification NN
of IN
the DT
CAG NN
repeats NNS
in IN
the DT
androgen NN
receptor NN
gene NN
. O

We PRP
report VBP
here RB
a DT
simple JJ
and CC
rapid JJ
strategy NN
to TO
detect VB
the DT
precise JJ
number NN
of IN
the DT
CAGs NNS
. O

After IN
the DT
DNA NN
fragment NN
containing VBG
the DT
CAG NN
repeats NNS
is VBZ
amplified VBN
by IN
the DT
polymerase NN
chain NN
reaction NN
, O
a DT
primer NN
extension NN
is VBZ
carried VBN
out RP
; O
the DT
extension NN
of IN
the DT
end-labelled JJ
reverse JJ
primer NN
adjacent JJ
to TO
3' JJ
end NN
of IN
CAG NN
repeats NNS
stops VBZ
at IN
the DT
first JJ
T NN
after IN
CAG NN
repeats NNS
with IN
the DT
incorporation NN
of IN
dideoxy JJ
ATP NN
in IN
the DT
reaction NN
mixture NN
. O

The DT
resultant JJ
primer NN
products NNS
are VBP
analysed VBN
by IN
denaturing VBG
polyacrylamide NN
gel NN
electrophoresis NN
and CC
autoradiography NN
. O

This DT
method NN
could MD
be VB
quite RB
useful JJ
to TO
detect VB
not RB
only RB
CAG NN
repeats NNS
in IN
SBMA NN
but CC
also RB
other JJ
polymorphic JJ
dinucleotide JJ
and CC
trinucleotide JJ
repeats NNS
. O

Activity NN
of IN
the DT
kappa NN
B NN
enhancer NN
of IN
the DT
interleukin-2 NN
receptor NN
alpha NN
chain NN
in IN
somatic JJ
cell NN
hybrids NNS
is VBZ
accompanied VBN
by IN
the DT
nuclear JJ
localization NN
of IN
NF-kappa NN
B NN
. O

The DT
two CD
nuclear JJ
proteins NNS
NF-kappa NN
B NN
( O
consisting VBG
of IN
subunits NNS
p50 NN
and CC
p65 NN
) O
and CC
the DT
DNA-binding JJ
subunit NN
of IN
NF-kappa NN
B NN
( O
p50 NN
) O
by IN
itself PRP
, O
also RB
called VBN
KBF1 NN
, O
are VBP
constitutively RB
expressed VBN
and CC
localized JJ
in IN
the DT
nucleus NN
of IN
the DT
human JJ
T-cell NN
line NN
IARC NN
301.5 CD
. O

In IN
order NN
to TO
define VB
the DT
roles NNS
of IN
these DT
two CD
factors NNS
, O
which WDT
bind VBP
to TO
the DT
same JJ
kappa NN
B NN
enhancers NNS
, O
in IN
transcription NN
activation NN
we PRP
have VBP
prepared VBN
somatic JJ
cell NN
hybrids NNS
between IN
IARC NN
301.5 CD
and CC
a DT
murine JJ
myeloma NN
. O

Most JJS
hybrids NNS
express VBP
both CC
KBF1 NN
and CC
NF-kappa NN
B NN
in IN
their PRP$
nuclei NNS
, O
but CC
one CD
hybrid NN
expresses VBZ
only RB
KBF1 NN
. O

The DT
kappa NN
B NN
enhancer NN
of IN
the DT
gene NN
encoding VBG
the DT
interleukin-2 NN
( O
IL-2 NN
) O
receptor NN
alpha NN
chain NN
( O
IL-2R NN
alpha NN
) O
is VBZ
functional JJ
only RB
in IN
the DT
hybrids NNS
expressing VBG
nuclear JJ
NF-kappa NN
B NN
. O

These DT
findings NNS
show VBP
that IN
nuclear JJ
NF-kappa NN
B NN
is VBZ
necessary JJ
to TO
activate VB
the DT
kappa NN
B NN
enhancer NN
, O
while IN
KBF1 NN
by IN
itself PRP
is VBZ
not RB
sufficient JJ
. O

We PRP
propose VBP
that IN
KBF1 NN
is VBZ
a DT
competitive JJ
inhibitor NN
of IN
NF-kappa NN
B NN
and CC
discuss VB
how WRB
these DT
factors NNS
may MD
be VB
involved VBN
in IN
the DT
transient JJ
expression NN
of IN
IL-2 NN
and CC
IL-2 NN
alpha NN
genes NNS
during IN
the DT
immune JJ
response NN
. O

Influence NN
of IN
estradiol NN
and CC
tamoxifen NN
on IN
susceptibility NN
of IN
human JJ
breast NN
cancer NN
cell NN
lines NNS
to TO
lysis NN
by IN
lymphokine-activated JJ
killer NN
cells NNS
. O

The DT
design NN
of IN
combination NN
hormonal JJ
and CC
immunotherapeutic JJ
protocols NNS
for IN
breast NN
cancer NN
patients NNS
may MD
be VB
facilitated VBN
by IN
analysis NN
of IN
preclinical JJ
in FW
vitro FW
model JJ
systems NNS
. O

Estrogen NN
receptor NN
positive JJ
( O
ER+ JJ
: O
MCF-7 NN
) O
and CC
negative JJ
( O
ER- JJ
: O
MDA-MB-231 NN
) O
human JJ
breast NN
cancer NN
cell NN
lines NNS
were VBD
utilized VBN
to TO
evaluate VB
the DT
effects NNS
of IN
tamoxifen NN
( O
TAM NN
) O
and CC
estradiol NN
( O
E2 NN
) O
on IN
modulation NN
of IN
breast NN
cancer NN
target NN
susceptibility NN
to TO
lysis NN
by IN
lymphokine-activated JJ
killer NN
( O
LAK NN
) O
cells NNS
. O

E2-stimulated JJ
ER+ JJ
cells NNS
were VBD
more RBR
susceptible JJ
to TO
lysis NN
by IN
LAK NN
cells NNS
than IN
corresponding VBG
TAM-treated JJ
or CC
control NN
cells NNS
, O
while IN
treatment NN
of IN
ER- JJ
cells NNS
with IN
either CC
E2 NN
or CC
TAM NN
alone RB
did VBD
not RB
alter VB
from IN
control NN
their PRP$
susceptibility NN
to TO
this DT
immune-mediated JJ
lysis NN
. O

All DT
ER+ JJ
and CC
ER- JJ
cells NNS
tested VBN
remained VBD
sensitive JJ
after IN
treatment NN
with IN
TAM NN
to TO
lysis NN
by IN
LAK NN
cells NNS
. O

In IN
addition NN
, O
an DT
adenocarcinoma NN
reactive JJ
human-mouse JJ
chimeric JJ
monoclonal JJ
antibody NN
( O
ING-1 NN
) O
was VBD
able JJ
to TO
significantly RB
boost VB
in FW
vivo FW
generated VBN
LAK NN
cell-mediated JJ
lysis NN
of IN
control NN
, O
E2-treated JJ
, O
and CC
TAM-treated JJ
ER+ JJ
and CC
ER- JJ
cells NNS
. O

These DT
in FW
vitro FW
results NNS
provide VBP
a DT
preclinical JJ
rationale NN
for IN
in FW
vivo FW
testing NN
of IN
TAM NN
, O
interleukin-2 NN
( O
IL-2 NN
) O
, O
and CC
breast NN
cancer NN
reactive JJ
antibody-dependent JJ
cellular JJ
cytotoxicity NN
facilitating VBG
antibody NN
in IN
patients NNS
with IN
refractory JJ
or CC
high JJ
risk NN
breast NN
cancer NN
. O

Glucocorticoid NN
receptor NN
and CC
inhibition NN
of IN
3-O-methyl-D-glucose NN
uptake NN
by IN
glucocorticoids NNS
in IN
peripheral JJ
blood NN
leukocytes NNS
from IN
normal JJ
humans NNS
: O
correlation NN
between IN
receptor NN
level NN
and CC
hormone NN
effect NN
in FW
vitro FW
. O

We PRP
have VBP
measured VBN
the DT
glucocorticoid NN
receptor NN
concentration NN
in IN
mononuclear JJ
and CC
polymorphonuclear JJ
leukocytes NNS
, O
both DT
of IN
which WDT
were VBD
isolated VBN
from IN
peripheral JJ
blood NN
from IN
ten CD
healthy JJ
male JJ
volunteers NNS
. O

In IN
parallel NN
, O
the DT
inhibitory JJ
effect NN
of IN
dexamethasone NN
on IN
3-O-methyl-D-glucose NN
uptake NN
was VBD
assayed VBN
in IN
the DT
corresponding JJ
mononuclear JJ
leukocytes NNS
. O

The DT
glucocorticoid NN
receptor NN
levels NNS
in IN
mononuclear JJ
leukocytes NNS
correlated VBD
with IN
those DT
in IN
polymorphonuclear JJ
leukocytes NNS
, O
and CC
there EX
was VBD
a DT
linear JJ
relationship NN
between IN
the DT
cellular JJ
glucocorticoid NN
receptor NN
levels NNS
and CC
glucocorticoid-mediated JJ
inhibition NN
of IN
the DT
uptake NN
of IN
3-O-methyl-D-glucose NN
in IN
mononuclear JJ
leukocytes NNS
. O

When WRB
mononuclear JJ
leukocytes NNS
were VBD
incubated VBN
in IN
the DT
presence NN
of IN
8-bromo-cAMP NN
, O
cellular JJ
glucocorticoid NN
receptor NN
levels NNS
increased VBD
and CC
a DT
more RBR
pronounced JJ
inhibitory JJ
effect NN
of IN
dexamethasone NN
was VBD
observed VBN
on IN
the DT
transport NN
of IN
3-O-methyl-D-glucose NN
. O

We PRP
conclude VBP
that IN
the DT
cellular JJ
glucocorticoid NN
receptor NN
levels NNS
in IN
peripheral JJ
blood NN
leukocytes NNS
reflect VBP
in FW
vitro FW
responsiveness NN
to TO
glucocorticoids NNS
in IN
mononuclear JJ
leukocytes NNS
from IN
healthy JJ
males NNS
, O
and CC
that IN
the DT
individual JJ
responsiveness NN
may MD
alter VB
upon IN
changes NNS
in IN
the DT
cellular JJ
levels NNS
of IN
glucocorticoid NN
receptor NN
. O

Stimulation NN
of IN
interferon NN
beta NN
gene NN
transcription NN
in FW
vitro FW
by IN
purified VBN
NF-kappa NN
B NN
and CC
a DT
novel JJ
TH NN
protein NN
. O

The DT
human JJ
interferon NN
beta NN
( O
IFN-beta NN
) O
regulatory JJ
element NN
consists VBZ
of IN
multiple JJ
enhanson NN
domains NNS
which WDT
are VBP
targets NNS
for IN
transcription NN
factors NNS
involved VBN
in IN
inducible JJ
expression NN
of IN
the DT
promoter NN
. O

To TO
further RB
characterize VB
the DT
protein-DNA JJ
interactions NNS
mediating VBG
IFN-beta NN
induction NN
, O
positive JJ
regulatory JJ
domain NN
( O
PRD NN
) O
II CD
binding NN
proteins NNS
were VBD
purified VBN
from IN
phorbol NN
ester NN
induced JJ
Jurkat NN
T-cells NNS
and CC
from IN
IFN NN
primed VBN
, O
cycloheximide/polyinosinic-polycytidylic JJ
acid NN
treated VBN
HeLa NN
S3 NN
cells NNS
. O

From IN
HeLa NN
cells NNS
, O
two CD
major JJ
proteins NNS
of IN
52 CD
and CC
45 CD
kilodaltons NNS
( O
kD NN
) O
copurified VBD
with IN
DNA NN
binding NN
activity NN
, O
whereas IN
from IN
T-cells NNS
, O
four CD
proteins NNS
-- O
a DT
major JJ
protein NN
of IN
52 CD
kD NN
and CC
three CD
minor JJ
proteins NNS
of IN
82 CD
, O
67 CD
, O
and CC
43-47 CD
kD NN
-- O
were VBD
purified VBN
. O

Also RB
, O
an DT
induction NN
specific JJ
DNA NN
binding NN
protein NN
was VBD
purified VBN
from IN
HeLa NN
cells NNS
that WDT
interacted VBD
with IN
the DT
( O
AAGTGA NN
) O
4 CD
tetrahexamer NN
sequence NN
and CC
the DT
PRDI NN
domain NN
. O

This DT
protein NN
is VBZ
immunologically RB
distinct JJ
from IN
IRF-1/ISGF2 NN
. O

Uninduced JJ
or CC
Sendai NN
virus NN
induced JJ
HeLa NN
extracts NNS
were VBD
used VBN
to TO
examine VB
transcription NN
in FW
vitro FW
using VBG
a DT
series NN
of IN
IFN NN
beta NN
promoter NN
deletions NNS
. O

Deletions NNS
upstream JJ
of IN
the DT
PRDII NN
element NN
increased VBD
transcription NN
in IN
the DT
uninduced JJ
extract NN
, O
indicating VBG
predominantly RB
negative JJ
regulation NN
of IN
the DT
promoter NN
. O

A DT
2-4-fold JJ
increase NN
in IN
IFN-beta NN
promoter NN
transcription NN
was VBD
observed VBN
in IN
Sendai NN
virus NN
induced JJ
extracts NNS
, O
and CC
deletion NN
of IN
PRDI NN
and CC
PRDII NN
elements NNS
decreased VBD
this DT
induced VBN
level NN
of IN
transcription NN
. O

When WRB
purified VBN
PRDII NN
and CC
tetrahexamer NN
binding NN
proteins NNS
were VBD
added VBN
to TO
the DT
induced VBN
extract NN
, O
a DT
4-fold JJ
increase NN
in IN
transcription NN
was VBD
observed VBN
. O

These DT
experiments NNS
demonstrate VBP
that IN
it PRP
is VBZ
possible JJ
to TO
modulate VB
IFN-beta NN
transcription NN
in FW
vitro FW
but CC
indicate VBP
that IN
additional JJ
proteins NNS
may MD
be VB
required VBN
to TO
fully RB
activate VB
IFN-beta NN
transcription NN
. O

Structure NN
function NN
analysis NN
of IN
vitamin NN
D NN
analogs NNS
with IN
C-ring NN
modifications NNS
. O

Analogs NNS
of IN
1 CD
alpha,25-dihydroxyvitamin NN
D3 NN
( O
1 CD
alpha,25-(OH) NN
2D3 NN
) O
with IN
substitutions NNS
on IN
C-11 NN
were VBD
synthesized VBN
. O

Small JJ
apolar JJ
substitutions NNS
( O
11 CD
alpha-methyl NN
, O
11 CD
alpha-fluoromethyl NN
) O
did VBD
not RB
markedly RB
decrease VB
the DT
affinity NN
for IN
the DT
vitamin NN
D NN
receptor NN
, O
but CC
larger JJR
( O
11 CD
alpha-chloromethyl NN
or CC
11 CD
alpha- NN
or CC
11 CD
beta-phenyl NN
) O
or CC
more RBR
polar JJ
substitutions NNS
( O
11 CD
alpha-hydroxymethyl NN
, O
11 CD
alpha-(2-hydroxyethyl NN
) O
decreased VBD
the DT
affinity NN
to TO
less JJR
than IN
5 CD
% NN
of IN
that DT
of IN
1 CD
alpha,25-OH)2D3 NN
. O

Their PRP$
affinity NN
for IN
the DT
vitamin NN
D-binding JJ
protein NN
, O
however RB
, O
increased VBD
up RB
to TO
4-fold RB
. O

The DT
biological JJ
activity NN
of IN
11 CD
alpha-methyl-1 NN
alpha,25-(OH)2D3 NN
closely RB
resembled VBD
that DT
of IN
the DT
natural JJ
hormone NN
on IN
normal JJ
and CC
leukemic JJ
cell NN
proliferation NN
and CC
bone NN
resorption NN
, O
whereas IN
its PRP$
in FW
vivo FW
effect NN
on IN
calcium NN
metabolism NN
of IN
the DT
rachitic JJ
chick NN
was VBD
about IN
50 CD
% NN
of IN
that DT
of IN
1 CD
alpha,25-(OH)2D3 NN
. O

The DT
11 CD
beta-methyl NN
analog NN
had VBD
a DT
greater JJR
than IN
10-fold RB
lower JJR
activity NN
. O

The DT
differentiating JJ
effects NNS
of IN
the DT
other JJ
C-11 NN
analogs NNS
on IN
human JJ
promyeloid JJ
leukemia NN
cells NNS
( O
HL-60 NN
) O
agreed VBD
well RB
with IN
their PRP$
bone-resorbing JJ
activity NN
and CC
receptor NN
affinity NN
, O
but CC
they PRP
demonstrated VBD
lower JJR
calcemic JJ
effects NNS
in FW
vivo FW
. O

Large JJ
or CC
polar JJ
substitutions NNS
on IN
C-11 NN
of IN
1 CD
alpha,25-(OH)2D3 NN
thus RB
impair VBP
the DT
binding NN
of IN
the DT
vitamin NN
D NN
receptor NN
but CC
increase VBP
the DT
affinity NN
to TO
vitamin NN
D-binding JJ
protein NN
. O

The DT
effects NNS
of IN
many JJ
C-11-substituted JJ
1 CD
alpha,25-(OH)2D3 NN
analogs NNS
on IN
HL-60 NN
cell NN
differentiation NN
exceeded VBD
their PRP$
activity NN
on IN
calcium NN
metabolism NN
. O

Transcriptional JJ
regulation NN
during IN
T-cell NN
development NN
: O
the DT
alpha NN
TCR NN
gene NN
as IN
a DT
molecular JJ
model NN
. O

The DT
regulation NN
of IN
gene NN
expression NN
during IN
lymphocyte NN
differentiation NN
is VBZ
a DT
complex JJ
process NN
involving VBG
interactions NNS
between IN
multiple JJ
positive JJ
and CC
negative JJ
transcriptional JJ
regulatory JJ
elements NNS
. O

In IN
this DT
article NN
, O
transcriptional JJ
regulation NN
of IN
the DT
archetypal JJ
T-cell-specific JJ
gene NN
, O
alpha NN
TCR NN
, O
is VBZ
discussed VBN
. O

Major JJ
recent JJ
developments NNS
, O
including VBG
the DT
identification NN
of IN
novel JJ
families NNS
of IN
transcription NN
factors NNS
that WDT
regulate VBP
multiple JJ
T-cell NN
genes NNS
during IN
thymocyte NN
ontogeny NN
and CC
T-cell NN
activation NN
, O
are VBP
described VBN
. O

Cortisol NN
resistance NN
in IN
acquired VBN
immunodeficiency NN
syndrome NN
. O

This DT
study NN
concerns VBZ
9 CD
iv NN
drug NN
abusers NNS
with IN
acquired VBN
immunodeficiency NN
syndrome NN
( O
AIDS NN
) O
who WP
developed VBD
hypercortisolism NN
without IN
the DT
clinical JJ
signs NNS
or CC
metabolic JJ
consequences NNS
of IN
hypercortisolism NN
. O

All DT
patients NNS
were VBD
characterized VBN
by IN
an DT
Addisonian JJ
picture NN
( O
weakness NN
, O
weight NN
loss NN
, O
hypotension NN
, O
hyponatremia NN
, O
and CC
intense JJ
mucocutaneous JJ
melanosis NN
) O
. O

An DT
acquired JJ
form NN
of IN
peripheral JJ
resistance NN
to TO
glucocorticoids NNS
was VBD
suspected VBN
. O

We PRP
, O
therefore RB
, O
examined VBD
glucocorticoid NN
receptor NN
characteristics NNS
on IN
mononuclear JJ
leukocytes NNS
by IN
measuring VBG
(3H)dexamethasone NN
binding NN
and CC
the DT
effect NN
of IN
dexamethasone NN
on IN
(3H)thymidine NN
incorporation NN
, O
which WDT
is VBZ
one CD
of IN
the DT
effects NNS
of IN
glucocorticoid NN
receptor NN
activation NN
. O

Glucocorticoid NN
receptor NN
density NN
was VBD
increased VBN
in IN
AIDS NN
patients NNS
with IN
an DT
Addisonian JJ
picture NN
( O
group NN
1 CD
; O
16.2 CD
+/- CC
9.4 CD
fmol/million NN
cells NNS
) O
compared VBN
to TO
values NNS
in IN
12 CD
AIDS NN
patients NNS
without IN
an DT
Addisonian JJ
picture NN
( O
group NN
2 CD
; O
6.05 CD
+/- CC
2.6 CD
fmol/million NN
cells NNS
; O
P NN
less JJR
than IN
0.01 CD
) O
and CC
sex- NN
and CC
age-matched JJ
controls NNS
( O
3.15 CD
+/- CC
2.3 CD
fmol/million NN
cells NNS
; O
P NN
less JJR
than IN
0.01 CD
) O
. O

The DT
affinity NN
of IN
glucocorticoid NN
receptors NNS
( O
Kd NN
) O
was VBD
strikingly RB
decreased VBN
( O
9.36 CD
+/- CC
3.44 CD
nM NN
in IN
group NN
1 CD
; O
3.2 CD
+/- CC
1.5 CD
nM NN
in IN
group NN
2 CD
; O
2.0 CD
+/- CC
0.8 CD
nM NN
in IN
controls NNS
; O
P NN
less JJR
than IN
0.01 CD
) O
. O

(3H)Thymidine NN
incorporation NN
was VBD
decreased VBN
dose-dependently RB
by IN
dexamethasone NN
in IN
controls NNS
and CC
patients NNS
; O
the DT
effect NN
was VBD
significantly RB
blunted VBN
( O
P NN
less JJR
than IN
0.05 CD
) O
in IN
group NN
1 CD
patients NNS
, O
which WDT
suggests VBZ
that IN
activation NN
of IN
glucocorticoid NN
receptor NN
is VBZ
impaired JJ
as IN
a DT
result NN
of IN
the DT
glucocorticoid NN
receptor NN
abnormality NN
. O

In IN
conclusion NN
, O
AIDS NN
patients NNS
with IN
hypercortisolism NN
and CC
clinical JJ
features NNS
of IN
peripheral JJ
resistance NN
to TO
glucocorticoids NNS
are VBP
characterized VBN
by IN
abnormal JJ
glucocorticoid NN
receptors NNS
on IN
lymphocytes NNS
. O

Resistance NN
to TO
glucocorticoids NNS
implies VBZ
a DT
complex JJ
change NN
in IN
immune-endocrine JJ
function NN
, O
which WDT
may MD
be VB
important JJ
in IN
the DT
course NN
of IN
immunodeficiency NN
syndrome NN
. O

Induction NN
of IN
monocytic JJ
differentiation NN
and CC
NF-kappa NN
B-like JJ
activities NNS
by IN
human JJ
immunodeficiency NN
virus NN
1 CD
infection NN
of IN
myelomonoblastic JJ
cells NNS
. O

The DT
effects NNS
of IN
human JJ
immunodeficiency NN
virus NN
1 CD
( O
HIV-1 NN
) O
infection NN
on IN
cellular JJ
differentiation NN
and CC
NF-kappa NN
B NN
DNA NN
binding NN
activity NN
have VBP
been VBN
investigated VBN
in IN
a DT
new JJ
model NN
of IN
myeloid JJ
differentiation NN
. O

PLB-985 NN
cells NNS
represent VBP
a DT
bipotential JJ
myelomonoblastic JJ
cell NN
population NN
capable JJ
of IN
either CC
granulocytic JJ
or CC
monocytic JJ
differentiation NN
after IN
induction NN
with IN
appropriate JJ
inducers NNS
. O

By IN
virtue NN
of IN
the DT
presence NN
of IN
CD4 NN
on IN
the DT
cell NN
surface NN
, O
PLB-985 NN
cells NNS
were VBD
chronically RB
infected VBN
with IN
HIV-1 NN
strain NN
IIIB NN
. O

PLB-IIIB NN
cells NNS
clearly RB
possessed VBD
a DT
more RBR
monocytic JJ
phenotype NN
than IN
the DT
parental JJ
myeloblasts NNS
, O
as IN
determined VBN
by IN
differential JJ
staining NN
, O
increased VBN
expression NN
of IN
the DT
myeloid-specific JJ
surface NN
markers NNS
, O
and CC
transcription NN
of IN
the DT
c-fms NN
proto-oncogene NN
. O

NF-kappa NN
B NN
binding NN
activity NN
was VBD
inducible JJ
by IN
tumor NN
necrosis NN
factor NN
and CC
phorbol NN
myristate NN
acetate NN
in IN
PLB-985 NN
. O

However RB
, O
in IN
PLB-IIIB NN
cells NNS
, O
constitutive JJ
expression NN
of IN
a DT
novel JJ
NF-kappa NN
B NN
complex NN
was VBD
detected VBN
, O
composed VBN
of IN
proteins NNS
ranging VBG
between IN
70 CD
and CC
110 CD
kD NN
. O

These DT
proteins NNS
interacted VBD
specifically RB
with IN
the DT
symmetric JJ
NF-kappa NN
B NN
site NN
from IN
the DT
interferon NN
beta NN
( O
IFN-beta NN
) O
promoter NN
. O

Mutations NNS
affecting VBG
the DT
5' JJ
guanine JJ
residues NNS
of IN
the DT
kappa NN
B NN
site NN
were VBD
unable JJ
to TO
compete VB
for IN
these DT
NF-kappa NN
B-related JJ
proteins NNS
. O

Inducibility NN
of IN
endogenous JJ
IFN-beta NN
and CC
IFN-alpha NN
RNA NN
was VBD
also RB
increased VBN
in IN
PLB-IIIB NN
cells NNS
. O

These DT
studies NNS
indicate VBP
that IN
HIV-1 NN
infection NN
of IN
myelomonoblastic JJ
cells NNS
may MD
select VB
for IN
a DT
more RBR
mature JJ
monocytic JJ
phenotype NN
and CC
that IN
unique JJ
subunit NN
associations NNS
of IN
NF-kappa NN
B NN
DNA NN
binding NN
proteins NNS
may MD
contribute VB
to TO
differential JJ
NF-kappa NN
B-mediated JJ
gene NN
expression NN
. O

The DT
AP-1 NN
site NN
at IN
-150 CD
bp NN
, O
but CC
not RB
the DT
NF-kappa NN
B NN
site NN
, O
is VBZ
likely JJ
to TO
represent VB
the DT
major JJ
target NN
of IN
protein NN
kinase NN
C NN
in IN
the DT
interleukin NN
2 CD
promoter NN
. O

Stimulation NN
of IN
T NN
cells NNS
with IN
antigen NN
results VBZ
in IN
activation NN
of IN
several JJ
kinases NNS
, O
including VBG
protein NN
kinase NN
C NN
( O
PKC NN
) O
, O
that WDT
may MD
mediate VB
the DT
later JJ
induction NN
of IN
activation-related JJ
genes NNS
. O

We PRP
have VBP
examined VBN
the DT
potential JJ
role NN
of IN
PKC NN
in IN
induction NN
of IN
the DT
interleukin NN
2 CD
( O
IL-2 NN
) O
gene NN
in IN
T NN
cells NNS
stimulated VBN
through IN
the DT
T NN
cell NN
receptor/CD3 NN
complex NN
. O

We PRP
have VBP
previously RB
shown VBN
that IN
prolonged JJ
treatment NN
of IN
the DT
untransformed JJ
T NN
cell NN
clone NN
Ar-5 NN
with IN
phorbol NN
esters NNS
results VBZ
in IN
downmodulation NN
of IN
the DT
alpha NN
and CC
beta NN
isozymes NNS
of IN
PKC NN
, O
and CC
abrogates VBZ
induction NN
of IN
IL-2 NN
mRNA NN
and CC
protein NN
. O

Here RB
we PRP
show VBP
that IN
phorbol NN
ester NN
treatment NN
also RB
abolishes VBZ
induction NN
of IN
chloramphenicol JJ
acetyltransferase NN
activity NN
in IN
Ar-5 NN
cells NNS
transfected VBN
with IN
a DT
plasmid NN
containing VBG
the DT
IL-2 NN
promoter NN
linked VBN
to TO
this DT
reporter NN
gene NN
. O

The DT
IL-2 NN
promoter NN
contains VBZ
binding VBG
sites NNS
for IN
nuclear JJ
factors NNS
including VBG
NFAT-1 NN
, O
Oct NN
, O
NF-kappa NN
B NN
, O
and CC
AP-1 NN
, O
which WDT
are VBP
all DT
potentially RB
sensitive JJ
to TO
activation NN
of IN
PKC NN
. O

We PRP
show VBP
that IN
induction NN
of IN
a DT
trimer NN
of IN
the DT
NFAT NN
and CC
Oct NN
sites NNS
is VBZ
not RB
sensitive JJ
to TO
phorbol NN
ester NN
treatment NN
, O
and CC
that IN
mutations NNS
in IN
the DT
NF-kappa NN
B NN
site NN
have VBP
no DT
effect NN
on IN
inducibility NN
of IN
the DT
IL-2 NN
promoter NN
. O

In IN
contrast NN
, O
mutations NNS
in IN
the DT
AP-1 NN
site NN
located JJ
at IN
-150 CD
bp NN
almost RB
completely RB
abrogate VBP
induction NN
of IN
the DT
IL-2 NN
promoter NN
, O
and CC
appearance NN
of IN
an DT
inducible JJ
nuclear JJ
factor NN
binding VBG
to TO
this DT
site NN
is VBZ
sensitive JJ
to TO
PKC NN
depletion NN
. O

Moreover RB
, O
cotransfections NNS
with IN
c-fos NN
and CC
c-jun NN
expression NN
plasmids NNS
markedly RB
enhance VBP
induction NN
of IN
the DT
IL-2 NN
promoter NN
in IN
minimally RB
stimulated VBN
T NN
cells NNS
. O

Our PRP$
results NNS
indicate VBP
that IN
the DT
AP-1 NN
site NN
at IN
-150 CD
bp NN
represents VBZ
a DT
major JJ
, O
if IN
not RB
the DT
only JJ
, O
site NN
of IN
PKC NN
responsiveness NN
in IN
the DT
IL-2 NN
promoter NN
. O

Interleukin NN
6-induced JJ
differentiation NN
of IN
a DT
human JJ
B NN
cell NN
line NN
into IN
IgM-secreting JJ
plasma NN
cells NNS
is VBZ
mediated VBN
by IN
c-fos NN
. O

The DT
role NN
of IN
the DT
protooncogene NN
c-fos NN
in IN
interleukin NN
( O
IL NN
) O
6-induced JJ
B NN
cell NN
differentiation NN
was VBD
assessed VBN
. O

Treatment NN
of IN
SKW NN
6.4 CD
cells NNS
with IN
IL NN
6 CD
induced VBD
a DT
transient JJ
and CC
early JJ
stimulation NN
of IN
c-fos NN
sense NN
mRNA NN
expression NN
. O

The DT
effect NN
appeared VBD
within IN
30 CD
min NN
and CC
returned VBD
to TO
basal JJ
levels NNS
after IN
2 CD
h NN
. O

The DT
addition NN
of IN
antisense JJ
oligonucleotides NNS
to TO
c-fos NN
significantly RB
inhibited VBD
IL NN
6-induced JJ
IgM NN
production NN
by IN
SKW NN
6.4 CD
cells NNS
( O
p NN
less JJR
than IN
0.001 CD
) O
, O
whereas IN
control NN
oligonucleotides NNS
had VBD
no DT
inhibitory JJ
effect NN
. O

These DT
results NNS
indicate VBP
that IN
activation NN
of IN
c-fos NN
is VBZ
involved VBN
in IN
IL NN
6-induced JJ
differentiation NN
of IN
SKW NN
6.4 CD
cells NNS
into IN
IgM-secreting JJ
cells NNS
. O

Binding NN
of IN
erythroid JJ
and CC
non-erythroid JJ
nuclear JJ
proteins NNS
to TO
the DT
silencer NN
of IN
the DT
human JJ
epsilon-globin-encoding JJ
gene NN
. O

To TO
clarify VB
the DT
molecular JJ
mechanisms NNS
involved VBN
in IN
the DT
developmental JJ
control NN
of IN
hemoglobin-encoding JJ
genes NNS
we PRP
have VBP
been VBN
studying VBG
the DT
expression NN
of IN
these DT
genes NNS
in IN
human JJ
cells NNS
in IN
continuous JJ
culture NN
. O

We PRP
have VBP
previously RB
reported VBN
the DT
presence NN
of IN
a DT
transcriptional JJ
control NN
element NN
with IN
the DT
properties NNS
of IN
a DT
silencer NN
extending VBG
from IN
-392 CD
to TO
-177 CD
bp NN
relative JJ
to TO
the DT
cap NN
site NN
of IN
the DT
human JJ
epsilon-globin-encoding JJ
gene NN
( O
Cao NNP
et FW
al. FW
, O
Proc.Natl.Acad.Sci.USA NNP
86 CD
( O
1989 CD
) O
5306-5309 CD
) O
. O

We PRP
also RB
showed VBD
that IN
this DT
silencer NN
has VBZ
stronger JJR
inhibitory JJ
activity NN
in IN
HeLa NN
cells NNS
, O
as IN
compared VBN
to TO
K562 NN
human JJ
erythroleukemia NN
cells NNS
. O

Using VBG
deletion NN
mutants NNS
and CC
cis-cloned JJ
synthetic JJ
oligodeoxyribonucleotides NNS
in IN
transient JJ
expression NN
assays NNS
, O
nucleotide NN
sequences NNS
responsible JJ
for IN
this DT
effect NN
have VBP
now RB
been VBN
further RBR
delimited VBN
to TO
44 CD
bp NN
located JJ
from IN
-294 CD
to TO
-251 CD
bp NN
. O

Gel NN
electrophoresis NN
mobility NN
shift NN
assays NNS
and CC
DNaseI NN
footprinting NN
assays NNS
demonstrate VBP
that IN
these DT
negative JJ
regulatory JJ
sequences NNS
are VBP
recognized VBN
differently RB
by IN
proteins NNS
present JJ
in IN
nuclear JJ
extracts NNS
obtained VBN
from IN
HeLa NN
and CC
K562 NN
cells NNS
. O

Two CD
binding VBG
proteins NNS
are VBP
detected VBN
in IN
K562 NN
nuclear JJ
extracts NNS
, O
while IN
only RB
one CD
is VBZ
found VBN
in IN
extracts NNS
from IN
HeLa NN
cells NNS
. O

Possible JJ
mechanisms NNS
by IN
which WDT
these DT
proteins NNS
may MD
regulate VB
transcription NN
of IN
the DT
epsilon-globin-encoding JJ
gene NN
in IN
erythroid JJ
and CC
non-erythroid JJ
cells NNS
are VBP
discussed VBN
. O

Gangliosides NN
suppress VBP
tumor NN
necrosis NN
factor NN
production NN
in IN
human JJ
monocytes NNS
. O

Both CC
normal JJ
and CC
malignant JJ
cells NNS
contain VBP
gangliosides NNS
as IN
important JJ
cell NN
membrane NN
constituents NNS
that WDT
, O
after IN
being VBG
shed VBN
, O
may MD
influence VB
cells NNS
of IN
the DT
immune JJ
system NN
. O

We PRP
have VBP
studied VBN
the DT
impact NN
of IN
gangliosides NNS
on IN
the DT
expression NN
of IN
TNF NN
in IN
blood NN
monocytes NNS
and CC
in IN
the DT
monocytic JJ
cell NN
line NN
Mono NN
Mac NN
6 CD
. O

Although IN
under IN
standard JJ
culture NN
conditions NNS
, O
bovine JJ
brain NN
gangliosides NNS
( O
100 CD
micrograms/ml NNS
) O
suppressed VBD
LPS-stimulated JJ
TNF NN
production NN
5-fold RB
in IN
PBMC NN
and CC
10-fold RB
in IN
Mono NN
Mac NN
6 CD
cells NNS
, O
suppression NN
was VBD
more RBR
efficient JJ
under IN
serum-free JJ
conditions NNS
. O

Looking VBG
at IN
highly RB
purified VBN
gangliosides NNS
, O
GD3 NN
, O
GD1a NN
, O
GM3 NN
, O
GM2 NN
, O
and CC
GM1 NN
were VBD
all DT
effective JJ
in IN
reducing VBG
TNF NN
production NN
in IN
PBMC NN
, O
and CC
in IN
Mono NN
Mac NN
6 CD
by IN
factor NN
10 CD
to TO
50 CD
. O

The DT
suppressive JJ
activity NN
was VBD
lost VBN
in IN
molecules NNS
, O
lacking VBG
the DT
sugar NN
moiety NN
or CC
the DT
lipid NN
moiety NN
. O

Gangliosides NNS
appear VBP
to TO
act VB
at IN
an DT
early JJ
step NN
of IN
activation NN
in IN
that IN
TNF NN
transcripts NNS
were VBD
reduced VBN
and CC
the DT
mobilization NN
of IN
the DT
nuclear JJ
factor NN
kappa NN
B NN
was VBD
blocked VBN
. O

Furthermore RB
, O
in IN
time NN
kinetics NNS
, O
gangliosides NNS
were VBD
effective JJ
for IN
up RB
to TO
30 CD
min NN
after IN
addition NN
of IN
LPS NN
, O
but CC
not RB
thereafter RB
. O

However RB
, O
the DT
expression NN
of IN
the DT
CD14 NN
Ag NN
, O
a DT
receptor NN
molecule NN
for IN
LPS-LPS NN
binding NN
protein NN
complexes NNS
, O
was VBD
unaffected JJ
by IN
gangliosides NNS
. O

Finally RB
, O
when WRB
using VBG
Staphylococcus FW
aureus FW
or CC
platelet NN
activating NN
factor NN
as IN
a DT
stimulus NN
, O
gangliosides NNS
were VBD
able JJ
to TO
suppress VB
TNF NN
production NN
in IN
Mono NN
Mac NN
6 CD
cells NNS
by IN
factor NN
5 CD
to TO
10 CD
, O
as RB
well RB
. O

On IN
the DT
other JJ
hand NN
, O
phorbol NN
ester-induced JJ
production NN
of IN
O2- NN
was VBD
similar JJ
in IN
cells NNS
treated VBN
with IN
and CC
without IN
gangliosides NNS
. O

Taken VBN
together RB
, O
our PRP$
data NNS
demonstrate VBP
that IN
TNF NN
gene NN
expression NN
in IN
monocytes NNS
induced VBN
by IN
different JJ
types NNS
of IN
stimuli NNS
can MD
be VB
blocked VBN
by IN
gangliosides NNS
at IN
an DT
early JJ
step NN
of IN
signal JJ
transduction NN
. O

T NN
cell-specific JJ
negative JJ
regulation NN
of IN
transcription NN
of IN
the DT
human JJ
cytokine NN
IL-4 NN
. O

IL-4 NN
secreted VBN
by IN
activated VBN
T NN
cells NNS
is VBZ
a DT
pleiotropic JJ
cytokine NN
affecting VBG
growth NN
and CC
differentiation NN
of IN
diverse JJ
cell NN
types NNS
such JJ
as IN
T NN
cells NNS
, O
B NN
cells NNS
, O
and CC
mast NN
cells NNS
. O

We PRP
investigated VBD
the DT
upstream JJ
regulatory JJ
elements NNS
of IN
the DT
human JJ
IL-4 NN
promoter NN
. O

A DT
novel JJ
T NN
cell-specific JJ
negative JJ
regulatory JJ
element NN
( O
NRE NN
) O
composed VBN
of IN
two CD
protein-binding JJ
sites NNS
were VBD
mapped VBN
in IN
the DT
5' JJ
flanking JJ
region NN
of IN
the DT
IL-4 NN
gene NN
: O
-311CTCCCTTCT-303 NN
( O
NRE-I NN
) O
and CC
-288CTTTTTGCTT-TGC-300 NN
( O
NRE-II NN
) O
. O

A DT
T NN
cell-specific JJ
protein NN
Neg-1 NN
and CC
a DT
ubiquitous JJ
protein NN
Neg-2 NN
binding VBG
to TO
NRE-I NN
and CC
NRE-II NN
, O
respectively RB
, O
were VBD
identified VBN
. O

Furthermore RB
, O
a DT
positive JJ
regulatory JJ
element NN
was VBD
found VBN
45 CD
bp NN
downstream RB
of IN
the DT
NRE NN
. O

The DT
enhancer NN
activity NN
of IN
the DT
PRE NN
was VBD
completely RB
suppressed VBN
when WRB
the DT
NRE NN
was VBD
present JJ
. O

These DT
data NNS
suggest VBP
that IN
IL-4 NN
promoter NN
activity NN
is VBZ
normally RB
down-regulated VBN
by IN
an DT
NRE NN
via IN
repression NN
of IN
the DT
enhancer NN
positive JJ
regulatory JJ
element NN
. O

These DT
data NNS
may MD
have VB
implications NNS
for IN
the DT
stringent JJ
control NN
of IN
IL-4 NN
expression NN
in IN
T NN
cells NNS
. O

( O
Regulatory JJ
effect NN
of IN
insulin NN
on IN
glucocorticoid NN
receptor NN
in IN
human JJ
peripheral JJ
leukocytes NNS
) O

The DT
regulatory JJ
effect NN
of IN
insulin NN
on IN
the DT
specific JJ
binding VBG
power NN
of IN
glucocorticoid NN
receptor NN
( O
GR NN
) O
of IN
human JJ
leukocytes NNS
was VBD
assessed VBN
by IN
the DT
unoccupied JJ
receptor NN
sites NNS
capable JJ
of IN
combining VBG
with IN
(3H) NN
labelled JJ
dexamethasone NN
measured VBN
at IN
3 CD
and CC
24 CD
h NN
after IN
incubation NN
with IN
various JJ
concentrations NNS
of IN
insulin NN
added VBN
to TO
the DT
medium NN
. O

After IN
3 CD
h NN
incubation NN
the DT
specific JJ
binding VBG
power NN
with IN
(3H) NN
Dex NN
was VBD
decreased VBN
by IN
23.3 CD
+/- CC
10.0 CD
, O
32.2 CD
+/- CC
13.2 CD
and CC
54.3 CD
+/- CC
9.2 CD
% NN
( O
P NN
greater JJR
than IN
0.05 CD
, O
P NN
greater JJR
than IN
0.05 CD
and CC
P NN
less JJR
than IN
0.01 CD
as IN
compared VBN
with IN
the DT
control NN
value NN
of IN
100 CD
in IN
the DT
absence NN
of IN
insulin NN
) O
respectively RB
in IN
the DT
presence NN
of IN
20 CD
mU/L NN
( O
physiological JJ
testing NN
concentration NN
) O
, O
200 CD
mU/L NN
( O
physiological JJ
upper JJ
limit NN
) O
and CC
2,000 CD
mU/L NN
( O
pharmacological JJ
concentration NN
) O
insulin NN
in IN
the DT
incubation NN
medium NN
. O

After IN
24 CD
h NN
incubation NN
the DT
decrease NN
of IN
these DT
values NNS
increased VBD
respectively RB
to TO
43.5 CD
+/- CC
19.0 CD
, O
56.1 CD
+/- CC
20.7 CD
and CC
80.2 CD
+/- CC
15.5 CD
( O
P NN
less JJR
than IN
0.05 CD
, O
P NN
less JJR
than IN
0.01 CD
and CC
P NN
less JJR
than IN
0.01 CD
compared VBN
with IN
control NN
) O
. O

Thus RB
the DT
inhibitory JJ
effect NN
of IN
insulin NN
on IN
the DT
GR NN
binding NN
power NN
is VBZ
both CC
dose- NN
and CC
time-dependent JJ
, O
which WDT
strongly RB
suggests VBZ
that IN
GR NN
is VBZ
tonically RB
controlled VBN
by IN
insulin NN
concentration NN
change NN
under IN
physiological JJ
conditions NNS
. O

Human JJ
T NN
cell NN
activation NN
through IN
the DT
activation-inducer JJ
molecule/CD69 NN
enhances VBZ
the DT
activity NN
of IN
transcription NN
factor NN
AP-1 NN
. O

The DT
induction NN
of IN
the DT
AP-1 NN
transcription NN
factor NN
has VBZ
been VBN
ascribed VBN
to TO
the DT
early JJ
events NNS
leading VBG
to TO
T NN
cell NN
differentiation NN
and CC
activation NN
. O

We PRP
have VBP
studied VBN
the DT
regulation NN
of IN
AP-1 NN
activity NN
in IN
human JJ
peripheral JJ
blood NN
T NN
lymphocytes NNS
stimulated VBN
through IN
the DT
activation NN
inducer NN
molecule NN
( O
AIM NN
) O
/CD69 NN
activation NN
pathway NN
. O

Phorbol NN
esters NNS
are VBP
required VBN
to TO
induce VB
AIM/CD69 NN
cell-surface JJ
expression NN
as RB
well RB
as IN
for IN
triggering VBG
the DT
proliferation NN
of IN
T NN
cells NNS
in IN
conjunction NN
with IN
anti-AIM JJ
mAb NN
. O

Mobility NN
shift NN
assays NNS
showed VBD
that IN
addition NN
of IN
anti-AIM JJ
mAb NN
to TO
PMA-treated JJ
T NN
lymphocytes NNS
markedly RB
enhanced VBD
the DT
binding NN
activity NN
of IN
AP-1 NN
to TO
its PRP$
cognate JJ
sequence NN
, O
the DT
phorbol NN
ester NN
response NN
element NN
. O

In IN
contrast NN
, O
anti-AIM NN
mAb NN
did VBD
not RB
induce VB
any DT
change NN
in IN
the DT
binding NN
activity NN
of IN
NF-kappa NN
B NN
, O
a DT
transcription NN
factor NN
whose WP$
activity NN
is VBZ
also RB
regulated VBN
by IN
protein NN
kinase NN
C NN
. O

The DT
increase NN
in IN
AP-1-binding JJ
activity NN
was VBD
accompanied VBN
by IN
the DT
marked JJ
stimulation NN
of IN
the DT
transcription NN
of IN
c-fos NN
but CC
not RB
that DT
of IN
c-jun NN
. O

Blockade NN
of IN
the DT
DNA-binding JJ
complexes NNS
with IN
an DT
anti-Fos JJ
mAb NN
demonstrated VBD
a DT
direct JJ
participation NN
of IN
c-Fos NN
in IN
the DT
AP-1 NN
complexes NNS
induced VBN
by IN
anti-AIM NN
mAb NN
. O

Most JJS
of IN
the DT
AP-1 NN
activity NN
could MD
be VB
eliminated VBN
when WRB
the DT
anti-AIM NN
mAb NN
was VBD
added VBN
to TO
the DT
culture NN
medium NN
in IN
the DT
presence NN
of IN
cycloheximide NN
, O
suggesting VBG
that IN
de FW
novo FW
protein NN
synthesis NN
is VBZ
crucial JJ
for IN
the DT
induction NN
of IN
AP-1-binding JJ
activity NN
. O

These DT
data NNS
provide VBP
the DT
evidence NN
that IN
activation NN
of IN
human JJ
peripheral JJ
blood NN
T NN
cells NNS
through IN
the DT
AIM NN
activation NN
pathway NN
regulate VBP
the DT
activity NN
of IN
AP-1 NN
. O

Therefore RB
, O
this DT
pathway NN
appears VBZ
as IN
a DT
crucial JJ
step NN
in IN
the DT
initiation NN
of IN
early JJ
T NN
cell NN
activation NN
events NNS
. O

cis-acting JJ
sequences NNS
required VBN
for IN
inducible JJ
interleukin-2 NN
enhancer NN
function NN
bind VBP
a DT
novel JJ
Ets-related JJ
protein NN
, O
Elf-1 NN
. O

The DT
recent JJ
definition NN
of IN
a DT
consensus NN
DNA NN
binding NN
sequence NN
for IN
the DT
Ets NN
family NN
of IN
transcription NN
factors NNS
has VBZ
allowed VBN
the DT
identification NN
of IN
potential JJ
Ets NN
binding NN
sites NNS
in IN
the DT
promoters NNS
and CC
enhancers NNS
of IN
many JJ
inducible JJ
T-cell NN
genes NNS
. O

In IN
the DT
studies NNS
described VBN
in IN
this DT
report NN
, O
we PRP
have VBP
identified VBN
two CD
potential JJ
Ets NNS
binding NN
sites NNS
, O
EBS1 NN
and CC
EBS2 NN
, O
which WDT
are VBP
conserved VBN
in IN
both CC
the DT
human JJ
and CC
murine JJ
interleukin-2 NN
enhancers NNS
. O

Within IN
the DT
human JJ
enhancer NN
, O
these DT
two CD
sites NNS
are VBP
located JJ
within IN
the DT
previously RB
defined VBN
DNase NN
I CD
footprints NNS
, O
NFAT-1 NN
and CC
NFIL-2B NN
, O
respectively RB
. O

Electrophoretic JJ
mobility NN
shift NN
and CC
methylation NN
interference NN
analyses NNS
demonstrated VBD
that IN
EBS1 NN
and CC
EBS2 NN
are VBP
essential JJ
for IN
the DT
formation NN
of IN
the DT
NFAT-1 NN
and CC
NFIL-2B NN
nuclear JJ
protein NN
complexes NNS
. O

Furthermore RB
, O
in FW
vitro FW
mutagenesis NN
experiments NNS
demonstrated VBD
that IN
inducible JJ
interleukin-2 NN
enhancer NN
function NN
requires VBZ
the DT
presence NN
of IN
either CC
EBS1 NN
or CC
EBS2 NN
. O

Two CD
well-characterized JJ
Ets NN
family NN
members NNS
, O
Ets-1 NN
and CC
Ets-2 NN
, O
are VBP
reciprocally RB
expressed VBN
during IN
T-cell NN
activation NN
. O

Surprisingly RB
, O
however RB
, O
neither DT
of IN
these DT
proteins NNS
bound VBD
in FW
vitro FW
to TO
EBS1 NN
or CC
EBS2 NN
. O

We PRP
therefore RB
screened VBD
a DT
T-cell NN
cDNA NN
library NN
under IN
low-stringency NN
conditions NNS
with IN
a DT
probe NN
from IN
the DT
DNA NN
binding NN
domain NN
of IN
Ets-1 NN
and CC
isolated VBD
a DT
novel JJ
Ets NN
family NN
member NN
, O
Elf-1 NN
. O

Elf-1 NN
contains VBZ
a DT
DNA NN
binding NN
domain NN
that WDT
is VBZ
nearly RB
identical JJ
to TO
that DT
of IN
E74 NN
, O
the DT
ecdysone-inducible JJ
Drosophila NN
transcription NN
factor NN
required VBN
for IN
metamorphosis NN
( O
hence RB
the DT
name NN
Elf-1 NN
, O
for IN
E74-like JJ
factor NN
1 CD
) O
. O

Elf-1 NN
bound VBD
specifically RB
to TO
both CC
EBS1 NN
and CC
EBS2 NN
in IN
electrophoretic JJ
mobility NN
shift NN
assays NNS
. O

It PRP
also RB
bound VBD
to TO
the DT
purine-rich JJ
CD3R NN
element NN
from IN
the DT
human JJ
immunodeficiency NN
virus NN
type NN
2 CD
long JJ
terminal JJ
repeat NN
, O
which WDT
is VBZ
required VBN
for IN
inducible JJ
virus NN
expression NN
in IN
response NN
to TO
signalling NN
through IN
the DT
T-cell NN
receptor NN
. O

Taken VBN
together RB
, O
these DT
results NNS
demonstrate VBP
that IN
multiple JJ
Ets NN
family NN
members NNS
with IN
apparently RB
distinct JJ
DNA NN
binding NN
specificities NNS
regulate VBP
differential JJ
gene NN
expression NN
in IN
resting VBG
and CC
activated VBN
T NN
cells NNS
. O

Mineralocorticoids NNPS
and CC
mineralocorticoid NN
receptors NNS
in IN
mononuclear JJ
leukocytes NNS
in IN
patients NNS
with IN
pregnancy-induced JJ
hypertension NN
. O

To TO
examine VB
the DT
role NN
of IN
mineralocorticoids NNS
in IN
the DT
pathophysiology NN
of IN
pregnancy-induced JJ
hypertension NN
( O
PIH NN
) O
, O
we PRP
studied VBD
plasma NN
aldosterone NN
and CC
18-hydroxycorticosterone NN
levels NNS
in IN
25 CD
women NNS
with IN
PIH NN
and CC
25 CD
normal JJ
pregnant JJ
women NNS
, O
as IN
controls NNS
. O

Furthermore RB
, O
we PRP
evaluated VBD
the DT
mineralocorticoid NN
receptor NN
( O
MR NN
) O
status NN
in IN
mononuclear JJ
leukocytes NNS
in IN
the DT
2 CD
groups NNS
. O

MR NN
count NN
was VBD
significantly RB
( O
P NN
less JJR
than IN
0.0005 CD
) O
decreased VBN
in IN
the DT
PIH NN
group NN
( O
148 CD
+/- CC
9 CD
binding VBG
sites/cell NNS
) O
compared VBN
with IN
the DT
control NN
group NN
( O
300 CD
+/- CC
17 CD
binding VBG
sites/cell NNS
; O
mean NN
+/- CC
SEM NN
) O
. O

Plasma NN
aldosterone NN
in IN
women NNS
with IN
PIH NN
was VBD
281 CD
+/- CC
61 CD
pmol/L NN
; O
in IN
normal JJ
pregnant JJ
women NNS
it PRP
was VBD
697 CD
+/- CC
172 CD
pmol/L NN
( O
P NN
less JJR
than IN
0.025 CD
) O
. O

Plasma NN
18-hydroxycorticosterone NN
was VBD
also RB
significantly RB
( O
P NN
less JJR
than IN
0.025 CD
) O
lower JJR
( O
PIH NN
, O
1071 CD
+/- CC
149 CD
pmol/L NN
; O
controls NNS
, O
1907 CD
+/- CC
318 CD
pmol/L NN
) O
. O

These DT
values NNS
were VBD
determined VBN
at IN
the DT
onset NN
of IN
clinical JJ
symptoms NNS
of IN
PIH NN
. O

These DT
results NNS
can MD
not RB
be VB
explained VBN
by IN
receptor NN
down-regulation NN
due JJ
to TO
higher JJR
levels NNS
of IN
mineralocorticoids NNS
in IN
PIH NN
; O
a DT
hitherto RB
unknown JJ
mineralocorticoid NN
may MD
, O
thus RB
, O
be VB
responsible JJ
for IN
the DT
hypertension NN
and CC
altered JJ
MR NN
status NN
. O

Mineralocorticoid NN
effector NN
mechanism NN
in IN
preeclampsia NN
. O

Mineralocorticoid NN
effector NN
mechanisms NNS
were VBD
evaluated VBN
in IN
29 CD
patients NNS
with IN
preeclampsia NN
and CC
in IN
25 CD
uncomplicated JJ
pregnancies NNS
by IN
measurement NN
of IN
plasma NN
aldosterone NN
, O
levels NNS
of IN
mineralocorticoid NN
receptor NN
( O
MR NN
) O
in IN
mononuclear JJ
leucocytes NNS
, O
and CC
subtraction NN
potential NN
difference NN
( O
SPD NN
; O
rectal JJ
minus CC
oral JJ
values NNS
) O
. O

Mean NN
values NNS
for IN
plasma NN
aldosterone NN
were VBD
not RB
different JJ
between IN
the DT
two CD
groups NNS
, O
but CC
significant JJ
differences NNS
were VBD
observed VBN
for IN
MR NN
( O
preeclampsia NN
, O
81 CD
+/- CC
44 CD
receptors/cell NNS
; O
controls NNS
, O
306 CD
+/- CC
168 CD
) O
and CC
SPD NN
( O
preeclampsia NN
, O
65 CD
+/- CC
7 CD
mV NN
; O
controls NNS
, O
12 CD
+/- CC
5 CD
mV NN
) O
. O

In IN
six CD
cases NNS
we PRP
determined VBD
MR NN
, O
plasma NN
aldosterone NN
, O
and CC
SPD NN
in IN
patients NNS
with IN
preeclampsia NN
before IN
and CC
3 CD
months NNS
after IN
delivery NN
. O

MR NNS
were VBD
reduced VBN
before IN
delivery NN
( O
96 CD
+/- CC
27 CD
receptors/cell NNS
) O
, O
and CC
SPD NN
increased VBD
( O
64 CD
+/- CC
8 CD
mV NN
) O
, O
with IN
both DT
parameters NNS
normalizing VBG
after IN
delivery NN
( O
MR NN
, O
242 CD
+/- CC
79 CD
; O
SPD NN
, O
14.0 CD
+/- CC
4 CD
mV NN
) O
. O

Aldosterone NN
levels NNS
returned VBD
to TO
normal JJ
nonpregnant JJ
values NNS
after IN
delivery NN
. O

These DT
data NNS
suggest VBP
an DT
important JJ
role NN
for IN
abnormalities NNS
in IN
mineralocorticoid NN
effector NN
mechanisms NNS
in IN
the DT
etiology NN
of IN
preeclampsia NN
and CC
could MD
be VB
an DT
useful JJ
marker NN
for IN
diagnosis NN
. O

A DT
lymphoid JJ
cell-specific JJ
nuclear JJ
factor NN
containing VBG
c-Rel-like JJ
proteins NNS
preferentially RB
interacts VBZ
with IN
interleukin-6 NN
kappa NN
B-related JJ
motifs NNS
whose WP$
activities NNS
are VBP
repressed VBN
in IN
lymphoid JJ
cells NNS
. O

The DT
proto-oncoprotein NN
c-Rel NN
is VBZ
a DT
member NN
of IN
the DT
nuclear JJ
factor NN
kappa NN
B NN
transcription NN
factor NN
family NN
, O
which WDT
includes VBZ
the DT
p50 NN
and CC
p65 NN
subunits NNS
of IN
nuclear JJ
factor NN
kappa NN
B NN
. O

We PRP
show VBP
here RB
that IN
c-Rel NN
binds VBZ
to TO
kappa NN
B NN
sites NNS
as IN
homodimers NNS
as RB
well RB
as IN
heterodimers NNS
with IN
p50 NN
. O

These DT
homodimers NNS
and CC
heterodimers NNS
show VBP
distinct JJ
DNA-binding JJ
specificities NNS
and CC
affinities NNS
for IN
various JJ
kappa NN
B NN
motifs NNS
. O

In IN
particular JJ
, O
the DT
c-Rel NN
homodimer NN
has VBZ
a DT
high JJ
affinity NN
for IN
interleukin-6 NN
( O
IL-6 NN
) O
and CC
beta NN
interferon NN
kappa NN
B NN
sites NNS
. O

In IN
spite NN
of IN
its PRP$
association NN
with IN
p50 NN
in FW
vitro FW
, O
however RB
, O
we PRP
found VBD
a DT
lymphoid JJ
cell-specific JJ
nuclear JJ
factor NN
in FW
vivo FW
that WDT
contains VBZ
c-Rel NN
but CC
not RB
p50 NN
epitopes NNS
; O
this DT
factor NN
, O
termed VBN
IL-6 NN
kappa NN
B NN
binding NN
factor NN
II CD
, O
appears VBZ
to TO
contain VB
the DT
c-Rel NN
homodimer NN
and CC
preferentially RB
recognizes VBZ
several JJ
IL-6 NN
kappa NN
B-related JJ
kappa NN
B NN
motifs NNS
. O

Although IN
it PRP
has VBZ
been VBN
previously RB
shown VBN
that IN
the DT
IL-6 NN
kappa NN
B NN
motif NN
functions VBZ
as IN
a DT
potent JJ
IL-1/tumor NN
necrosis NN
factor-responsive JJ
element NN
in IN
nonlymphoid JJ
cells NNS
, O
its PRP$
activity NN
was VBD
found VBN
to TO
be VB
repressed VBN
in IN
lymphoid JJ
cells NNS
such JJ
as IN
a DT
Jurkat NN
T-cell NN
line NN
. O

We PRP
also RB
present VBP
evidence NN
that IN
IL-6 NN
kappa NN
B NN
binding NN
factor NN
II CD
functions VBZ
as IN
a DT
repressor NN
specific JJ
for IN
IL-6 NN
kappa NN
B-related JJ
kappa NN
B NN
motifs NNS
in IN
lymphoid JJ
cells NNS
. O

Modulation NN
of IN
normal JJ
erythroid JJ
differentiation NN
by IN
the DT
endogenous JJ
thyroid NN
hormone NN
and CC
retinoic JJ
acid NN
receptors NNS
: O
a DT
possible JJ
target NN
for IN
v-erbA NN
oncogene NN
action NN
. O

The DT
v-erbA NN
oncogene NN
, O
a DT
mutated VBN
version NN
of IN
the DT
thyroid NN
hormone NN
receptor NN
alpha NN
( O
c-erbA/TR-alpha NN
) O
, O
inhibits VBZ
erythroid JJ
differentiation NN
and CC
constitutively RB
represses VBZ
transcription NN
of IN
certain JJ
erythrocyte NN
genes NNS
, O
suggesting VBG
a DT
normal JJ
function NN
of IN
the DT
proto-oncogene NN
c-erbA NN
in IN
erythropoiesis NN
. O

Here RB
we PRP
demonstrate VBP
that IN
the DT
endogenous JJ
thyroid NN
hormone NN
receptor NN
alpha NN
( O
c-erbA/TR-alpha NN
) O
and CC
the DT
closely RB
related JJ
retinoic JJ
acid NN
receptor NN
alpha NN
( O
RAR-alpha NN
) O
play VBP
a DT
role NN
in IN
the DT
regulation NN
of IN
normal JJ
erythroid JJ
differentiation NN
. O

Retinoic JJ
acid NN
( O
RA NN
) O
distinctly RB
modulated VBD
the DT
erythroid JJ
differentiation NN
program NN
of IN
normal JJ
erythroid JJ
progenitors NNS
and CC
erythroblasts NNS
reversibly RB
transformed VBN
by IN
a DT
conditional JJ
tyrosine NN
kinase NN
oncogene NN
. O

When WRB
added VBN
pulsewise RB
to TO
immature JJ
cells NNS
, O
differentiation NN
was VBD
accelerated VBN
while IN
more RBR
mature JJ
cells NNS
underwent VBD
premature JJ
cell NN
death NN
. O

Thyroid NN
hormone NN
( O
T3 NN
) O
alone RB
caused VBD
similar JJ
but CC
weaker JJR
effects NNS
. O

Interestingly RB
, O
T3 NN
strongly RB
enhanced VBD
the DT
action NN
of IN
RA NN
, O
suggesting VBG
cooperative JJ
action NN
of IN
the DT
two CD
receptors NNS
in IN
modulating VBG
erythroid JJ
differentiation NN
. O

Expression NN
of IN
the DT
human JJ
RAR-alpha NN
in IN
receptor-negative JJ
erythroblasts NNS
conferred VBD
RA-induced JJ
regulation NN
of IN
differentiation NN
to TO
the DT
otherwise RB
unresponsive JJ
cells NNS
, O
thus RB
showing VBG
that IN
the DT
RAR-alpha NN
is VBZ
essential JJ
for IN
the DT
RA NN
effect NN
. O

Likewise RB
, O
enhanced VBN
expression NN
of IN
exogenous JJ
c-erbA/TR-alpha NN
in IN
erythroblasts NNS
rendered VBD
them PRP
susceptible JJ
to TO
modulation NN
of IN
differentiation NN
by IN
T3 NN
, O
suggesting VBG
a DT
similar JJ
function NN
of IN
both DT
receptors NNS
. O

Leukotriene NN
B4 NN
stimulates VBZ
c-fos NN
and CC
c-jun NN
gene NN
transcription NN
and CC
AP-1 NN
binding NN
activity NN
in IN
human JJ
monocytes NNS
. O

We PRP
have VBP
examined VBN
the DT
effect NN
of IN
leukotriene NN
B4 NN
( O
LTB4 NN
) O
, O
a DT
potent JJ
lipid NN
proinflammatory JJ
mediator NN
, O
on IN
the DT
expression NN
of IN
the DT
proto-oncogenes NNS
c-jun NN
and CC
c-fos NN
. O

In IN
addition NN
, O
we PRP
looked VBD
at IN
the DT
modulation NN
of IN
nuclear JJ
factors NNS
binding VBG
specifically RB
to TO
the DT
AP-1 NN
element NN
after IN
LTB4 NN
stimulation NN
. O

LTB4 NN
increased VBD
the DT
expression NN
of IN
the DT
c-fos NN
gene NN
in IN
a DT
time- NN
and CC
concentration-dependent JJ
manner NN
. O

The DT
c-jun NN
mRNA NN
, O
which WDT
is VBZ
constitutively RB
expressed VBN
in IN
human JJ
peripheral-blood NN
monocytes NNS
at IN
relatively RB
high JJ
levels NNS
, O
was VBD
also RB
slightly RB
augmented JJ
by IN
LTB4 NN
, O
although IN
to TO
a DT
much RB
lower JJR
extent NN
than IN
c-fos NN
. O

The DT
kinetics NNS
of IN
expression NN
of IN
the DT
two CD
genes NNS
were VBD
also RB
slightly RB
different JJ
, O
with IN
c-fos NN
mRNA NN
reaching VBG
a DT
peak NN
at IN
15 CD
min NN
after IN
stimulation NN
and CC
c-jun NN
at IN
30 CD
min NN
. O

Both DT
messages NNS
rapidly RB
declined VBD
thereafter RB
. O

Stability NN
of IN
the DT
c-fos NN
and CC
c-jun NN
mRNA NN
was VBD
not RB
affected VBN
by IN
LTB4 NN
, O
as IN
assessed VBN
after IN
actinomycin NN
D NN
treatment NN
. O

Nuclear JJ
transcription NN
studies NNS
in FW
vitro FW
showed VBD
that IN
LTB4 NN
increased VBD
the DT
transcription NN
of IN
the DT
c-fos NN
gene NN
7-fold RB
and CC
the DT
c-jun NN
gene NN
1.4-fold RB
. O

Resting VBG
monocytes NNS
contained VBD
nuclear JJ
factors NNS
binding VBG
to TO
the DT
AP-1 NN
element NN
, O
but CC
stimulation NN
of IN
monocytes NNS
with IN
LTB4 NN
induced VBD
greater JJR
AP-1-binding JJ
activity NN
of IN
nuclear JJ
proteins NNS
. O

These DT
results NNS
indicate VBP
that IN
LTB4 NN
may MD
regulate VB
the DT
production NN
of IN
different JJ
cytokines NNS
by IN
modulating VBG
the DT
yield NN
and/or CC
the DT
function NN
of IN
transcription NN
factors NNS
such JJ
as IN
AP-1-binding JJ
proto-oncogene NN
products NNS
. O

An DT
11-base-pair JJ
DNA NN
sequence NN
motif NN
apparently RB
unique JJ
to TO
the DT
human JJ
interleukin NN
4 CD
gene NN
confers VBZ
responsiveness NN
to TO
T-cell NN
activation NN
signals NNS
. O

We PRP
have VBP
identified VBN
a DT
DNA NN
segment NN
that WDT
confers VBZ
responsiveness NN
to TO
antigen NN
stimulation NN
signals NNS
on IN
the DT
human JJ
interleukin NN
( O
IL NN
) O
4 CD
gene NN
in IN
Jurkat NN
cells NNS
. O

The DT
human JJ
IL-4 NN
gene NN
, O
of IN
10 CD
kilobases NNS
, O
is VBZ
composed VBN
of IN
four CD
exons NNS
and CC
three CD
introns NNS
. O

A DT
cis-acting JJ
element NN
( O
P NN
sequence NN
) O
resides VBZ
in IN
the DT
5' JJ
upstream JJ
region NN
; O
no DT
additional JJ
DNA NN
segments NNS
with IN
enhancer NN
activity NN
were VBD
identified VBN
in IN
the DT
human JJ
IL-4 NN
gene NN
. O

For IN
further JJ
mapping NN
purposes NNS
, O
a DT
fusion NN
promoter NN
was VBD
constructed VBN
with IN
the DT
granulocyte/macrophage JJ
colony-stimulating JJ
factor NN
basic JJ
promoter NN
containing VBG
60 CD
base NN
pairs NNS
of IN
sequence NN
upstream JJ
from IN
the DT
cap NN
site NN
of IN
the DT
mouse NN
granulocyte/macrophage JJ
colony-stimulating JJ
factor NN
gene NN
and CC
various JJ
lengths NNS
of IN
the DT
5' JJ
upstream JJ
sequence NN
of IN
the DT
IL-4 NN
gene NN
. O

The DT
P NN
sequence NN
was VBD
located JJ
between IN
positions NNS
-79 CD
and CC
-69 CD
relative JJ
to TO
the DT
transcription NN
start NN
site NN
of IN
the DT
human JJ
IL-4 NN
gene NN
, O
and CC
this DT
location NN
was VBD
confirmed VBN
by IN
base-substitution NN
mutations NNS
. O

The DT
plasmids NNS
carrying VBG
multiple JJ
copies NNS
of IN
the DT
P NN
sequence NN
showed VBD
higher JJR
responsiveness NN
to TO
the DT
stimulation NN
. O

The DT
binding VBG
protein NN
( O
s NNS
) O
that WDT
recognize VBP
the DT
P NN
sequence NN
of IN
the DT
IL-4 NN
gene NN
were VBD
identified VBN
by IN
DNA-mobility-shift JJ
assays NNS
. O

The DT
binding NN
of IN
NF(P) NN
( O
a DT
DNA NN
binding NN
protein NN
that WDT
specifically RB
recognizes VBZ
the DT
P NN
sequence NN
) O
to TO
the DT
P NN
sequence NN
was VBD
abolished VBN
when WRB
oligonucleotides NNS
carrying VBG
base NN
substitutions NNS
were VBD
used VBN
, O
indicating VBG
that IN
the DT
NF(P) NN
interaction NN
is VBZ
sequence-specific JJ
and CC
that IN
binding NN
specificity NN
of IN
the DT
protein NN
paralleled VBD
the DT
sequence NN
requirements NNS
for IN
IL-4 NN
expression NN
in FW
vivo FW
. O

The DT
P NN
sequence NN
does VBZ
not RB
share VB
homology NN
with IN
the DT
5' JJ
upstream JJ
sequence NN
of IN
the DT
IL-2 NN
gene NN
, O
even RB
though IN
surrounding VBG
sequences NNS
of IN
the DT
IL-4 NN
gene NN
share NN
high JJ
homology NN
with IN
the DT
IL-2 NN
gene NN
. O

We PRP
conclude VBP
that IN
a DT
different JJ
set NN
of IN
proteins NNS
recognize VBP
IL-2 NN
and CC
IL-4 NN
genes NNS
. O

Glucocorticoid NN
receptor NN
binding NN
in IN
three CD
different JJ
cell NN
types NNS
in IN
major JJ
depressive JJ
disorder NN
: O
lack NN
of IN
evidence NN
of IN
receptor NN
binding NN
defect NN
. O

1 LS
. O
In IN
order NN
to TO
further RB
understand VB
the DT
apparent JJ
glucocorticoid NN
resistance NN
in IN
major JJ
depressive JJ
disorder NN
, O
circadian JJ
variation NN
in IN
cortisol NN
concentration NN
, O
dexamethasone NN
suppression NN
and CC
glucocorticoid NN
receptor NN
binding NN
in IN
mononuclear JJ
leukocytes NNS
, O
polymorphonuclear JJ
leukocytes NNS
and CC
cultured VBN
skin NN
fibroblasts NNS
were VBD
measured VBN
in IN
rigidly RB
defined VBN
major JJ
depressive JJ
disorder NN
patients NNS
and CC
non-depressed JJ
psychiatric JJ
controls NNS
. O

2 LS
. O
Mononuclear JJ
leukocytes NNS
binding VBG
to TO
glucocorticoid NN
correlated VBD
significantly RB
with IN
polymorphonuclear JJ
leukocytes NNS
binding VBG
to TO
glucocorticoid NN
, O
but CC
both DT
determinations NNS
failed VBD
to TO
differentiate VB
major JJ
depressive JJ
disorder NN
and CC
control NN
subjects NNS
. O

3 LS
. O
Initial JJ
and CC
post-dexamethasone JJ
in FW
vitro FW
fibroblast NN
binding VBG
to TO
glucocorticoid NN
was VBD
not RB
different JJ
between IN
major JJ
depressive JJ
disorder NN
and CC
non-depressed JJ
control NN
subjects NNS
. O

4 LS
. O
The DT
phenomenon NN
of IN
glucocorticoid NN
resistance NN
in IN
major JJ
depressive JJ
disorder NN
remains VBZ
unexplained JJ
. O

Kinetics NNS
of IN
nuclear JJ
translocation NN
and CC
turnover NN
of IN
the DT
vitamin NN
D NN
receptor NN
in IN
human JJ
HL60 NN
leukemia NN
cells NNS
and CC
peripheral JJ
blood NN
lymphocytes NNS
-- O
coincident JJ
rise NN
of IN
DNA-relaxing JJ
activity NN
in IN
nuclear JJ
extracts NNS
. O

High JJ
affinity NN
receptors NNS
( O
VDR NN
) O
for IN
1,25-dihydroxycholecalciferol NN
( O
calcitriol NN
) O
are VBP
expressed VBN
in IN
HL60 NN
human JJ
leukemia NN
cells NNS
and CC
in IN
low JJ
numbers NNS
in IN
peripheral JJ
blood NN
lymphocytes NNS
( O
PBL NN
) O
. O

HL60 NN
cells NNS
, O
expressing VBG
some DT
characteristics NNS
of IN
promyelocytes NNS
, O
can MD
be VB
induced VBN
to TO
monocytoid NN
differentiation NN
by IN
calcitriol NN
. O

Specific JJ
nuclear JJ
translocation NN
of IN
(3H)calcitriol/VDR NN
was VBD
examined VBN
after IN
exposure NN
of IN
whole JJ
cells NNS
to TO
10(-9) CD
M/l NN
calcitriol NN
in IN
the DT
presence NN
and CC
absence NN
of IN
a DT
500-fold JJ
excess NN
of IN
unlabeled JJ
ligand NN
and CC
subsequent JJ
isolation NN
of IN
nuclei NNS
. O

Specific JJ
nuclear JJ
translocation NN
of IN
(3H)calcitriol/VDR NN
was VBD
found VBN
to TO
be VB
time NN
dependent JJ
reaching VBG
a DT
maximum NN
of IN
approximately RB
2100 CD
binding VBG
sites/nucleus NNS
after IN
3 CD
h NN
of IN
incubation NN
in IN
HL60 NN
cells NNS
, O
whereas IN
a DT
maximum NN
of IN
approximately RB
310 CD
binding VBG
sites/nucleus NNS
was VBD
found VBN
after IN
3 CD
h NN
in IN
PBL NN
. O

Pulse NN
exposure NN
of IN
HL60 NN
to TO
radiolabeled VBN
hormone NN
for IN
3 CD
h NN
followed VBN
by IN
culture NN
in IN
medium NN
without IN
serum NN
and CC
calcitriol NN
lead VBD
to TO
nuclear JJ
retention NN
of IN
approximately RB
1600 CD
radiolabeled VBN
VDR NN
by IN
8 CD
h NN
and CC
approximately RB
1000 CD
VDR NN
by IN
24 CD
h NN
. O

Radiolabeled VBN
VDR NN
disappeared VBD
from IN
the DT
nuclear JJ
compartment NN
with IN
a DT
halflife NN
of IN
approximately RB
30 CD
min NN
if IN
cells NNS
were VBD
cultured VBN
with IN
identical JJ
concentrations NNS
of IN
unlabeled JJ
hormone NN
after IN
the DT
pulse NN
( O
pulse/chase-experiments NNS
) O
. O

No DT
difference NN
of IN
VDR NN
retention NN
in IN
pulse NN
and CC
pulse/chase-experiments NNS
was VBD
seen VBN
in IN
PBL NN
, O
where WRB
VDR NN
halflife NN
was VBD
approximately RB
30 CD
min NN
. O

No DT
specific JJ
translocation NN
into IN
the DT
nuclear JJ
compartment NN
was VBD
seen VBN
when WRB
isolated VBN
nuclei NNS
were VBD
incubated VBN
in IN
(3H)calcitriol NN
. O

Radiolabeled VBN
hormone/receptor NN
complexes NNS
of IN
nuclei NNS
isolated VBN
from IN
cells NNS
exposed VBN
for IN
3 CD
h NN
to TO
radiolabeled VBN
hormone NN
-- O
in IN
contrast NN
to TO
identical JJ
experiments NNS
with IN
intact JJ
cells NNS
-- O
did VBD
not RB
disappear VB
from IN
the DT
nuclear JJ
compartment NN
upon IN
incubation NN
of IN
nuclei NNS
with IN
identical JJ
concentrations NNS
of IN
the DT
unlabeled JJ
compound NN
. O

The DT
activity NN
of IN
DNA NN
relaxing NN
enzymes NNS
( O
e.g. FW
topoisomerases NNS
I CD
and CC
II CD
) O
in IN
nuclear JJ
extracts NNS
was VBD
measured VBN
using VBG
a DT
PBR NN
322-relaxation-assay NN
. O

Enhanced VBN
overall JJ
enzyme NN
activity NN
was VBD
found VBN
in IN
nuclear JJ
extracts NNS
by IN
1 CD
h NN
after IN
incubation NN
with IN
calcitriol NN
( O
final JJ
ethanol NN
concentration NN
0.0001 CD
% NN
v/v NN
) O
in IN
HL60 NN
and CC
PBL NN
. O

The DT
enhanced VBN
activity NN
disappeared VBD
after IN
2 CD
h NN
in IN
PBL NN
, O
whereas IN
it PRP
was VBD
still RB
enhanced VBN
by IN
4 CD
h NN
in IN
HL60 NN
. O

No DT
effect NN
was VBD
seen VBN
in IN
ethanol NN
treated JJ
controls NNS
. O

We PRP
conclude VBP
that IN
a DT
specific JJ
nuclear JJ
translocation NN
mechanism NN
exists VBZ
for IN
calcitriol NN
in IN
both DT
cell NN
types NNS
examined VBN
, O
most RBS
likely RB
due IN
to TO
translocation NN
of IN
receptor NN
proteins NNS
after IN
hormone NN
binding NN
. O

Translocated VBN
hormone/receptor NN
complexes NNS
compete VBP
for IN
a DT
limited JJ
number NN
of IN
specific JJ
nuclear JJ
binding VBG
sites NNS
. O

Enhanced VBN
activity NN
of IN
topoisomerases NNS
in IN
nuclear JJ
extracts NNS
upon IN
translocation NN
of IN
VDR NN
might MD
reflect VB
interaction NN
of IN
both DT
within IN
the DT
nuclear JJ
compartment NN
, O
thus RB
initiating VBG
DNA-unwinding NN
, O
a DT
prerequisite NN
of IN
transcription NN
initiation NN
. O

The DT
B NN
cell-specific JJ
nuclear JJ
factor NN
OTF-2 NN
positively RB
regulates VBZ
transcription NN
of IN
the DT
human JJ
class NN
II CD
transplantation NN
gene NN
, O
DRA NN
. O

The DT
promoter NN
of IN
the DT
major JJ
histocompatibility NN
class NN
II CD
gene NN
DRA NN
contains VBZ
an DT
octamer NN
element NN
( O
ATTTGCAT NN
) O
that WDT
is VBZ
required VBN
for IN
efficient JJ
DRA NN
expression NN
in IN
B NN
cells NNS
. O

Several JJ
DNA-binding JJ
proteins NNS
are VBP
known VBN
to TO
bind VB
this DT
sequence NN
. O

The DT
best RBS
characterized VBN
are VBP
the DT
B NN
cell-specific JJ
OTF-2 NN
and CC
the DT
ubiquitous JJ
OTF-1 NN
. O

This DT
report NN
directly RB
demonstrates VBZ
that IN
OTF-2 NN
but CC
not RB
OTF-1 NN
regulates VBZ
the DT
DRA NN
gene NN
. O

In FW
vitro FW
transcription NN
analysis NN
using VBG
protein NN
fractions NNS
enriched VBN
for IN
the DT
octamer-binding JJ
protein NN
OTF-2 NN
demonstrate VBP
a DT
positive JJ
functional JJ
role NN
for IN
OTF-2 NN
in IN
DRA NN
gene NN
transcription NN
. O

In IN
contrast NN
, O
OTF-1-enriched JJ
protein NN
fractions NNS
did VBD
not RB
affect VB
DRA NN
gene NN
transcription NN
although IN
it PRP
functionally RB
enhanced VBD
the DT
transcription NN
of IN
another DT
gene NN
. O

Recombinant JJ
OTF-2 NN
protein NN
produced VBN
by IN
in FW
vitro FW
transcription/translation NN
could MD
also RB
enhance VB
DRA NN
gene NN
transcription NN
in FW
vitro FW
. O

In FW
vivo FW
transient JJ
transfection NN
studies NNS
utilizing VBG
an DT
OTF-2 NN
expression NN
vector NN
resulted VBD
in IN
similar JJ
findings NNS
: O
that IN
OTF-2 NN
protein NN
enhanced VBD
DRA NN
gene NN
transcription NN
, O
and CC
that IN
this DT
effect NN
requires VBZ
an DT
intact JJ
octamer NN
element NN
. O

Together RB
these DT
results NNS
constitute VBP
the DT
first JJ
direct JJ
evidence NN
of IN
a DT
positive JJ
role NN
for IN
the DT
lymphoid-specific JJ
octamer-binding JJ
factor NN
in IN
DRA NN
gene NN
transcription NN
. O

( O
Regulation NN
of IN
intracellular JJ
cholesterol NN
synthesis NN
in IN
hypercholesterolemia NN
by IN
glucocorticoids NNS
) O

The DT
rate NN
of IN
endogenous JJ
cholesterol NN
synthesis NN
in IN
blood NN
lymphocytes NNS
and CC
skin NN
fibroblasts NNS
from IN
patients NNS
with IN
type NN
IIa NN
hyperlipidemia NN
was VBD
found VBN
to TO
be VB
increased VBN
in IN
comparison NN
with IN
healthy JJ
donors NNS
. O

The DT
cells NNS
of IN
hyperlipidemic JJ
patients NNS
had VBD
lowered JJ
levels NNS
of IN
glucocorticoid NN
receptors NNS
concomitantly RB
with IN
a DT
partial JJ
loss NN
of IN
their PRP$
sensitivity NN
to TO
glucocorticoids NNS
. O

In IN
fibroblasts NNS
from IN
patients NNS
with IN
hereditary JJ
hypercholesteremia NN
of IN
homozygous JJ
type NN
the DT
number NN
of IN
glucocorticoid NN
receptors NNS
did VBD
not RB
exceed VB
10 CD
% NN
of IN
their PRP$
content NN
in IN
normal JJ
cells NNS
. O

The DT
decrease NN
of IN
the DT
number NN
of IN
glucocorticoid NN
receptors NNS
in IN
patients NNS
with IN
type NN
IIa NN
hyperlipidemia NN
seems VBZ
to TO
be VB
a DT
compensatory JJ
response NN
of IN
cells NNS
culminating VBG
in IN
activation NN
of IN
endogenous JJ
cholesterol NN
synthesis NN
. O

Transcription NN
factor NN
activation NN
and CC
functional JJ
stimulation NN
of IN
human JJ
monocytes NNS
. O

Activation NN
of IN
expression NN
of IN
genes NNS
encoding VBG
transcription NN
factors NNS
: O
c-fos NN
and CC
c-jun NN
and CC
formation NN
of IN
AP1 NN
transcriptional JJ
complex NN
in IN
human JJ
monocytes NNS
was VBD
investigated VBN
. O

It PRP
was VBD
found VBN
that IN
lipopolysaccharide NN
induced VBD
strongly RB
both CC
c-fos NN
and CC
c-jun NN
expression NN
as RB
well RB
as IN
AP1 NN
formation NN
. O

Interferon NN
gamma NN
activated VBD
strongly RB
c-fos NN
and CC
weakly RB
c-jun NN
and CC
AP1 NN
. O

Tumor NN
necrosis NN
factor NN
induced VBD
slightly RB
c-fos NN
and CC
had VBD
almost RB
no DT
effect NN
on IN
c-jun NN
and CC
AP1 NN
. O

The DT
data NNS
suggest VBP
that IN
differences NNS
in IN
functional JJ
responses NNS
elicited VBN
in IN
monocytes NNS
by IN
all DT
three CD
factors NNS
may MD
be VB
dependent JJ
on IN
different JJ
routes NNS
on IN
nuclear JJ
signalling NN
employed VBN
by IN
the DT
factors NNS
. O

Corticosteroid NN
receptors NNS
and CC
lymphocyte NN
subsets NNS
in IN
mononuclear JJ
leukocytes NNS
in IN
aging NN
. O

Plasma NN
cortisol NN
and CC
aldosterone NN
levels NNS
and CC
number NN
of IN
related JJ
receptors NNS
in IN
mononuclear JJ
leukocytes NNS
were VBD
measured VBN
in IN
49 CD
healthy JJ
aged JJ
subjects NNS
( O
62-97 CD
yr NN
) O
and CC
in IN
21 CD
adult JJ
controls NNS
( O
21-50 CD
yr NN
) O
. O

In IN
all DT
subjects NNS
, O
in IN
addition NN
, O
lymphocyte NN
subsets NNS
were VBD
determined VBN
as IN
an DT
index NN
of IN
corticosteroid NN
action NN
. O

The DT
mean NN
number NN
of IN
type NN
I CD
and CC
type NN
II CD
receptors NNS
was VBD
significantly RB
lower JJR
in IN
aged JJ
subjects NNS
than IN
in IN
controls NNS
( O
respectively RB
, O
198 CD
+/- CC
96 CD
and CC
272 CD
+/- CC
97 CD
receptors/cell NNS
for IN
type NN
I CD
, O
and CC
1,794 CD
+/- CC
803 CD
and CC
3,339 CD
+/- CC
918 CD
for IN
type NN
II CD
receptors NNS
) O
. O

Plasma NN
aldosterone NN
and CC
cortisol NN
and CC
lymphocyte NN
subsets NNS
were VBD
not RB
different JJ
in IN
the DT
two CD
groups NNS
. O

All DT
of IN
the DT
parameters NNS
were VBD
also RB
tested VBN
for IN
correlation NN
, O
and CC
a DT
significant JJ
inverse JJ
correlation NN
was VBD
found VBN
between IN
age NN
and CC
type NN
I CD
and CC
type NN
II CD
receptors NNS
when WRB
all DT
subjects NNS
were VBD
plotted VBN
and CC
between IN
aged JJ
and CC
CD4 NN
and CC
age NN
and CC
CD4/CD8 NN
in IN
the DT
aged JJ
group NN
. O

These DT
data NNS
show VBP
that IN
aged JJ
subjects NNS
have VBP
reductions NNS
of IN
corticosteroid NN
receptors NNS
that WDT
are VBP
not RB
associated VBN
with IN
increase NN
of IN
related JJ
steroids NNS
and CC
that IN
this DT
situation NN
probably RB
represents VBZ
a DT
concomitant NN
of IN
the DT
normal JJ
aging NN
process NN
. O

Stable JJ
expression NN
of IN
HB24 NN
, O
a DT
diverged JJ
human JJ
homeobox NN
gene NN
, O
in IN
T NN
lymphocytes NNS
induces VBZ
genes NNS
involved VBN
in IN
T NN
cell NN
activation NN
and CC
growth NN
. O

A DT
diverged JJ
homeobox NN
gene NN
, O
HB24 NN
, O
which WDT
is VBZ
known VBN
to TO
be VB
induced VBN
following VBG
lymphocyte NN
activation NN
, O
was VBD
introduced VBN
into IN
Jurkat NN
T NN
cells NNS
under IN
the DT
control NN
of IN
a DT
constitutive JJ
promoter NN
. O

Stable JJ
transfectants NNS
of IN
HB24 NN
were VBD
established VBN
that WDT
expressed VBD
high JJ
levels NNS
of IN
HB24 NN
mRNA NN
and CC
possessed VBD
an DT
altered JJ
phenotype NN
suggestive JJ
of IN
activated VBN
T NN
cells NNS
. O

A DT
number NN
of IN
genes NNS
known VBN
to TO
be VB
induced VBN
following VBG
T NN
cell NN
activation NN
and CC
associated VBN
with IN
cell NN
growth NN
were VBD
increased VBN
in IN
the DT
transfectants NNS
, O
including VBG
c-fos NN
, O
c-myc NN
, O
c-myb NN
, O
HLA-DR NN
, O
lck NN
, O
NF-kappa NN
B NN
, O
interleukin-2 NN
and CC
interleukin-2 NN
receptor NN
alpha NN
( O
IL-2R NN
alpha NN
) O
. O

Analysis NN
of IN
IL-2R NN
alpha NN
expression NN
by IN
transient JJ
transfection NN
of IN
IL-2R NN
alpha NN
promoter NN
constructs NNS
into IN
the DT
HB24 NN
transfectants NNS
revealed VBD
constitutive JJ
expression NN
( O
about RB
60 CD
% NN
of IN
phytohemagglutinin- NN
and CC
phorbol NN
ester-activated JJ
Jurkat NN
cells NNS
) O
that WDT
was VBD
dependent JJ
on IN
the DT
kappa NN
B NN
site NN
in IN
the DT
IL-2R NN
alpha NN
promoter NN
. O

Furthermore RB
, O
as IN
a DT
consequence NN
of IN
the DT
increased VBN
HB24 NN
mRNA NN
levels NNS
, O
the DT
Jurkat NN
HB24 NN
transfectants NNS
proliferated VBD
more RBR
rapidly RB
than IN
control NN
cell NN
lines NNS
. O

Thus RB
, O
stable JJ
expression NN
of IN
HB24 NN
confers VBZ
an DT
activation NN
phenotype NN
on IN
a DT
human JJ
T NN
cell NN
line NN
, O
implicating VBG
this DT
gene NN
as IN
an DT
important JJ
transcriptional JJ
factor NN
during IN
T NN
cell NN
activation NN
and CC
growth NN
. O

Studies NNS
on IN
the DT
biological JJ
activity NN
of IN
triiodothyronine NN
sulfate NN
. O

Hepatic JJ
microsomes NNS
and CC
isolated VBN
hepatocytes NNS
in IN
short JJ
term NN
culture NN
desulfate VBP
T3 NN
sulfate NN
( O
T3SO4 NN
) O
. O

We PRP
, O
therefore RB
, O
wished VBD
to TO
determine VB
whether IN
T3SO4 NN
could MD
mimic VB
the DT
action NN
of IN
thyroid NN
hormone NN
in FW
vitro FW
. O

T3SO4 NN
had VBD
no DT
thyromimetic JJ
effect NN
on IN
the DT
activity NN
of IN
Ca(2+)-ATPase NN
in IN
human JJ
erythrocyte NN
membranes NNS
at IN
doses NNS
up RB
to TO
10,000 CD
times NNS
the DT
maximally RB
effective JJ
dose NN
of IN
T3 NN
( O
10/(-10) CD
mol/L NN
) O
. O

In IN
GH4C1 NN
pituitary JJ
cells NNS
, O
T3SO4 NN
failed VBD
to TO
displace VB
(125I)T3 NN
from IN
nuclear JJ
receptors NNS
in IN
intact JJ
cells NNS
or CC
soluble JJ
preparations NNS
. O

Thus RB
, O
T3SO4 NN
was VBD
not RB
directly RB
thyromimetic JJ
in IN
either CC
an DT
isolated VBN
human JJ
membrane NN
system NN
or CC
a DT
pituitary JJ
cell NN
system NN
in IN
which WDT
nuclear JJ
receptor NN
occupancy NN
correlates VBZ
with IN
GH NN
synthesis NN
. O

Thyroid NN
hormones NNS
inhibit VBP
(3H)glycosaminoglycan NN
synthesis NN
by IN
cultured VBN
human JJ
dermal JJ
fibroblasts NNS
, O
and CC
T3SO4 NN
displayed VBN
about IN
0.5 CD
% NN
the DT
activity NN
of IN
T3 NN
at IN
72 CD
h NN
. O

Human JJ
fibroblasts NNS
contained VBD
roughly RB
the DT
same JJ
level NN
of IN
microsomal JJ
p-nitrophenyl NN
sulfatase NN
activity NN
as IN
that DT
previously RB
observed VBN
in IN
hepatic JJ
microsomes NNS
. O

Propylthiouracil NN
( O
50 CD
mumol/L NN
) O
did VBD
not RB
affect VB
the DT
action NN
of IN
T3SO4 NN
, O
suggesting VBG
that IN
deiodination NN
was VBD
not RB
important JJ
for IN
this DT
activity NN
of IN
T3SO4 NN
. O

Thus RB
, O
it PRP
appears VBZ
T3SO4 NN
has VBZ
no DT
intrinsic JJ
biological JJ
activity NN
, O
but CC
, O
under IN
certain JJ
circumstances NNS
, O
may MD
be VB
reactivated VBN
by IN
desulfation NN

Nuclear JJ
factor NN
of IN
activated VBN
T NN
cells NNS
contains VBZ
Fos NN
and CC
Jun NN
. O

The DT
nuclear JJ
factor NN
NF-AT NN
( O
ref. NN
1 CD
) O
is VBZ
induced VBN
in IN
T NN
cells NNS
stimulated VBN
through IN
the DT
T-cell NN
receptor/CD3 NN
complex NN
, O
and CC
is VBZ
required VBN
for IN
interleukin-2 NN
( O
IL-2 NN
) O
gene NN
induction NN
. O

Although IN
NF-AT NN
has VBZ
not RB
been VBN
cloned VBN
or CC
purified VBN
, O
there EX
is VBZ
evidence NN
that IN
it PRP
is VBZ
a DT
major JJ
target NN
for IN
immunosuppression NN
by IN
cyclosporin NN
A NN
( O
CsA NN
) O
and CC
FK506 NN
( O
refs NNS
2-7 CD
) O
. O

NF-AT NN
induction NN
may MD
require VB
two CD
activation-dependent JJ
events NNS
: O
the DT
CsA-sensitive JJ
translocation NN
of IN
a DT
pre-existing JJ
component NN
and CC
the DT
CsA-resistant JJ
synthesis NN
of IN
a DT
nuclear JJ
component NN
. O

Here RB
we PRP
report VBP
that IN
the DT
newly RB
synthesized VBN
nuclear JJ
component NN
of IN
NF-AT NN
is VBZ
the DT
transcription NN
factor NN
AP-1 NN
. O

We PRP
show VBP
that IN
the DT
inducible JJ
nuclear JJ
form NN
of IN
NF-AT NN
contains VBZ
Fos NN
and CC
Jun NN
proteins NNS
. O

Furthermore RB
, O
we PRP
identify VBP
a DT
pre-existing JJ
NF-AT-binding JJ
factor NN
that WDT
is VBZ
present JJ
in IN
hypotonic JJ
extracts NNS
of IN
unstimulated JJ
T NN
cells NNS
. O

On IN
the DT
basis NN
of IN
binding NN
, O
reconstitution NN
and CC
cotransfection NN
experiments NNS
, O
we PRP
propose VBP
that IN
activation NN
of IN
NF-AT NN
occurs VBZ
in IN
at IN
least JJS
two CD
stages NNS
: O
a DT
CsA-sensitive JJ
stage NN
involving VBG
modification NN
and/or CC
translocation NN
of IN
the DT
pre-existing JJ
NF-AT NN
complex NN
, O
and CC
a DT
CsA-insensitive JJ
stage NN
involving VBG
the DT
addition NN
of IN
newly RB
synthesized VBN
Fos NN
or CC
Fos/Jun NN
proteins NNS
to TO
the DT
pre-existing JJ
complex NN
. O

Interferon-gamma NN
potentiates VBZ
the DT
antiviral JJ
activity NN
and CC
the DT
expression NN
of IN
interferon-stimulated JJ
genes NNS
induced VBN
by IN
interferon-alpha NN
in IN
U937 NN
cells NNS
. O

Binding NN
of IN
type NN
I CD
interferon NN
( O
IFN-alpha/beta NN
) O
to TO
specific JJ
receptors NNS
results VBZ
in IN
the DT
rapid JJ
transcriptional JJ
activation NN
, O
independent JJ
of IN
protein NN
synthesis NN
, O
of IN
IFN-alpha-stimulated JJ
genes NNS
( O
ISGs NNS
) O
in IN
human JJ
fibroblasts NNS
and CC
HeLa NN
and CC
Daudi NN
cell NN
lines NNS
. O

The DT
binding NN
of IN
ISGF3 NN
( O
IFN-stimulated JJ
gene NN
factor NN
3 CD
) O
to TO
the DT
conserved VBN
IFN-stimulated JJ
response NN
element NN
( O
ISRE NN
) O
results VBZ
in IN
transcriptional JJ
activation NN
. O

This DT
factor NN
is VBZ
composed VBN
of IN
a DT
DNA-binding JJ
protein NN
( O
ISGF3 NN
gamma NN
) O
, O
which WDT
normally RB
is VBZ
present JJ
in IN
the DT
cytoplasm NN
, O
and CC
other JJ
IFN-alpha-activated JJ
proteins NNS
which WDT
preexist VBP
as IN
latent JJ
cytoplasmic JJ
precursors NNS
( O
ISGF3 NN
alpha NN
) O
. O

We PRP
have VBP
found VBN
that IN
ISG NN
expression NN
in IN
the DT
monocytic JJ
U937 NN
cell NN
line NN
differs VBZ
from IN
most JJS
cell NN
lines NNS
previously RB
examined VBN
. O

U937 NN
cells NNS
express VBP
both CC
type NN
I CD
and CC
type NN
II CD
IFN NN
receptors NNS
, O
but CC
only RB
IFN-alpha NN
is VBZ
capable JJ
of IN
inducing VBG
antiviral JJ
protection NN
in IN
these DT
cells NNS
. O

Pretreatment NN
with IN
IFN-gamma NN
potentiates VBZ
the DT
IFN-alpha-induced JJ
protection NN
, O
but CC
IFN-gamma NN
alone RB
does VBZ
not RB
have VB
any DT
antiviral JJ
activity NN
. O

ISG15 NN
mRNA NN
accumulation NN
in IN
U937 NN
cells NNS
is VBZ
not RB
detectable JJ
before IN
6 CD
h NN
of IN
IFN-alpha NN
treatment NN
, O
peaks VBZ
at IN
24 CD
h NN
, O
and CC
requires VBZ
protein NN
synthesis NN
. O

Although IN
IFN-gamma NN
alone RB
does VBZ
not RB
induce VB
ISG NN
expression NN
, O
IFN-gamma NN
pretreatment NN
markedly RB
increases VBZ
and CC
hastens VBZ
ISG NN
expression NN
and CC
transcriptional JJ
induction NN
. O

Nuclear JJ
extracts NNS
assayed VBN
for IN
the DT
presence NN
of IN
ISRE NN
binding NN
factors NNS
by IN
electrophoretic JJ
mobility NN
shift NN
assays NNS
show VBP
that IN
ISGF3 NN
is VBZ
induced VBN
by IN
IFN-alpha NN
within IN
6 CD
h NN
from IN
undetectable JJ
basal JJ
levels NNS
in IN
untreated JJ
U937 NN
cells NNS
. O

Activation NN
of IN
ISGF3 NN
alpha NN
, O
the DT
latent JJ
component NN
of IN
ISGF3 NN
, O
occurs VBZ
rapidly RB
. O

However RB
, O
the DT
increase NN
in IN
ISGF3 NN
activity NN
ultimately RB
correlates VBZ
with IN
the DT
accumulation NN
of IN
ISGF3 NN
gamma NN
induced VBN
by IN
IFN-alpha NN
or CC
IFN-gamma NN
. O

( O
ABSTRACT NN
TRUNCATED VBN
AT IN
250 CD
WORDS NNS
) O

The DT
mechanism NN
of IN
action NN
of IN
cyclosporin NN
A NN
and CC
FK506 NN
. O

CsA NN
and CC
FK506 NN
are VBP
powerful JJ
suppressors NNS
of IN
the DT
immune JJ
system NN
, O
most RBS
notably RB
of IN
T NN
cells NNS
. O

They PRP
act VBP
at IN
a DT
point NN
in IN
activation NN
that WDT
lies VBZ
between IN
receptor NN
ligation NN
and CC
the DT
transcription NN
of IN
early JJ
genes NNS
. O

Here RB
, O
Stuart NNP
Schreiber NNP
and CC
Gerald NNP
Crabtree NNP
review VBP
recent JJ
findings NNS
that WDT
indicate VBP
CsA NN
and CC
FK506 NN
operate VBP
as IN
prodrugs NNS
: O
they PRP
bind VBP
endogenous JJ
intracellular JJ
receptors NNS
, O
the DT
immunophilins NNS
, O
and CC
the DT
resulting VBG
complex NN
targets VBZ
the DT
protein NN
phosphatase NN
, O
calcineurin NN
, O
to TO
exert VB
the DT
immunosuppressive JJ
effect NN
. O

( O
Plasma NN
cortisol NN
concentration NN
and CC
blood NN
leukocyte NN
content NN
of IN
glucocorticoid NN
receptors NNS
in IN
patients NNS
with IN
deficiency-cold JJ
vs CC
deficiency-heat JJ
syndromes NNS
) O

Plasma NN
cortisol NN
concentration NN
and CC
blood NN
leukocyte NN
content NN
of IN
glucocorticoid NN
receptors NNS
( O
GCR NN
) O
were VBD
assayed VBN
in IN
20 CD
patients NNS
with IN
deficiency NN
syndromes NNS
, O
10 CD
cold JJ
in IN
property NN
( O
deficiency-cold JJ
) O
, O
the DT
other JJ
10 CD
hot JJ
in IN
property NN
( O
deficiency-heat JJ
) O
, O
and CC
also RB
in IN
10 CD
healthy JJ
individuals NNS
as IN
normal JJ
control NN
for IN
the DT
purpose NN
of IN
investigating VBG
the DT
nature NN
of IN
cold NN
and CC
heat NN
syndromes NNS
. O

As IN
a DT
result NN
, O
the DT
cases NNS
of IN
deficiency-cold JJ
syndrome NN
( O
DCS NN
) O
had VBD
a DT
normal JJ
concentration NN
of IN
plasma NN
cortisol NN
but CC
a DT
lowered JJ
content NN
of IN
GCR NN
in IN
leukocytes NNS
when WRB
compared VBN
with IN
the DT
normal JJ
control NN
( O
P NN
less JJR
than IN
0.05 CD
) O
; O
the DT
cases NNS
of IN
deficiency-heat JJ
syndrome NN
( O
DHS NN
) O
had VBD
a DT
higher JJR
concentration NN
of IN
plasma NN
cortisol NN
than IN
the DT
normal JJ
control NN
( O
P NN
less JJR
than IN
0.05 CD
) O
and CC
a DT
slightly RB
higher JJR
content NN
of IN
GCR NN
in IN
leukocytes NNS
. O

It PRP
was VBD
concluded VBN
that IN
the DT
DCS NN
is VBZ
characterized VBN
by IN
diminished VBN
biological JJ
effects NNS
of IN
adrenocortical JJ
activity NN
, O
while IN
the DT
DHS NN
, O
by IN
augmented JJ
biological JJ
effects NNS
of IN
adrenocortical JJ
activity NN
. O

Specific JJ
NF-kappa NN
B NN
subunits NNS
act VBP
in IN
concert NN
with IN
Tat NN
to TO
stimulate VB
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
transcription NN
. O

NF-kappa NN
B NN
is VBZ
a DT
protein NN
complex NN
which WDT
functions VBZ
in IN
concert NN
with IN
the DT
tat-I NN
gene NN
product NN
to TO
stimulate VB
human JJ
immunodeficiency NN
virus NN
( O
HIV NN
) O
transcription NN
. O

To TO
determine VB
whether IN
specific JJ
members NNS
of IN
the DT
NF-kappa NN
B NN
family NN
contribute VBP
to TO
this DT
effect NN
, O
we PRP
have VBP
examined VBN
the DT
abilities NNS
of IN
different JJ
NF-kappa NN
B NN
subunits NNS
to TO
act VB
with IN
Tat-I NN
to TO
stimulate VB
transcription NN
of IN
HIV NN
in IN
Jurkat NN
T-leukemia NN
cells NNS
. O

We PRP
have VBP
found VBN
that IN
the DT
p49 NN
( O
100 CD
) O
DNA NN
binding NN
subunit NN
, O
together RB
with IN
p65 NN
, O
can MD
act VB
in IN
concert NN
with IN
Tat-I NN
to TO
stimulate VB
the DT
expression NN
of IN
HIV-CAT NN
plasmid NN
. O

Little JJ
effect NN
was VBD
observed VBN
with IN
50-kDa JJ
forms NNS
of IN
p105 NN
NF-kappa NN
B NN
or CC
rel NN
, O
in IN
combination NN
with IN
p65 NN
or CC
full-length JJ
c-rel NN
, O
which WDT
do VBP
not RB
stimulate VB
the DT
HIV NN
enhancer NN
in IN
these DT
cells NNS
. O

These DT
findings NNS
suggest VBP
that IN
the DT
combination NN
of IN
p49 NN
( O
100 CD
) O
and CC
p65 NN
NF-kappa NN
B NN
can MD
act VB
in IN
concert NN
with IN
the DT
tat-I NN
gene NN
product NN
to TO
stimulate VB
the DT
synthesis NN
of IN
HIV NN
RNA NN
. O

Activation NN
of IN
the DT
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
enhancer NN
is VBZ
not RB
dependent JJ
on IN
NFAT-1 NN
. O

The DT
function NN
of IN
a DT
putative JJ
NFAT-1 NN
site NN
in IN
the DT
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
enhancer NN
has VBZ
been VBN
analyzed VBN
. O

Activation NN
by IN
the DT
T-cell NN
antigen NN
receptor NN
is VBZ
minimal JJ
in IN
Jurkat NN
cells NNS
and CC
is VBZ
mediated VBN
by IN
the DT
kappa NN
B NN
sites NNS
. O

The DT
putative JJ
NFAT-1 NN
region NN
is VBZ
not RB
required VBN
for IN
the DT
response NN
to TO
anti-CD3 NN
or CC
to TO
mitogens NNS
in IN
T-cell NN
, O
B-cell NN
, O
or CC
monocyte/macrophage NN
leukemia NN
lines NNS
, O
nor CC
is VBZ
it PRP
a DT
cis-acting JJ
negative JJ
regulatory JJ
element NN
. O

Protein NN
kinase NN
C NN
activation NN
and CC
protooncogene NN
expression NN
in IN
differentiation/retrodifferentiation NN
of IN
human JJ
U-937 NN
leukemia NN
cells NNS
. O

Human JJ
U-937 NN
leukemia NN
cells NNS
differentiate VBP
along IN
the DT
monocytic JJ
lineage NN
following VBG
3-day JJ
exposures NNS
to TO
12-O-tetradecanoylphorbol-13-acetate NN
( O
TPA NN
) O
. O

This DT
induction NN
of IN
differentiation NN
is VBZ
accompanied VBN
by IN
adherence NN
and CC
loss NN
of IN
proliferation NN
, O
as RB
well RB
as IN
expression/repression NN
of IN
differentiation-associated JJ
genes NNS
. O

Long JJ
term NN
culture NN
of IN
TPA-differentiated JJ
U-937 NN
cells NNS
in IN
the DT
absence NN
of IN
phorbol NN
ester NN
for IN
32-36 CD
days NNS
resulted VBD
in IN
a DT
process NN
of IN
retrodifferentiation NN
. O

The DT
retrodifferentiated VBN
cells NNS
detached VBD
from IN
the DT
substrate NN
and CC
reinitiated VBD
proliferation NN
. O

Other JJ
cellular JJ
parameters NNS
, O
such JJ
as IN
glycosidase NN
activities NNS
, O
cytokine NN
release NN
, O
and CC
filament NN
expression NN
, O
returned VBD
to TO
levels NNS
similar JJ
to TO
that DT
observed VBN
in IN
uninduced JJ
cells NNS
. O

Treatment NN
of IN
U-937 NN
cells NNS
with IN
TPA NN
resulted VBD
in IN
a DT
rapid JJ
translocation NN
of IN
protein NN
kinase NN
C NN
( O
PKC NN
) O
from IN
the DT
cytosol NN
to TO
cell NN
membrane NN
fractions NNS
within IN
2-8 CD
min NN
. O

Increased VBN
levels NNS
of IN
membrane-associated JJ
PKC NN
activity NN
persisted VBD
until IN
17-29 CD
days NNS
. O

However RB
, O
longer JJR
periods NNS
of IN
incubation NN
were VBD
associated VBN
with IN
a DT
return NN
to TO
the DT
distribution NN
of IN
PKC NN
in IN
control NN
cells NNS
. O

Activation NN
of IN
PKC NN
has VBZ
been VBN
implicated VBN
in IN
the DT
regulation NN
of IN
certain JJ
immediate JJ
early JJ
response NN
genes NNS
, O
and CC
in IN
the DT
present JJ
studies NNS
, O
TPA NN
rapidly RB
induced VBD
c-fos NN
and CC
c-jun NN
gene NN
expression NN
. O

Levels NNS
of IN
c-fos NN
and CC
c-jun NN
transcripts NNS
remained VBD
elevated JJ
during IN
periods NNS
of IN
PKC NN
activation NN
and CC
also RB
returned VBD
to TO
levels NNS
observed VBN
in IN
control NN
cells NNS
by IN
30-36 CD
days NNS
, O
when WRB
the DT
cells NNS
entered VBD
retrodifferentiation NN
. O

Staurosporine NN
, O
a DT
nonspecific JJ
inhibitor NN
of IN
PKC NN
, O
partially RB
blocked VBD
TPA-induced JJ
adherence NN
and CC
growth NN
inhibition NN
and CC
concomitantly RB
prevented VBD
TPA-induced JJ
c-fos NN
and CC
c-jun NN
gene NN
expression NN
. O

( O
ABSTRACT NN
TRUNCATED VBN
AT IN
250 CD
WORDS NNS
) O

The DT
promoter NN
of IN
the DT
CD19 NN
gene NN
is VBZ
a DT
target NN
for IN
the DT
B-cell-specific JJ
transcription NN
factor NN
BSAP NN
. O

The DT
CD19 NN
protein NN
is VBZ
expressed VBN
on IN
the DT
surface NN
of IN
all DT
B-lymphoid JJ
cells NNS
with IN
the DT
exception NN
of IN
terminally RB
differentiated VBN
plasma NN
cells NNS
and CC
has VBZ
been VBN
implicated VBN
as IN
a DT
signal-transducing JJ
receptor NN
in IN
the DT
control NN
of IN
proliferation NN
and CC
differentiation NN
. O

Here RB
we PRP
demonstrate VBP
complete JJ
correlation NN
between IN
the DT
expression NN
pattern NN
of IN
the DT
CD19 NN
gene NN
and CC
the DT
B-cell-specific JJ
transcription NN
factor NN
BSAP NN
in IN
a DT
large JJ
panel NN
of IN
B-lymphoid JJ
cell NN
lines NNS
. O

The DT
human JJ
CD19 NN
gene NN
has VBZ
been VBN
cloned VBN
, O
and CC
several JJ
BSAP-binding JJ
sites NNS
have VBP
been VBN
mapped VBN
by IN
in FW
vitro FW
protein-DNA JJ
binding NN
studies NNS
. O

In IN
particular JJ
, O
a DT
high-affinity JJ
BSAP-binding JJ
site NN
instead RB
of IN
a DT
TATA NN
sequence NN
is VBZ
located JJ
in IN
the DT
-30 CD
promoter NN
region NN
upstream JJ
of IN
a DT
cluster NN
of IN
heterogeneous JJ
transcription NN
start NN
sites NNS
. O

Moreover RB
, O
this DT
site NN
is VBZ
occupied VBN
by IN
BSAP NN
in FW
vivo FW
in IN
a DT
CD19-expressing JJ
B-cell NN
line NN
but CC
not RB
in IN
plasma NN
or CC
HeLa NN
cells NNS
. O

This DT
high-affinity JJ
site NN
has VBZ
been VBN
conserved VBN
in IN
the DT
promoters NNS
of IN
both CC
human JJ
and CC
mouse NN
CD19 NN
genes NNS
and CC
was VBD
furthermore RB
shown VBN
to TO
confer VB
B-cell NN
specificity NN
to TO
a DT
beta-globin NN
reporter NN
gene NN
in IN
transient JJ
transfection NN
experiments NNS
. O

In IN
addition NN
, O
BSAP NN
was VBD
found VBN
to TO
be VB
the DT
only RB
abundant JJ
DNA-binding JJ
activity NN
of IN
B-cell NN
nuclear JJ
extracts NNS
that WDT
interacts VBZ
with IN
the DT
CD19 NN
promoter NN
. O

Together RB
, O
this DT
evidence NN
strongly RB
implicates VBZ
BSAP NN
in IN
the DT
regulation NN
of IN
the DT
CD19 NN
gene NN
. O

Reduced VBN
susceptibility NN
to TO
HIV-1 NN
infection NN
of IN
ethyl-methanesulfonate-treated JJ
CEM NN
subclones NNS
correlates VBZ
with IN
a DT
blockade NN
in IN
their PRP$
protein NN
kinase NN
C NN
signaling NN
pathway NN
. O

We PRP
have VBP
described VBN
the DT
isolation NN
of IN
chemically RB
induced VBN
CEM NN
subclones NNS
that WDT
express VBP
CD4 NN
receptors NNS
and CC
bind VBP
soluble JJ
gp120 NN
, O
yet RB
show VBP
a DT
markedly RB
reduced VBN
susceptibility NN
to TO
infection NN
with IN
HIV-1 NN
. O

Two CD
subclones NNS
were VBD
found VBN
to TO
have VB
an DT
abnormal JJ
response NN
to TO
the DT
protein NN
kinase NN
C NN
( O
PKC NN
) O
activator NN
PMA NN
. O

PMA NN
treatment NN
induced VBD
CD3 NN
and CC
CD25 NN
( O
IL-2R NN
) O
receptors NNS
on IN
the DT
parental JJ
line NN
and CC
on IN
other JJ
ethyl-methanesulfonate-derived JJ
subclones NNS
, O
but CC
not RB
on IN
these DT
two CD
mutants NNS
. O

Direct JJ
assays NNS
of IN
PKC NN
activity NN
were VBD
conducted VBN
. O

Total JJ
cellular JJ
PKC NN
enzymatic JJ
activity NN
was VBD
found VBN
to TO
be VB
normal JJ
in IN
these DT
subclones NNS
. O

PMA-induced JJ
CD4 NN
down-modulation NN
occurred VBD
normally RB
. O

In IN
addition NN
, O
activation NN
of IN
c-raf NN
kinase NN
was VBD
normal JJ
. O

Since IN
HIV-1 NN
long JJ
terminal JJ
repeat NN
contains VBZ
two CD
functional JJ
nuclear JJ
factor NN
kB NN
( O
NF-kB NN
) O
regulatory JJ
elements NNS
, O
we PRP
studied VBD
the DT
ability NN
of IN
PMA NN
to TO
induce VB
NF-kB NN
binding NN
activity NN
by IN
different JJ
assays NNS
. O

Chloramphenicol NN
acetyl NN
transferase NN
( O
CAT NN
) O
assays NNS
using VBG
the DT
HIV-1 NN
( O
-139 CD
) O
long JJ
terminal JJ
repeat-CAT JJ
construct NN
showed VBD
no DT
PMA NN
induction NN
of IN
CAT NN
activity NN
in IN
these DT
subclones NNS
( O
unlike IN
the DT
parental JJ
line NN
and CC
other JJ
subclones NNS
) O
. O

Okadaic JJ
acid NN
, O
an DT
inhibitor NN
of IN
phosphatases NNS
1 CD
and CC
2A NN
, O
did VBD
not RB
overcome VB
the DT
defect NN
in IN
these DT
subclones NNS
. O

Gel NN
retardation NN
assays NNS
, O
using VBG
a DT
32P-probe NN
containing VBG
the DT
HIV-1 NN
NF-kB NN
probe NN
and CC
nuclear JJ
extracts NNS
from IN
PMA-treated JJ
cells NNS
, O
showed VBD
significantly RB
reduced VBN
induction NN
of IN
nuclear JJ
NF-kB NN
binding NN
proteins NNS
in IN
these DT
two CD
subclones NNS
compared VBN
with IN
wild JJ
type NN
CEM NN
and CC
a DT
control NN
subclone NN
. O

Deoxycholate JJ
treatment NN
of IN
cytoplasmic JJ
extracts NNS
from IN
these DT
subclones NNS
released VBD
much JJ
reduced VBN
NF-kB NN
binding NN
proteins NNS
from IN
their PRP$
cytoplasmic JJ
pools NNS
. O

Thus RB
, O
reduced JJ
levels NNS
of IN
PKC-induced JJ
nuclear JJ
NF-kB NN
activity NN
in IN
two CD
T NN
cell NN
subclones NNS
did VBD
not RB
affect VB
their PRP$
normal JJ
cell NN
growth NN
, O
but CC
correlated VBD
with IN
a DT
pronounced JJ
reduction NN
in IN
their PRP$
susceptibility NN
to TO
HIV-1 NN
infection NN
. O

Eicosanoids NNS
in IN
breast NN
cancer NN
patients NNS
before IN
and CC
after IN
mastectomy NN
. O

In IN
19 CD
patients NNS
with IN
a DT
malignant JJ
breast NN
tumor NN
, O
tumor NN
tissue NN
and CC
blood NN
were VBD
taken VBN
to TO
determine VB
the DT
eicosanoid NN
profile NN
and CC
platelet NN
aggregation NN
. O

Values NNS
were VBD
compared VBN
with IN
those DT
of IN
patients NNS
with IN
benign JJ
tumors NNS
( O
n NN
= JJ
4 CD
) O
, O
or CC
undergoing VBG
a DT
mammary JJ
reduction NN
( O
n NN
= JJ
7 CD
) O
. O

Postoperatively RB
, O
blood NN
was VBD
taken VBN
as RB
well RB
in IN
order NN
to TO
compare VB
pre- JJ
and CC
postoperative JJ
values NNS
. O

Eicosanoids NNS
were VBD
measured VBN
in IN
peripheral JJ
blood NN
monocytes NNS
and CC
mammary JJ
tissue NN
by IN
means NNS
of IN
HPLC NN
; O
furthermore RBR
, O
TXA2 NN
, O
6-keto-PGF1 NN
alpha NN
, O
and CC
PGE2 NN
were VBD
determined VBN
by IN
RIA NN
. O

Differences NNS
in IN
pre- JJ
and CC
postoperative JJ
values NNS
of IN
cancer NN
patients NNS
were VBD
seen VBN
in IN
plasma NN
RIA NN
values NNS
: O
PGE2 NN
and CC
6-k-PGF1 NN
alpha NN
were VBD
significantly RB
higher JJR
preoperatively RB
when WRB
compared VBN
with IN
postoperatively RB
, O
however RB
, O
such JJ
differences NNS
were VBD
seen VBN
in IN
the DT
control NN
groups NNS
as RB
well RB
. O

Compared VBN
to TO
benign JJ
tumor NN
or CC
mammary JJ
reduction NN
test NN
material NN
the DT
eicosanoid NN
profile NN
of IN
tissue NN
obtained VBN
from IN
malignant JJ
mammary JJ
tumors NNS
showed VBD
important JJ
differences NNS
. O

Except IN
for IN
PGF2 NN
alpha NN
, O
HHT NN
and CC
15-HETE NN
no DT
detectable JJ
quantities NNS
of IN
eicosanoids NNS
were VBD
found VBN
in IN
the DT
non-tumor JJ
material NN
, O
whereas IN
in IN
the DT
malignant JJ
tumor NN
material NN
substantial JJ
quantities NNS
of IN
a DT
number NN
of IN
eicosanoid NN
metabolites NNS
were VBD
present JJ
. O

Statistically RB
significant JJ
correlations NNS
could MD
be VB
established VBN
between IN
patient/histopathology NN
data NNS
and CC
the DT
results NNS
of IN
the DT
platelet NN
aggregation NN
assays NNS
, O
e.g. FW
between IN
menopausal JJ
status NN
and CC
ADP NN
aggregation NN
; O
oestrogen NN
receptor NN
( O
+/- CC
) O
and CC
collagen NN
and CC
arachidonic JJ
acid NN
aggregation NN
, O
inflammatory JJ
cell NN
infiltration NN
score NN
and CC
arachidonic JJ
acid NN
aggregation NN
and CC
fibrosis NN
score NN
and CC
ADP NN
aggregation NN
. O

The DT
results NNS
show VBP
that IN
eicosanoid NN
synthesis NN
in IN
material NN
from IN
mammary JJ
cancer NN
patients NNS
is VBZ
different JJ
from IN
that DT
in IN
benign JJ
mammary JJ
tissue NN
. O

The DT
implications NNS
, O
in IN
particular JJ
, O
in IN
relation NN
to TO
future JJ
prognosis NN
of IN
the DT
patient NN
, O
remain VBP
obscure JJ
. O

c-myc NN
mRNA NN
expression NN
in IN
minor JJ
salivary JJ
glands NNS
of IN
patients NNS
with IN
Sjogren NN
's POS
syndrome NN
. O

c-myc NN
protooncogene NN
is VBZ
implicated VBN
in IN
the DT
pathogenesis NN
of IN
B NN
cell NN
lymphoid JJ
malignancies NNS
and CC
high JJ
levels NNS
of IN
c-myc NN
mRNA NN
expression NN
are VBP
observed VBN
in IN
activated VBN
blood NN
mononuclear JJ
cells NNS
. O

Sjogren NN
's POS
syndrome NN
( O
SS NN
) O
is VBZ
characterized VBN
by IN
lymphocytic JJ
infiltrates NNS
of IN
exocrine JJ
glands NNS
, O
remarkable JJ
B NN
cell NN
hyperreactivity NN
and CC
a DT
strong JJ
predisposition NN
to TO
B NN
cell NN
neoplasia NN
. O

In IN
this DT
study NN
, O
c-myc NN
protooncogene NN
mRNA NN
expression NN
in IN
29 CD
labial JJ
minor JJ
salivary JJ
gland NN
biopsies NNS
from IN
patients NNS
with IN
primary JJ
SS NNS
and CC
15 CD
controls NNS
was VBD
examined VBN
using VBG
in FW
situ FW
hybridization NN
histochemistry NN
. O

Two CD
40mer JJ
oligonucleotides NNS
from IN
the DT
1st JJ
and CC
the DT
2nd JJ
exon NN
of IN
the DT
c-myc NN
gene NN
, O
labeled VBN
with IN
35S NN
, O
were VBD
used VBN
as IN
probes NNS
. O

To TO
detect VB
the DT
origin NN
of IN
the DT
cell NN
hybridized VBN
with IN
a DT
c-myc NN
probe NN
, O
a DT
combined JJ
immunochemistry NN
in FW
situ FW
hybridization NN
histochemistry NN
technique NN
was VBD
used VBN
. O

High JJ
c-myc NN
mRNA NN
expression NN
was VBD
detected VBN
on IN
acinar JJ
epithelial JJ
cells NNS
. O

c-myc NN
did VBD
not RB
correlate VB
with IN
c-fos NN
and CC
c-jun NN
protein NN
expression NN
. O

Stronger JJR
c-myc NN
mRNA NN
expression NN
was VBD
detected VBN
in IN
labial JJ
salivary JJ
glands NNS
of IN
patients NNS
with IN
longer JJR
disease NN
duration NN
( O
p NN
less JJR
than IN
or CC
equal JJ
to TO
0.002 CD
) O
and CC
more RBR
intense JJ
T NN
lymphocyte NN
infiltrates NNS
( O
p NN
less JJR
than IN
0.05 CD
) O
although IN
these DT
patients NNS
revealed VBD
no DT
hypergammaglobulinemia NN
. O

No DT
correlation NN
was VBD
observed VBN
between IN
c-myc NN
mRNA NN
and CC
B NN
lymphocyte NN
monoclonicity NN
or CC
lymphoma NN
. O

In IN
conclusion NN
, O
strong JJ
c-myc NN
mRNA NN
expression NN
was VBD
observed VBN
on IN
epithelial JJ
cells NNS
of IN
labial JJ
salivary JJ
glands NNS
from IN
patients NNS
with IN
primary JJ
SS NN
. O

Our PRP$
findings NNS
may MD
indicate VB
the DT
presence NN
of IN
a DT
reactivated VBN
virus NN
hosted VBN
in IN
these DT
cells NNS
. O

Cytoplasmic JJ
domain NN
heterogeneity NN
and CC
functions NNS
of IN
IgG NN
Fc NN
receptors NNS
in IN
B NN
lymphocytes NNS
. O

B NN
lymphocytes NNS
and CC
macrophages NNS
express VBP
closely RB
related JJ
immunoglobulin NN
G NN
( O
IgG NN
) O
Fc NN
receptors NNS
( O
Fc NN
gamma NN
RII NN
) O
that WDT
differ VBP
only RB
in IN
the DT
structures NNS
of IN
their PRP$
cytoplasmic JJ
domains NNS
. O

Because IN
of IN
cell NN
type-specific JJ
alternative JJ
messenger NN
RNA NN
splicing NN
, O
B-cell NN
Fc NN
gamma NN
RII NN
contains VBZ
an DT
insertion NN
of IN
47 CD
amino NN
acids NNS
that WDT
participates VBZ
in IN
determining VBG
receptor NN
function NN
in IN
these DT
cells NNS
. O

Transfection NN
of IN
an DT
Fc NN
gamma NN
RII-negative JJ
B-cell NN
line NN
with IN
complementary JJ
DNA NN
's POS
encoding VBG
the DT
two CD
splice NN
products NNS
and CC
various JJ
receptor NN
mutants NNS
indicated VBD
that IN
the DT
insertion NN
was VBD
responsible JJ
for IN
preventing VBG
both CC
Fc NN
gamma NN
RII-mediated JJ
endocytosis NN
and CC
Fc NN
gamma NN
RII-mediated JJ
antigen NN
presentation NN
. O

The DT
insertion NN
was VBD
not RB
required VBN
for IN
Fc NN
gamma NN
RII NN
to TO
modulate VB
surface NN
immunoglobulin-triggered JJ
B-cell NN
activation NN
. O

Instead RB
, O
regulation NN
of IN
activation NN
involved VBD
a DT
region NN
of IN
the DT
cytoplasmic JJ
domain NN
common JJ
to TO
both CC
the DT
lymphocyte NN
and CC
macrophage NN
receptor NN
isoforms NNS
. O

In IN
contrast NN
, O
the DT
insertion NN
did VBD
contribute VB
to TO
the DT
formation NN
of IN
caps NNS
in IN
response NN
to TO
receptor NN
cross-linking NN
, O
consistent JJ
with IN
suggestions NNS
that IN
the DT
lymphocyte NN
but CC
not RB
macrophage NN
form NN
of IN
the DT
receptor NN
can MD
associate VB
with IN
the DT
detergent-insoluble JJ
cytoskeleton NN
. O

Every DT
enhancer NN
works VBZ
with IN
every DT
promoter NN
for IN
all PDT
the DT
combinations NNS
tested VBN
: O
could MD
new JJ
regulatory JJ
pathways NNS
evolve VBP
by IN
enhancer NN
shuffling NN
? O

The DT
promoters NNS
and CC
enhancers NNS
of IN
cell NN
type-specific JJ
genes NNS
are VBP
often RB
conserved VBN
in IN
evolution NN
, O
and CC
hence RB
one NN
might MD
expect VB
that IN
a DT
given JJ
enhancer NN
has VBZ
evolved VBN
to TO
work VB
best RBS
with IN
its PRP$
own JJ
promoter NN
. O

While IN
this DT
expectation NN
may MD
be VB
realized VBN
in IN
some DT
cases NNS
, O
we PRP
have VBP
not RB
found VBN
evidence NN
for IN
it PRP
. O

A DT
total NN
of IN
27 CD
combinations NNS
of IN
different JJ
promoters NNS
and CC
enhancers NNS
were VBD
tested VBN
by IN
transfection NN
into IN
cultured VBN
cells NNS
. O

We PRP
found VBD
that IN
the DT
relative JJ
efficiency NN
of IN
the DT
enhancers NNS
is VBZ
approximately RB
the DT
same JJ
, O
irrespective JJ
of IN
the DT
type NN
of IN
promoter NN
used VBN
, O
i.e. FW
, O
there EX
was VBD
no DT
strong JJ
preference NN
for IN
any DT
given JJ
enhancer/promoter JJ
combination NN
. O

Notably RB
, O
we PRP
do VBP
not RB
see VB
particularly RB
strong JJ
transcription NN
when WRB
the DT
immunoglobulin NN
kappa NN
enhancer NN
( O
or CC
the DT
immunoglobulin NN
heavy JJ
chain NN
enhancer NN
) O
is VBZ
used VBN
to TO
activate VB
a DT
kappa NN
gene NN
promoter NN
. O

We PRP
propose VBP
that IN
a DT
generally RB
permissive JJ
enhancer/promoter JJ
interaction NN
is VBZ
of IN
evolutionary JJ
benefit NN
for IN
higher JJR
eukaryotes NNS
: O
by IN
enhancer NN
shuffling NN
, O
genes NNS
could MD
be VB
easily RB
brought VBN
under IN
a DT
new JJ
type NN
of IN
inducibility/cell NN
type NN
specificity NN
. O

Heterodimerization NN
and CC
transcriptional JJ
activation NN
in FW
vitro FW
by IN
NF-kappa NN
B NN
proteins NNS
. O

The DT
NF-kappa NN
B NN
family NN
of IN
transcription NN
proteins NNS
represents VBZ
multiple JJ
DNA NN
binding NN
, O
rel NN
related JJ
polypeptides NNS
that WDT
contribute VBP
to TO
regulation NN
of IN
genes NNS
involved VBN
in IN
immune JJ
responsiveness NN
and CC
inflammation NN
, O
as RB
well RB
as IN
activation NN
of IN
the DT
HIV NN
long JJ
terminal JJ
repeat NN
. O

In IN
this DT
study NN
multiple JJ
NF-kappa NN
B NN
related JJ
polypeptides NNS
ranging VBG
from IN
85 CD
to TO
45 CD
kDa NN
were VBD
examined VBN
for IN
their PRP$
capacity NN
to TO
interact VB
with IN
the DT
PRDII NN
regulatory JJ
element NN
of IN
interferon NN
beta NN
and CC
were VBD
shown VBN
to TO
possess VB
distinct JJ
intrinsic JJ
DNA NN
binding NN
affinities NNS
for IN
this DT
NF-kappa NN
B NN
site NN
and CC
form VB
multiple JJ
DNA NN
binding NN
homo- JJ
and CC
heterodimer NN
complexes NNS
in IN
co-renaturation NN
experiments NNS
. O

Furthermore RB
, O
using VBG
DNA NN
templates NNS
containing VBG
two CD
copies NNS
of IN
the DT
PRDII NN
domain NN
linked VBN
to TO
the DT
rabbit NN
beta NN
globin NN
gene NN
, O
the DT
purified VBN
polypeptides NNS
specifically RB
stimulated VBD
NF-kappa NN
B NN
dependent JJ
transcription NN
in IN
an DT
in FW
vitro FW
reconstitution NN
assay NN
as IN
heterodimers NNS
but CC
not RB
as IN
p50 NN
homodimers NNS
. O

These DT
experiments NNS
emphasize VBP
the DT
role NN
of IN
NF-kappa NN
B NN
dimerization NN
as IN
a DT
distinct JJ
level NN
of IN
transcriptional JJ
control NN
that WDT
may MD
permit VB
functional JJ
diversification NN
of IN
a DT
limited JJ
number NN
of IN
regulatory JJ
proteins NNS
. O

Oct2 NN
transactivation NN
from IN
a DT
remote JJ
enhancer NN
position NN
requires VBZ
a DT
B-cell-restricted JJ
activity NN
. O

Previous JJ
cotransfection NN
experiments NNS
had VBD
demonstrated VBN
that IN
ectopic JJ
expression NN
of IN
the DT
lymphocyte-specific JJ
transcription NN
factor NN
Oct2 NN
could MD
efficiently RB
activate VB
a DT
promoter NN
containing VBG
an DT
octamer NN
motif NN
. O

Oct2 NN
expression NN
was VBD
unable JJ
to TO
stimulate VB
a DT
multimerized JJ
octamer NN
enhancer NN
element NN
in IN
HeLa NN
cells NNS
, O
however RB
. O

We PRP
have VBP
tested VBN
a DT
variety NN
of IN
Oct2 NN
isoforms VBZ
generated VBN
by IN
alternative JJ
splicing NN
for IN
the DT
capability NN
to TO
activate VB
an DT
octamer NN
enhancer NN
in IN
nonlymphoid JJ
cells NNS
and CC
a DT
B-cell NN
line NN
. O

Our PRP$
analyses NNS
show VBP
that IN
several JJ
Oct2 NN
isoforms NNS
can MD
stimulate VB
from IN
a DT
remote JJ
position NN
but CC
that IN
this DT
stimulation NN
is VBZ
restricted JJ
to TO
B NN
cells NNS
. O

This DT
result NN
indicates VBZ
the DT
involvement NN
of IN
either CC
a DT
B-cell-specific JJ
cofactor NN
or CC
a DT
specific JJ
modification NN
of IN
a DT
cofactor NN
or CC
the DT
Oct2 NN
protein NN
in IN
Oct2-mediated JJ
enhancer NN
activation NN
. O

Mutational JJ
analyses NNS
indicate VBP
that IN
the DT
carboxy-terminal JJ
domain NN
of IN
Oct2 NN
is VBZ
critical JJ
for IN
enhancer NN
activation NN
. O

Moreover RB
, O
this DT
domain NN
conferred VBD
enhancing NN
activity NN
when WRB
fused VBN
to TO
the DT
Oct1 NN
protein NN
, O
which WDT
by IN
itself PRP
was VBD
unable JJ
to TO
stimulate VB
from IN
a DT
remote JJ
position NN
. O

The DT
glutamine-rich JJ
activation NN
domain NN
present JJ
in IN
the DT
amino-terminal JJ
portion NN
of IN
Oct2 NN
and CC
the DT
POU NN
domain NN
contribute VBP
only RB
marginally RB
to TO
the DT
transactivation NN
function NN
from IN
a DT
distal JJ
position NN
. O

Induction NN
of IN
the DT
POU NN
domain NN
transcription NN
factor NN
Oct-2 NN
during IN
T-cell NN
activation NN
by IN
cognate JJ
antigen NN
. O

Oct-2 NN
is VBZ
a DT
transcription NN
factor NN
that WDT
binds VBZ
specifically RB
to TO
octamer NN
DNA NN
motifs NNS
in IN
the DT
promoters NNS
of IN
immunoglobulin NN
and CC
interleukin-2 NN
genes NNS
. O

All DT
tumor NN
cell NN
lines NNS
from IN
the DT
B-cell NN
lineage NN
and CC
a DT
few JJ
from IN
the DT
T-cell NN
lineage NN
express VBP
Oct-2 NN
. O

To TO
address VB
the DT
role NN
of IN
Oct-2 NN
in IN
the DT
T-cell NN
lineage NN
, O
we PRP
studied VBD
the DT
expression NN
of IN
Oct-2 NN
mRNA NN
and CC
protein NN
in IN
nontransformed JJ
human JJ
and CC
mouse NN
T NN
cells NNS
. O

Oct-2 NN
was VBD
found VBN
in IN
CD4+ JJ
and CC
CD8+ JJ
T NN
cells NNS
prepared VBN
from IN
human JJ
peripheral JJ
blood NN
and CC
in IN
mouse NN
lymph NN
node NN
T NN
cells NNS
. O

In IN
a DT
T-cell NN
clone NN
specific JJ
for IN
pigeon NN
cytochrome NN
c NN
in IN
the DT
context NN
of IN
I-Ek NN
, O
Oct-2 NN
was VBD
induced VBN
by IN
antigen NN
stimulation NN
, O
with IN
the DT
increase NN
in IN
Oct-2 NN
protein NN
seen VBN
first RB
at IN
3 CD
h NN
after IN
activation NN
and CC
continuing VBG
for IN
at IN
least JJS
24 CD
h NN
. O

Oct-2 NN
mRNA NN
induction NN
during IN
antigen-driven JJ
T-cell NN
activation NN
was VBD
blocked VBN
by IN
cyclosporin NN
A NN
, O
as RB
well RB
as IN
by IN
protein NN
synthesis NN
inhibitors NNS
. O

These DT
results NNS
suggest VBP
that IN
Oct-2 NN
participates VBZ
in IN
transcriptional JJ
regulation NN
during IN
T-cell NN
activation NN
. O
The DT
relatively RB
delayed VBN
kinetics NNS
of IN
Oct-2 NN
induction NN
suggests VBZ
that IN
Oct-2 NN
mediates VBZ
the DT
changes NNS
in IN
gene NN
expression NN
which WDT
occur VBP
many JJ
hours NNS
or CC
days NNS
following VBG
antigen NN
stimulation NN
of IN
T NN
lymphocytes NNS
. O

( O
Changes NNS
in IN
plasma NN
interleukin-1 NN
and CC
their PRP$
possible JJ
relationship NN
with IN
the DT
changes NNS
in IN
glucocorticoid NN
receptor NN
in IN
aged JJ
long-distance JJ
runner NN
) O

For IN
the DT
study NN
of IN
the DT
changes NNS
in IN
plasma NN
interleukin-1 NN
( O
IL-1 NN
) O
and CC
their PRP$
possible JJ
relationship NN
with IN
the DT
changes NNS
in IN
glucocorticoid NN
receptor NN
( O
GR NN
) O
, O
plasma NN
IL-1 NN
and CC
GR NN
in IN
peripheral JJ
blood NN
leukocytes NNS
in IN
aged JJ
long-distance JJ
runner NN
were VBD
measured VBN
simultaneously RB
. O

The DT
activity NN
of IN
IL-1 NN
was VBD
expressed VBN
as IN
its PRP$
ability NN
to TO
stimulate VB
3H-TdR NN
incorporation NN
in IN
the DT
thymocytes NNS
of IN
C57 NN
mice NNS
. O

GR NN
was VBD
determined VBN
by IN
whole JJ
cell NN
assay NN
with IN
3H-Dex NN
. O

The DT
results NNS
showed VBD
that IN
the DT
activity NN
of IN
plasma NN
IL-1 NN
in IN
aged JJ
long-distance JJ
runner NN
was VBD
209 CD
% NN
, O
223 CD
% NN
and CC
145 CD
% NN
of IN
the DT
control NN
at IN
14.7-18.7 CD
, O
3.8-7.0 CD
and CC
1.5-2.6 CD
KD NN
fractions NNS
. O

The DT
GR NN
in IN
peripheral JJ
blood NN
leukocytes NNS
in IN
aged JJ
runner NN
was VBD
65 CD
% NN
of IN
the DT
control NN
. O

Possible JJ
relationship NN
between IN
the DT
changes NNS
in IN
IL-1 NN
and CC
GR NN
in NN
aged JJ
long-distance JJ
runner NN
and CC
its PRP$
physiological JJ
significance NN
are VBP
discussed VBN
. O

Transcription NN
factor NN
AP-2 NN
activates VBZ
gene NN
expression NN
of IN
HTLV-I NN
. O

The DT
HTLV-I NN
LTR NN
contains VBZ
three CD
conserved VBN
regulatory JJ
elements NNS
known VBN
as IN
21 CD
base NN
pair NN
repeats NNS
which WDT
are VBP
required VBN
for IN
stimulation NN
of IN
gene NN
expression NN
by IN
the DT
transactivator NN
protein NN
tax NN
. O

Mutagenesis NN
indicates VBZ
that IN
the DT
21 CD
bp NN
repeats NNS
can MD
be VB
subdivided VBN
into IN
three CD
motifs NNS
, O
A NN
, O
B NN
and CC
C NN
, O
each DT
of IN
which WDT
influences VBZ
the DT
level NN
of IN
tax NN
activation NN
. O

The DT
A NN
site NN
in IN
the DT
21 CD
bp NN
repeat NN
has VBZ
strong JJ
homology NN
with IN
previously RB
described VBN
binding VBG
sites NNS
for IN
the DT
transcription NN
factor NN
AP-2 NN
. O

We PRP
demonstrated VBD
that IN
AP-2 NN
mRNA NN
was VBD
present JJ
in IN
T-lymphocytes NNS
and CC
that IN
cellular JJ
factors NNS
from IN
both CC
non-transformed JJ
and CC
transformed VBN
T-lymphocytes NNS
specifically RB
bound VBD
to TO
the DT
consensus NN
motif NN
for IN
AP-2 NN
in IN
each DT
21 CD
bp NN
. O

To TO
determine VB
the DT
role NN
of IN
AP-2 NN
in IN
the DT
regulation NN
of IN
the DT
HTLV-I NN
LTR NN
gene NN
expression NN
, O
we PRP
used VBD
an DT
AP-2 NN
cDNA NN
in IN
DNA NN
binding NN
and CC
transient JJ
expression NN
assays NNS
. O

Gel NN
retardation NN
and CC
methylation NN
interference NN
studies NNS
revealed VBD
that IN
bacterially RB
produced VBN
AP-2 NN
bound VBD
specifically RB
and CC
with IN
high JJ
affinity NN
to TO
all DT
three CD
21 CD
bp NN
repeats NNS
, O
and CC
that IN
it PRP
required VBD
the DT
core NN
sequence NN
AGGC NN
for IN
specific JJ
binding NN
. O

Binding NN
of IN
AP-2 NN
prevented VBD
the DT
subsequent JJ
binding NN
of IN
members NNS
of IN
the DT
CREB/ATF NN
family NN
to TO
an DT
adjacent JJ
regulatory JJ
motif NN
in IN
the DT
21 CD
bp NN
repeat NN
. O

Transfection NN
of IN
an DT
AP-2 NN
expression NN
construct NN
into IN
T-lymphocytes NNS
activated VBD
gene NN
expression NN
from IN
the DT
HTLV-I NN
LTR NN
. O

At IN
least JJS
two CD
21 CD
bp NN
repeats NNS
were VBD
required VBN
for IN
high JJ
levels NNS
of IN
AP-2 NN
activation NN
and CC
mutagenesis NN
of IN
the DT
AP-2 NN
consensus NN
binding NN
sequences NNS
in IN
the DT
21 CD
bp NN
repeats NNS
eliminate VBP
this DT
activation NN
. O

( O
ABSTRACT NN
TRUNCATED VBN
AT IN
250 CD
WORDS NNS
) O

Cell NN
cycle-dependent JJ
initiation NN
and CC
lineage-dependent JJ
abrogation NN
of IN
GATA-1 NN
expression NN
in IN
pure JJ
differentiating VBG
hematopoietic JJ
progenitors NNS
. O

The DT
programmed VBN
activation/repression NN
of IN
transcription NN
factors NNS
in IN
early JJ
hematopoietic JJ
differentiation NN
has VBZ
not RB
yet RB
been VBN
explored VBN
. O

The DT
DNA-binding JJ
protein NN
GATA-1 NN
is VBZ
required VBN
for IN
normal JJ
erythroid JJ
development NN
and CC
regulates VBZ
erythroid-expressed JJ
genes NNS
in IN
maturing VBG
erythroblasts NNS
. O

We PRP
analyzed VBD
GATA-1 NN
expression NN
in IN
early JJ
human JJ
adult JJ
hematopoiesis NN
by IN
using VBG
an DT
in FW
vitro FW
system NN
in IN
which WDT
" [[DQS]]
pure JJ
" [[DQE]]
early JJ
hematopoietic JJ
progenitors NNS
are VBP
induced VBN
to TO
gradual JJ
and CC
synchronized VBD
differentiation NN
selectively RB
along IN
the DT
erythroid JJ
or CC
granulocyte-macrophage JJ
pathway NN
by IN
differential JJ
treatment NN
with IN
hematopoietic JJ
growth NN
factors NNS
. O

The DT
GATA-1 NN
gene NN
, O
though IN
virtually RB
silent JJ
in IN
quiescent JJ
progenitors NNS
, O
is VBZ
activated VBN
after IN
entrance NN
into IN
the DT
cell NN
cycle NN
upon IN
stimulation NN
with IN
hematopoietic JJ
growth NN
factors NNS
. O

Subsequently RB
, O
increasing VBG
expression NN
along IN
the DT
erythroid JJ
pathway NN
contrasts VBZ
with IN
an DT
abrupt JJ
downregulation NN
in IN
the DT
granulocyte-macrophage JJ
lineage NN
. O

These DT
results NNS
suggest VBP
a DT
microenvironment-directed JJ
, O
two-step JJ
model NN
for IN
GATA-1 NN
expression NN
in IN
differentiating VBG
hematopoietic JJ
progenitors NNS
that WDT
involves VBZ
( O
i LS
) O
cycle-dependent JJ
initiation NN
and CC
( O
ii LS
) O
lineage-dependent JJ
maintenance NN
or CC
suppression NN
. O

Hypothetically RB
, O
on/off JJ
switches NNS
of IN
lineage-restricted JJ
transactivators NNS
may MD
underlie VB
the DT
binary JJ
fate NN
decisions NNS
of IN
hematopoietic JJ
progenitors NNS
. O

( O
Age-related JJ
changes NNS
in IN
glucocorticoid NN
and CC
mineralocorticoid NN
receptors NNS
in IN
lymphocytes NNS
of IN
healthy JJ
persons NNS
and CC
patients NNS
with IN
hypertension NN
) O

It PRP
has VBZ
been VBN
found VBN
that IN
the DT
number NN
of IN
glucocorticoid NN
receptors NNS
in IN
lymphocytes NNS
of IN
the DT
peripheral JJ
blood NN
of IN
healthy JJ
elderly JJ
subjects NNS
increases VBZ
, O
while IN
the DT
number NN
of IN
mineralocorticoid NN
receptors NNS
decreases VBZ
. O

The DT
mechanisms NNS
of IN
hormone-receptor NN
interactions NNS
in IN
hypertension NN
are VBP
activated VBN
: O
the DT
number NN
of IN
glucocorticoid NN
and CC
mineralocorticoid NN
binding NN
sites NNS
grows VBZ
in IN
hypertensive JJ
patients NNS
. O

Still RB
a DT
more RBR
essential JJ
rise NN
in IN
the DT
number NN
of IN
receptors NNS
is VBZ
observed VBN
in IN
mid-age JJ
hypertensive NN
patients NNS
than IN
in IN
elderly JJ
ones NNS
. O

In FW
vivo FW
footprint NN
analysis NN
of IN
the DT
HLA-DRA NN
gene NN
promoter NN
: O
cell-specific JJ
interaction NN
at IN
the DT
octamer NN
site NN
and CC
up-regulation NN
of IN
X NN
box NN
binding NN
by IN
interferon NN
gamma NN
. O

Analysis NN
of IN
the DT
major JJ
histocompatibility NN
complex NN
class NN
II CD
gene NN
promoter NN
DRA NN
has VBZ
previously RB
identified VBN
at IN
least JJS
five CD
cis-acting JJ
regions NNS
required VBN
for IN
maximal JJ
expression NN
. O

We PRP
have VBP
examined VBN
the DT
DRA NN
promoter NN
for IN
protein-DNA JJ
interactions NNS
in IN
the DT
intact JJ
cell NN
, O
which WDT
may MD
mediate VB
transcriptional JJ
activation NN
. O

Using VBG
in FW
vivo FW
genomic JJ
footprinting NN
we PRP
identified VBD
interactions NNS
in IN
B-cell NN
lines NNS
at IN
the DT
octamer NN
site NN
and CC
the DT
Y NN
, O
X1 NN
, O
and CC
X2 NN
boxes NNS
. O

Class NN
II CD
antigen NN
expressing VBG
T-cell NN
lines NNS
maintained VBD
contacts NNS
identical JJ
to TO
B-cell NN
lines NNS
, O
while IN
class NN
II-negative JJ
T-cell NN
lines NNS
exhibited VBD
no DT
interactions NNS
. O

In IN
lymphoid JJ
cell NN
lines NNS
, O
the DT
octamer NN
site NN
is VBZ
occupied VBN
and CC
required VBN
for IN
maximal JJ
expression NN
. O

This DT
is VBZ
most RBS
likely RB
due JJ
to TO
the DT
presence NN
of IN
the DT
lymphoid-specific JJ
OTF-2 NN
factor NN
. O

In IN
contrast NN
, O
the DT
class NN
II-positive JJ
nonlymphoid JJ
glioblastoma NN
cell NN
line NN
does VBZ
not RB
exhibit VB
interactions NNS
at IN
the DT
octamer NN
site NN
despite IN
the DT
presence NN
of IN
the DT
ubiquitous JJ
OTF-1 NN
factor NN
and CC
an DT
open JJ
binding VBG
site NN
. O

Thus RB
, O
the DT
DRA NN
promoter NN
discriminates VBZ
against IN
OTF-1 NN
activation NN
at IN
the DT
level NN
of IN
DNA NN
binding NN
in IN
the DT
glioblastoma NN
line NN
. O

Interferon NN
gamma NN
induces VBZ
class NN
II CD
expression NN
in IN
this DT
glioblastoma NN
cell NN
line NN
and CC
, O
in IN
parallel NN
, O
up-regulates VBZ
X1 NN
and CC
X2 NN
box NN
protein-DNA JJ
interactions NNS
, O
while IN
all DT
other JJ
interactions NNS
remain VBP
unchanged JJ
. O

These DT
results NNS
suggest VBP
that IN
interferon NN
gamma NN
functions VBZ
on IN
a DT
poised VBN
promoter NN
by IN
altering VBG
weak JJ
, O
nonproductive JJ
interactions NNS
at IN
the DT
X NN
boxes NNS
to TO
strong JJ
interactions NNS
. O

These DT
findings NNS
provide VBP
direct JJ
in FW
vivo FW
evidence NN
to TO
strongly RB
suggest VB
that IN
the DT
modulation NN
of IN
X1 NN
and CC
X2 NN
interactions NNS
is VBZ
an DT
important JJ
constituent NN
of IN
the DT
interferon NN
gamma NN
induction NN
pathway NN
. O

Simple JJ
derivation NN
of IN
TFIID-dependent JJ
RNA NN
polymerase NN
II CD
transcription NN
systems NNS
from IN
Schizosaccharomyces FW
pombe FW
and CC
other JJ
organisms NNS
, O
and CC
factors NNS
required VBN
for IN
transcriptional JJ
activation NN
. O

Resolution NN
of IN
whole JJ
cell NN
extract NN
through IN
two CD
chromatographic JJ
steps NNS
yields VBZ
a DT
single JJ
protein NN
fraction NN
requiring VBG
only RB
the DT
addition NN
of IN
TFIID NN
for IN
the DT
initiation NN
of IN
transcription NN
at IN
RNA NN
polymerase NN
II CD
promoters NNS
. O

This DT
approach NN
allows VBZ
the DT
convenient JJ
generation NN
of IN
RNA NN
polymerase NN
II CD
transcription NN
systems NNS
from IN
Saccharomyces FW
cerevisiae FW
, O
human JJ
lymphocytes NNS
, O
and CC
Schizosaccharomyces FW
pombe FW
. O

TFIIDs NNS
from IN
all DT
three CD
organisms NNS
are VBP
interchangeable JJ
among IN
all DT
three CD
systems NNS
. O

The DT
S. FW
cerevisiae FW
and CC
Sch. FW
pombe FW
systems NNS
support VBP
effects NNS
of IN
acidic JJ
activator NN
proteins NNS
, O
provided VBN
a DT
further JJ
protein NN
fraction NN
from IN
S. FW
cerevisiae FW
is VBZ
supplied VBN
. O

This DT
further JJ
fraction NN
is VBZ
distinct JJ
from IN
the DT
mediator NN
of IN
transcriptional JJ
activation NN
described VBN
previously RB
and CC
represents VBZ
a DT
second JJ
component NN
in IN
addition NN
to TO
general JJ
initiation NN
factors NNS
that WDT
may MD
facilitate VB
a DT
response NN
to TO
acidic JJ
activators NNS
. O

NF-kappa NN
B-dependent JJ
induction NN
of IN
the DT
NF-kappa NN
B NN
p50 NN
subunit NN
gene NN
promoter NN
underlies VBZ
self-perpetuation NN
of IN
human JJ
immunodeficiency NN
virus NN
transcription NN
in IN
monocytic JJ
cells NNS
. O

The DT
molecular JJ
mechanisms NNS
underlying VBG
the DT
sustained JJ
nuclear JJ
translocation NN
of IN
NF-kappa NN
B NN
observed VBN
in IN
U937 NN
monocytic JJ
cells NNS
chronically RB
infected VBN
with IN
human JJ
immunodeficiency NN
virus NN
( O
HIV NN
) O
were VBD
studied VBN
. O

The DT
activity NN
of IN
the DT
promoter NN
regulating VBG
the DT
synthesis NN
of IN
the DT
p105 NN
precursor NN
of IN
the DT
NF-kappa NN
B NN
p50 NN
subunit NN
was VBD
enhanced VBN
in IN
these DT
cells NNS
. O

Deletions NNS
in IN
this DT
promoter NN
indicated VBD
that IN
this DT
upregulation NN
was VBD
mediated VBN
through IN
the DT
NF-kappa NN
B- NN
but CC
not RB
the DT
AP-1-binding JJ
motif NN
, O
by IN
bona FW
fide FW
p50/p65 NN
heterodimers NNS
. O

Analysis NN
of IN
cytosolic JJ
extracts NNS
indicated VBD
that IN
NF-kappa NN
B NN
levels NNS
were VBD
increased VBN
in IN
HIV-infected JJ
cells NNS
. O

In IN
contrast NN
to TO
the DT
transient JJ
NF-kappa NN
B NN
activation NN
induced VBN
by IN
phorbol NN
ester NN
, O
the DT
permanent JJ
NF-kappa NN
B NN
translocation NN
induced VBN
by IN
HIV NN
infection NN
was VBD
not RB
dependent JJ
on IN
PKC NN
isoenzymes NNS
alpha NN
and CC
beta NN
as IN
shown VBN
by IN
the DT
use NN
of IN
a DT
specific JJ
inhibitor NN
( O
GF NN
109203X NN
) O
. O

These DT
observations NNS
indicate VBP
that IN
during IN
chronic JJ
HIV NN
infection NN
of IN
U937 NN
cells NNS
, O
continuous JJ
NF-kappa NN
B NN
( O
p50/p65 NN
) O
translocation NN
results VBZ
in IN
p105 NN
promoter NN
upregulation NN
with IN
subsequent JJ
cytosolic JJ
NF-kappa NN
B NN
accumulation NN
, O
ready JJ
for IN
further JJ
translocation NN
. O

This DT
HIV-mediated JJ
mechanism NN
results VBZ
in IN
a DT
self-perpetuating JJ
loop NN
of IN
NF-kappa NN
B NN
production NN
. O

The DT
development NN
of IN
functionally RB
responsive JJ
T NN
cells NNS
. O

The DT
work NN
reviewed VBN
in IN
this DT
article NN
separates VBZ
T NN
cell NN
development NN
into IN
four CD
phases NNS
. O

First JJ
is VBZ
an DT
expansion NN
phase NN
prior RB
to TO
TCR NN
rearrangement NN
, O
which WDT
appears VBZ
to TO
be VB
correlated VBN
with IN
programming NN
of IN
at IN
least JJS
some DT
response NN
genes NNS
for IN
inducibility NN
. O

This DT
phase NN
can MD
occur VB
to TO
some DT
extent NN
outside IN
of IN
the DT
thymus NN
. O

However RB
, O
the DT
profound JJ
T NN
cell NN
deficit NN
of IN
nude JJ
mice NNS
indicates VBZ
that IN
the DT
thymus NN
is VBZ
by IN
far RB
the DT
most RBS
potent JJ
site NN
for IN
inducing VBG
the DT
expansion NN
per FW
se FW
, O
even RB
if IN
other JJ
sites NNS
can MD
induce VB
some DT
response NN
acquisition NN
. O

Second JJ
is VBZ
a DT
controlled JJ
phase NN
of IN
TCR NN
gene NN
rearrangement NN
. O

The DT
details NNS
of IN
the DT
regulatory JJ
mechanism NN
that WDT
selects VBZ
particular JJ
loci NNS
for IN
rearrangement NN
are VBP
still RB
not RB
known VBN
. O

It PRP
seems VBZ
that IN
the DT
rearrangement NN
of IN
the DT
TCR NN
gamma NN
loci NNS
in IN
the DT
gamma NN
delta NN
lineage NN
may MD
not RB
always RB
take VB
place NN
at IN
a DT
developmental JJ
stage NN
strictly RB
equivalent JJ
to TO
the DT
rearrangement NN
of IN
TCR NN
beta NN
in IN
the DT
alpha NN
beta NN
lineage NN
, O
and CC
it PRP
is VBZ
not RB
clear JJ
just RB
how WRB
early RB
the DT
two CD
lineages NNS
diverge VBP
. O

In IN
the DT
TCR NN
alpha NN
beta NN
lineage NN
, O
however RB
, O
the DT
final JJ
gene NN
rearrangement NN
events NNS
are VBP
accompanied VBN
by IN
rapid JJ
proliferation NN
and CC
an DT
interruption NN
in IN
cellular JJ
response NN
gene NN
inducibility NN
. O

The DT
loss NN
of IN
conventional JJ
responsiveness NN
is VBZ
probably RB
caused VBN
by IN
alterations NNS
at IN
the DT
level NN
of IN
signaling NN
, O
and CC
may MD
be VB
a DT
manifestation NN
of IN
the DT
physiological JJ
state NN
that WDT
is VBZ
a DT
precondition NN
for IN
selection NN
. O

Third JJ
is VBZ
the DT
complex JJ
process NN
of IN
selection NN
. O

Whereas IN
peripheral JJ
T NN
cells NNS
can MD
undergo VB
forms NNS
of IN
positive JJ
selection NN
( O
by IN
antigen-driven JJ
clonal JJ
expansion NN
) O
and CC
negative JJ
selection NN
( O
by IN
abortive JJ
stimulation NN
leading VBG
to TO
anergy NN
or CC
death NN
) O
, O
neither DT
is VBZ
exactly RB
the DT
same JJ
phenomenon NN
that WDT
occurs VBZ
in IN
the DT
thymic JJ
cortex NN
. O

Negative JJ
selection NN
in IN
the DT
cortex NN
appears VBZ
to TO
be VB
a DT
suicidal JJ
inversion NN
of IN
antigen NN
responsiveness NN
: O
instead RB
of IN
turning VBG
on IN
IL-2 NN
expression NN
, O
the DT
activated VBN
cell NN
destroys VBZ
its PRP$
own JJ
chromatin NN
. O

The DT
genes NNS
that WDT
need VBP
to TO
be VB
induced VBN
for IN
this DT
response NN
are VBP
not RB
yet RB
identified VBN
, O
but CC
it PRP
is VBZ
unquestionably RB
a DT
form NN
of IN
activation NN
. O

It PRP
is VBZ
interesting JJ
that IN
in IN
humans NNS
and CC
rats NNS
, O
cortical JJ
thymocytes NNS
undergoing VBG
negative JJ
selection NN
can MD
still RB
induce VB
IL-2R NN
alpha NN
expression NN
and CC
even RB
be VB
rescued VBN
in FW
vitro FW
, O
if IN
exogenous JJ
IL-2 NN
is VBZ
provided VBN
. O

Perhaps RB
murine JJ
thymocytes NNS
are VBP
denied VBN
this DT
form NN
of IN
rescue NN
because IN
they PRP
shut VBD
off RP
IL-2R NN
beta NN
chain NN
expression NN
at IN
an DT
earlier JJR
stage NN
or CC
because IN
they PRP
may MD
be VB
uncommonly RB
Bcl-2 NN
deficient JJ
( O
cf. VBP
Sentman NNP
et FW
al. FW
, O
1991 CD
; O
Strasser NNP
et FW
al. FW
, O
1991 CD
) O
. O

Even RB
so RB
, O
medullary JJ
thymocytes NNS
remain VBP
at IN
least JJS
partially RB
susceptible JJ
to TO
negative JJ
selection NN
even RB
as IN
they PRP
continue VBP
to TO
mature VB
. O

SRC-related JJ
proto-oncogenes NNS
and CC
transcription NN
factors NNS
in IN
primary JJ
human JJ
T NN
cells NNS
: O
modulation NN
by IN
cyclosporin NN
A NN
and CC
FK506 NN
. O

Activation NN
of IN
T NN
lymphocytes NNS
induces VBZ
transcription NN
of IN
genes NNS
encoding VBG
for IN
lymphokines NNS
. O

Interleukin-2 NN
( O
IL-2 NN
) O
gene NN
expression NN
is VBZ
controlled VBN
transcriptionally RB
by IN
the DT
cooperative JJ
activity NN
of IN
specific JJ
trans-activating JJ
factors NNS
that WDT
bind VBP
to TO
the DT
IL-2 NN
enhancer NN
. O

Cyclosporin NN
A NN
( O
CsA NN
) O
and CC
FK506 NN
inhibit VBP
the DT
production NN
of IN
IL-2 NN
in IN
T NN
lymphocytes NNS
at IN
the DT
level NN
of IN
gene NN
transcription NN
. O

A DT
member NN
of IN
the DT
src NN
gene NN
family NN
, O
the DT
lymphocyte-specific JJ
protein NN
tyrosine NN
kinase NN
, O
p56lck NN
, O
has VBZ
been VBN
implicated VBN
in IN
IL-2 NN
production NN
. O

CsA NN
was VBD
found VBN
not RB
to TO
inhibit VB
lck NN
gene NN
expression NN
, O
nor CC
the DT
activity NN
of IN
the DT
lck NN
gene NN
product NN
. O

However RB
, O
CsA NN
and CC
FK506 NN
inhibit VBP
the DT
appearance NN
of IN
DNA NN
binding NN
activity NN
of IN
factors NNS
that WDT
bind VBP
to TO
the DT
NF-AT NN
and CC
AP-1 NN
sites NNS
in IN
the DT
IL-2 NN
enhancer NN
. O

Since IN
the DT
induction NN
of IN
NF-AT NN
and CC
AP-1 NN
is VBZ
induced VBN
by IN
the DT
same JJ
stimuli NNS
that WDT
stimulate VBP
IL-2 NN
production NN
, O
these DT
results NNS
indicate VBP
that IN
the DT
immunosuppressant JJ
action NN
of IN
CsA NN
and CC
FK506 NN
is VBZ
exerted VBN
at IN
the DT
level NN
of IN
these DT
trans-activating JJ
factors NNS
. O

TAR-independent JJ
transactivation NN
by IN
Tat NN
in IN
cells NNS
derived VBN
from IN
the DT
CNS NN
: O
a DT
novel JJ
mechanism NN
of IN
HIV-1 NN
gene NN
regulation NN
. O

The DT
Tat NN
protein NN
of IN
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
( O
HIV-1 NN
) O
is VBZ
essential JJ
for IN
productive JJ
infection NN
and CC
is VBZ
a DT
potential JJ
target NN
for IN
antiviral JJ
therapy NN
. O

Tat NN
, O
a DT
potent JJ
activator NN
of IN
HIV-1 NN
gene NN
expression NN
, O
serves VBZ
to TO
greatly RB
increase VB
the DT
rate NN
of IN
transcription NN
directed VBN
by IN
the DT
viral JJ
promoter NN
. O

This DT
induction NN
, O
which WDT
seems VBZ
to TO
be VB
an DT
important JJ
component NN
in IN
the DT
progression NN
of IN
acquired VBN
immune JJ
deficiency NN
syndrome NN
( O
AIDS NN
) O
, O
may MD
be VB
due JJ
to TO
increased VBN
transcriptional JJ
initiation NN
, O
increased VBN
transcriptional JJ
elongation NN
, O
or CC
a DT
combination NN
of IN
these DT
processes NNS
. O

Much JJ
attention NN
has VBZ
been VBN
focused VBN
on IN
the DT
interaction NN
of IN
Tat NN
with IN
a DT
specific JJ
RNA NN
target NN
termed VBN
TAR NN
( O
transactivation NN
responsive NN
) O
which WDT
is VBZ
present JJ
in IN
the DT
leader NN
sequence NN
of IN
all DT
HIV-1 NN
mRNAs NNS
. O

This DT
interaction NN
is VBZ
believed VBN
to TO
be VB
an DT
important JJ
component NN
of IN
the DT
mechanism NN
of IN
transactivation NN
. O

In IN
this DT
report NN
we PRP
demonstrate VBP
that IN
in IN
certain JJ
CNS-derived JJ
cells NNS
Tat NN
is VBZ
capable JJ
of IN
activating VBG
HIV-1 NN
through IN
a DT
TAR-independent JJ
pathway NN
. O

A DT
Tat-responsive JJ
element NN
is VBZ
found VBN
upstream RB
within IN
the DT
viral JJ
promoter NN
that WDT
in IN
glial-derived JJ
cell NN
lines NNS
allows VBZ
transactivation NN
in IN
the DT
absence NN
of IN
TAR NN
. O

Deletion NN
mapping NN
and CC
hybrid NN
promoter NN
constructs NNS
demonstrate VBP
that IN
the DT
newly RB
identified VBN
Tat-responsive JJ
element NN
corresponds VBZ
to TO
a DT
sequence NN
within IN
the DT
viral JJ
long JJ
terminal JJ
repeat NN
( O
LTR NN
) O
previously RB
identified VBN
as IN
the DT
HIV-1 NN
enhancer NN
, O
or CC
NF-kappa NN
B NN
domain NN
. O

DNA NN
band-shift JJ
analysis NN
reveals VBZ
NF-kappa NN
B NN
binding NN
activity NN
in IN
glial JJ
cells NNS
that WDT
differs VBZ
from IN
that DT
present JJ
in IN
T NN
lymphoid JJ
cells NNS
. O

Further RB
, O
we PRP
observe VBP
that IN
TAR-deleted JJ
mutants NNS
of IN
HIV-1 NN
demonstrate VBP
normal JJ
late JJ
gene NN
expression NN
in IN
glial JJ
cells NNS
as IN
evidenced VBN
by IN
syncytia NN
formation NN
and CC
production NN
of IN
viral JJ
p24 NN
antigen NN
. O

( O
ABSTRACT NN
TRUNCATED VBN
AT IN
250 CD
WORDS NNS
) O

Bcl-2 NN
: O
a DT
repressor NN
of IN
lymphocyte NN
death NN
. O

The DT
genes NNS
and CC
mechanisms NNS
that WDT
control VBP
programmed VBN
cell NN
death NN
are VBP
currently RB
the DT
subject NN
of IN
intense JJ
study NN
. O

The DT
bcl-2 NN
gene NN
, O
a DT
repressor NN
of IN
lymphocyte NN
death NN
, O
is VBZ
perhaps RB
the DT
best JJS
understood VBN
of IN
the DT
programmed VBN
cell NN
death NN
associated JJ
genes NNS
. O

Here RB
, O
Stanley NNP
Korsmeyer NNP
provides VBZ
a DT
brief JJ
overview NN
of IN
bcl-2 NN
, O
concentrating VBG
on IN
its PRP$
roles NNS
in IN
B- NN
and CC
T-cell NN
development NN
and CC
in IN
oncogenesis NN
. O

Mitogen NN
stimulation NN
of IN
T-cells NNS
increases VBZ
c-Fos NN
and CC
c-Jun NN
protein NN
levels NNS
, O
AP-1 NN
binding NN
and CC
AP-1 NN
transcriptional JJ
activity NN
. O

We PRP
have VBP
analysed VBN
the DT
effect NN
of IN
mitogenic JJ
lectins NNS
on IN
c-Fos NN
and CC
c-Jun NN
protein NN
levels NNS
as RB
well RB
as IN
on IN
activator NN
protein-1 NN
( O
AP-1 NN
) O
binding NN
and CC
enhancer NN
activity NN
in IN
Jurkat NN
T-cells NNS
. O

Both CC
c-Fos NN
and CC
c-Jun NN
protein NN
levels NNS
were VBD
increased VBN
after IN
Con NN
A NN
and CC
PHA NN
stimulation NN
. O

Since IN
T-cell NN
stimulation NN
increases VBZ
both CC
intracellular JJ
Ca2+ NN
and CC
cAMP NN
levels NNS
and CC
activates VBZ
protein NN
kinase NN
C NN
( O
PKC NN
) O
, O
the DT
possible JJ
involvement NN
of IN
these DT
intracellular JJ
messengers NNS
in IN
c-Fos NN
and CC
c-Jun NN
induction NN
was VBD
tested VBN
. O

PMA NN
, O
which WDT
directly RB
activates VBZ
PKC NN
, O
mimicked VBD
the DT
effect NN
of IN
the DT
lectins NNS
on IN
c-Fos NN
and CC
c-Jun NN
, O
but CC
elevation NN
of IN
either CC
intracellular JJ
Ca2+ NN
or CC
cAMP NN
levels NNS
had VBD
little JJ
or CC
no DT
effect NN
. O

The DT
mitogen-induced JJ
increase NN
of IN
c-Fos NN
and CC
c-Jun NN
immunoreactivity NN
was VBD
inhibited VBN
by IN
H-7 NN
, O
a DT
kinase NN
inhibitor NN
with IN
relatively RB
high JJ
specificity NN
for IN
PKC NN
, O
and CC
less RBR
efficiently RB
by IN
H-8 NN
, O
a DT
structurally RB
related JJ
kinase NN
inhibitor NN
less RBR
active JJ
on IN
PKC NN
, O
but CC
more RBR
active JJ
on IN
cyclic JJ
nucleotide-dependent JJ
kinases NNS
. O

Con NN
A NN
stimulation NN
was VBD
found VBN
to TO
increase VB
both CC
binding NN
of IN
AP-1 NN
to TO
the DT
AP-1 NN
consensus NN
sequence NN
, O
TRE NN
, O
and CC
AP-1 NN
enhancer NN
activity NN
, O
in IN
Jurkat NN
cells NNS
. O

PMA NN
was VBD
also RB
found VBN
to TO
increase VB
the DT
AP-1 NN
enhancer NN
activity NN
, O
whereas IN
elevation NN
of IN
Ca2+ NN
or CC
cAMP NN
had VBD
only RB
minor JJ
effects NNS
. O

We PRP
conclude VBP
that IN
stimulation NN
with IN
mitogenic JJ
lectins NNS
is VBZ
sufficient JJ
to TO
increase VB
both CC
c-Fos NN
and CC
c-Jun NN
protein NN
levels NNS
, O
AP-1 NN
binding NN
and CC
AP-1 NN
enhancer NN
activity NN
in IN
Jurkat NN
cells NNS
and CC
that IN
they PRP
act VBP
via IN
mechanisms NNS
that WDT
could MD
involve VB
the DT
activation NN
of IN
PKC NN
. O

Functional JJ
interaction NN
between IN
the DT
two CD
zinc NN
finger NN
domains NNS
of IN
the DT
v-erb NN
A NN
oncoprotein NN
. O

The DT
v-erb NN
A NN
oncogene NN
of IN
avian JJ
erythroblastosis NN
virus NN
is VBZ
a DT
mutated VBN
and CC
virally RB
transduced VBN
copy NN
of IN
a DT
host NN
cell NN
gene NN
encoding VBG
a DT
thyroid NN
hormone NN
receptor NN
. O

The DT
protein NN
expressed VBN
by IN
the DT
v-erb NN
A NN
oncogene NN
binds VBZ
to TO
DNA NN
and CC
acts VBZ
as IN
a DT
dominant JJ
negative JJ
inhibitor NN
of IN
both CC
the DT
thyroid NN
hormone NN
receptor NN
and CC
the DT
closely RB
related JJ
retinoic JJ
acid NN
receptor NN
. O

The DT
v-erb NN
A NN
protein NN
has VBZ
sustained VBN
two CD
amino NN
acid NN
alterations NNS
within IN
its PRP$
DNA-binding JJ
domain NN
relative JJ
to TO
that DT
of IN
c-erb NN
A NN
, O
one CD
of IN
which WDT
, O
at IN
serine NN
61 CD
, O
is VBZ
known VBN
to TO
be VB
important JJ
for IN
v-erb NN
A NN
function NN
in IN
the DT
neoplastic JJ
cell NN
. O

We PRP
report VBP
here RB
that IN
the DT
second JJ
alteration NN
, O
at IN
threonine NN
78 CD
, O
also RB
plays VBZ
an DT
important JJ
, O
although IN
more RBR
indirect JJ
, O
role NN
: O
alteration NN
of IN
the DT
sequence NN
at IN
threonine NN
78 CD
such JJ
that IN
it PRP
resembles VBZ
that DT
of IN
c-erb NN
A NN
can MD
act VB
as IN
an DT
intragenic JJ
suppressor NN
and CC
can MD
partially RB
restore VB
function NN
to TO
a DT
v-erb NN
A NN
protein NN
rendered VBN
defective JJ
due JJ
to TO
a DT
mutation NN
at IN
position NN
61 CD
. O

Threonine NN
78 CD
lies VBZ
within IN
the DT
D-box NN
of IN
the DT
v-erb NN
A NN
protein NN
, O
a DT
region NN
thought VBN
to TO
mediate VB
receptor-receptor JJ
dimerizations NNS
, O
and CC
is VBZ
not RB
in IN
physical JJ
proximity NN
to TO
the DT
serine NN
at IN
position NN
61 CD
. O

It PRP
therefore RB
appears VBZ
that IN
an DT
indirect JJ
interaction NN
occurs VBZ
between IN
these DT
two CD
sites NNS
and CC
that IN
this DT
interaction NN
is VBZ
crucial JJ
for IN
v-erb NN
A NN
function NN
. O

Pax-5 NN
encodes VBZ
the DT
transcription NN
factor NN
BSAP NN
and CC
is VBZ
expressed VBN
in IN
B NN
lymphocytes NNS
, O
the DT
developing VBG
CNS NNS
, O
and CC
adult JJ
testis NN
. O

BSAP NN
has VBZ
been VBN
identified VBN
previously RB
as IN
a DT
transcription NN
factor NN
that WDT
is VBZ
expressed VBN
at IN
early JJ
, O
but CC
not RB
late JJ
, O
stages NNS
of IN
B-cell NN
differentiation NN
. O

Biochemical JJ
purification NN
and CC
cDNA NN
cloning NN
has VBZ
now RB
revealed VBN
that IN
BSAP NN
belongs VBZ
to TO
the DT
family NN
of IN
paired JJ
domain NN
proteins NNS
. O

BSAP NN
is VBZ
encoded VBN
by IN
the DT
Pax-5 NN
gene NN
and CC
has VBZ
been VBN
highly RB
conserved VBN
between IN
human JJ
and CC
mouse NN
. O

An DT
intact JJ
paired JJ
domain NN
was VBD
shown VBN
to TO
be VB
both CC
necessary JJ
and CC
sufficient JJ
for IN
DNA NN
binding NN
of IN
BSAP NN
. O

Binding VBG
studies NNS
with IN
several JJ
BSAP NN
recognition NN
sequences NNS
demonstrated VBD
that IN
the DT
sequence NN
specificity NN
of IN
BSAP NN
differs VBZ
from IN
that DT
of IN
the DT
distantly RB
related JJ
paired JJ
domain NN
protein NN
Pax-1 NN
. O

During IN
embryogenesis NN
, O
the DT
BSAP NN
gene NN
is VBZ
transiently RB
expressed VBN
in IN
the DT
mesencephalon NN
and CC
spinal JJ
cord NN
with IN
a DT
spatial JJ
and CC
temporal JJ
expression NN
pattern NN
that WDT
is VBZ
distinct JJ
from IN
that DT
of IN
other JJ
Pax NN
genes NNS
in IN
the DT
developing VBG
central JJ
nervous JJ
system NN
( O
CNS NN
) O
. O

Later RB
, O
the DT
expression NN
of IN
the DT
BSAP NN
gene NN
shifts VBZ
to TO
the DT
fetal JJ
liver NN
where WRB
it PRP
correlates VBZ
with IN
the DT
onset NN
of IN
B NN
lymphopoiesis NN
. O

BSAP NN
expression NN
persists VBZ
in IN
B NN
lymphocytes NNS
and CC
is VBZ
also RB
seen VBN
in IN
the DT
testis NN
of IN
the DT
adult JJ
mouse NN
. O

All DT
of IN
this DT
evidence NN
indicates VBZ
that IN
the DT
transcription NN
factor NN
BSAP NN
may MD
not RB
only RB
play VB
an DT
important JJ
role NN
in IN
B-cell NN
differentiation NN
but CC
also RB
in IN
neural JJ
development NN
and CC
spermatogenesis NN
. O

Okadaic JJ
acid NN
is VBZ
a DT
potent JJ
inducer NN
of IN
AP-1 NN
, O
NF-kappa NN
B NN
, O
and CC
tumor NN
necrosis NN
factor-alpha NN
in IN
human JJ
B NN
lymphocytes NNS
. O

Treatment NN
of IN
human JJ
B NN
lymphocytes NNS
with IN
an DT
optimal JJ
concentration NN
of IN
okadaic JJ
acid NN
, O
an DT
inhibitor NN
of IN
phosphatases NNS
1 CD
and CC
2A NN
, O
resulted VBD
in IN
the DT
induction NN
of IN
the DT
transcription NN
factor NN
, O
AP-1 NN
and CC
a DT
marked JJ
increase NN
in IN
NF-kappa NN
B NN
levels NNS
. O

In IN
contrast NN
, O
no DT
effect NN
on IN
the DT
levels NNS
of IN
the DT
octamer NN
binding NN
proteins NNS
, O
Oct-1 NN
or CC
Oct-2 NN
, O
were VBD
found VBN
. O

Since IN
both CC
AP-1 NN
and CC
NF-kappa NN
B NN
have VBP
been VBN
reported VBN
to TO
be VB
important JJ
in IN
the DT
induction NN
of IN
the DT
tumor NN
necrosis NN
factor-alpha NN
( O
TNF-alpha NN
) O
gene NN
we PRP
examined VBD
the DT
effects NNS
of IN
okadaic JJ
acid NN
on IN
TNF-alpha NN
mRNA NN
levels NNS
. O

Treatment NN
with IN
okadaic JJ
acid NN
resulted VBD
in IN
a DT
striking JJ
increase NN
in IN
TNF-alpha NN
mRNA NN
transcripts NNS
within IN
1 CD
h NN
of IN
stimulation NN
and CC
large JJ
amounts NNS
of IN
TNF-alpha NN
were VBD
released VBN
into IN
the DT
culture NN
media NNS
. O

Although IN
okadaic JJ
acid NN
provides VBZ
a DT
potent JJ
inductive JJ
signal NN
for IN
AP-1 NN
and CC
NF-kappa NN
B NN
it PRP
did VBD
not RB
induce VB
either CC
B NN
cell NN
proliferation NN
or CC
immunoglobulin NN
secretion NN
. O

A DT
novel JJ
Ets-related JJ
transcription NN
factor NN
, O
Elf-1 NN
, O
binds VBZ
to TO
human JJ
immunodeficiency NN
virus NN
type NN
2 CD
regulatory JJ
elements NNS
that WDT
are VBP
required VBN
for IN
inducible JJ
trans JJ
activation NN
in IN
T NN
cells NNS
. O

Human JJ
immunodeficiency NN
virus NN
type NN
1 CD
( O
HIV-1 NN
) O
and CC
HIV-2 NN
are VBP
structurally RB
related JJ
retroviruses NNS
which WDT
both DT
cause VBP
AIDS NN
in IN
humans NNS
. O

Although IN
both DT
viruses NNS
establish VBP
latency NN
in IN
quiescent JJ
human-peripheral-blood JJ
T NN
cells NNS
, O
the DT
asymptomatic JJ
phase NN
of IN
HIV-2 NN
infection NN
may MD
be VB
more JJR
prolonged JJ
than IN
that DT
of IN
HIV-1 NN
. O

The DT
latent JJ
phases NNS
of IN
both CC
HIV-1 NN
and CC
HIV-2 NN
infection NN
have VBP
been VBN
shown VBN
to TO
be VB
disrupted VBN
by IN
T-cell NN
activation NN
, O
a DT
process NN
that WDT
requires VBZ
host NN
cell NN
transcription NN
factors NNS
. O

In IN
the DT
case NN
of IN
HIV-1 NN
, O
the DT
transcription NN
factor NN
NF-kappa NN
B NN
is VBZ
sufficient JJ
for IN
inducible JJ
transcriptional JJ
activation NN
. O

In IN
contrast NN
, O
factors NNS
in IN
addition NN
to TO
NF-kappa NN
B NN
are VBP
required VBN
to TO
activate VB
HIV-2 NN
transcription NN
in IN
infected JJ
T NN
cells NNS
. O

In IN
this DT
report NN
, O
we PRP
demonstrate VBP
that IN
a DT
novel JJ
Ets-related JJ
transcription NN
factor NN
, O
Elf-1 NN
, O
binds VBZ
specifically RB
to TO
two CD
purine-rich JJ
motifs NNS
in IN
the DT
HIV-2 NN
enhancer NN
. O

Mutagenesis NN
experiments NNS
demonstrated VBD
that IN
these DT
Elf-1 NN
binding NN
sites NNS
are VBP
required VBN
for IN
induction NN
of IN
HIV-2 NN
transcription NN
following VBG
T-cell-receptor-mediated JJ
T-cell NN
activation NN
. O

Moreover RB
, O
Elf-1 NN
is VBZ
the DT
only JJ
factor NN
present JJ
in IN
activated VBN
T-cell NN
nuclear JJ
extracts NNS
that WDT
binds VBZ
to TO
these DT
sites NNS
in IN
electrophoretic JJ
mobility NN
shift NN
assays NNS
. O

Thus RB
, O
Elf-1 NN
is VBZ
a DT
novel JJ
transcription NN
factor NN
that WDT
appears VBZ
to TO
be VB
required VBN
for IN
the DT
T-cell-receptor-mediated JJ
trans JJ
activation NN
of IN
HIV-2 NN
gene NN
expression NN
. O

These DT
results NNS
may MD
explain VB
differences NNS
in IN
the DT
clinical JJ
spectra NNS
of IN
diseases NNS
caused VBN
by IN
HIV-1 NN
and CC
HIV-2 NN
and CC
may MD
also RB
have VB
implications NNS
for IN
the DT
design NN
of IN
therapeutic JJ
approaches NNS
to TO
HIV-2 NN
infection NN
. O

Human JJ
immunodeficiency NN
virus NN
type NN
1 CD
Nef NN
protein NN
inhibits VBZ
NF-kappa NN
B NN
induction NN
in IN
human JJ
T NN
cells NNS
. O

Human JJ
immunodeficiency NN
virus NN
type NN
1 CD
( O
HIV-1 NN
) O
can MD
establish VB
a DT
persistent JJ
and CC
latent JJ
infection NN
in IN
CD4+ JJ
T NN
lymphocytes NNS
( O
W.C.Greene NNP
, O
N.Engl.J. NNP
Med.324 NNP
: O
308-317 CD
, O
1991 CD
; O
S.M.Schnittman NNP
, O
M.C.Psallidopoulos NNP
, O
H.C. NNP
Lane NNP
, O
L.Thompson NNP
, O
M.Baseler NNP
, O
F.Massari NNP
, O
C.H.Fox NNP
, O
N.P.Salzman NNP
, O
and CC
A.S.Fauci NNP
, O
Science NNP
245 CD
: O
305-308 CD
, O
1989 CD
) O
. O

Production NN
of IN
HIV-1 NN
from IN
latently RB
infected JJ
cells NNS
requires VBZ
host NN
cell NN
activation NN
by IN
T-cell NN
mitogens NNS
( O
T.Folks NNP
, O
D.M.Powell NNP
, O
M.M.Lightfoote NNP
, O
S.Benn NNP
, O
M.A. NNP
Martin NNP
, O
and CC
A.S.Fauci NNP
, O
Science NNP
231 CD
: O
600-602 CD
, O
1986 CD
; O
D.Zagury NNP
, O
J. NNP
Bernard NNP
, O
R.Leonard NNP
, O
R.Cheynier NNP
, O
M.Feldman NNP
, O
P.S.Sarin NNP
, O
and CC
R.C. NNP
Gallo NNP
, O
Science NNP
231 CD
: O
850-853 CD
, O
1986 CD
) O
. O

This DT
activation NN
is VBZ
mediated VBN
by IN
the DT
host NN
transcription NN
factor NN
NF-kappa NN
B NN
( O
G.Nabel NNP
and CC
D.Baltimore NNP
, O
Nature NNP
( O
London NNP
) O
326 CD
: O
711-717 CD
, O
1987 CD
) O
. O

We PRP
report VBP
here RB
that IN
the DT
HIV-1-encoded JJ
Nef NN
protein NN
inhibits VBZ
the DT
induction NN
of IN
NF-kappa NN
B NN
DNA-binding JJ
activity NN
by IN
T-cell NN
mitogens NNS
. O

However RB
, O
Nef NN
does VBZ
not RB
affect VB
the DT
DNA-binding JJ
activity NN
of IN
other JJ
transcription NN
factors NNS
implicated VBN
in IN
HIV-1 NN
regulation NN
, O
including VBG
SP-1 NN
, O
USF NN
, O
URS NN
, O
and CC
NF-AT NN
. O

Additionally RB
, O
Nef NN
inhibits VBZ
the DT
induction NN
of IN
HIV-1- NN
and CC
interleukin NN
2-directed JJ
gene NN
expression NN
, O
and CC
the DT
effect NN
on IN
HIV-1 NN
transcription NN
depends VBZ
on IN
an DT
intact JJ
NF-kappa NN
B-binding JJ
site NN
. O

These DT
results NNS
indicate VBP
that IN
defective JJ
recruitment NN
of IN
NF-kappa NN
B NN
may MD
underlie VB
Nef NN
's POS
negative JJ
transcriptional JJ
effects NNS
on IN
the DT
HIV-1 NN
and CC
interleukin NN
2 CD
promoters NNS
. O

Further JJ
evidence NN
suggests VBZ
that IN
Nef NN
inhibits VBZ
NF-kappa NN
B NN
induction NN
by IN
interfering VBG
with IN
a DT
signal NN
derived VBN
from IN
the DT
T-cell NN
receptor NN
complex NN
. O

( O
Effect NN
of IN
antihypertensive JJ
therapy NN
with IN
captopril NN
on IN
gluco- JJ
and CC
mineralocorticoid NN
receptors NNS
of IN
peripheral JJ
blood NN
lymphocytes NNS
in IN
hypertensive JJ
patients NNS
of IN
various JJ
age NN
) O

Binding NN
of IN
3H-dexamethasone NN
and CC
3H-aldosterone NN
by IN
peripheral JJ
lymphocyte NN
receptors NNS
was VBD
investigated VBN
in IN
healthy JJ
persons NNS
and CC
hypertensive JJ
patients NNS
before IN
and CC
after IN
2-week JJ
captopril NN
treatment NN
. O

The DT
number NN
of IN
glucocorticoid NN
and CC
mineralocorticoid NN
binding NN
sites NNS
was VBD
increased VBN
in IN
hypertensives NNS
vs CC
normotensives NNS
. O

The DT
treatment NN
with IN
the DT
ACE NN
inhibitor NN
captopril NN
led VBD
to TO
activation NN
of IN
hormone-receptor NN
interactions NNS
. O

There EX
was VBD
a DT
more RBR
marked JJ
rise NN
of IN
the DT
number NN
of IN
receptors NNS
in IN
middle-aged JJ
( O
44-55 CD
years NNS
) O
hypertensives NNS
vs CC
elderly JJ
( O
61-80 CD
years NNS
) O
subjects NNS
after IN
captopril NN
treatment NN
. O

Leukotriene NN
B4 NN
transcriptionally RB
activates VBZ
interleukin-6 NN
expression NN
involving VBG
NK-chi NN
B NN
and CC
NF-IL6 NN
. O

Leukotriene NN
B4 NN
( O
LTB4 NN
) O
is VBZ
a DT
notable JJ
participant NN
in IN
inflammation NN
and CC
chemotaxis NN
. O

It PRP
is VBZ
, O
however RB
, O
still RB
unclear JJ
whether IN
LTB4 NN
acts VBZ
in IN
this DT
regard NN
directly RB
or CC
indirectly RB
by IN
stimulating VBG
the DT
release NN
of IN
chemotactic JJ
and CC
inflammatory JJ
cytokines NNS
. O

Here RB
we PRP
report VBP
that IN
LTB4 NN
induces VBZ
synthesis NN
of IN
interleukin NN
( O
IL NN
) O
-6 CD
by IN
human JJ
blood NN
monocytes NNS
through IN
transcriptional JJ
activation NN
of IN
the DT
IL-6 NN
gene NN
. O

We PRP
furthermore RB
demonstrate VBP
that IN
this DT
process NN
involves VBZ
activation NN
of IN
the DT
transcription NN
factor NN
NF-chi NN
B NN
and CC
, O
to TO
a DT
lesser JJR
extent NN
, O
of IN
NF-IL6 NN
, O
while IN
the DT
activity NN
of IN
the DT
transcription NN
factor NN
AP-1 NN
, O
shown VBN
to TO
otherwise RB
confer VB
IL-6 NN
inducibility NN
, O
appeared VBD
to TO
be VB
unaffected JJ
by IN
LTB4 NN
. O

Involvement NN
of IN
NF-chi NN
B NN
and CC
NF-IL6 NN
in IN
induction NN
of IN
IL-6 NN
transcription NN
by IN
monocytes NNS
was VBD
demonstrated VBN
using VBG
deleted JJ
forms NNS
of IN
the DT
IL-6 NN
promoter NN
. O

Activation NN
of IN
the DT
IL-6 NN
promoter NN
by IN
LTB4 NN
was VBD
not RB
only RB
associated VBN
with IN
accumulation NN
of IN
the DT
respective JJ
transcripts NNS
but CC
resulted VBD
in IN
synthesis NN
of IN
functional JJ
IL-6 NN
protein NN
as RB
well RB
. O

In IN
addition NN
, O
LTB4 NN
mediated VBD
transactivation NN
of IN
a DT
heterologous JJ
promoter NN
construct NN
containing VBG
the DT
NF-chi NN
B NN
or CC
the DT
NF-IL6 NN
enhancer NN
, O
but CC
not RB
the DT
AP-1 NN
enhancer NN
. O

The DT
signaling NN
events NNS
mediating VBG
this DT
effect NN
appeared VBD
to TO
involve VB
the DT
release NN
of IN
H2O2 NN
, O
since IN
LTB4 NN
failed VBD
to TO
induce VB
NF-chi NN
B NN
or CC
NF-IL6 NN
in IN
the DT
presence NN
of IN
the DT
scavenger NN
of IN
H2O2 NN
, O
N-acetyl-L-cysteine NN
. O

Estrogen NN
binding NN
sites NNS
in IN
peripheral JJ
blood NN
monocytes NNS
and CC
effects NNS
of IN
danazol NN
on IN
their PRP$
sites NNS
in FW
vitro FW
. O

1 LS
. O
This DT
study NN
was VBD
designed VBN
to TO
investigate VB
the DT
presence NN
of IN
estrogen NN
type NN
I CD
( O
high JJ
affinity NN
, O
low JJ
capacity NN
) O
and CC
type NN
II CD
( O
low JJ
affinity NN
, O
high JJ
capacity NN
) O
binding NN
sites NNS
in IN
human JJ
peripheral JJ
blood NN
monocytes NNS
and CC
the DT
effects NNS
of IN
danazol NN
on IN
these DT
sites NNS
. O

2 LS
. O
These DT
two CD
types NNS
of IN
estrogen NN
binding NN
sites NNS
existed VBD
in IN
human JJ
peripheral JJ
blood NN
monocytes NNS
. O

3 LS
. O
Danazol NN
bound VBD
to TO
these DT
sites NNS
in IN
high JJ
concentration NN
( O
10(-6) CD
M NN
, O
clinical JJ
serum NN
concentration NN
during IN
danazol NN
therapy NN
) O
and CC
decreased VBD
the DT
number NN
of IN
both DT
sites NNS
. O

4 LS
. O
It PRP
is VBZ
suggested VBN
that IN
danazol NN
has VBZ
an DT
anti-estrogenic JJ
action NN
to TO
the DT
monocytes NNS
through IN
the DT
competition NN
and CC
suppression NN
of IN
estrogen NN
binding NN
sites NNS
as IN
seen VBN
in IN
the DT
estrogen NN
target NN
organ NN
. O

( O
Mechanism NN
of IN
action NN
of IN
steroid NN
hormones NNS
. O
I LS
. O
Estrogens NNS
) O

The DT
steroid NN
hormone NN
are VBP
very RB
versatile JJ
molecules NNS
: O
although IN
they PRP
are VBP
related JJ
among IN
them PRP
by IN
their PRP$
chemical JJ
structure NN
, O
they PRP
have VBP
very RB
diverse JJ
functions NNS
and CC
including VBG
antagonic JJ
. O

Their PRP$
action NN
mechanism NN
is VBZ
not RB
completely RB
cleared VBN
. O

The DT
estrogens NNS
participate VBP
in IN
the DT
regulation NN
of IN
practically RB
all PDT
the DT
reproductive JJ
and CC
sexual JJ
events NNS
of IN
the DT
female NN
, O
although IN
the DT
intracellular JJ
actions NNS
by IN
which WDT
they PRP
take VBP
place NN
are VBP
not RB
well RB
known VBN
and CC
the DT
proposed JJ
models NNS
do VBP
not RB
adequately RB
satisfy VB
the DT
questions NNS
. O

Currently RB
it PRP
is VBZ
accepted VBN
the DT
existence NN
of IN
a DT
cytoplasmic JJ
and/or CC
nuclear JJ
receptor NN
, O
without IN
explaining VBG
satisfactorily RB
how WRB
the DT
hormones NNS
come VBN
to TO
the DT
nucleus NN
. O

The DT
endocrine JJ
events NNS
that WDT
are VBP
rapidly RB
expressed VBN
( O
seconds NNS
) O
are VBP
due JJ
to TO
a DT
possible JJ
interaction NN
with IN
cellular JJ
membrane NN
. O

The DT
purpose NN
of IN
this DT
review NN
is VBZ
to TO
analyze VB
and CC
concilliate VB
the DT
reported VBN
data NNS
on IN
the DT
mechanism NN
of IN
action NN
of IN
estrogens NNS
. O

Stable JJ
expression NN
of IN
transdominant JJ
Rev NN
protein NN
in IN
human JJ
T NN
cells NNS
inhibits VBZ
human JJ
immunodeficiency NN
virus NN
replication NN
. O

The DT
human JJ
immunodeficiency NN
virus NN
( O
HIV NN
) O
Rev NN
protein NN
is VBZ
essential JJ
for IN
viral JJ
structural JJ
protein NN
expression NN
( O
Gag NN
, O
Pol NN
, O
and CC
Env NN
) O
and CC
, O
hence RB
, O
for IN
viral JJ
replication NN
. O

In IN
transient JJ
transfection NN
assays NNS
, O
mutant JJ
forms NNS
of IN
Rev NN
have VBP
been VBN
identified VBN
that WDT
inhibit VBP
wild-type JJ
Rev NN
activity NN
and CC
therefore RB
suppress VBP
viral JJ
replication NN
. O

To TO
determine VB
whether IN
such JJ
transdominant JJ
Rev NN
proteins NNS
could MD
provide VB
long-term JJ
protection NN
against IN
HIV NN
infection NN
without IN
affecting VBG
T NN
cell NN
function NN
, O
T NN
leukemia NN
cell NN
lines NNS
were VBD
stably RB
transduced VBN
with IN
a DT
retroviral JJ
vector NN
encoding VBG
a DT
transdominant JJ
mutant NN
of IN
the DT
Rev NN
protein NN
, O
M10 NN
. O

While IN
all PDT
the DT
M10-expressing JJ
cell NN
lines NNS
remained VBD
infectable JJ
by IN
HIV-1 NN
, O
these DT
same JJ
cells NNS
failed VBD
to TO
support VB
a DT
productive JJ
replication NN
cycle NN
when WRB
infected VBN
with IN
a DT
cloned VBN
isolate NN
of IN
HIV-1 NN
. O

In IN
addition NN
, O
two CD
out IN
of IN
three CD
M10-expressing JJ
CEM NN
clones NNS
were VBD
also RB
resistant JJ
to TO
highly RB
productive JJ
infection NN
by IN
a DT
heterogeneous JJ
HIV-1 NN
pool NN
. O

Expression NN
of IN
M10 NN
did VBD
not RB
affect VB
induction NN
of IN
HIV NN
transcription NN
mediated VBN
by IN
the DT
kappa NN
B NN
regulatory JJ
element NN
or CC
Tat NN
. O

Importantly RB
, O
constitutive JJ
expression NN
of IN
Rev NN
M10 NN
did VBD
not RB
alter VB
the DT
secretion NN
of IN
interleukin NN
2 CD
in IN
response NN
to TO
mitogen NN
stimulation NN
of IN
EL-4 NN
and CC
Jurkat NN
cells NNS
. O

The DT
inhibition NN
of IN
HIV NN
infection NN
in IN
cells NNS
stably RB
expressing VBG
a DT
transdominant JJ
Rev NN
protein NN
, O
in IN
the DT
absence NN
of IN
any DT
deleterious JJ
effect NN
on IN
T NN
cell NN
function NN
, O
suggests VBZ
that IN
such PDT
a DT
strategy NN
could MD
provide VB
a DT
therapeutic JJ
effect NN
in IN
the DT
T NN
lymphocytes NNS
of IN
acquired VBN
immunodeficiency NN
syndrome NN
patients NNS
. O

Glucocorticoid NN
receptor NN
in IN
patients NNS
with IN
lupus NN
nephritis NN
: O
relationship NN
between IN
receptor NN
levels NNS
in IN
mononuclear JJ
leukocytes NNS
and CC
effect NN
of IN
glucocorticoid NN
therapy NN
. O

We PRP
investigated VBD
the DT
clinical JJ
significance NN
of IN
glucocorticoid NN
receptor NN
determination NN
in IN
20 CD
patients NNS
with IN
systemic JJ
lupus NN
erythematosus NN
( O
SLE NN
) O
who WP
afterwards RB
developed VBD
nephrotic JJ
syndrome NN
. O

Glucocorticoid NN
receptor NN
concentrations NNS
in IN
mononuclear JJ
leukocytes NNS
( O
MNL NNS
) O
in IN
these DT
patients NNS
were VBD
comparable JJ
with IN
those DT
in IN
both CC
other JJ
patients NNS
with IN
SLE NN
and CC
healthy JJ
persons NNS
. O

Improvement NN
in IN
urinary JJ
protein NN
excretion NN
and CC
in IN
disease NN
activity NN
, O
which WDT
was VBD
scored VBN
according VBG
to TO
the DT
SLE NNP
Disease NNP
Activity NNP
Index NNP
system NN
of IN
the DT
University NNP
of IN
Toronto NNP
, O
closely RB
related JJ
to TO
the DT
glucocorticoid NN
receptor NN
concentrations NNS
in IN
MNL NN
isolated VBN
from IN
the DT
corresponding JJ
patients NNS
. O

In IN
summary NN
, O
glucocorticoid NN
receptor NN
determination NN
in IN
patients NNS
with IN
lupus NN
nephritis NN
may MD
be VB
a DT
predictive JJ
clue NN
for IN
assessing VBG
responsiveness NN
to TO
glucocorticoid NN
therapy NN
. O

Selection NN
of IN
optimal JJ
kappa NN
B/Rel NN
DNA-binding JJ
motifs NNS
: O
interaction NN
of IN
both DT
subunits NNS
of IN
NF-kappa NN
B NN
with IN
DNA NN
is VBZ
required VBN
for IN
transcriptional JJ
activation NN
. O

Analysis NN
of IN
the DT
p50 NN
and CC
p65 NN
subunits NNS
of IN
the DT
NF-kappa NN
B NN
transcription NN
factor NN
complex NN
has VBZ
revealed VBN
that IN
both DT
proteins NNS
can MD
interact VB
with IN
related JJ
DNA NN
sequences NNS
through IN
either CC
homo- JJ
or CC
heterodimer NN
formation NN
. O

In IN
addition NN
, O
the DT
product NN
of IN
the DT
proto-oncogene NN
c-rel NN
can MD
bind VB
to TO
similar JJ
DNA NN
motifs NNS
by IN
itself PRP
or CC
as IN
a DT
heterodimer NN
with IN
p50 NN
or CC
p65 NN
. O

However RB
, O
these DT
studies NNS
have VBP
used VBN
a DT
limited JJ
number NN
of IN
known JJ
kappa NN
B NN
DNA NN
motifs NNS
, O
and CC
the DT
question NN
of IN
the DT
optimal JJ
DNA NN
sequences NNS
preferred VBN
by IN
each DT
homodimer NN
has VBZ
not RB
been VBN
addressed VBN
. O

Using VBG
purified VBN
recombinant JJ
p50 NN
, O
p65 NN
, O
and CC
c-Rel NN
proteins NNS
, O
optimal JJ
DNA-binding JJ
motifs NNS
were VBD
selected VBN
from IN
a DT
pool NN
of IN
random JJ
oligonucleotides NNS
. O

Alignment NN
of IN
the DT
selected VBN
sequences NNS
allowed VBD
us PRP
to TO
predict VB
a DT
consensus NN
sequence NN
for IN
binding NN
of IN
the DT
individual JJ
homodimeric JJ
Rel-related JJ
proteins NNS
, O
and CC
DNA-protein NN
binding NN
analysis NN
of IN
the DT
selected VBN
DNA NN
sequences VBZ
revealed VBD
sequence NN
specificity NN
of IN
the DT
proteins NNS
. O

Contrary JJ
to TO
previous JJ
assumptions NNS
, O
we PRP
observed VBD
that IN
p65 NN
homodimers NNS
can MD
interact VB
with IN
a DT
subset NN
of IN
DNA NN
sequences VBZ
not RB
recognized VBN
by IN
p50 NN
homodimers NNS
. O

Differential JJ
binding NN
affinities NNS
were VBD
also RB
obtained VBN
with IN
p50- NN
and CC
c-Rel-selected JJ
sequences NNS
. O

Using VBG
either CC
a DT
p50- NN
or CC
p65-selected JJ
kappa NN
B NN
motif NN
, O
which WDT
displayed VBD
differential JJ
binding NN
with IN
respect NN
to TO
the DT
other JJ
protein NN
, O
little JJ
to TO
no DT
binding NN
was VBD
observed VBN
with IN
the DT
heterodimeric JJ
NF-kappa NN
B NN
complex NN
. O

Similarly RB
, O
in IN
transfection NN
experiments NNS
in IN
which WDT
the DT
selective JJ
kappa NN
B NN
binding NN
sites NNS
were VBD
used VBN
to TO
drive VB
the DT
expression NN
of IN
a DT
chloramphenicol NN
acetyltransferase NN
reporter NN
construct NN
, O
the DT
p65- NN
and CC
p50-selected JJ
motifs NNS
were VBD
activated VBN
only RB
in IN
the DT
presence NN
of IN
p65 NN
and CC
p50/65 NN
( O
a DT
chimeric JJ
protein NN
with IN
the DT
p50 NN
DNA NN
binding NN
domain NN
and CC
p65 NN
activation NN
domain NN
) O
expression NN
vectors NNS
, O
respectively RB
, O
and CC
neither DT
demonstrated VBD
a DT
significant JJ
response NN
to TO
stimuli NNS
that WDT
induce VBP
NF-kappa NN
B NN
activity NN
. O

These DT
findings NNS
demonstrate VBP
that IN
interaction NN
of IN
both DT
subunits NNS
of IN
the DT
heterodimeric JJ
NF-kappa NN
B NN
complex NN
with IN
DNA NN
is VBZ
required VBN
for IN
DNA NN
binding NN
and CC
transcriptional JJ
activation NN
and CC
suggest VBP
that IN
transcriptional JJ
activation NN
mediated VBN
by IN
the DT
individual JJ
rel-related JJ
proteins NNS
will MD
differ VB
dramatically RB
, O
depending VBG
on IN
the DT
specific JJ
kappa NN
B NN
motifs NNS
present JJ
. O

Characterization NN
of IN
a DT
new JJ
tissue-specific JJ
transcription NN
factor NN
binding VBG
to TO
the DT
simian JJ
virus NN
40 CD
enhancer NN
TC-II NN
( O
NF-kappa NN
B NN
) O
element NN
. O

We PRP
have VBP
biochemically RB
and CC
functionally RB
characterized VBN
a DT
new JJ
transcription NN
factor NN
, O
NP-TCII NN
, O
which WDT
is VBZ
present JJ
in IN
nuclei NNS
from IN
unstimulated JJ
T NN
and CC
B NN
lymphocytes NNS
but CC
is VBZ
not RB
found VBN
in IN
nonhematopoietic JJ
cells NNS
. O

This DT
factor NN
has VBZ
a DT
DNA-binding JJ
specificity NN
similar JJ
to TO
that DT
of IN
NF-kappa NN
B NN
but CC
is VBZ
unrelated JJ
to TO
this DT
or CC
other JJ
Rel NN
proteins NNS
by IN
functional JJ
and CC
biochemical JJ
criteria NNS
. O

It PRP
can MD
also RB
be VB
distinguished VBN
from IN
other JJ
previously RB
described VBN
lymphocyte-specific JJ
DNA-binding JJ
proteins NNS
. O

The DT
candidate NN
oncoprotein NN
Bcl-3 NN
is VBZ
an DT
antagonist NN
of IN
p50/NF-kappa NN
B-mediated JJ
inhibition NN
. O

The DT
candidate NN
oncogene NN
bcl-3 NN
was VBD
discovered VBN
as IN
a DT
translocation NN
into IN
the DT
immunoglobulin NN
alpha-locus NN
in IN
some DT
cases NNS
of IN
B-cell NN
chronic JJ
lymphocytic JJ
leukaemias NNS
. O

The DT
protein NN
Bcl-3 NN
contains VBZ
seven CD
so-called JJ
ankyrin NN
repeats NNS
. O

Similar JJ
repeat NN
motifs NNS
are VBP
found VBN
in IN
a DT
number NN
of IN
diverse JJ
regulatory JJ
proteins NNS
but CC
the DT
motifs NNS
of IN
Bcl-3 NN
are VBP
most RBS
closely RB
related JJ
to TO
those DT
found VBN
in IN
I NN
kappa NN
B NN
proteins NNS
in IN
which WDT
the DT
ankyrin NN
repeat NN
domain NN
is VBZ
thought VBN
to TO
be VB
directly RB
involved VBN
in IN
inhibition NN
of IN
NF-kappa NN
B NN
activity NN
. O

No DT
biological JJ
function NN
has VBZ
yet RB
been VBN
described VBN
for IN
Bcl-3 NN
, O
but CC
it PRP
was VBD
noted VBN
recently RB
that IN
Bcl-3 NN
interferes VBZ
with IN
DNA-binding NN
of IN
the DT
p50 NN
subunit NN
of IN
NF-kappa NN
B NN
in FW
vitro FW
. O

Here RB
we PRP
demonstrate VBP
that IN
Bcl-3 NN
can MD
aid VB
kappa NN
B NN
site-dependent JJ
transcription NN
in FW
vivo FW
by IN
counteracting VBG
the DT
inhibitory JJ
effects NNS
of IN
p50/NF-kappa NN
B NN
homodimers NNS
. O

Bcl-3 NN
may MD
therefore RB
aid VB
activation NN
of IN
select JJ
NF-kappa NN
B-regulated JJ
genes NNS
, O
including VBG
those DT
of IN
the DT
human JJ
immunodeficiency NN
virus NN
. O

A DT
microtitre NN
assay NN
system NN
for IN
glucocorticoid NN
receptors NNS
: O
decreased VBN
receptor NN
concentration NN
in IN
myocardial JJ
infarction NN
. O

A DT
major JJ
difficulty NN
in IN
determination NN
of IN
glucocorticoid NN
receptor NN
sites NNS
is VBZ
the DT
very RB
complicated JJ
assay NN
procedure NN
. O

Therefore RB
, O
we PRP
describe VBP
a DT
microtitre NN
assay NN
system NN
for IN
glucocorticoid NN
receptors NNS
which WDT
is VBZ
a DT
whole-cell JJ
competitive JJ
binding NN
radioassay NN
using VBG
(3H)-dexamethasone NN
as IN
radioligand NN
. O

This DT
modification NN
of IN
a DT
previously RB
described VBN
protocol NN
simplifies VBZ
and CC
reduces VBZ
laboratory NN
work NN
and CC
allows VBZ
assay NN
reproducibility NN
to TO
be VB
controlled VBN
more RBR
reliably RB
. O

Thus RB
enabled VBN
to TO
perform VB
the DT
test NN
on IN
multiple JJ
blood NN
samples NNS
in IN
parallel NN
, O
we PRP
investigated VBD
cardiac JJ
infarction NN
patients NNS
over IN
a DT
12-day JJ
period NN
to TO
test VB
if IN
glucocorticoid NN
receptor NN
binding NN
is VBZ
altered VBN
in IN
this DT
' [[DQS]]
stressful JJ
' [[DQE]]
disease NN
. O

On IN
the DT
first JJ
day NN
of IN
the DT
disease NN
, O
glucocorticoid NN
receptor NN
capacity NN
was VBD
significantly RB
decreased VBN
without IN
alteration NN
of IN
the DT
receptor-ligand JJ
affinity NN
, O
whereas IN
on IN
days NNS
4 CD
and CC
12 CD
the DT
number NN
of IN
receptor NN
sites NNS
was VBD
normal JJ
again RB
. O

This DT
result NN
fits VBZ
well RB
into IN
the DT
general JJ
observation NN
of IN
stress-induced JJ
down-regulation NN
of IN
immune JJ
responses NNS
. O

Regulation NN
of IN
c-jun NN
expression NN
during IN
induction NN
of IN
monocytic JJ
differentiation NN
by IN
okadaic JJ
acid NN
. O

The DT
present JJ
work NN
has VBZ
examined VBN
the DT
effects NNS
of IN
okadaic JJ
acid NN
, O
an DT
inhibitor NN
of IN
type NN
1 CD
and CC
2A NN
protein NN
phosphatases NNS
, O
on IN
the DT
regulation NN
of IN
c-jun NN
expression NN
during IN
monocytic JJ
differentiation NN
of IN
U-937 NN
leukemia NN
cells NNS
. O

The DT
results NNS
demonstrate VBP
that IN
okadaic JJ
acid NN
treatment NN
is VBZ
associated VBN
with IN
induction NN
of IN
a DT
differentiated VBN
monocyte NN
phenotype NN
characterized VBN
by IN
: O
( O
a LS
) O
growth NN
arrest NN
; O
( O
b LS
) O
increases NNS
in IN
Mac-1 NN
cell NN
surface NN
antigen NN
expression NN
; O
( O
c LS
) O
down-regulation NN
of IN
c-myc NN
transcripts NNS
; O
and CC
( O
d LS
) O
induction NN
of IN
tumor NN
necrosis NN
factor NN
gene NN
expression NN
. O

This DT
induction NN
of IN
monocytic JJ
differentiation NN
was VBD
associated VBN
with IN
transient JJ
increases NNS
in IN
c-jun NN
mRNA NN
levels NNS
, O
which WDT
were VBD
maximal JJ
at IN
6 CD
h NN
. O

Similar JJ
effects NNS
were VBD
obtained VBN
for IN
the DT
c-fos NN
gene NN
. O

Run-on JJ
analysis NN
demonstrated VBD
detectable JJ
levels NNS
of IN
c-jun NN
transcription NN
in IN
U-937 NN
cells NNS
and CC
that IN
this DT
rate NN
is VBZ
increased VBN
approximately RB
40-fold RB
following VBG
okadaic JJ
acid NN
exposure NN
. O

c-jun NN
mRNA NN
levels NNS
were VBD
superinduced VBN
in IN
cells NNS
treated VBN
with IN
both CC
okadaic JJ
acid NN
and CC
cycloheximide NN
, O
whereas IN
inhibition NN
of IN
protein NN
synthesis NN
had VBD
little JJ
, O
if IN
any DT
, O
effect NN
on IN
okadaic JJ
acid-induced JJ
c-jun NN
transcription NN
. O

The DT
half-life NN
of IN
c-jun NN
mRNA NN
was VBD
similar JJ
( O
45-50 CD
min NN
) O
in IN
both CC
untreated JJ
and CC
okadaic JJ
acid-induced JJ
cells NNS
. O

In IN
contrast NN
, O
treatment NN
with IN
both DT
okadaic JJ
acid NN
and CC
cycloheximide NN
was VBD
associated VBN
with IN
stabilization NN
( O
t NN
1/2 CD
= JJ
90 CD
min NN
) O
of IN
c-jun NN
transcripts NNS
. O

Taken VBN
together RB
, O
these DT
findings NNS
indicate VBP
that IN
the DT
induction NN
of IN
c-jun NN
transcription NN
by IN
okadaic JJ
acid NN
is VBZ
controlled VBN
primarily RB
by IN
a DT
transcriptional JJ
mechanism NN
. O

Since IN
previous JJ
studies NNS
have VBP
demonstrated VBN
that IN
the DT
c-jun NN
gene NN
is VBZ
autoinduced VBN
by IN
Jun/AP-1 NN
, O
we PRP
also RB
studied VBD
transcription NN
of IN
c-jun NN
promoter NN
( O
positions NNS
-132/+170 CD
) O
-reporter JJ
gene NN
constructs NNS
with IN
and CC
without IN
a DT
mutated VBN
AP-1 NN
element NN
. O

( O
ABSTRACT NN
TRUNCATED VBN
AT IN
250 CD
WORDS NNS
) O

Activation NN
of IN
NF-kappa NN
B NN
by IN
interleukin NN
2 CD
in IN
human JJ
blood NN
monocytes NNS
. O

We PRP
report VBP
here RB
that IN
interleukin NN
2 CD
( O
IL-2 NN
) O
acts VBZ
on IN
human JJ
blood NN
monocytes NNS
by IN
enhancing VBG
binding NN
activity NN
of IN
the DT
transcription NN
factor NN
NF-kappa NN
B NN
to TO
its PRP$
consensus NN
sequence NN
in IN
the DT
5' JJ
regulatory JJ
enhancer NN
region NN
of IN
the DT
IL-2 NN
receptor NN
alpha NN
chain NN
( O
p55 NN
) O
. O

Similarly RB
, O
IL-2 NN
activates VBZ
NF-kappa NN
B NN
in IN
the DT
human JJ
monocytic JJ
cell NN
line NN
U NN
937 CD
, O
but CC
not RB
in IN
resting VBG
human JJ
T-cells NNS
. O

This DT
effect NN
is VBZ
detectable JJ
within IN
15 CD
min NN
and CC
peaks VBZ
1 CD
h NN
after IN
exposure NN
to TO
IL-2 NN
. O

Enhanced VBN
NF-kappa NN
B NN
binding NN
activity NN
is VBZ
followed VBN
by IN
functional JJ
activation NN
in IN
that IN
inducibility NN
of IN
the DT
IL-2 NN
receptor NN
alpha NN
chain NN
is VBZ
mediated VBN
by IN
enhanced VBN
NF-kappa NN
B NN
binding NN
and CC
that IN
a DT
heterologous JJ
promoter NN
containing VBG
the DT
NF-kappa NN
B NN
consensus NN
sequence NN
( O
-291 CD
to TO
-245 CD
) O
of IN
the DT
IL-2 NN
receptor NN
alpha NN
chain NN
gene NN
is VBZ
activated VBN
. O

In IN
addition NN
, O
IL-2 NN
is VBZ
capable JJ
of IN
increasing VBG
transcript NN
levels NNS
of IN
the DT
p50 NN
gene NN
coding VBG
for IN
the DT
p50 NN
subunit NN
of IN
the DT
NF-kappa NN
B NN
transcription NN
factor NN
, O
whereas IN
mRNA NN
levels NNS
of IN
the DT
p65 NN
NF-kappa NN
B NN
gene NN
remained VBD
unchanged JJ
. O

Single JJ
point NN
estimation NN
of IN
glucocorticoid NN
receptors NNS
in IN
lymphocytes NNS
of IN
normal JJ
subjects NNS
and CC
of IN
children NNS
under IN
long JJ
term NN
glucocorticoid NN
treatment NN
. O

A DT
single JJ
point NN
assay NN
of IN
glucocorticoid NN
receptors NNS
( O
GR NN
) O
in IN
human JJ
lymphocytes NNS
based VBN
on IN
the DT
measurement NN
of IN
specific JJ
dexamethasone NN
binding NN
has VBZ
been VBN
developed VBN
and CC
compared VBN
with IN
a DT
common JJ
multi-point JJ
Scatchard NN
analysis NN
. O

The DT
assay NN
conditions NN
- O
concentration NN
of IN
the DT
ligand NN
20 CD
nmol/l NN
, O
incubation NN
time NN
2 CD
h NN
and CC
the DT
cell NN
count NN
2-6 CD
mil. CD
cells/tube NNS
in IN
the DT
assay NN
volume NN
0.25 CD
ml NN
were VBD
found VBN
to TO
be VB
optimal JJ
. O

An DT
attempt NN
was VBD
also RB
undertaken VBN
to TO
use VB
a DT
cell NN
harvester NN
for IN
the DT
separation NN
of IN
cells NNS
from IN
unbound JJ
ligand NN
. O

Though IN
specifically RB
bound VBN
dexamethasone NN
measured VBN
by IN
whole-cell JJ
assay NN
and CC
that DT
using VBG
cell NN
harvester NN
correlated VBD
well RB
, O
almost RB
by IN
one CD
order NN
lower JJR
values NNS
obtained VBN
with IN
the DT
latter JJ
method NN
render VBP
it PRP
non-applicable JJ
for IN
receptor NN
quantitation NN
. O

The DT
results NNS
from IN
9 CD
healthy JJ
volunteers NNS
( O
average JJ
GR NN
concentration NN
7131 CD
+/- CC
1256 CD
sites/cell NNS
) O
correlated VBD
excellently RB
with IN
those DT
obtained VBN
by IN
the DT
Scatchard NN
analysis NN
. O

The DT
single JJ
point NN
assay NN
has VBZ
been VBN
also RB
applied VBN
for IN
determination NN
of IN
GH NN
in IN
10 CD
children NNS
treated VBN
with IN
large JJ
doses NNS
of IN
prednisone NN
. O

The DT
average JJ
values NNS
from IN
healthy JJ
volunteers NNS
did VBD
not RB
differ VB
significantly RB
from IN
those DT
found VBN
in IN
these DT
children NNS
, O
though RB
much RB
broader JJR
range NN
was VBD
found VBN
in IN
patients NNS
. O

A DT
novel JJ
B NN
cell-derived JJ
coactivator NN
potentiates VBZ
the DT
activation NN
of IN
immunoglobulin NN
promoters NNS
by IN
octamer-binding JJ
transcription NN
factors NNS
. O

A DT
novel JJ
B NN
cell-restricted JJ
activity NN
, O
required VBN
for IN
high JJ
levels NNS
of IN
octamer/Oct-dependent JJ
transcription NN
from IN
an DT
immunoglobulin NN
heavy JJ
chain NN
( O
IgH NN
) O
promoter NN
, O
was VBD
detected VBN
in IN
an DT
in FW
vitro FW
system NN
consisting VBG
of IN
HeLa NN
cell-derived JJ
extracts NNS
complemented VBN
with IN
fractionated VBN
B NN
cell NN
nuclear JJ
proteins NNS
. O

The DT
factor NN
responsible JJ
for IN
this DT
activity NN
was VBD
designated VBN
Oct NN
coactivator NN
from IN
B NN
cells NNS
( O
OCA-B NN
) O
. O

OCA-B NN
stimulates VBZ
the DT
transcription NN
from IN
an DT
IgH NN
promoter NN
in IN
conjunction NN
with IN
either CC
Oct-1 NN
or CC
Oct-2 NN
but CC
shows VBZ
no DT
significant JJ
effect NN
on IN
the DT
octamer/Oct-dependent JJ
transcription NN
of IN
the DT
ubiquitously RB
expressed VBN
histone NN
H2B NN
promoter NN
and CC
the DT
transcription NN
of IN
USF- NN
and CC
Sp1-regulated JJ
promoters NNS
. O

Taken VBN
together RB
, O
our PRP$
results NNS
suggest VBP
that IN
OCA-B NN
is VBZ
a DT
tissue- NN
, O
promoter- NN
, O
and CC
factor-specific JJ
coactivator NN
and CC
that IN
OCA-B NN
may MD
be VB
a DT
major JJ
determinant NN
for IN
B NN
cell-specific JJ
activation NN
of IN
immunoglobulin NN
promoters NNS
. O

In IN
light NN
of IN
the DT
evidence NN
showing VBG
physical JJ
and CC
functional JJ
interactions NNS
between IN
Oct NN
factors NNS
and CC
OCA-B NN
, O
we PRP
propose VBP
a DT
mechanism NN
of IN
action NN
for IN
OCA-B NN
and CC
discuss VBP
the DT
implications NNS
of IN
OCA-B NN
for IN
the DT
transcriptional JJ
regulation NN
of IN
other JJ
tissue-specific JJ
promoters NNS
. O

The DT
regulation NN
of IN
the DT
human JJ
tumor NN
necrosis NN
factor NN
alpha NN
promoter NN
region NN
in IN
macrophage NN
, O
T NN
cell NN
, O
and CC
B NN
cell NN
lines NNS
. O

The DT
1311-base JJ
pair NN
human JJ
tumor NN
necrosis NN
factor NN
( O
TNF NN
) O
alpha NN
promoter NN
region NN
was VBD
fused VBN
to TO
the DT
luciferase NN
( O
Luc NN
) O
reporter NN
gene NN
and CC
studied VBN
in IN
a DT
transient JJ
transfection NN
system NN
in IN
three CD
TNF NN
producing NN
cell NN
lines NNS
, O
the DT
U937 NN
macrophage NN
cell NN
line NN
, O
the DT
MLA NN
144 CD
T NN
cell NN
line NN
, O
and CC
the DT
729-6 CD
B NN
cell NN
line NN
. O

This DT
full JJ
length NN
promoter NN
construct NN
can MD
be VB
induced VBN
by IN
phorbol NN
13-myristate NN
acetate NN
( O
PMA NN
) O
in IN
each DT
of IN
these DT
cell NN
types NNS
. O

Analysis NN
of IN
a DT
series NN
of IN
5'-truncations NNS
showed VBD
several JJ
peaks NNS
of IN
basal JJ
and CC
PMA NN
induced JJ
activity NN
suggesting VBG
the DT
presence NN
of IN
several JJ
positive JJ
and CC
negative JJ
regulatory JJ
elements NNS
. O

A DT
PMA NN
responsive JJ
element NN
was VBD
localized JJ
to TO
a DT
region NN
between IN
-95 CD
and CC
-36 CD
bp NN
relative JJ
to TO
the DT
transcription NN
start NN
site NN
. O

Within IN
this DT
region NN
, O
single JJ
AP-2- NN
and CC
AP-1-like JJ
consensus NN
sequences NNS
were VBD
noted VBN
. O

These DT
AP-2 NN
and CC
AP-1 NN
sites NNS
were VBD
each DT
modified VBN
with IN
a DT
double JJ
point NN
mutation NN
. O

A DT
modest JJ
( O
20-50 CD
% NN
) O
reduction NN
in IN
TNF NN
promoter NN
activity NN
was VBD
observed VBN
with IN
the DT
AP-2 NN
site NN
mutation NN
. O

However RB
, O
mutation NN
of IN
the DT
AP-1 NN
site NN
markedly RB
diminished VBD
both CC
the DT
basal JJ
and CC
PMA-activated JJ
promoter NN
activity NN
. O

Also RB
co-transfections NNS
of IN
the DT
wild-type JJ
promoter NN
construct NN
with IN
an DT
AP-1/c-jun NN
expression NN
vector NN
resulted VBD
in IN
augmented JJ
basal JJ
and CC
PMA-induced JJ
promoter NN
activity NN
. O

Redox NN
status NN
of IN
cells NNS
influences VBZ
constitutive JJ
or CC
induced VBN
NF-kappa NN
B NN
translocation NN
and CC
HIV NN
long JJ
terminal JJ
repeat NN
activity NN
in IN
human JJ
T NN
and CC
monocytic JJ
cell NN
lines NNS
. O

We PRP
have VBP
tested VBN
the DT
hypothesis NN
that IN
cellular JJ
activation NN
events NNS
occurring VBG
in IN
T NN
lymphocytes NNS
and CC
monocytes NNS
and CC
mediated VBN
through IN
translocation NN
of IN
the DT
transcription NN
factor NN
NF-kappa NN
B NN
are VBP
dependent JJ
upon IN
the DT
constitutive JJ
redox NN
status NN
of IN
these DT
cells NNS
. O

We PRP
used VBD
phenolic JJ
, O
lipid-soluble JJ
, O
chain-breaking JJ
antioxidants NNS
( O
butylated VBN
hydroxyanisole NN
( O
BHA NN
) O
, O
nordihydroquairetic JJ
acid NN
, O
or CC
alpha-tocopherol NN
( O
vitamin NN
E NN
) O
to TO
show VB
that IN
peroxyl JJ
radical JJ
scavenging NN
in IN
unstimulated JJ
and CC
PMA- NN
or CC
TNF-stimulated JJ
cells NNS
blocks VBZ
the DT
functions NNS
depending VBG
on IN
NF-kappa NN
B NN
activation NN
. O

BHA NN
was VBD
found VBN
to TO
suppress VB
not RB
only RB
PMA- NN
or CC
TNF-induced JJ
, O
but CC
also RB
constitutive JJ
, O
HIV-enhancer JJ
activity NN
concomitant JJ
to TO
an DT
inhibition NN
of IN
NF-kappa NN
B NN
binding NN
activity NN
in IN
both CC
lymphoblastoid JJ
T NN
( O
J.Jhan NN
) O
and CC
monocytic JJ
( O
U937 NN
) O
cell NN
lines NNS
. O

This DT
was VBD
also RB
true JJ
for IN
KBF NN
( O
p50 NN
homodimer NN
) O
binding NN
activity NN
in IN
U937 NN
cells NNS
. O

Secretion NN
of IN
TNF NN
, O
the DT
product NN
of IN
another DT
NF-kappa NN
B-dependent JJ
gene NN
, O
was VBD
abolished VBN
by IN
BHA NN
in IN
PMA-stimulated JJ
U937 NN
cells NNS
. O

The DT
anti-oxidative JJ
effect NN
of IN
BHA NN
was VBD
accompanied VBN
by IN
an DT
increase NN
in IN
thiol NN
, O
but CC
not RB
glutathione NN
, O
content NN
in IN
stimulated VBN
and CC
unstimulated JJ
T NN
cell NN
, O
whereas IN
TNF NN
stimulation NN
itself PRP
barely RB
modified VBD
the DT
cellular JJ
thiol NN
level NN
. O

Oxidative JJ
stress NN
obtained VBN
by IN
the DT
addition NN
of IN
H2O2 NN
to TO
the DT
culture NN
medium NN
of IN
J.Jhan NN
or CC
U937 NN
cells NNS
could MD
not RB
by IN
itself PRP
induce VB
NF-kappa NN
B NN
activation NN
. O

These DT
observations NNS
suggest VBP
that IN
TNF NN
and CC
PMA NN
do VBP
not RB
lead VB
to TO
NF-kappa NN
B NN
activation NN
through IN
induction NN
of IN
changes NNS
in IN
the DT
cell NN
redox NN
status NN
. O

Rather RB
, O
TNF NN
and CC
PMA NN
can MD
exert VB
their PRP$
effect NN
only RB
if IN
cells NNS
are VBP
in IN
an DT
appropriate JJ
redox NN
status NN
, O
because IN
prior JJ
modification NN
toward IN
reduction NN
with IN
BHA NN
treatment NN
prevents VBZ
this DT
activation NN
. O

It PRP
appears VBZ
that IN
a DT
basal JJ
redox NN
equilibrium NN
tending VBG
toward IN
oxidation NN
is VBZ
a DT
prerequisite NN
for IN
full JJ
activation NN
of IN
transduction NN
pathways NNS
regulating VBG
the DT
activity NN
of IN
NF-kappa NN
B-dependent JJ
genes NNS
. O

Expression NN
of IN
c-fos NN
, O
c-jun NN
and CC
jun NN
B NN
in IN
peripheral JJ
blood NN
lymphocytes NNS
from IN
young JJ
and CC
elderly JJ
adults NNS
. O

The DT
expression NN
of IN
c-fos NN
, O
c-jun NN
and CC
jun NN
B NN
proto-oncogenes NNS
was VBD
studied VBN
in IN
phytohemagglutinin NN
( O
PHA NN
) O
activated VBN
peripheral JJ
blood NN
lymphocytes NNS
( O
PBL NN
) O
from IN
young JJ
and CC
aged JJ
humans NNS
. O

Specific JJ
mRNAs NNS
for IN
c-fos NN
and CC
c-jun NN
were VBD
detectable JJ
within IN
30 CD
min NN
after IN
cell NN
activation NN
and CC
reached VBD
maximal JJ
levels NNS
within IN
2 CD
h NN
. O

Both CC
c-fos NN
and CC
jun NN
B NN
mRNAs NNS
decreased VBD
to TO
pre-activation NN
levels NNS
within IN
6 CD
h NN
, O
while IN
c-jun NN
mRNA NN
remained VBD
elevated JJ
. O

In IN
PHA-activated JJ
PBL NN
, O
no DT
age-related JJ
differences NNS
were VBD
observed VBN
in IN
c-fos NN
or CC
jun NN
B NN
mRNA NN
expression NN
. O

However RB
, O
c-jun NN
mRNA NN
levels NNS
decreased VBD
significantly RB
( O
1.73 CD
+/- CC
0.08 CD
vs. CC
1.16 CD
+/- CC
0.09 CD
arbitrary JJ
units NNS
, O
P NN
&lt[[SEMICOLON]] JJR
0.01 CD
, O
young JJ
vs. CC
old JJ
) O
in IN
PBL NN
from IN
elderly JJ
individuals NNS
activated VBN
with IN
PHA NN
. O

Because IN
previous JJ
work NN
has VBZ
demonstrated VBN
that IN
T NN
cells NNS
from IN
elderly JJ
individuals NNS
may MD
display VB
normal JJ
proliferative JJ
responses NNS
when WRB
activated VBN
via IN
the DT
anti-CD2 JJ
pathway NN
, O
c-jun NN
and CC
jun NN
B NN
mRNA NN
expression NN
was VBD
also RB
studied VBN
in IN
anti-CD2-activated JJ
purified VBN
T NN
cells NNS
. O

No DT
age-related JJ
differences NNS
were VBD
found VBN
in IN
the DT
expression NN
of IN
either DT
of IN
these DT
two CD
proto-oncogenes NNS
by IN
anti-CD2 NN
activated JJ
T NN
cells NNS
. O

These DT
results NNS
suggest VBP
that IN
the DT
decreased VBN
IL-2 NN
production NN
and CC
proliferative JJ
response NN
displayed VBN
by IN
PHA-activated JJ
PBL NN
from IN
elderly JJ
adults NNS
may MD
be VB
related JJ
to TO
age-related JJ
changes NNS
in IN
c-jun NN
mRNA NN
expression NN
and CC
in IN
the DT
ratio NN
of IN
c-fos NN
to TO
c-jun NN
mRNA NN
. O

Characterization NN
of IN
a DT
novel JJ
T NN
lymphocyte NN
protein NN
which WDT
binds VBZ
to TO
a DT
site NN
related JJ
to TO
steroid/thyroid JJ
hormone NN
receptor NN
response NN
elements NNS
in IN
the DT
negative JJ
regulatory JJ
sequence NN
of IN
the DT
human JJ
immunodeficiency NN
virus NN
long JJ
terminal JJ
repeat NN
. O

We PRP
have VBP
previously RB
identified VBN
a DT
T NN
lymphocyte NN
protein NN
which WDT
binds VBZ
to TO
a DT
site NN
within IN
the DT
LTR NN
of IN
the DT
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
( O
HIV-1 NN
) O
and CC
exerts VBZ
an DT
inhibitory JJ
effect NN
on IN
virus NN
gene NN
expression NN
. O

The DT
palindromic JJ
site NN
( O
site NN
B NN
) O
recognized VBN
by IN
this DT
protein NN
is VBZ
related JJ
to TO
the DT
palindromic JJ
binding VBG
sites NNS
of IN
members NNS
of IN
the DT
steroid/thyroid JJ
hormone NN
receptor NN
family NN
. O

Here RB
we PRP
characterize VBP
the DT
T NN
cell NN
protein NN
binding VBG
to TO
this DT
site NN
as IN
a DT
100 CD
kD NN
protein NN
which WDT
is VBZ
most RBS
abundant JJ
in IN
T NN
cells NNS
and CC
which WDT
binds VBZ
to TO
site NN
B NN
as IN
a DT
200 CD
kD NN
complex NN
. O

This DT
protein NN
is VBZ
distinct JJ
from IN
other JJ
members NNS
of IN
the DT
steroid/thyroid JJ
hormone NN
receptor NN
family NN
including VBG
the DT
COUP NN
protein NN
which WDT
has VBZ
a DT
closely RB
related JJ
DNA NN
binding NN
specificity NN
. O

A DT
mechanism NN
for IN
the DT
antiinflammatory JJ
effects NNS
of IN
corticosteroids NNS
: O
the DT
glucocorticoid NN
receptor NN
regulates VBZ
leukocyte NN
adhesion NN
to TO
endothelial JJ
cells NNS
and CC
expression NN
of IN
endothelial-leukocyte JJ
adhesion NN
molecule NN
1 CD
and CC
intercellular JJ
adhesion NN
molecule NN
1 CD
. O

Corticosteroids NNS
are VBP
the DT
preeminent JJ
antiinflammatory JJ
agents NNS
although IN
the DT
molecular JJ
mechanisms NNS
that WDT
impart VBP
their PRP$
efficacy NN
have VBP
not RB
been VBN
defined VBN
. O

The DT
endothelium NN
plays VBZ
a DT
critical JJ
role NN
in IN
inflammation NN
by IN
directing VBG
circulating VBG
leukocytes NNS
into IN
extravascular JJ
tissues NNS
by IN
expressing VBG
adhesive JJ
molecules NNS
for IN
leukocytes NNS
( O
e.g. FW
, O
endothelial-leukocyte JJ
adhesion NN
molecule NN
1 CD
( O
ELAM-1 NN
) O
and CC
intercellular JJ
adhesion NN
molecule NN
1 CD
( O
ICAM-1 NN
) O
. O

We PRP
therefore RB
determined VBD
whether IN
corticosteroids NNS
suppress VBP
inflammation NN
by IN
inhibiting VBG
endothelial JJ
expression NN
of IN
adhesion NN
molecules NNS
for IN
neutrophils NNS
( O
polymorphonuclear JJ
leukocytes NNS
) O
. O

Preincubation NN
of IN
endothelial JJ
cells NNS
with IN
endotoxin NN
( O
lipopolysaccharide NN
( O
LPS NN
) O
, O
1 CD
microgram/ml NN
) O
led VBD
to TO
a DT
4-fold JJ
increase NN
in IN
subsequent JJ
adherence NN
of IN
polymorphonuclear JJ
leukocytes NNS
( O
P NN
< JJR
0.0001 CD
, O
n NN
= JJ
10 CD
) O
to TO
endothelial JJ
cells NNS
, O
an DT
increase NN
that WDT
was VBD
markedly RB
attenuated VBN
when WRB
endothelial JJ
cells NNS
were VBD
treated VBN
with IN
dexamethasone NN
( O
IC50 NN
< JJR
1 CD
nM NN
, O
P NN
< JJR
0.0001 CD
, O
n NN
= JJ
6 CD
or CC
7 CD
) O
during IN
preincubation NN
with IN
LPS NN
. O

Moreover RB
, O
the DT
steroid NN
receptor NN
agonist NN
cortisol NN
( O
10 CD
microM NN
) O
, O
but CC
not RB
its PRP$
inactive JJ
metabolite NN
tetrahydrocortisol NN
( O
10 CD
microM NN
) O
, O
diminished VBD
LPS-induced JJ
endothelial JJ
cell NN
adhesiveness NN
. O

Further JJ
evidence NN
that IN
the DT
action NN
of IN
dexamethasone NN
was VBD
mediated VBN
through IN
ligation NN
of IN
corticosteroid NN
receptors NNS
( O
human JJ
glucocorticoid NN
receptors NNS
( O
hGRs NNS
) O
) O
was VBD
provided VBN
by IN
experiments NNS
utilizing VBG
the DT
steroid NN
antagonist NN
RU-486 NN
. O

RU-486 NN
( O
10 CD
microM NN
) O
, O
which WDT
prevents VBZ
translocation NN
of IN
ligated VBN
hGR NN
to TO
the DT
nucleus NN
by IN
inhibiting VBG
dissociation NN
of IN
hGR NN
from IN
heat NN
shock NN
protein NN
90 CD
, O
completely RB
aborted VBD
the DT
effect NN
of IN
dexamethasone NN
on IN
adhesiveness NN
of IN
endothelial JJ
cells NNS
( O
P NN
< JJR
0.0005 CD
, O
n NN
= JJ
3 CD
) O
. O

Treatment NN
of IN
endothelial JJ
cells NNS
with IN
LPS NN
( O
1 CD
microgram/ml NN
) O
stimulated VBD
transcription NN
of IN
ELAM-1 NN
, O
as IN
shown VBN
by IN
Northern NN
blot NN
analysis NN
, O
and CC
expression NN
of IN
membrane-associated JJ
ELAM-1 NN
and CC
ICAM-1 NN
, O
as IN
shown VBN
by IN
quantitative JJ
immunofluorescence NN
( O
both DT
P NN
< JJR
0.001 CD
, O
n NN
= JJ
9 CD
) O
. O

Dexamethasone NN
markedly RB
inhibited VBD
LPS-stimulated JJ
accumulation NN
of IN
mRNA NN
for IN
ELAM-1 NN
and CC
expression NN
of IN
ELAM-1 NN
and CC
ICAM-1 NN
( O
IC50 NN
< JJR
10 CD
nM NN
, O
both DT
P NN
< JJR
0.001 CD
, O
n NN
= JJ
4-9 CD
) O
; O
inhibition NN
of IN
expression NN
by IN
dexamethasone NN
was VBD
reversed VBN
by IN
RU-486 NN
( O
both DT
P NN
< JJR
0.005 CD
, O
n NN
= JJ
4-6 CD
) O
. O

As IN
in IN
the DT
adhesion NN
studies NNS
, O
cortisol NN
but CC
not RB
tetrahydrocortisol NN
inhibited VBD
expression NN
of IN
ELAM-1 NN
and CC
ICAM-1 NN
( O
both DT
P NN
< JJR
0.005 CD
, O
n NN
= JJ
3 CD
or CC
4 CD
) O
. O

In IN
contrast NN
, O
sodium NN
salicylate NN
( O
1 CD
mM NN
) O
inhibited VBD
neither CC
adhesion NN
nor CC
expression NN
of IN
these DT
adhesion NN
molecules NNS
. O

These DT
studies NNS
suggest VBP
that IN
antagonism NN
by IN
dexamethasone NN
of IN
endotoxin-induced JJ
inflammation NN
is VBZ
a DT
specific JJ
instance NN
of IN
the DT
general JJ
biological JJ
principle NN
that IN
the DT
glucocorticoid NN
receptor NN
is VBZ
a DT
hormone-dependent JJ
regulator NN
of IN
transcription NN
. O

Membrane NN
receptors NNS
for IN
aldosterone NN
: O
a DT
novel JJ
pathway NN
for IN
mineralocorticoid NN
action NN
. O

Rapid JJ
nongenomic JJ
in FW
vitro FW
effects NNS
of IN
aldosterone NN
on IN
intracellular JJ
electrolytes NNS
, O
cell NN
volume NN
, O
and CC
Na(+)-H+ JJ
antiport NN
have VBP
been VBN
found VBN
in IN
human JJ
mononuclear JJ
leukocytes NNS
( O
HML NN
) O
. O

Binding NN
of IN
125I-labeled JJ
aldosterone NN
to TO
plasma NN
membranes NNS
of IN
HML NN
shares VBZ
important JJ
features NNS
with IN
these DT
functional JJ
data NNS
. O

This DT
includes VBZ
a DT
very RB
low JJ
apparent JJ
dissociation NN
constant NN
( O
Kd NN
) O
of IN
0.1 CD
nM NN
for IN
both CC
aldosterone NN
and CC
the DT
effect NN
on IN
the DT
Na(+)-H(+)-antiport NN
, O
a DT
high JJ
turnover NN
rate NN
, O
and CC
the DT
almost RB
exclusive JJ
binding NN
selectivity NN
for IN
aldosterone NN
. O

Dexamethasone NN
, O
RU NN
26988 CD
, O
corticosterone NN
, O
ouabain NN
, O
amiloride NN
, O
and CC
18-hydroxyprogesterone NN
were VBD
inactive JJ
as IN
ligands NNS
. O

Deoxycorticosterone NN
acetate NN
had VBD
an DT
intermediate JJ
activity NN
with IN
an DT
apparent JJ
Kd NN
of IN
100 CD
nM NN
. O

These DT
findings NNS
are VBP
the DT
first JJ
to TO
demonstrate VB
membrane NN
binding NN
of IN
aldosterone NN
being VBG
compatible JJ
with IN
major JJ
aspects NNS
of IN
its PRP$
nongenomic JJ
effects NNS
. O

Reticuloendotheliosis NN
virus NN
long JJ
terminal JJ
repeat NN
elements NNS
are VBP
efficient JJ
promoters NNS
in IN
cells NNS
of IN
various JJ
species NNS
and CC
tissue NN
origin NN
, O
including VBG
human JJ
lymphoid JJ
cells NNS
. O

Promiscuous JJ
transcriptional JJ
activity NN
of IN
the DT
reticuloendotheliosis NN
virus NN
( O
REV NN
) O
long JJ
terminal JJ
repeat NN
( O
LTR NN
) O
was VBD
detected VBN
in IN
transient JJ
expression NN
assays NNS
using VBG
LTR-chloramphenicol NN
acetyltransferase-encoding JJ
gene NN
chimeras NNS
, O
and CC
cells NNS
of IN
diverse JJ
species NNS
and CC
tissue NN
type NN
; O
levels NNS
of IN
expression NN
from IN
two CD
different JJ
REV NN
LTRs NNS
correlate VBP
with IN
reports NNS
of IN
pathogenicity NN
of IN
the DT
respective JJ
viruses NNS
in FW
vivo FW
. O

REVs NNS
do VBP
not RB
encode VB
a DT
transactivator NN
targeted VBN
to TO
the DT
viral JJ
LTR NN
, O
and CC
cells NNS
infected VBN
with IN
Marek NN
's POS
disease NN
virus NN
, O
a DT
herpesvirus NN
with IN
an DT
overlapping VBG
host NN
range NN
, O
do VBP
not RB
express VB
factors NNS
that WDT
preferentially RB
enhance VBP
expression NN
from IN
REV NN
or CC
avian JJ
sarcoma/leukemia NN
virus NN
LTRs NNS
. O

REV NN
LTRs NNS
work VBP
efficiently RB
in IN
human JJ
lymphoid JJ
cells NNS
, O
and CC
are VBP
viable JJ
alternatives NNS
to TO
promoters NNS
commonly RB
used VBN
for IN
expression NN
of IN
cloned VBN
genes NNS
. O

They PRP
may MD
also RB
prove VB
useful JJ
in IN
the DT
identification NN
of IN
new JJ
, O
ubiquitous JJ
cellular JJ
transcription NN
factors NNS
. O

Natural JJ
variants NNS
of IN
the DT
HIV-1 NN
long JJ
terminal JJ
repeat NN
: O
analysis NN
of IN
promoters NNS
with IN
duplicated JJ
DNA NN
regulatory JJ
motifs NNS
. O

Sequence NN
variation NN
in IN
the DT
long JJ
terminal JJ
repeat NN
( O
LTR NN
) O
region NN
of IN
HIV-1 NN
was VBD
analyzed VBN
in IN
viral JJ
isolates NNS
of IN
17 CD
infected JJ
individuals NNS
. O

Two CD
classes NNS
of IN
LTR NN
size NN
variants NNS
were VBD
found VBN
. O

One CD
HIV-1 NN
variant NN
was VBD
detected VBN
containing VBG
an DT
additional JJ
binding VBG
site NN
for IN
the DT
transcription NN
factor NN
Sp1 NN
. O

Another DT
LTR NN
size NN
variation NN
was VBD
observed VBN
in IN
four CD
patients NNS
in IN
a DT
region NN
just RB
upstream JJ
of IN
the DT
NF-kappa NN
B NN
enhancer NN
. O

This DT
variation NN
was VBD
the DT
result NN
of IN
a DT
duplication NN
of IN
a DT
short JJ
DNA NN
sequence NN
( O
CTG-motif NN
) O
. O

Cell NN
culture NN
experiments NNS
demonstrated VBD
that IN
the DT
natural JJ
variant NN
with IN
four CD
Sp1 NN
sites NNS
had VBD
a DT
slightly RB
higher JJR
promoter NN
activity NN
and CC
viral JJ
replication NN
rate NN
than IN
the DT
isogenic JJ
control NN
LTR NN
with IN
three CD
Sp1 NN
sites NNS
. O

No DT
positive JJ
effect NN
of IN
the DT
duplicated JJ
CTG-motif NN
could MD
be VB
detected VBN
. O

In IN
order NN
to TO
measure VB
small JJ
differences NNS
in IN
virus NN
production NN
more RBR
accurately RB
, O
equal JJ
amounts NNS
of IN
a DT
size NN
variant NN
and CC
the DT
wild-type JJ
plasmid NN
were VBD
cotransfected VBN
into IN
T-cells NNS
. O

The DT
virus NN
with IN
four CD
Sp1 NN
sites NNS
did VBD
outgrow VB
the DT
three CD
Sp1 NN
virus NN
in IN
35 CD
days NNS
of IN
culture NN
and CC
CTG-monomer NN
virus NN
outcompeted VBD
the DT
CTG-dimer NN
virus NN
in IN
42 CD
days NNS
. O

Based VBN
on IN
these DT
results NNS
we PRP
estimate VBP
a DT
5-10 CD
% NN
difference NN
in IN
virus NN
production NN
of IN
the DT
LTR NN
variants NNS
when WRB
compared VBN
to TO
that DT
of IN
wild-type NN
. O

SCL NN
and CC
related JJ
hemopoietic JJ
helix-loop-helix JJ
transcription NN
factors NNS
. O

The DT
helix-loop-helix JJ
( O
HLH JJ
) O
proteins NNS
are VBP
a DT
family NN
of IN
transcription NN
factors NNS
that WDT
include VBP
proteins NNS
critical JJ
to TO
differentiation NN
and CC
development NN
in IN
species NNS
ranging VBG
from IN
plants NNS
to TO
mammals NNS
. O

Five CD
members NNS
of IN
this DT
family NN
( O
MYC NN
, O
SCL NN
, O
TAL-2 NN
, O
LYL-1 NN
and CC
E2A NN
) O
are VBP
implicated VBN
in IN
oncogenic JJ
events NNS
in IN
human JJ
lymphoid JJ
tumors NNS
because IN
of IN
their PRP$
consistent JJ
involvement NN
in IN
chromosomal JJ
translocations NNS
. O

Although IN
activated VBN
in IN
T NN
cell NN
leukemias NNS
, O
expression NN
of IN
SCL NN
and CC
LYL-1 NN
is VBZ
low JJ
or CC
undetectable JJ
in IN
normal JJ
T NN
cell NN
populations NNS
. O

SCL NN
is VBZ
expressed VBN
in IN
erythroid JJ
, O
megakaryocyte NN
and CC
mast NN
cell NN
populations NNS
( O
the DT
same JJ
cell NN
lineages NNS
as IN
GATA-1 NN
, O
a DT
zinc-finger NN
transcription NN
factor NN
) O
. O

In IN
addition NN
, O
both CC
SCL NN
and CC
GATA-1 NN
undergo VBP
coordinate JJ
modulation NN
during IN
chemically RB
induced VBN
erythroid JJ
differentiation NN
of IN
mouse NN
erythroleukemia NN
cells NNS
and CC
are VBP
down-modulated VBN
during IN
myeloid JJ
differentiation NN
of IN
human JJ
K562 NN
cells NNS
, O
thus RB
implying VBG
a DT
role NN
for IN
SCL NN
in IN
erythroid JJ
differentiation NN
events NNS
. O

However RB
, O
in IN
contrast NN
to TO
GATA-1 NN
, O
SCL NN
is VBZ
expressed VBN
in IN
the DT
developing VBG
brain NN
. O

Studies NNS
of IN
the DT
function NN
of IN
SCL NN
suggest VBP
it PRP
is VBZ
also RB
important JJ
in IN
proliferation NN
and CC
self-renewal JJ
events NNS
in IN
erythroid JJ
cells NNS
. O

Transcription NN
of IN
the DT
hypersensitive JJ
site NN
HS2 NN
enhancer NN
in IN
erythroid JJ
cells NNS
. O

In IN
the DT
human JJ
genome NN
, O
the DT
erythroid-specific JJ
hypersensitive JJ
site NN
HS2 NN
enhancer NN
regulates VBZ
the DT
transcription NN
of IN
the DT
downstream JJ
beta-like JJ
globin NN
genes NNS
10-50 CD
kilobases NNS
away RB
. O

The DT
mechanism NN
of IN
HS2 NN
enhancer NN
function NN
is VBZ
not RB
known VBN
. O

The DT
present JJ
study NN
employs VBZ
RNA NN
protection NN
assays NNS
to TO
analyze VB
the DT
transcriptional JJ
status NN
of IN
the DT
HS2 NN
enhancer NN
in IN
transfected VBN
recombinant JJ
chloramphenicol NN
acetyltransferase NN
( O
CAT NN
) O
plasmids NNS
. O

In IN
erythroid JJ
K562 NN
cells NNS
in IN
which WDT
the DT
HS2 NN
enhancer NN
is VBZ
active JJ
, O
the DT
HS2 NN
sequence NN
directs VBZ
the DT
synthesis NN
of IN
long JJ
enhancer NN
transcripts NNS
that WDT
are VBP
initiated VBN
apparently RB
from IN
within IN
the DT
enhancer NN
and CC
elongated VBN
through IN
the DT
intervening VBG
DNA NN
into IN
the DT
cis-linked JJ
CAT NN
gene NN
. O

In IN
nonerythroid JJ
HL-60 NN
cells NNS
in IN
which WDT
the DT
HS2 NN
enhancer NN
is VBZ
inactive JJ
, O
long JJ
enhancer NN
transcripts NNS
are VBP
not RB
detectable JJ
. O

Splitting VBG
the DT
HS2 NN
enhancer NN
between IN
two CD
tandem JJ
Ap1 NN
sites NNS
abolishes VBZ
the DT
synthesis NN
of IN
a DT
group NN
of IN
long JJ
enhancer NN
transcripts NNS
and CC
results VBZ
in IN
loss NN
of IN
enhancer NN
function NN
and CC
transcriptional JJ
silencing NN
of IN
the DT
cis-linked JJ
CAT NN
gene NN
. O

In IN
directing VBG
the DT
synthesis NN
of IN
RNA NN
through IN
the DT
intervening VBG
DNA NN
and CC
the DT
gene NN
by IN
a DT
tracking NN
and CC
transcription NN
mechanism NN
, O
the DT
HS2 NN
enhancer NN
may MD
( O
i LS
) O
open VB
up RP
the DT
chromatin NN
structure NN
of IN
a DT
gene NN
domain NN
and CC
( O
ii LS
) O
deliver VB
enhancer NN
binding NN
proteins NNS
to TO
the DT
promoter NN
sequence NN
where WRB
they PRP
may MD
stimulate VB
the DT
transcription NN
of IN
the DT
gene NN
at IN

Phorbol NN
ester NN
reduces VBZ
constitutive JJ
nuclear JJ
NF NN
kappa NN
B NN
and CC
inhibits VBZ
HIV-1 NN
production NN
in IN
mature JJ
human JJ
monocytic JJ
cells NNS
. O

NF NN
kappa NN
B NN
is VBZ
a DT
potent JJ
mediator NN
of IN
specific JJ
gene NN
expression NN
in IN
human JJ
monocytes NNS
and CC
has VBZ
been VBN
shown VBN
to TO
play VB
a DT
role NN
in IN
transcription NN
of IN
the DT
HIV-1 NN
genome NN
in IN
promonocytic JJ
leukemias NNS
. O

There EX
is VBZ
little JJ
information NN
available JJ
on IN
the DT
response NN
of IN
NF NN
kappa NN
B NN
to TO
cytokines NNS
in IN
normal JJ
human JJ
monocytes NNS
. O

We PRP
have VBP
used VBN
a DT
32P-labeled JJ
oligonucleotide NN
derived VBN
from IN
human JJ
immunodeficiency NN
virus NN
( O
HIV-1 NN
) O
long JJ
terminal JJ
repeat NN
, O
which WDT
contains VBZ
a DT
tandem JJ
repeat NN
of IN
the DT
NF NN
kappa NN
B NN
binding NN
sequence NN
, O
as IN
a DT
probe NN
in IN
a DT
gel NN
retardation NN
assay NN
to TO
study VB
this DT
transcription NN
factor NN
. O

Using VBG
this DT
assay NN
, O
we PRP
have VBP
detected VBN
NF NN
kappa NN
B NN
in IN
extracts NNS
of IN
nuclei NNS
from IN
normal JJ
human JJ
monocytes NNS
. O

Treatment NN
of IN
normal JJ
monocytes NNS
with IN
12-0-tetradecanoyl JJ
phorbol-13-acetate NN
( O
TPA NN
) O
for IN
4-24 CD
h NN
caused VBD
the DT
complete JJ
disappearance NN
of IN
NF NN
kappa NN
B NN
from IN
nuclear JJ
extracts NNS
of IN
monocytes NNS
. O

A DT
similar JJ
result NN
was VBD
obtained VBN
with IN
the DT
mature JJ
monocytic JJ
leukemia NN
cell NN
line NN
THP-1 NN
. O

The DT
constitutive JJ
transcription NN
factor NN
SP1 NN
was VBD
unaffected JJ
by IN
addition NN
of IN
TPA NN
. O

The DT
disappearance NN
of IN
NF NN
kappa NN
B NN
from IN
the DT
nucleus NN
was VBD
concentration NN
dependent JJ
between IN
10 CD
and CC
50 CD
ng/ml NN
of IN
phorbol NN
ester NN
. O

In IN
THP-1 NN
cells NNS
, O
TPA NN
also RB
induced VBD
a DT
new JJ
, O
faster-migrating JJ
NF NN
kappa NN
B NN
species NNS
not RB
induced VBN
in IN
monocytes NNS
. O

Protein NN
kinase NN
C NN
inhibitor NN
staurosporine NN
, O
but CC
not RB
cyclic JJ
nucleotide-dependent JJ
protein NN
kinase NN
inhibitor NN
HA-1004 NN
, O
also RB
dramatically RB
reduced VBD
constitutive JJ
levels NNS
of IN
nuclear JJ
NF NN
kappa NN
B NN
. O

Finally RB
, O
TPA NN
addition NN
to TO
monocytes NNS
infected VBN
with IN
HIV-1 NN
inhibited VBD
HIV-1 NN
replication NN
, O
as IN
determined VBN
by IN
reverse JJ
transcriptase NN
assays NNS
, O
in IN
a DT
concentration-dependent JJ
manner NN
. O

These DT
results NNS
are VBP
in IN
striking JJ
contrast NN
to TO
the DT
increase NN
in IN
nuclear JJ
NF NN
kappa NN
B NN
and CC
HIV-1 NN
replication NN
induced VBN
by IN
phorbol NN
esters NNS
in IN
promonocytic JJ
leukemia NN
cells NNS
U937 NN
and CC
HL-60 NN
, O
and CC
emphasize VBP
the DT
importance NN
of IN
studying VBG
cytokine NN
regulation NN
of IN
HIV-1 NN
in IN
normal JJ
monocytes NNS
. O

Ablation NN
of IN
transplanted VBN
HTLV-I NN
Tax-transformed JJ
tumors NNS
in IN
mice NNS
by IN
antisense JJ
inhibition NN
of IN
NF-kappa NN
B NN
( O
published VBN
erratum NN
appears VBZ
in IN
Science NNP
1993 CD
Mar NNP
12 CD
; O
259 CD
( O
5101 CD
) O
: O
1523 CD
) O

Mice NNS
transgenic JJ
for IN
the DT
human JJ
T NN
cell NN
leukemia NN
virus NN
( O
HTLV-I NN
) O
Tax NN
gene NN
develop VBP
fibroblastic JJ
tumors NNS
that WDT
express VBP
NF-kappa NN
B-inducible JJ
early JJ
genes NNS
. O

In FW
vitro FW
inhibition NN
of IN
NF-kappa NN
B NN
expression NN
by IN
antisense JJ
oligodeoxynucleotides NNS
( O
ODNs NNS
) O
inhibited VBD
growth NN
of IN
these DT
culture-adapted JJ
Tax-transformed JJ
fibroblasts NNS
as RB
well RB
as IN
an DT
HTLV-I-transformed JJ
human JJ
lymphocyte NN
line NN
. O

In IN
contrast NN
, O
antisense JJ
inhibition NN
of IN
Tax NN
itself PRP
had VBD
no DT
apparent JJ
effect NN
on IN
cell NN
growth NN
. O

Mice NNS
treated VBN
with IN
antisense NN
to TO
NF-kappa NN
B NN
ODNs NNS
showed VBD
rapid JJ
regression NN
of IN
transplanted VBN
fibrosarcomas NNS
. O

This DT
suggests VBZ
that IN
NF-kappa NN
B NN
expression NN
may MD
be VB
necessary JJ
for IN
the DT
maintenance NN
of IN
the DT
malignant JJ
phenotype NN
and CC
provides VBZ
a DT
therapeutic JJ
approach NN
for IN
HTLV-I-associated JJ
disease NN
. O

Inhibition NN
of IN
anti-CD3 JJ
monoclonal JJ
antibody-induced JJ
T-cell NN
proliferation NN
by IN
dexamethasone NN
, O
isoproterenol NN
, O
or CC
prostaglandin NN
E2 NN
either CC
alone RB
or CC
in IN
combination NN
. O

1 LS
. O
The DT
purpose NN
of IN
these DT
studies NNS
was VBD
to TO
investigate VB
the DT
modulation NN
of IN
the DT
proliferation NN
of IN
human JJ
T NN
cells NNS
obtained VBN
from IN
peripheral JJ
blood NN
by IN
dexamethasone NN
( O
DEX NN
) O
, O
isoproterenol NN
( O
ISO NN
) O
, O
and CC
prostaglandin NN
E2 NN
( O
PGE2 NN
) O
. O

The DT
former JJ
two CD
substances NNS
interact VBP
with IN
T NN
cells NNS
via IN
the DT
glucocorticoid NN
and CC
beta-adrenergic JJ
receptors NNS
respectively RB
. O

When WRB
occupied VBN
by IN
their PRP$
natural JJ
ligands NNS
, O
glucocorticosteroids NNS
and CC
catecholamines NNS
, O
these DT
receptors NNS
have VBP
a DT
role NN
in IN
modulating VBG
T-cell NN
function NN
during IN
stress NN
. O

During IN
the DT
inflammatory JJ
response NN
increased VBN
levels NNS
of IN
PGE2 NN
bind VBP
to TO
their PRP$
receptors NNS
on IN
T NN
cells NNS
and CC
thus RB
alter VBP
responsiveness NN
. O

Proliferation NN
of IN
T NN
cells NNS
was VBD
induced VBN
by IN
immobilized VBN
anti-CD3 JJ
monoclonal JJ
antibody NN
( O
mAb NN
) O
in IN
the DT
presence NN
or CC
absence NN
of IN
an DT
additional JJ
costimulatory JJ
signal NN
delivered VBN
by IN
anti-CD28 JJ
mAb NN
. O

2 LS
. O
Various JJ
physiologic JJ
concentrations NNS
of IN
DEX NN
, O
ISO NN
, O
or CC
PGE2 NN
were VBD
added VBN
at IN
the DT
time NN
of IN
initiation NN
of IN
the DT
cultures NNS
and CC
subsequent JJ
proliferation NN
of IN
the DT
unstimulated JJ
T NN
cells NNS
was VBD
determined VBN
. O

The DT
results NNS
demonstrate VBP
that IN
physiologic JJ
concentrations NNS
of IN
all DT
three CD
of IN
these DT
agents NNS
inhibit VBP
the DT
anti-CD3 JJ
mAb-induced JJ
proliferation NN
of IN
T NN
cells NNS
. O

3 LS
. O
Although IN
DEX NN
and CC
PGE2 NN
were VBD
equipotent JJ
in IN
suppressing JJ
T-cell NN
proliferation NN
, O
ISO NN
was VBD
much RB
less RBR
effective JJ
. O

4 LS
. O
Because IN
concomitant JJ
elevations NNS
in IN
the DT
peripheral JJ
levels NNS
of IN
these DT
substances NNS
may MD
occur VB
, O
experiments NNS
were VBD
performed VBN
to TO
determine VB
the DT
T-cell NN
inhibitory JJ
effects NNS
of IN
DEX NN
together RB
with IN
either CC
PGE2 NN
or CC
ISO NN
. O

Synergistic JJ
suppression NN
of IN
T-cell NN
proliferation NN
was VBD
observed VBN
when WRB
various JJ
concentrations NNS
of IN
DEX NN
and CC
PGE2 NN
, O
but CC
not RB
DEX NN
and CC
ISO NN
, O
were VBD
added VBN
to TO
cultures NNS
. O

This DT
synergistic JJ
suppression NN
could MD
not RB
be VB
explained VBN
by IN
an DT
increase NN
in IN
cAMP NN
accumulation NN
in IN
T NN
cells NNS
stimulated VBN
with IN
DEX NN
and CC
PGE2 NN
. O

5 LS
. O
Finally RB
, O
the DT
addition NN
of IN
anti-CD28 JJ
mAb NN
to TO
anti-CD3 JJ
mAb-stimulated JJ
T NN
cells NNS
overcame VBD
much JJ
of IN
the DT
suppression NN
of IN
proliferation NN
induced VBN
by IN
PGE2 NN
or CC
ISO NN
but CC
less RBR
so RB
than IN
that DT
induced VBN
by IN
DEX NN
. O

Targeted VBN
degradation NN
of IN
c-Fos NN
, O
but CC
not RB
v-Fos NN
, O
by IN
a DT
phosphorylation-dependent JJ
signal NN
on IN
c-Jun NN
. O

The DT
proto-oncogene NN
products NNS
c-Fos NN
and CC
c-Jun NN
heterodimerize VBP
through IN
their PRP$
leucine NN
zippers NNS
to TO
form VB
the DT
AP-1 NN
transcription NN
factor NN
. O

The DT
transcriptional JJ
activity NN
of IN
the DT
heterodimer NN
is VBZ
regulated VBN
by IN
signal-dependent JJ
phosphorylation NN
and CC
dephosphorylation NN
events NNS
. O

The DT
stability NN
of IN
c-Fos NN
was VBD
found VBN
to TO
also RB
be VB
controlled VBN
by IN
intracellular JJ
signal NN
transduction NN
. O

In IN
transient JJ
expression NN
and CC
in FW
vitro FW
degradation NN
experiments NNS
, O
the DT
stability NN
of IN
c-Fos NN
was VBD
decreased VBN
when WRB
the DT
protein NN
was VBD
dimerized JJ
with IN
phosphorylated VBN
c-Jun NN
. O

c-Jun NN
protein NN
isolated VBN
from IN
phorbol NN
ester-induced JJ
cells NNS
did VBD
not RB
target VB
c-Fos NN
for IN
degradation NN
, O
which WDT
suggests VBZ
that IN
c-Fos NN
is VBZ
transiently RB
stabilized VBN
after IN
stimulation NN
of IN
cell NN
growth NN
. O

v-Fos NN
protein NN
, O
the DT
retroviral JJ
counterpart NN
of IN
c-Fos NN
, O
was VBD
not RB
susceptible JJ
to TO
degradation NN
targeted VBN
by IN
c-Jun NN
. O

Mutations NNS
in IN
the DT
Pit-1 NN
gene NN
in IN
children NNS
with IN
combined JJ
pituitary JJ
hormone NN
deficiency NN
. O

Pit-1 NN
is VBZ
a DT
pituitary-specific JJ
transcription NN
factor NN
that WDT
binds VBZ
to TO
and CC
transactivates VBZ
promoters NNS
of IN
growth NN
hormone NN
and CC
prolactin NN
genes NNS
. O

In IN
three CD
unrelated JJ
Japanese JJ
children NNS
with IN
combined JJ
pituitary JJ
hormone NN
deficiency NN
, O
we PRP
identified VBD
three CD
point NN
mutations NNS
in IN
the DT
Pit-1 NN
gene NN
, O
Pro24Leu NN
, O
Arg143Gln NN
, O
and CC
Arg271Trp NN
, O
located JJ
on IN
the DT
major JJ
transactivation NN
region NN
, O
POU-specific JJ
domain NN
, O
and CC
POU-homeodomain NN
, O
respectively RB
. O

Calcitriol NN
: O
a DT
hematolymphopoietrope NN
? O
( O
editorial NN
) O

A DT
MEDLINE NN
search NN
of IN
the DT
English-language JJ
literature NN
was VBD
conducted VBN
using VBG
the DT
indexing NN
terms NNS
' [[DQS]]
immunology NN
, O
calcitriol NN
and CC
vitamin NN
D NN
' [[DQE]]
to TO
identify VB
studies NNS
indicating VBG
a DT
role NN
for IN
calcitriol NN
as IN
a DT
primary JJ
immunomodulator NN
. O

Sixty-six CD
papers NNS
published VBN
between IN
January NNP
1956 CD
and CC
June NNP
1991 CD
were VBD
identified VBN
. O

Forty-five CD
of IN
these DT
reports NNS
are VBP
cited VBN
in IN
this DT
review NN
. O

The DT
data NNS
strongly RB
suggest VBP
an DT
endocrine NN
, O
autocrine NN
and/or CC
paracrine NN
role NN
for IN
calcitriol NN
in IN
immune JJ
regulation NN
. O

No DT
unifying JJ
hypothesis NN
has VBZ
yet RB
emerged VBN
explaining VBG
this DT
collection NN
of IN
data NNS
. O

This DT
paper NN
provides VBZ
a DT
brief JJ
review NN
of IN
immune JJ
properties NNS
currently RB
attributed VBN
to TO
calcitriol NN
. O

Activation NN
of IN
protein NN
kinase NN
C NN
and CC
elevation NN
of IN
cAMP NN
interact VBP
synergistically RB
to TO
raise VB
c-Fos NN
and CC
AP-1 NN
activity NN
in IN
Jurkat NN
cells NNS
. O

We PRP
have VBP
earlier RBR
found VBN
that IN
in IN
Jurkat NN
cells NNS
activation NN
of IN
protein NN
kinase NN
C NN
( O
PKC NN
) O
enhances VBZ
the DT
cyclic JJ
adenosine NN
monophosphate NN
( O
cAMP NN
) O
accumulation NN
induced VBN
by IN
adenosine NN
receptor NN
stimulation NN
or CC
activation NN
of IN
Gs NN
. O

Here RB
we PRP
have VBP
therefore RB
examined VBN
the DT
effect NN
of IN
the DT
phorbol NN
ester NN
PMA NN
( O
phorbol NN
12-myristate NN
13-acetate NN
) O
which WDT
stimulates VBZ
PKC NN
and CC
a DT
combination NN
of IN
the DT
adenosine NN
receptor NN
agonist NN
NECA NN
( O
5'-(N-ethyl)-carboxamido JJ|NN
adenosine NN
) O
and CC
forskolin NN
to TO
raise VB
cAMP NN
, O
on IN
the DT
levels NNS
of IN
c-Fos NN
and CC
Jun NN
and CC
on IN
the DT
binding VBG
and CC
transcriptional JJ
activity NN
of IN
the DT
transcription NN
factor NN
, O
activator NN
protein-1 NN
( O
AP-1 NN
) O
. O

PMA NN
treatment NN
caused VBD
a DT
concentration- NN
and CC
time-dependent JJ
increase NN
in IN
both CC
c-Fos NN
and CC
Jun NN
immunoreactivity NN
in IN
contrast NN
to TO
cAMP NN
elevation NN
that WDT
had VBD
only RB
a DT
slight JJ
effect NN
. O

Both CC
PMA NN
and CC
the DT
combination NN
of IN
NECA NN
and CC
forskolin NN
acted VBD
together RB
either CC
to TO
increase VB
( O
c-Fos NN
) O
or CC
decrease VB
( O
Jun NN
) O
protein NN
levels NNS
as RB
well RB
as IN
increasing VBG
AP-1 NN
binding NN
, O
as IN
judged VBN
by IN
gel-shift NN
assay NN
, O
and CC
AP-1 NN
transcriptional JJ
activity NN
. O

Furthermore RB
there EX
was VBD
a DT
clear-cut JJ
synergy NN
between IN
the DT
PKC NN
stimulator NN
and CC
the DT
cAMP NN
elevating NN
agents NNS
. O

The DT
results NNS
demonstrate VBP
that IN
the DT
simultaneous JJ
activation NN
of IN
PKC NN
and CC
elevation NN
of IN
cAMP NN
leads VBZ
to TO
an DT
enhanced VBN
AP-1 NN
transcriptional JJ
activity NN
in IN
a DT
T-leukemia NN
cell NN
line NN
, O
suggesting VBG
that IN
the DT
previously RB
observed VBN
interaction NN
between IN
the DT
parallel JJ
signal NN
transduction NN
pathways NNS
may MD
have VB
functional JJ
consequences NNS
at IN
the DT
level NN
of IN
gene NN
transcription NN
. O

The DT
use NN
of IN
interferon-gamma-treated JJ
U937 NN
cells NNS
in IN
chemiluminescence NN
assays NNS
to TO
detect VB
red JJ
cell NN
, O
platelet NN
and CC
granulocyte NN
antibodies NNS
of IN
potential JJ
clinical JJ
significance NN
. O

The DT
chemiluminescent JJ
( O
CL JJ
) O
response NN
of IN
interferon-gamma-treated JJ
U937 NN
( O
IFN-U937 NN
) O
cells NNS
to TO
sensitized VBN
target NN
cells NNS
has VBZ
been VBN
used VBN
to TO
detect VB
red JJ
cell NN
, O
platelet NN
and CC
granulocyte NN
antibodies NNS
. O

A DT
clone NN
of IN
U937 NN
cells NNS
was VBD
selected VBN
which WDT
expressed VBD
Fc NN
receptor NN
I NN
( O
Fc NN
gamma NN
RI NN
) O
and CC
which WDT
, O
after IN
incubation NN
with IN
IFN-gamma NN
for IN
72 CD
h NN
, O
was VBD
capable JJ
of IN
generating VBG
high JJ
levels NNS
of IN
lucigenin-enhanced JJ
CL NN
. O

The DT
CL NN
responses NNS
of IN
IFN-U937 NN
cells NNS
and CC
peripheral JJ
blood NN
human JJ
monocytes NNS
to TO
sensitized VBN
red JJ
cells NNS
, O
platelets NNS
or CC
granulocytes NNS
were VBD
then RB
compared VBN
. O

Assays NNS
using VBG
monocytes NNS
or CC
IFN-U937 NN
cells NNS
were VBD
of IN
comparable JJ
sensitivity NN
for IN
detection NN
of IN
antibodies NNS
against IN
all DT
three CD
types NNS
of IN
target NN
cell NN
. O

In IN
addition NN
, O
the DT
use NN
of IN
IFN-U937 NN
cells NNS
reduced VBD
interassay JJ
variation NN
and CC
simplified VBD|VBN
assay NN
performance NN
. O

The DT
potential JJ
clinical JJ
usefulness NN
of IN
these DT
CL NN
assays NNS
was VBD
suggested VBN
by IN
the DT
ability NN
of IN
both CC
monocytes NNS
and CC
IFN-U937 NN
cells NNS
to TO
respond VB
to TO
red JJ
cells NNS
, O
platelets NNS
or CC
granulocytes NNS
sensitized VBN
with IN
sera NN
from IN
pregnant JJ
women NNS
whose WP$
babies NNS
had VBD
either CC
haemolytic JJ
disease NN
of IN
the DT
newborn JJ
( O
HDN NN
) O
, O
alloimmune JJ
thrombocytopenia NN
or CC
alloimmune JJ
neutropenia NN
respectively RB
. O

In IN
addition NN
, O
monocytes NNS
and CC
IFN-U937 NN
cells NNS
both DT
responded VBD
to TO
red JJ
cells NNS
sensitized VBN
with IN
antibodies NNS
against IN
a DT
variety NN
of IN
specificities NNS
of IN
assumed VBN
( O
although IN
not RB
documented VBN
) O
clinical JJ
significance NN
for IN
blood NN
transfusion NN
recipients NNS
. O

In IN
contrast NN
, O
monocytes NNS
and CC
IFN-U937 NN
cells NNS
responded VBD
only RB
weakly RB
to TO
red JJ
cells NNS
sensitized VBN
with IN
either CC
anti-D JJ
in IN
sera NN
from IN
mothers NNS
of IN
babies NNS
unaffected JJ
by IN
HDN NN
, O
or CC
with IN
antisera NNS
containing VBG
high JJ
titre NN
antibodies NNS
with IN
specificities NNS
not RB
normally RB
associated VBN
with IN
significantly RB
reduced VBN
red JJ
cell NN
survival NN
. O

Photoaffinity NN
labeling NN
of IN
plasma NN
membrane NN
receptors NNS
for IN
aldosterone NN
from IN
human JJ
mononuclear JJ
leukocytes NNS
. O

Non-genomic JJ
effects NNS
of IN
aldosterone NN
on IN
the DT
sodium-proton-antiport NN
have VBP
been VBN
shown VBN
in IN
human JJ
mononuclear JJ
leukocytes NNS
which WDT
could MD
be VB
related JJ
to TO
a DT
new JJ
aldosterone NN
membrane NN
receptor NN
. O

In IN
the DT
present JJ
paper NN
plasma NN
membranes NNS
from IN
human JJ
mononuclear JJ
leukocytes NNS
were VBD
covalently RB
photolabeled VBN
with IN
a DT
(125I)-aldosterone NN
derivative NN
. O

Sodium NN
dodecyl NN
sulfate-polyacrylamide JJ
gel NN
electrophoresis NN
showed VBD
significant JJ
aldosterone NN
binding NN
at IN
a DT
molecular JJ
weight NN
of IN
approximately RB
50000 CD
Dalton NN
which WDT
was VBD
absent JJ
with IN
1 CD
microM NN
cold JJ
aldosterone NN
, O
but CC
not RB
cortisol NN
in IN
the DT
binding VBG
media NNS
. O

The DT
presence NN
of IN
the DT
sulfhydryl NN
agent NN
dithiothreitol NN
did VBD
not RB
affect VB
results NNS
suggesting VBG
the DT
absence NN
of IN
disulfide NN
bridges NNS
in IN
the DT
steroid NN
binding NN
domain NN
of IN
the DT
receptor NN
. O

These DT
data NNS
are VBP
the DT
first JJ
to TO
define VB
the DT
molecular JJ
weight NN
of IN
the DT
membrane NN
receptor NN
for IN
aldosterone NN
. O

Alpha-lipoic JJ
acid NN
is VBZ
a DT
potent JJ
inhibitor NN
of IN
NF-kappa NN
B NN
activation NN
in IN
human JJ
T NN
cells NNS
. O

Acquired VBN
immunodeficiency NN
syndrome NN
( O
AIDS NN
) O
results VBZ
from IN
infection NN
with IN
a DT
human JJ
immunodeficiency NN
virus NN
( O
HIV NN
) O
. O

The DT
long JJ
terminal JJ
repeat NN
( O
LTR NN
) O
region NN
of IN
HIV NN
proviral JJ
DNA NN
contains VBZ
binding VBG
sites NNS
for IN
nuclear JJ
factor NN
kappa NN
B NN
( O
NF-kappa NN
B NN
) O
, O
and CC
this DT
transcriptional JJ
activator NN
appears VBZ
to TO
regulate VB
HIV NN
activation NN
. O

Recent JJ
findings NNS
suggest VBP
an DT
involvement NN
of IN
reactive JJ
oxygen NN
species NNS
( O
ROS NN
) O
in IN
signal NN
transduction NN
pathways NNS
leading VBG
to TO
NF-kappa NN
B NN
activation NN
. O

The DT
present JJ
study NN
was VBD
based VBN
on IN
reports NNS
that IN
antioxidants NNS
which WDT
eliminate VBP
ROS NN
should MD
block VB
the DT
activation NN
of IN
NF-kappa NN
B NN
and CC
subsequently RB
HIV NN
transcription NN
, O
and CC
thus RB
antioxidants NNS
can MD
be VB
used VBN
as IN
therapeutic JJ
agents NNS
for IN
AIDS NN
. O

Incubation NN
of IN
Jurkat NN
T NN
cells NNS
( O
1 CD
x CC
10(6) CD
cells/ml NNS
) O
with IN
a DT
natural JJ
thiol NN
antioxidant NN
, O
alpha-lipoic JJ
acid NN
, O
prior JJ
to TO
the DT
stimulation NN
of IN
cells NNS
was VBD
found VBN
to TO
inhibit VB
NF-kappa NN
B NN
activation NN
induced VBN
by IN
tumor NN
necrosis NN
factor-alpha NN
( O
25 CD
ng/ml NN
) O
or CC
by IN
phorbol NN
12-myristate NN
13-acetate NN
( O
50 CD
ng/ml NN
) O
. O

The DT
inhibitory JJ
action NN
of IN
alpha-lipoic JJ
acid NN
was VBD
found VBN
to TO
be VB
very RB
potent JJ
as IN
only RB
4 CD
mM NN
was VBD
needed VBN
for IN
a DT
complete JJ
inhibition NN
, O
whereas IN
20 CD
mM NN
was VBD
required VBN
for IN
N-acetylcysteine NN
. O

These DT
results NNS
indicate VBP
that IN
alpha-lipoic JJ
acid NN
may MD
be VB
effective JJ
in IN
AIDS NN
therapeutics NNS
. O

Activation NN
of IN
lymphokine NN
genes NNS
in IN
T NN
cells NNS
: O
role NN
of IN
cis-acting JJ
DNA NN
elements NNS
that WDT
respond VBP
to TO
T NN
cell NN
activation NN
signals NNS
. O

Activation NN
of IN
T NN
cells NNS
is VBZ
initiated VBN
by IN
the DT
recognition NN
of IN
antigen NN
on IN
antigen NN
presenting NN
cells NNS
to TO
exert VB
the DT
effector NN
functions NNS
in IN
immune JJ
and CC
inflammatory JJ
responses NNS
. O

Two CD
types NNS
of IN
helper NN
T NN
cell NN
( O
Th NN
) O
clones NNS
( O
Th1 NN
and CC
Th2 NN
) O
are VBP
defined VBN
on IN
the DT
basis NN
of IN
different JJ
patterns NNS
of IN
cytokine NN
( O
lymphokine NN
) O
secretion NN
. O

They PRP
determine VBP
the DT
outcome NN
of IN
an DT
antigenic JJ
response NN
toward IN
humoral JJ
or CC
cell-mediated JJ
immunity NN
. O

Although IN
lymphokine NN
genes NNS
are VBP
coordinately RB
regulated VBN
upon IN
antigen NN
stimulation NN
, O
they PRP
are VBP
regulated VBN
by IN
the DT
mechanisms NNS
common JJ
to TO
all DT
as RB
well RB
as IN
those DT
which WDT
are VBP
unique JJ
to TO
each DT
gene NN
. O

For IN
most JJS
lymphokine NN
genes NNS
, O
a DT
combination NN
of IN
phorbol NN
esters NNS
( O
phorbol NN
12-myristate NN
13 CD
acetate NN
, O
PMA NN
) O
and CC
calcium NN
ionophores NNS
( O
A23187 NN
) O
is VBZ
required VBN
for IN
their PRP$
maximal JJ
induction NN
. O

Yet RB
phorbol NN
ester NN
alone RB
or CC
calcium NN
ionophore NN
alone RB
produce VBP
several JJ
lymphokines NNS
. O

The DT
production NN
of IN
the DT
granulocyte-macrophage JJ
colony NN
stimulating NN
factor NN
( O
GM-CSF NN
) O
is VBZ
completely RB
dependent JJ
on IN
the DT
two CD
signals NNS
. O

We PRP
have VBP
previously RB
found VBN
a DT
cis-acting JJ
region NN
spanning VBG
the DT
GM-CSF NN
promoter NN
region NN
( O
positions NNS
-95 CD
to TO
+27 CD
) O
that WDT
confers VBZ
inducibility NN
to TO
reporter NN
genes NNS
in IN
transient JJ
transfection NN
assays NNS
. O

Further JJ
analysis NN
identified VBD
three CD
elements NNS
required VBN
for IN
efficient JJ
induction NN
, O
referred VBN
to TO
as IN
GM2 NN
, O
GC-box NN
and CC
conserved VBN
lymphokine NN
element NN
( O
CLE0 NN
) O
. O

GM2 NN
defines VBZ
a DT
binding VBG
site NN
for IN
protein NN
( O
s NNS
) O
whose WP$
binding NN
is VBZ
inducible JJ
by IN
PMA NN
. O

One CD
protein NN
, O
NF-GM2 NN
is VBZ
similar JJ
to TO
the DT
transcription NN
factor NN
NF-kB NN
. O

GC-box NN
is VBZ
a DT
binding VBG
site NN
for IN
constitutively RB
bound VBN
proteins NNS
. O

CLEO NN
defines VBZ
a DT
binding VBG
site NN
for IN
protein NN
( O
s NNS
) O
whose WP$
optimum NN
binding NN
is VBZ
stimulated VBN
by IN
PMA NN
and CC
A23187 NN
. O

Viral JJ
trans-activators NNS
such JJ
as IN
Tax NN
( O
human JJ
T NN
cell NN
leukemia NN
virus-1 NN
, O
HTLV-1 NN
) O
and CC
E2 NN
( O
bovine JJ
papilloma NN
virus NN
, O
BPV NN
) O
proteins NNS
are VBP
other JJ
agents NNS
which WDT
activate VBP
lymphokine NN
gene NN
expression NN
by IN
bypassing VBG
T NN
cell NN
receptor NN
( O
TCR NN
) O
mediated JJ
signaling NN
. O

The DT
trans-activation NN
domain NN
of IN
E2 NN
and CC
Tax NN
is VBZ
interchangeable JJ
although IN
they PRP
have VBP
no DT
obvious JJ
sequence NN
homology NN
between IN
them PRP
. O

The DT
viral JJ
trans-activators NNS
appear VBP
to TO
target VB
specific JJ
DNA NN
binding NN
protein NN
such JJ
as IN
NF-kB NN
and CC
Sp1 NN
to TO
cis-acting JJ
DNA NN
site NN
and CC
promote VB
lymphokine NN
gene NN
expression NN
without IN
TCR-mediated JJ
stimulation NN
. O

I NN
kappa NN
B/MAD-3 NN
masks VBZ
the DT
nuclear JJ
localization NN
signal NN
of IN
NF-kappa NN
B NN
p65 NN
and CC
requires VBZ
the DT
transactivation NN
domain NN
to TO
inhibit VB
NF-kappa NN
B NN
p65 NN
DNA NN
binding NN
. O

The DT
active JJ
nuclear JJ
form NN
of IN
the DT
NF-kappa NN
B NN
transcription NN
factor NN
complex NN
is VBZ
composed VBN
of IN
two CD
DNA NN
binding NN
subunits NNS
, O
NF-kappa NN
B NN
p65 NN
and CC
NF-kappa NN
B NN
p50 NN
, O
both DT
of IN
which WDT
share VBP
extensive JJ
N-terminal JJ
sequence NN
homology NN
with IN
the DT
v-rel NN
oncogene NN
product NN
. O

The DT
NF-kappa NN
B NN
p65 NN
subunit NN
provides VBZ
the DT
transactivation NN
activity NN
in IN
this DT
complex JJ
and CC
serves VBZ
as IN
an DT
intracellular JJ
receptor NN
for IN
a DT
cytoplasmic JJ
inhibitor NN
of IN
NF-kappa NN
B NN
, O
termed VBN
I NN
kappa NN
B NN
. O

In IN
contrast NN
, O
NF-kappa NN
B NN
p50 NN
alone RB
fails VBZ
to TO
stimulate VB
kappa NN
B-directed JJ
transcription NN
, O
and CC
based VBN
on IN
prior JJ
in FW
vitro FW
studies NNS
, O
is VBZ
not RB
directly RB
regulated VBN
by IN
I NN
kappa NN
B NN
. O

To TO
investigate VB
the DT
molecular JJ
basis NN
for IN
the DT
critical JJ
regulatory JJ
interaction NN
between IN
NF-kappa NN
B NN
and CC
I NN
kappa NN
B/MAD-3 NN
, O
a DT
series NN
of IN
human JJ
NF-kappa NN
B NN
p65 NN
mutants NNS
was VBD
identified VBN
that WDT
functionally RB
segregated VBD
DNA NN
binding NN
, O
I NN
kappa NN
B-mediated JJ
inhibition NN
, O
and CC
I NN
kappa NN
B-induced JJ
nuclear JJ
exclusion NN
of IN
this DT
transcription NN
factor NN
. O

Results NNS
from IN
in FW
vivo FW
expression NN
studies NNS
performed VBN
with IN
these DT
NF-kappa NN
B NN
p65 NN
mutants NNS
revealed VBD
the DT
following NN
: O
1 LS
) O
I NN
kappa NN
B/MAD-3 NN
completely RB
inhibits VBZ
NF-kappa NN
B NN
p65-dependent JJ
transcriptional JJ
activation NN
mediated VBN
through IN
the DT
human JJ
immunodeficiency NN
virus NN
type NN
1 CD
kappa NN
B NN
enhancer NN
in IN
human JJ
T NN
lymphocytes NNS
, O
2 LS
) O
the DT
binding NN
of IN
I NN
kappa NN
B/MAD-3 NN
to TO
NF-kappa NN
B NN
p65 NN
is VBZ
sufficient JJ
to TO
retarget VB
NF-kappa NN
B NN
p65 NN
from IN
the DT
nucleus NN
to TO
the DT
cytoplasm NN
, O
3 LS
) O
selective JJ
deletion NN
of IN
the DT
functional JJ
nuclear JJ
localization NN
signal NN
present JJ
in IN
the DT
Rel NN
homology NN
domain NN
of IN
NF-kappa NN
B NN
p65 NN
disrupts VBZ
its PRP$
ability NN
to TO
engage VB
I NN
kappa NN
B/MAD-3 NN
, O
and CC
4 LS
) O
the DT
unique JJ
C-terminus NN
of IN
NF-kappa NN
B NN
p65 NN
attenuates VBZ
its PRP$
own JJ
nuclear JJ
localization NN
and CC
contains VBZ
sequences NNS
that WDT
are VBP
required VBN
for IN
I NN
kappa NN
B-mediated JJ
inhibition NN
of IN
NF-kappa NN
B NN
p65 NN
DNA NN
binding NN
activity NN
. O

Together RB
, O
these DT
findings NNS
suggest VBP
that IN
the DT
nuclear JJ
localization NN
signal NN
and CC
transactivation NN
domain NN
of IN
NF-kappa NN
B NN
p65 NN
constitute VBP
a DT
bipartite JJ
system NN
that WDT
is VBZ
critically RB
involved VBN
in IN
the DT
inhibitory JJ
function NN
of IN
I NN
kappa NN
B/MAD-3 NN
. O

Unexpectedly RB
, O
our PRP$
in FW
vivo FW
studies NNS
also RB
demonstrate VBP
that IN
I NN
kappa NN
B/MAD-3 NN
binds VBZ
directly RB
to TO
NF-kappa NN
B NN
p50 NN
. O

This DT
interaction NN
is VBZ
functional JJ
as IN
it PRP
leads VBZ
to TO
retargeting NN
of IN
NF-kappa NN
B NN
p50 NN
from IN
the DT
nucleus NN
to TO
the DT
cytoplasm NN
. O

However RB
, O
no DT
loss NN
of IN
DNA NN
binding NN
activity NN
is VBZ
observed VBN
, O
presumably RB
reflecting VBG
the DT
unique JJ
C-terminal JJ
domain NN
that WDT
is VBZ
distinct JJ
from IN
that DT
present JJ
in IN
NF-kappa NN
B NN
p65 NN
. O

Surrogate NN
thyroglobulin NN
receptors NNS
and CC
T NN
cell NN
proliferation NN
in IN
Hashimoto NN
's POS
thyroiditis NN
. O

Immunoglobulin NN
molecules NNS
on IN
the DT
surface NN
of IN
a DT
B NN
lymphocyte NN
are VBP
the DT
endogenous JJ
" [[DQS]]
receptors NNS
" [[DQE]]
to TO
which WDT
specific JJ
antigens NNS
bind VBP
. O

Studies NNS
in IN
mice NNS
have VBP
shown VBN
that IN
a DT
monoclonal JJ
antibody NN
, O
conjugated VBN
with IN
palmitate NN
to TO
provide VB
a DT
lipid NN
tail NN
, O
can MD
be VB
inserted VBN
into IN
the DT
cell NN
membrane NN
to TO
provide VB
a DT
" [[DQS]]
surrogate JJ
" [[DQE]]
antigen NN
receptor NN
. O

We PRP
have VBP
investigated VBN
whether IN
a DT
palmitate JJ
conjugate NN
of IN
a DT
human JJ
monoclonal JJ
antibody NN
specific JJ
for IN
thyroglobulin NN
( O
TG NN
) O
could MD
function VB
as IN
a DT
surrogate JJ
TG NN
receptor NN
on IN
blood NN
mononuclear JJ
cells NNS
separated VBN
into IN
fractions NNS
enriched VBN
for IN
T NN
cells NNS
or CC
depleted VBN
of IN
T NN
cells NNS
( O
non-T JJ
cells NNS
) O
. O

Using VBG
flow NN
cytometry NN
, O
we PRP
detected VBD
surrogate JJ
TG NN
receptors NNS
on IN
non-T JJ
( O
but CC
not RB
on IN
T NN
) O
cells NNS
from IN
11 CD
of IN
11 CD
individuals NNS
studied VBN
( O
5 CD
Hashimoto NN
patients NNS
and CC
6 CD
control NN
donors NNS
) O
. O

In IN
contrast NN
, O
endogenous JJ
TG NN
receptors NNS
could MD
only RB
be VB
detected VBN
on IN
non-T JJ
cells NNS
from IN
1 CD
of IN
3 CD
Hashimoto NN
patients NNS
and CC
from IN
0 CD
of IN
4 CD
control NN
donors NNS
. O

Because IN
of IN
the DT
efficient JJ
binding NN
of IN
TG NN
by IN
surrogate JJ
receptors NNS
on IN
non-T JJ
cells NNS
, O
we PRP
assessed VBD
the DT
ability NN
of IN
such JJ
cells NNS
to TO
present VB
TG NN
to TO
T NN
cells NNS
. O

Proliferation NN
in IN
response NN
to TO
TG NN
was VBD
observed VBN
in IN
T NN
cells NNS
from IN
only RB
1 CD
of IN
5 CD
Hashimoto NN
patients NNS
. O

This DT
low JJ
frequency NN
of IN
response NN
was VBD
no RB
different JJ
from IN
that DT
previously RB
detected VBN
using VBG
cultures NNS
of IN
T NN
cells NNS
and CC
autologous JJ
dendritic JJ
cells NNS
. O

Therefore RB
, O
the DT
successful JJ
generation NN
of IN
surrogate JJ
receptors NNS
on IN
non-T JJ
cells NNS
is VBZ
not RB
associated VBN
with IN
more RBR
efficient JJ
TG NN
presentation NN
of IN
T NN
cells NNS
. O

Furthermore RB
, O
the DT
significance NN
of IN
the DT
present JJ
study NN
is VBZ
that IN
the DT
T NN
cells NNS
, O
not RB
the DT
antigen-presenting JJ
cells NNS
, O
are VBP
likely JJ
to TO
be VB
the DT
limiting VBG
element NN
in IN
the DT
T NN
cell NN
proliferative JJ
response NN
to TO
TG NN
and CC
other JJ
thyroid NN
autoantigens NNS
. O

Aldosterone-specific JJ
membrane NN
receptors NNS
and CC
rapid JJ
non-genomic JJ
actions NNS
of IN
mineralocorticoids NNS
. O

Functional JJ
studies NNS
in IN
extrarenal JJ
, O
non-epithelial JJ
cells NNS
such JJ
as IN
smooth JJ
muscle NN
cells NNS
and CC
more RBR
recently RB
circulating VBG
human JJ
lymphocytes NNS
have VBP
provided VBN
increasing VBG
evidence NN
that IN
aldosterone NN
produces VBZ
not RB
only RB
classical JJ
genomic JJ
effects NNS
, O
but CC
also RB
rapid JJ
, O
non-genomic JJ
effects NNS
on IN
transmembrane NN
electrolyte NN
movements NNS
. O

These DT
involve VBP
activation NN
of IN
the DT
sodium/proton NN
exchanger NN
of IN
the DT
cell NN
membrane NN
at IN
very RB
low JJ
, O
physiological JJ
concentrations NNS
of IN
aldosterone NN
with IN
an DT
acute JJ
onset NN
within IN
1-2 CD
min NN
. O

A DT
second JJ
messenger NN
cascade NN
involved VBN
is VBZ
the DT
inositol NN
1,4,5-trisphosphate/calcium NN
pathway NN
which WDT
responds VBZ
over IN
the DT
same JJ
rapid JJ
time NN
course NN
. O

Such JJ
changes NNS
clearly RB
can MD
not RB
be VB
explained VBN
by IN
genomic JJ
mechanisms NNS
, O
which WDT
are VBP
responsible JJ
for IN
later JJ
effects NNS
than IN
the DT
membrane NN
related JJ
rapid JJ
responses NNS
. O

The DT
mechanisms NNS
underlying VBG
these DT
rapid JJ
effects NNS
of IN
aldosterone NN
on IN
electrolytes NNS
have VBP
been VBN
extensively RB
studied VBN
in IN
human JJ
lymphocytes NNS
, O
which WDT
thus RB
may MD
represent VB
valuable JJ
tools NNS
in IN
the DT
delineation NN
of IN
the DT
receptor-effector JJ
mechanisms NNS
involved VBN
. O

The DT
unique JJ
characteristics NNS
of IN
this DT
new JJ
pathway NN
for IN
steroid NN
action NN
include VBP
its PRP$
rapid JJ
time NN
course NN
, O
10,000-fold JJ
selectivity NN
for IN
aldosterone NN
over IN
cortisol NN
and CC
the DT
ineffectiveness NN
of IN
spironolactones NNS
, O
classical JJ
mineralocorticoid NN
antagonists NNS
, O
as IN
antagonists NNS
of IN
the DT
response NN
. O

Cellular JJ
immune JJ
and CC
cytokine NN
pathways NNS
resulting VBG
in IN
tissue NN
factor NN
expression NN
and CC
relevance NN
to TO
septic JJ
shock NN
. O

Cells NNS
of IN
monocyte NN
lineage NN
serve VBP
as IN
effector NN
cells NNS
in IN
the DT
cellular JJ
immune JJ
response NN
. O

In IN
addition NN
, O
they PRP
respond VBP
to TO
LPS NN
and CC
cytokines NNS
with IN
activation NN
and CC
expression NN
of IN
inflammatory JJ
effector NN
gene NN
products NNS
similar JJ
to TO
those DT
elicited VBN
by IN
the DT
antigen NN
driven JJ
response NN
. O

The DT
response NN
to TO
antigen NN
proceeds VBZ
at IN
the DT
T NN
helper NN
cell NN
level NN
through IN
two CD
independent JJ
forms NNS
of IN
cellular JJ
collaboration NN
, O
contact NN
and CC
lymphokine NN
. O

We PRP
review VBP
the DT
control NN
of IN
expression NN
of IN
the DT
Tissue NN
Factor NN
( O
TF NN
) O
gene NN
and CC
the DT
function NN
of IN
the DT
TF NN
protein NN
. O

The DT
enhanced VBN
initiation NN
of IN
transcription NN
of IN
the DT
TF NN
gene NN
appears VBZ
to TO
require VB
engagement NN
of IN
a DT
56 CD
bp NN
LPS NN
Response NN
Element NN
, O
an DT
enhancer NN
that WDT
is VBZ
engaged VBN
by IN
both DT
AP-1 NN
type NN
heterodimeric JJ
complexes NNS
as RB
well RB
as IN
NF NN
kappa NN
B NN
like IN
heterodimeric JJ
complexes NNS
. O

Dissociation NN
of IN
NF NN
kappa NN
B NN
from IN
Ig NN
kappa NN
B NN
by IN
cytokine NN
and CC
LPS NN
stimulation NN
, O
and CC
possibly RB
activated VBN
T NN
cells NNS
, O
may MD
represent VB
a DT
common JJ
pathway NN
to TO
induction NN
of IN
the DT
TF NN
and CC
other JJ
inflammatory JJ
genes NNS
. O

Enhancement NN
of IN
expression NN
of IN
TF NN
is VBZ
observed VBN
upon IN
adhesion NN
of IN
Mo NN
to TO
endothelial JJ
cells NNS
and CC
extracellular JJ
matrix JJ
proteins NNS
, O
as RB
well RB
as IN
upon IN
engagement NN
of IN
leukocyte NN
integrins NNS
. O

The DT
biological JJ
effects NNS
that WDT
follow VBP
from IN
expression NN
of IN
TF NN
by IN
vascular JJ
cells NNS
have VBP
been VBN
resolved VBN
by IN
analysis NN
of IN
function NN
aided VBN
by IN
the DT
use NN
of IN
recombinant JJ
full JJ
length NN
TF NN
and CC
truncated VBN
surface NN
domain NN
of IN
TF NN
. O

The DT
rules NNS
of IN
assembly NN
of IN
the DT
cognate JJ
ligands NNS
of IN
TF NN
, O
namely RB
the DT
zymogen NN
plasma NN
factors NNS
VII NN
and CC
the DT
serine NN
protease NN
factor NN
VIIa NN
, O
with IN
the DT
soluble JJ
surface NN
domain NN
of IN
TF NN
in IN
free JJ
solution NN
, O
in IN
the DT
presence NN
of IN
phospholipid JJ
surfaces NNS
and CC
cell NN
surface NN
and CC
of IN
the DT
anchored VBN
TF NN
molecule NN
have VBP
been VBN
described VBN
. O

It PRP
is VBZ
evident JJ
that IN
assembly NN
of IN
the DT
surface NN
domain NN
of IN
TF NN
with IN
VIIa NN
to TO
form VB
the DT
binary JJ
TF.VIIa NN
complex NN
induces VBZ
a DT
significant JJ
increase NN
in IN
the DT
Kcat NN
of IN
the DT
catalytic JJ
domain NN
of IN
VIIa NN
for IN
small JJ
peptidyl JJ
substrates NNS
and CC
more JJR
profoundly RB
for IN
protein NN
substrate NN
. O

This DT
provides VBZ
substantial JJ
evidence NN
for IN
an DT
allosteric JJ
effect NN
on IN
the DT
catalytic JJ
cleft NN
of IN
VIIa NN
that WDT
is VBZ
imparted VBN
by IN
binding VBG
to TO
TF NN
, O
its PRP$
cognate JJ
catalytic JJ
cofactor NN
. O

It PRP
is VBZ
also RB
evident JJ
that IN
the DT
TF.VIIa NN
complex NN
is VBZ
proteolytically RB
active JJ
and CC
can MD
activate VB
the DT
zymogen NN
plasma NN
factor NN
X NN
to TO
the DT
serine NN
protease NN
Xa NN
in IN
free JJ
solution NN
, O
inferring VBG
that IN
extended VBN
substrate NN
recognition NN
by IN
induced VBN
structural JJ
loci NNS
of IN
the DT
TF.VIIa NN
complex NN
are VBP
created VBN
from IN
either DT
or CC
both DT
proteins NNS
to TO
constitute VB
a DT
new JJ
recognition NN
structure NN
. O

It PRP
is VBZ
also RB
evident JJ
that IN
association NN
of IN
X NN
with IN
charged JJ
phospholipid JJ
surfaces NNS
enhances VBZ
the DT
proteolytic JJ
activation NN
of IN
this DT
zymogen NN
by IN
increasing VBG
recognition NN
and CC
susceptibility NN
of IN
the DT
sessile NN
peptide NN
bond NN
deduced VBN
from IN
the DT
markedly RB
decreased VBN
Km NN
and CC
increased VBN
Kcat NN
. O

